ידיעות כלליות - נבו - המאגר המשפטי - 13-04-2008... · Web viewG06F 188828 22/08/2006 מערכת ושיטה למשלוח הודעות MESSAGING SYSTEM AND

2/2008ח'/התשס"ח

רשומותISRAEL STATE RECORDS

April 13, 2008 התשס"ח ח' בניסן

והמדגמים הפטנטים יומןPATENTS AND DESIGNS JOURNAL

PATENTSעמודפטנטיםPage

Applications filedשהוגשו בקשות639Applications acceptedשקובלו בקשות846Patents grantedשניתנו פטנטים847Patents renewedשחודשו פטנטים849Patents not in forceפקעו שתוקפם פטנטים850Patents renewed for 20 yearsשנה לעשרים שחודשו פטנטים851Patents expiredתוקפם שפג פטנטים852Noticesהודעותרשומים בפרטים שינויים

862בפנקס Changes in particulars entered

in register863Corrigendaטעויות תיקוני864Country codesלמדינות קודים

iIndices of applications acceptedשקובלו לבקשות מפתחות

DESIGNSמדגמים866Designs registeredשנרשמו מדגמים877Designs renewedשחודשו מדגמים878Designs voidשבוטלו מדגמיםרשומים בפרטים שינויים

879בפנקס Changes in particulars entered

in register

כלליות ידיעות

אל: לשלוח יש ומדגמים פטנטים מכתבים, מסמכים, וכו' בענייני, ירושלים4 והמדגמים, רח' הסדנא הפטנטים רשם

חול בימי לציבור פתוחה והיא , תלפיות, ירושלים4 ברח' הסדנא נמצאת הפטנטים לשכת.12:30 ו- 8:30 השעות בין מועד או שבת ערבי שאינם כל בעד שקלים2.50 של במחיר ושרטוטים פירוטים של תצלומים מספקת הפטנטים לשכתממנו. חלק או עמוד

מס' הדואר בבנק הלשכה לחשבון תשלום ידי על ורק אך מתקבלות הפטנטים ללשכת אגרות האגרה שעבורה לפעולה הבקשה עם יחד ללשכה הדואר בנק קבלת להציג . יש0-24145-2

שולמה.

GENERAL INFORMATION

Letters, documents, etc. concerning Patents and Designs should be addressed to:The Commissioner of Patents and Designs, 4 Hasadnah St., Jerusalem

The Patent Office is located at 4 Hasadnah St., Talpiot, Jerusalem and is open to the public on weekdays, except on Fridays or on the eves of holydays, from 08:30 to 12:30 hrs.

The Patent Office supplies photocopies of specifications and drawings at the rate of NIS 2.50 per page or part thereof.

Fees to the Patent Office can be accepted only by payment to the Postal Bank Account of the Office, No. 0-24145-2. The receipt of the Postal Bank must be presented to the office together with the application for the action for which the fee has been paid.

שמורה אלה בתקצירים היוצרים זכותמת להעתיק ישראל, אין למדינתקצירים

הפטנטים. לשכת ברשות אלא אלה

Copyright by the State of Israel. No Extracts may be published except with the permission of the Patent Office.

.Price per single issue (incl. VAT) : NIS 96.₪ 96מ.ע.מ.( )כולל בודדת חוברת מחיר: לכל

:Annual subscription (incl. VAT).₪ 1,152מ.ע.מ.( )כולל לשנה חתימה דמיNIS 1,152.

אצל: להשיג אפשר ב' הממשלה, רחוב פרסומי של ההפצה שרות, הקריה, תל-אביב.29מס'

Available at the Distribution Service of Government Publications, 29 B-Street, Hakirya, Tel-Aviv.

April 13, 2008 –התשס"ח ח' בניסן 452

הפטנטים לחוק16 סעיף לפי הודעה1967- תשכ"ז

NOTICE UNDER SECTION 16 OF THE PATENTS LAW, 5727-1967

חדשות בקשות רשימת להלןשנקבעו הדרישות אחר הממלאות

הפטנטים, )א( לתקנות32 בתקנה:1968תשכ"ח–

In the following there are listed newApplications complying with theProvisions of rule 32(a) of the PatentRegulations, 5728-1968

לפי מובאים הבקשות פרטיזה: סדר

Particulars of the applications aregiven in the following order:

הגשתה ותאריך – הבקשה מספרשל הראשונים הסמנים וארבעה

הבינלאומי הסיווג

Number and date of application And the first four symbols of theInternational Classification

ע"י שהוצע )כפי האמצאה שםהמבקש(

Title of invention(as proposed by applicant)

Applicantהמבקש– האיגוד קדימה: מדינת דין

ומספר תאריך החוץ בקשת

Priority right: Convention country – Number and date of Foreign application

International Application Numberבינלאומית בקשה מספר

International Publication Numberבינלאומי מס' פרסום

A01N17432516/09/2004

DNA VACCINE COMPOSITIONS ANDלשימוש ושיטות דנ"א חיסון תרכיביMETHODS OF USE

April 13, 2008453 –התשס"ח ח' בניסן

UNIVERSITY OF KANSAS MEDICAL CENTER

16/09/2003

60/503197US

15/09/2004

10/941164US

PCT/US/2004/030512WO/2005/027844

A61K17453622/09/2004

THERAPEUTIC TREATMENTרפואי טיפולASTRAZENECA UK LIMITED

26/09/2003

0322552.1GB

PCT/GB/2004/004120WO/2005/030215

A61K17474119/11/2004

רדיותראפיים קומבינציה תכשיריושיטות וכמותראפיים

COMBINATIONAL RADIOTHERAPY AND CHEMOTHERAPY COMPOSITIONS AND METHODSNOVOGEN RESEARCH PTY LTD.

19/11/2003

2003906386AU

PCT/AU/2004/001619WO/2005/049008

A61K17476308/10/2004

של יתר בביטוי המעורבת במחלה טיפולErbB2 קינאז

TREATMENT OF DISEASES INVOLVING ErbB2 KINASE OVEREXPRESSIONMARS, INCORPORATED

10/10/2003

60/510604US

PCT/US/2004/033355WO/2005/034879


A61K17476508/10/2004

אויר נתיבי במחלות לטיפול שיטה נגדיים אגוניסטיים באמצעות

בתא–אדרנרגים

METHOD OF TREATING AIRWAY DISEASES WITH BETA-ADRENERGIC INVERSE AGONISTSINVERSEON, INC.

09/10/2003

60/510250US

23/03/2004

60/555797US

PCT/US/2004/033157WO/2005/034871

H05C17477607/10/2004

בעזרת תנועה למניעת ושיטות מערכותחשמליים מטענים מתן

SYSTEMS AND METHODS FOR IMMOBILIZATION USING CHARGE DELIVERYTASER INTERNATIONAL, INC.

07/10/2003

60/509577US

08/10/2003

60/509480US

13/11/2003

10/714572US

31/12/2003

10/750374US

PCT/US/2004/033105WO/2005/086618

C07H17480006/10/2004

BONE MORPHOGENETIC PROTEIN ושימושיוBMP 2A חלבון(BMP) 2A AND USES THEREOFQUARK PHARMACEUTICALS, INC.

07/10/2003

60/509279US

PCT/IL/2004/000924WO/2005/041857


A61K17480722/10/2004

בריפוי לשימושENOS שעתוק מגביריאיסכמיות לב במחלות תאים

eNOS TRANSCRIPTION ENHANCERS FOR USE IN THE CELL THERAPY OF ISCHEMIC HEART DISEASESSANOFI-AVENTIS DEUTSCHLAND GMBH

06/11/2003

03025512.9EP

PCT/EP/2004/011944WO/2005/044249

A61K17483008/10/2004

PELLETS CONTAININGהידרוכלוריד ונלאפקסין המכילות טבליותVENLAFAXINE HYDROCHLORIDEEGIS GYOGYSZERGYAR RT.

10/10/2003P0303382HU

PCT/HU/2004/000095WO/2005/034930

A61K17486412/10/2004

וריבאוויריןVX–497 של תרופתי שילובאותן המכילות וערכות

A THERAPEUTIC COMBINATION OF VX-497 AND RIBAVIRIN AND KITS CONTAINING THE SAMEVERTEX PHARMACEUTICALS INCORPORATED

11/10/2003

60/510733US

PCT/US/2004/033739WO/2005/037274


A61K17491813/10/2004

בהפרעה טיפול עבור תגובה וחומרי שיטותחיסונית כתגובה דלקתית

METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERSCOMBINATORX, INC.

15/10/2003

60/512415US

PCT/US/2004/033656WO/2005/037203

A61K17492719/10/2004

USE OF ORGANIC COMPOUNDSאורגניות בתרכובות שימושNOVARTIS AG

20/10/2003

60/512634US

PCT/EP/2004/011824WO/2005/037278

A61K17495828/10/2004

המכילים מבוקר לשחרור רוקחות תכשיריותולדותיו אפילינדור

SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING APLINDORE AND DERIVATIVES THEREOFWYETH


29/10/2003

60/515315US

PCT/US/2004/036013WO/2005/044262

A61K17496821/10/2004

THE USE OF IFENPRODIL IN THEבכאב בטיפול איפאנפרודיל של השימושTREATMENT OF PAINARAKIS LTD.

21/10/2003

0324583.4GB

07/07/2004

0415267.4GB

PCT/GB/2004/004459WO/2005/041964

A61K17498625/10/2004

על תרכיב לפיתוח ושיטה אימונוגני הרכבמחובר חלבון בסיס

IMMUNOGENIC COMPOSITION AND METHOD OF DEVELOPING A VACCINE BASED ON FUSION PROTEINNMK RESEARCH, LLC

23/10/2003

60/513827US

PCT/US/2004/035317WO/2005/039501

A61K17503222/10/2004

לקטאז המכיל לשאיפה רוקחות תכשירהתכשיר למתן ושיטות אנהידראט

INHALABLE PHARMACEUTICAL FORMULATIONS EMPLOYING LACTOSE ANHYDRATE NAD METHODS OF ADMINISTERING THE SAMEGLAXO GROUP LIMITED

28/10/2003

60/515077US

PCT/US/2004/035129WO/2005/044187


A61K17505529/10/2004

סדרים באי לטיפול המשמשים צירופיםנוירונאלים

COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERSPROBIODRUG AG

03/11/2003

60/516717US

PCT/EP/2004/012301WO/2005/049027

A61K17506405/11/2004

ידי על משלים שיפעול של רגישות ביטולומאקרופאגים מונוציטים מעכבות תרכובות

DESENSITIZATION OF COMPLEMENT ACTIVATION USING MONOCYTE/MACROPHAGE INHIBITORY COMPOUNDS

.BIOREST LTDבע"מ ביורסט07/11/2003

60/518405US

PCT/IB/2004/003620WO/2005/044175

A01N17507423/04/2004

תרופות המכילים והרכבים לשימוש שיטות לטיפול, סלקטיבי באופן ציטוקין מעכבות

כאב של וניהול תיקון

METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATEMENT, MODIFICATION AND MANAGEMENT OF PAINCELGENE CORPORATION


23/10/2003

10/693794US

PCT/US/2004/012722WO/2005/043971

A61P17508013/10/2004

MODERATING THE EFFECT OFאנדוטוקסינים של ההשפעה מיתוןENDOTOXINSNESTEC S.A.

13/10/2003

03023015.5EP

PCT/EP/2004/011470WO/2005/039609

A61K17508519/10/2004

ל– אנטגוניסטיות בתרכובות שימושCRTH2בטיפול

USE OF CRTH2 ANTAGONIST COMPOUNDS IN THERAPYOXAGEN LIMITED

23/10/2003

0324763.2GB

PCT/GB/2004/004417WO/2005/044260

A61K17509822/10/2004

לטיפול תלידומיד המכילים והרכבים שיטותבפיברומיאלגיה

METHODS AND COMPOSITIONS COMPRISING THALIDOMIDE FOR TREATMENT OF FIBROMYALGIACELGENE CORPORATION

24/10/2003

60/514548US


PCT/US/2004/035180WO/2005/039497

A61K17510322/10/2004

להכנת פיראזול של בתולדה שימוש וטיפול במניעה השימושיים רפואיים מוצרים

הקשורות ומחלות דיסליפידאמיאס שללשמינות ו/או לדיסליפידאמיאס

USE OF A PYRAZOLE DERIVATIVE FOR PREPARING MEDICAMENTS FOR THE PREVENTION AND THE TREATMENT OF DYSLIPIDEMIA AND ILLNESSES ASSOCIATED WITH DYSLIPIDEMIA AND/OR OBESITYSANOFI-AVENTIS

24/10/20030312553FR

15/12/20030314763FR

05/02/20040401193FR

26/03/20040403252FR

PCT/FR/2004/002715WO/2005/046689

A61K17512828/10/2004

779 – CCIקרום של בלימפומה לטיפול התא

CCI-779 FOR TREATING MANTLE CELL LYMPHOMAMAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

04/11/2003

60/517329US

PCT/US/2004/035900WO/2005/046681


A61K17514730/10/2004

טעם חומרי המכילות רוקחיות פורמולציותמשופרות רוקחיות תכונות בעלות

PHARMACEUTICAL FORMULATIONS CONTAINING FLAVOURING SUBSTANCES WITH IMPROVED PHARMACEUTICAL PROPERTIESBAYER HEALTHCARE AG

04/11/2003

10351448.1DE

PCT/EP/2004/012327WO/2005/044271

A61K17519328/10/2004

במתן–מבוקר, אוקסיקודון של מינון צורותביום אוראלי, פעם

ONCE-A-DAY, ORAL, CONTROLLED-RELEASE, OXYCODONE DOSAGE FORMSALZA CORPORATION

29/10/2003

60/515880US

PCT/US/2004/036132WO/2005/041968

G06F17522812/11/2004

ציבורית ממותגת טלפונית ברשת שימוש און בעיסקות אלקטרוניות חתימות לקבלת

ליין

USE OF PUBLIC SWITCHED TELEPHONE NETWORK FOR CAPTURING ELECTRONIC SIGNATURES IN ON-LINE TRANSACTIONSAUTHENTIFY, INC.

14/11/2003

10/714314US


PCT/US/2004/038579WO/2005/076782

A61K17523528/10/2004

להכנה ביוקומפטביליים בפולימרים שימושרפואי מכשיר או תכשיר של

USE OF BIOCOMPATIBLE POLYMERS FOR THE PREPARATION OF A COMPOSITION OR A MEDICAL DEVICEORGANES TISSUS REGENERATION REPARATION REMPLACEMENT-OTR3

28/10/20030312605FR

05/04/20040403550FR

PCT/FR/2004/002780WO/2005/041986

A61K17524705/11/2004

המסוגלות מונומתילואליניות תרכובותלליגנדות להתחבר

MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDSSEATTLE GENETICS, INC.

06/11/2003

60/518534US

26/03/2004

60/557116US

04/08/2004

60/598899US

27/10/2004

60/622455US

PCT/US/2004/038392WO/2005/081711

B29C17525731/10/2004


METHOD FOR PRODUCINGלא–ארוג שורט בד לייצור שיטהABRASIVE NON-WOVEN CLOTH

.N.R. SPUNTECH INDUSTRIES LTDבע"מ תעשיות נ.ר. ספונטק06/11/2003158781IL

16/04/2004

10/825287US

PCT/IL/2004/000997WO/2005/044177

A61K17531128/04/2004

בניוון לטיפול ציטוקין מעכבות תרופותמקולרי

CYTOKINE INHIBITORY DRUGS FOR TREATMENT OF MACULAR DEGENERATIONCELGENE CORPORATION

30/10/2003

10/699110US

PCT/US/2004/013253WO/2005/044269

A61K17531228/04/2004

מקולרי בניוון לטיפול ושיטה תרכובתCOMPOSITION AND METHOD FOR TREATING MACULAR DEGENERATIONCELGENE CORPORATION

30/10/2003

10/699154US

PCT/US/2004/013252WO/2005/044259

A61K17533425/10/2004

מחומצה הליד נגזרת של שימושעצבי ניוון במחלות לטיפול הידרוקסימית

USE OF A HYDROXIMIC ACID HALIDE DERIVATIVE IN THE TREATMENT OF NEURODEGENERATIVE DISEASESCYTRX CORPORATION

30/10/2003P0303584HU


PCT/HU/2004/000098WO/2005/041965

A61K17534003/11/2004

לשימוש רכים סטרואידים של הרכביםיבשה אבקה במשאפי

SOFT STEROID COMPOSITIONS FOR USE IN DRY POWDER INHALERSNORTON HEALTHCARE LTD.

03/11/2003

60/517324US

PCT/US/2004/036477WO/2005/041980

A61K17536912/11/2004

תואמים, הכנה חדשה, תכשירים תרכובתטיפול שיטות ו/או

NOVEL COMPOUND, CORRESPONDING COMPOSITIONS, PREPARATION AND/OR TREATMENT METHODSSMITHKLINE BEECHAM CORPORATION

12/11/2003

60/519160US

24/11/2003

60/524574US

PCT/US/2004/037626WO/2005/046608

A61K17538022/11/2004

תרכובת המכילים לעניים רוקחות תכשיריהידרוקסילאמין

OPHTHALMOLOGIC PHARMACEUTICAL COMPOSITIONS CONTAINING A HYDROXYLAMINE COMPOUNDOTHERA PHARMACEUTICALS, INC.

20/11/2003

60/523802US

PCT/US/2004/039719WO/2005/051328


A61K17538505/11/2004

קווינולינוניות תרכובות של מלחים תכונות בעלי רוקחית מבחינה המקובלים

משופרות רוקחיות

PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIESNOVARTIS VACCINES AND DIAGNOSTICS, INC.

07/11/2003

60/517915US

02/12/2003

60/526425US

02/12/2003

60/526426US

19/02/2004

60/546017US

PCT/US/2004/036941WO/2005/046589

H01P17540128/10/2004

BI-LEVEL COUPLERעסקי מידע בטכנולוגיית מצמדWERLATONE, INC.

08/12/2003

10/731174US

PCT/US/2004/035936WO/2005/060436

A61K17542403/11/2004

–קוינולינקרבוניטרילים3–אנילינו–4) כרונית מיאלוג'נוס בלוקמיה לטיפול

CML)

4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML)WYETH


06/11/2003

60/517819US

PCT/US/2004/036722WO/2005/046693

A61K17542604/11/2004

המכילות ותרכובות שימוש שיטות וניהול לטיפולPDE 4 של מודולטורים

לאזבסט הקשורות והפרעות מחלות

METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERSCELGENE CORPORATION

06/11/2003

60/518603US

PCT/US/2004/037082WO/2005/046592

A61K17542704/11/2004

שימוש העושות ותרכובות שיטות מחלות של וניהול לטיפול בתלידומיד

אחרות ומחלות הסרטן

METHODS AND COMPOSITIONS USING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASESCELGENE CORPORATION

06/11/2003

60/517405US

PCT/US/2004/037083WO/2005/046593

A61K17542804/11/2004


מעכב הכוללים ותכשירים לשימוש שיטותJNKוהפרעות מחלות וניהול לטיפול

לאזבסט הקשורות

METHODS OF USING AND COMPOSITIONS COMPRISING A JNK INHIBITOR FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERSCELGENE CORPORATION

06/11/2003

60/518601US

PCT/US/2004/037084WO/2005/046594

A61K17543619/04/2004

במחלות לטיפול קטפסין במעכבי שימושחמור עצם דלדול

USE OF CATHEPSIN K INHIBITORS FOR TREATING OF SEVERE BONE LOSS DISEASESNOVARTIS AG

19/11/2003

03026430.3EP

PCT/EP/2004/004155WO/2005/049028

G06F17544614/12/2004

מסר של מידית להעברה והתקן שיטהמחשב מכל עבודה אודות ונוכחות

METHOD AND DEVICE FOR GRAB TRANSFERRING AN INSTANT MESSAGING AND PRESENCE (IMP) SESSIONMOTOROLA, INC.

23/12/2003

10/744894US

PCT/US/2004/041739WO/2005/065163


A61K17549822/11/2004

–N תולדות המכילים רוקחות תכשיריהידרוקסיפיפראדין

PHARMACEUTICAL COMPOSITIONS CONTAINING N-HYDROXYPIPERIDINE DERIVATIVESOTHERA PHARMACEUTICALS, INC.

20/11/2003

60/523803US

PCT/US/2004/039716WO/2005/055926

A61K17555609/11/2004

נגזרת של פומי למתן תרופתי תכשיר–קרבוקסאמיד3פירזול–

PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF A PYRAZOL-3-CARBOXAMIDE DERIVATIVESANOFI AVENTIS

10/11/20030313259FR

PCT/FR/2004/002875WO/2005/046690

A61K17556215/09/2004

מטריצה המכילה שכבתית רב מתן צורתמאפנן חומר שחרור על משפיעה אשר

MULTILAYER DOSAGE FORM COMPRISING A MATRIX THAT INFLUENCES RELEASE OF A MODULATORY SUBSTANCEROHM GMBH & CO. KG

13/11/2003

10353196.3DE

PCT/EP/2004/010300April 13, 2008469 –התשס"ח ח' בניסן

WO/2005/046561

A61K17557817/11/2004

INHIBITORS OF THE MUTANT FORMערכה של מוטנטית צורה בעלי מעכביםOF KITNOVARTIS AG

18/11/2003

60/520714US

PCT/EP/2004/013045WO/2005/049032

A61F17559912/11/2004

בר כאמצעי שטח פעיל חומר בסיס על ג'לתרופה של מושהה לשחרור הזרקה

SURFACTANT-BASED GEL AS AN INJECTABLE, SUSTAINED DRUG DELIVERY VEHICLEALZA CORPORATION

14/11/2003

60/519989US

10/11/2004

10/985228US

PCT/US/2004/037782WO/2005/048930

A61K17561109/11/2004

המתרבות במחלות טיפול עבור צירופיםבמהירות

COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES


COMBINATORX, INC.12/11/2003

60/519551US

27/05/2004

10/855130US

PCT/US/2004/037527WO/2005/046607

A61K17561519/11/2004

מעכב המכילים וערכות רוקחות תכשירידיכאון ודוחה כולינאסטרז

PHARMACEUTICAL COMPOSITIONS AND KITS CONTAINING A CHOLINESTERASE INHIBITOR AND AN ANTIDEPRESSANTTHERACOS, INC

19/11/2003

60/523610US

18/11/2004

10/993496US

PCT/US/2004/038981WO/2005/051297

A61K17566508/12/2004

מחמצן המכילים וערכות רוקחות תכשירי אנטיניופלסטי מיטוכונדריאלי גרעין וחומצת המקשר–טיול

מקשר חומר המהוה אנטיניופלסטית

PHARMACEUTICAL COMPOSITIONS AND KITS CONTAINING AN ANTINEOPLASTIC THIOL-BINDING MITOCHONDRIAL OXIDANT AND AN ANTINEOPLASTIC NUCLEIC ACID BINDING AGENTTHE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

08/12/2003

60/528181US


PCT/US/2004/041093WO/2005/055952

G01N17568019/11/2004

ביולוגי חומר לאיתור ומכשיר שיטהMETHODOLOGY AND APPARATUS FOR THE DETECTION OF BIOLOGICAL SUBSTANCESBIOWARN, LLC.

20/11/2003

60/523303US

16/11/2004

10/988709US

PCT/US/2004/037184WO/2005/081707

G06F17568415/11/2004

שימוש ידי על מידע לאחסון ומכשיר שיטהבפסים

METHOD AND APPARATUS FOR DATA STORAGE USING STRIPINGSPINNAKER NETWORKS, INC.

02/12/2003

10/727169US

PCT/US/2004/038423WO/2005/060477

A61K17574608/11/2004

ושימושים דסוקסיפגנין של פומיים תכשיריםשלהם

ORAL FORMULATIONS OF DESOXYPEGANINE AND USES THEREOFHF ARZNEIMITTELFORSCHUNG GMBH


24/11/2003

10354894.7DE

PCT/EP/2004/012606WO/2005/053698

A61K17574924/11/2004

CHAPERONE - BASED THERAPY FORניימן–פיק במחלת צ'פרון מבוסס טיפולNIEMANN-PICK DISEASEMOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY

25/11/2003

60/525497US

PCT/US/2004/041345WO/2005/051331

A61K17576223/12/2004

מותמרים טטראלינים –אמינו2ב– שימושפרקינסון מחלת של מונע לטיפול

USE OF SUBSTITUTED 2-AMINOTETRALINES FOR THE PREVENTATIVE TREATMENT OF PARKINSON'S DISEASESCHWARZ PHARMA AG

24/12/2003

10361258.0DE

PCT/EP/2004/014656WO/2005/063238

A61K17576402/12/2004


PHARMACEUTICAL PREPARATIONגאבאפנטין המכיל רוקחות תכשירCONTAINING GABAPENTINZAMBON GROUP S.P.A.

09/12/2003MI2003A002399IT

PCT/EP/2004/053233WO/2005/055993

A61K17577208/11/2004

בפסיכוזה לטיפול בדאוקסיפגנין שימושסכיזופרנית

USE OF DEOXYPEGANINE FOR TREATING SCHIZOPHRENIC PSYCHOSESHF ARZNEIMITTELFORSCHUNG GMBH

24/11/2003

10354893.9DE

PCT/EP/2004/012605WO/2005/053673

A61K17577417/12/2004

USE OF SIRAMESINE IN THEבסרטן בטיפול בסירמסין שימושTREATMENT OF CANCERH. LUNDBECK A/S

19/12/2003PA200301889DK

PCT/DK/2004/000885WO/2005/058324


A61K17578017/11/2004

במחלות לטיפול ותכשירים שיטות באמצעות פילורי בהליקובקטר הקשורותאנדופראוקסיד המכילות תרכובות

METHODS AND COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI-ASSOCIATED DISEASES USING ENDOPEROXIDE BRIDGE-CONTAINING COMPOUNDS

.VECTA LTDבר-פלד דר' אסנת אצל בע"מ וקטה19/11/2003

60/523114US

PCT/IB/2004/003759WO/2005/048912

A61K17578117/11/2004

בהפרעה טיפול עבור תגובה וחומרי שיטותדלקתית

METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERSCOMBINATORX, INC.

21/11/2003

60/524117US

PCT/US/2004/038512WO/2005/051293

A61K17579226/11/2004

לעליה כאינדיקטור בשתן צינורי חלבוןקרדיו–וסקולרי בסיכון

TUBULAR PROTEINURIA AS INDICATOR FOR ELEVATED CARDIOVASCULAR RISKSANOFI-AVENTIS DEUTSCHLAND GMBH

26/11/2003

03027312.2EP

PCT/EP/2004/013511WO/2005/051379


A61K17581206/12/2004

לטיפול [ פירימידיןD–3,2] פירולו תרכובותשתל בדחיית

PYRROLO [2,3-D] PYRIMIDINE COMPOUNDS FOR TREATING TRANSPLANT REJECTIONPFIZER PRODUCTS, INC.

17/12/2003

60/531180US

PCT/IB/2004/004034WO/2005/060972

G01V17606803/12/2004

מימדי רב ספקטרום לקבלת והתקן שיטה בסריקה משופרת חד–מימדית וספקטרא

אחת

METHOD AND APPARATUS FOR ACQUIRING MULTIDIMENSIONAL SPECTRA AND IMPROVED UNIDIMENSIONAL SPECTRA WITHIN A SINGLE SCAN

YEDA RESEARCH ANDבע"מ ופיתוח למחקר חברה ידעDEVELOPMENT CO. LTD

04/12/2003

10/728069US

PCT/US/2004/040449WO/2005/062753

H04N17633517/12/2004

OPERATOR CONTROL UNIT WITHמעקב עם למפעיל בקרה יחידתTRACKINGANTHROTRONIX, INC.

18/12/2003

10/739603US

PCT/US/2004/042353WO/2005/060666


C07K17638220/12/2004

מסוג עצבי רעלן לגילוי ותרכובות שיטהבוטולינום

METHOD AND COMPOSITIONS FOR DETECTING BOTULINUM NEUROTOXINWISCONSIN ALUMNI RESEARCH FOUNDATION

19/12/2003

60/530645US

15/06/2004

60/579254US

PCT/US/2004/042366WO/2005/076785

A61B17639302/12/2004

PATTERNED LASER TREATMENT OFהרישתית של בלייזר תבניתי טיפולTHE RETINATHE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

24/12/2003

10/745954US

PCT/US/2004/040562WO/2005/065116

H04B17643607/01/2005

להעברה פורמאט ובחירת תצריפיםאלחוטית שידור/קליטה ביחידת

TRANSPORT FORMAT COMBINATION SELECTION IN A WIRELESS TRANSMIT/RECEIVE UNIT


INTERDIGITAL TECHNOLOGY CORPORATION

09/01/2004

60/535426US

22/12/2004

11/019489US

PCT/US/2005/000571WO/2005/067659

C07K17656510/01/2005

O-LINKED GLYCOSYLATION OFחלבונים שלOלקשר– גליקולזילציהPEPTIDESNEOSE TECHNOLOGIES, INC.

08/01/2004

60/535284US

12/02/2004

60/544411US

20/02/2004

60/546631US

23/03/2004

60/555813US

12/05/2004

60/570891US

PCT/US/2005/000799WO/2005/070138

A61K17657903/12/2004

צמח תאי של בליאופיליסאט שימוש ו/או העור של לדפיגמנטציה דה–מובחנים

הבהרה

USE OF A LYOPHILISATE OF DEDIFFERENTIATED PLANT CELLS FOR SKIN DEPIGMENTATION AND/OR LIGHTENINGBIOTECHMARINE

29/12/20030315521FR

PCT/FR/2004/003109


WO/2005/072697

G06Q17658022/12/2004

תמריצים להרוויח ושיטות תשלום מערכתפיננסיים כלים שני בלפחות המשתמשות

PAYMENT SYSTEMS AND METHODS FOR EARNING INCENTIVES USING AT LEAST TWO FINANCIAL INSTRUMENTSBCD REWARDS, LLC

30/12/2003

10/748710US

PCT/US/2004/043667WO/2005/065314

C07H17659428/01/2005

ושימושיהם שוניםHB4 פוליפפטידיםMODIFIED HUMAN FOUR HELICAL BUNDLE POLYPEPTIDES AND THEIR USESAMBRX, INC.

02/02/2004

60/541528US

18/06/2004

60/581314US

18/06/2004

60/581175US

18/06/2004

60/580885US

22/12/2004

60/638616US

PCT/US/2005/003537WO/2005/074650

C12P17659528/01/2005


גדילה הורמון של שונים פוליפפטידיםושימושיהם אנושי

MODIFIED HUMAN GROWTH HORMONE POLYPEPTIDES AND THEIR USESAMBRX, INC.

02/02/2004

60/541528US

18/06/2004

60/581314US

18/06/2004

60/581175US

18/06/2004

60/580885US

22/12/2004

60/638616US

PCT/US/2005/002724WO/2005/074546

C07K17659628/01/2005

אנושי אינטרפרון של שונים פוליפפטידיםושימושיהם

MODIFIED HUMAN INTERFERON POLYPEPTIDES AND THEIR USESAMBRX, INC.

02/02/2004

60/541528US

18/06/2004

60/581314US

18/06/2004

60/581175US

18/06/2004

60/580885US

22/12/2004

60/638616US

PCT/US/2005/002599WO/2005/074524

A61K17701221/01/2005

כמעכבות ושימושן קווינוליניות תולדותמיקובקטריות

QUINOLINE DERIVATIVES AND USE THEREOF AS MYCOBACTERIAL INHIBITORSJANSSEN PHARMACEUTICA N.V.

23/01/2004

60/538907US


PCT/EP/2005/050271WO/2005/070430

A61K17715517/01/2005

THERAPEUTIC COMBINATIONSרפואיים צירופיםPFIZER INC

30/01/2004

60/540749US

01/10/2004

60/615000US

PCT/IB/2005/000101WO/2005/082362

C07C17727106/02/2005

HEPARANASE INHIBITORS ANDשלהם ושימושים הפאראנז מעכביUSES THEREOF

INSIGHT BIOPHARMACEUTICALSבע"מ ביופרמצבטיקה אינסייטLTD.

06/02/2004

60/541904US

PCT/IL/2005/000149WO/2005/074375

G01N17733022/02/2005


מסלולים דרך מולקולרי שטף קבצי סימון באמצעות הנמדדים קריטיים

ביולוגיים החי, כסמנים בגוף באיזוטופיםמחלה של ופעילות תרופות של פעילות של

MOLECULAR FLUX RATES THROUGH CRITICAL PATHWAYS MEASURED BY STABLE ISOTOPE LABELING IN VIVO, AS BIOMAKERS OF DRUG ACTION AND DISEASE ACTIVITYTHE REGENTS OF THE UNIVERSITY OF CALIFORNIA

20/02/2004

60/546580US

17/06/2004

60/581028US

PCT/US/2005/005660WO/2005/081943

A61K17764423/02/2005

ויסות עבורIV דיפפטידילפפטידאז מעכביגלוקוז של חומרים חילוף

INHIBITORS OF DIPEPTIDYLPEPTIDASE IV FOR REGULATING GLUCOSE METABOLISMTRUSTEES OF TUFTS COLLEGE

23/02/2004

60/547227US

06/08/2004

60/599336US

PCT/US/2005/006128WO/2005/082348

A61K17821527/05/2005

של האנטישחפתית הפעילות של הגברהSALICORNIA BRACHIATAמיצויי

ENHANCEMENT OF ANTITUBERCULAR ACTIVITY OF EXTRACTS OF SALICORNIA BRACHIATACOUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH

27/05/20040969DEL2004IN

PCT/IN/2005/000168WO/2005/115424


C07H17839929/04/2004

USE OF SPINOSYNS FOR WOUNDפצעים לריפוי בספינוסינס שימושHEALINGELI LILLY AND COMPANY

PCT/US/2004/011268WO/2005/112950

A61K17845829/04/2005

ממושכים במשטרים בדימום טיפולהריון למניעת הורמונליים

MANAGEMENT OF BREAKTHROUGH BLEEDING IN EXTENDED HORMONAL CONTRACEPTIVE REGIMENSBAYER SCHERING PHARMA AKTIENGESELLSCHAFT

30/04/2004

60/566443US

28/05/2004

60/575024US

07/06/2004

60/577199US

27/12/2004

60/638380US

10/03/2005

60/660068US

PCT/EP/2005/004777WO/2005/105103

G06K17889522/04/2005

פספורט, פספורט עבור חכם כרטיס לאימות ומתקן ושיטה, מערכת אלקטרוני

או חכם בכרטיס המחזיק אדם של זהותאלקטרוני פספורט

SMART CARD FOR PASSPORT, ELECTRONIC PASSPORT, AND METHOD, SYSTEM, AND APPARATUS FOR AUTHENTICATING PERSON HOLDING SMART CARD OR ELECTRONIC PASSPORTE-SMART TECHNOLOGIES, INC.


26/04/2004

10/823781US

PCT/US/2005/013896WO/2005/104704

A61K17924816/05/2005

/ICE מעכב המכילים רוקחות תכשירי1קספז–

PHARMACEUTICAL COMPOSITIONS CONTAINING AN ICE/CASPASE-1 INHIBITORVERTEX PHARMACEUTICALS INCORPORATED

15/05/2004

60/571314US

PCT/US/2005/017177WO/2005/115362

H01L17964102/06/2005

METHOD FOR TRANSFERRINGשבבים להעברת שיטהPLATESTRACIT TECHNOLOGIES

02/06/20040451085FR

PCT/FR/2005/050411WO/2005/124826

C07C18015923/06/2005

סולפונימידים, סולפונים, סולפוקסידים סולפינימידים, אצילסולפונאמידים

בלתי אלפא–ביטא ואצ'לסולפינאמידיםשלהם הרפואי רוויים, והשימוש

ALPHA, BETA-UNSATURATED SULFONES, SULFOXIDES, SULFONIMIDES, SULFINIMIDES, ACYLSULFINAMIDES AND THERAPEUTIC USES THEREOFTEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION


24/06/2004

60/583009US

PCT/US/2005/022394WO/2006/025924

C12N18019620/06/2005

הגן את הכוללים טרנסגניים צמחיםדהידרין

TRANSGENIC PLANTS CONTAINING A DEHYDRIN GENE

אוניברסיטת של הכלכלית כרמל-החברהבע"מ חיפה

CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD.

21/06/2004

60/580726US

PCT/IL/2005/000656WO/2005/122697

A23G18038420/06/2005

ICE-CONTAINING PRODUCTSקרח המכילים מוצריםUNILEVER PLC

19/07/2004

04254315.7EP

PCT/EP/2005/006700WO/2006/007924

A23G18038620/06/2005

ICE-CONTAINING PRODUCTSקרח המכילים מוצריםUNILEVER PLC

19/07/2004

04254314.0EP

19/07/2004

04254315.7EP


PCT/EP/2005/006698WO/2006/007922

C07K18057411/07/2005

פולימורפי חלבון של פנוטיפ לזיהוי שיטותMETHODS OF DETECTING A PHENOTYPE OF A POLYMORPHIC PROTEIN

ע"ש הרפואה במדעי למחקר המכוןרפפורט משפחת

RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES

12/07/2004

60/586733US

PCT/IB/2005/004185WO/2006/092669

C07H18057507/07/2005

לטיפול תרופה להכנת בממנטין שימוש לא אנטיפסיכוטיים לתכשירים משלים

סכיזופרניה לחולי טיפוסיים

THE USE OF MEMANTINE FOR THE PREPARATION OF A MEDICAMENT FOR THE ADJUNCTIVE TREATMENT TO ATYPICAL ANTIPSYCHOTICS IN SCHIZOPHRENIA PATIENTSFOREST LABORATORIES, INC.

09/07/2004

60/586553US

PCT/US/2005/024285WO/2006/017188

C07C18062208/06/2005

של לאיזומריזציה דו–מרכבית זרז מערכתקסילן

XYLENE ISOMERIZATION TWO-COMPONENT CATALYST SYSTEMEXXONMOBIL CHEMICAL PATENTS INC.

29/07/2004

10/902322US

PCT/US/2005/020413WO/2006/022991


C07C18063119/07/2005

A PHARMACEUTICAL COMPOSITIONגאבאפנטין המכיל רוקחות תכשירCOMPRISING GABAPENTINZAMBON GROUP S.P.A.

20/07/2004MI2004A001447IT

PCT/EP/2005/053473WO/2006/008295

C07C18063412/07/2005

הפחמן מדותחמוצת דלק לייצור שיטהלכוד

METHOD FOR PRODUCING FUEL FROM CAPTURED CARBON DIOXIDE

בע"מ, חברה ופיתוח מחקר אנג'יניואיטיהדרומי התעשיה מאזור ישראלית

ENGINEUITY RESEARCH & DEVELOPMENT LTD

12/07/2004

60/586869US

PCT/IL/2005/000739WO/2006/006164

C07D18064514/07/2005

CMETHODS FOR TREATING מטיפוס בצהבת לטיפול שיטהHEPATITIS CPTC THERAPEUTICS, INC

14/07/2004

60/587487US

13/12/2004

60/634979US

24/01/2005

60/645586US

28/03/2005

60/665349US

28/04/2005

60/675440US

PCT/US/2005/024881WO/2006/019831

A61K18065121/07/2005


–5 מעכבי המכילים תכשירים סלקטיבים ומאפננים אלפא–רדוקטאז

לשימושם האסטרוגן, ושיטות לקולטן

COMPOSITIONS COMPRISING 5-ALPHA REDUCTASE INHIBITORS, AND SERMS AND METHODS OF USE THEREOFGTX, INC.

21/07/2004

10/895401US

PCT/US/2005/025840WO/2006/010162

C07D18067712/07/2005

לטיפול ושיטות תרכובות, תכשיריםבמהירות, כגון, סרטן המתפשטות במחלות

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, SUCH AS CANCERIDUN PHARMACEUTICALS, INC.

12/07/2004

60/587471US

23/05/2005

60/683875US

PCT/US/2005/024700WO/2006/017295

C07K18083928/07/2005

LT אוCT טוקסין המכיל תרכיבריקומביננטי

VACCINE COMPRISING RECOMBINANT CT OR LT TOXIN

GAVISH-GALILEE BIOבע"מ יישומים ביו גביש-גלילAPPLICATIONS LTD

28/07/2004163249IL

PCT/IL/2005/000808WO/2006/011151


A61K18087925/07/2005

ו/או לעצר, להשמיד ותכשירים שיטותוירוסים להבטיל

METHODS AND COMPOSITIONS FOR INHIBITING, DESTROYING, AND/OR INACTIVATING VIRUSESSINOFRESH HEALTHCARE, INC.

23/07/2004

60/590781US

22/07/2005

11/187575US

PCT/US/2005/026138WO/2007/001323

A61B18107231/07/2005

עצם ברקמת לטיפול ומכשיר חומריםאחרות וברקמות

METHODS, MATERIALS AND APPARATUS FOR TREATING BONE AND OTHER TISSUE

DISC-O-TECH MEDICALבע"מ רפואיות טכנולוגיות דיסקוטקTECHNOLOGIES, LTD

30/07/2004

60/592149US

28/12/2004166017IL

31/01/2005

60/647784US

22/02/2005

60/654495US

PCT/IL/2005/000812WO/2006/011152

H04Q18117909/08/2005

אלחוטית גישה במערכת תקופתי טיווחרדום במצב ניידת תחנה עבור

PERIODIC RANGING IN A WIRELESS ACCESS SYSTEM FOR MOBILE STATION IN SLEEP MODE


LG ELECTRONICS INC.09/08/2004

10-2004-0062623KR

PCT/KR/2005/002582WO/2006/016765

A61K18122805/10/2005

בהם ושימושVLPאנטיגן– תצמידיכחיסונים

VLP-ANTIGEN CONJUGATES AND THEIR USES AS VACCINESCYTOS BIOTECHNOLOGY AG

05/10/2004

60/615637US

14/06/2005

05105228.0EP

PCT/EP/2005/055009WO/2006/037787

C07K18123310/08/2005

BINDING DOMAIN FUSIONלאתרים הנקשרים איחוי חלבוניPROTEINSTRUBION PHARMACEUTICALS, INC.

11/08/2004

60/600755US

PCT/US/2005/028496WO/2007/011363


A61B18126111/08/2005

גרעינית קרינה מקור של מיקומו קביעתהגוף בתוך

LOCALIZATION OF A RADIOACTIVE SOURCE WITHIN A BODY OF A SUBJECT

NAVOTEK MEDICAL LTDבע"מ מדיקל נבוטק12/08/2004

60/600725US

19/10/2004

60/619792US

19/10/2004

60/619897US

PCT/IL/2005/000871WO/2006/016368

C07D18130022/07/2005

מפעיל–רגישות חומרים של פורמולציותושימושיהן לאור

PHOTOSENSITIZER FORMULATIONS AND USES THEREOFCERAMOPTEC INDUSTRIES, INC.

16/08/2004

60/602264US

15/06/2005

11/153703US

PCT/US/2005/026051WO/2006/023194

C23C18139402/08/2005

ATMOSPHERIC PRESSUREאטמוספירי בלחץ כימיים אדים שיקועCHEMICAL VAPOR DEPOSITIONSOLAR FIELDS, LLC

18/08/2004

60/602405US

PCT/US/2005/027368WO/2006/023262

B66B18140512/08/2005

REMOVABLE SURFACE COVERINGלהורדה הניתן למשטח כיסויAZULINDUS Y MARTI, S.A


20/08/2004P200402065ES

08/02/2005P200500247ES

10/06/2005P200501392ES

PCT/ES/2005/000458WO/2006/042883

C12N18143808/09/2005

CULTURING HUMAN EMBRYONICבתרבית אדם עובר תאי גידולSTEM CELLSWISCONSIN ALUMNI RESEARCH FOUNDATION

08/09/2004

60/608040US

29/06/2005

60/695100US

PCT/US/2005/031839WO/2006/029198

C12N18148701/09/2005

SALT RESISTANT TRANSGENICלמלח עמידים טרנסגניים צמחיםPLANTS

YEDA RESEARCH AND( בע"מ1998) רה"ן תרביותDEVELOPMENT CO. LTD

02/09/2004

60/606415US

PCT/IL/2005/000932WO/2006/025059

C12N18148801/09/2005

צמחים ליצירת ויעילים למלח שמגיבים גניםלמלח עמידים טרנסגניים

SALT RESPONSIVE GENES USEFUL FOR GENERATING SALT RESISTANT TRANSGENIC PLANTS

YEDA RESEARCH AND( בע"מ1998) רה"ן תרביותDEVELOPMENT CO. LTD

02/09/2004

60/606414US

PCT/IL/2005/000933


WO/2006/025060

A61K18174025/07/2005

–NCca לתעלה המכוונים רפואיים גורמיםatpבהם לשימוש ושיטות

THERAPEUTIC AGENTS TARGETING THE NCca-atp CHANNEL AND METHODS OF USE THEREOFUNIVERSITY OF MARYLAND

18/09/2004

60/610758US

PCT/US/2005/026455WO/2006/036278

A61K18174819/09/2005

אנזימי של בחוסרים ושימושם הרכביםליזוזום

COMPOSITIONS AND THEIR USES FOR LYSOSOMAL ENZYME DEFICIENCIESUNIVERSITY OF MASSACHUSETTS

17/09/2004

60/610872US

PCT/US/2005/033300WO/2006/032039

C07H18181013/09/2005

אורידין, ושיטות המכילים תכשיריםלשימושם

COMPOSITIONS CONTAINING URIDINE, AND METHODS UTILIZING SAME


MASSACHUSETTS INSTITUTE OF TECHNOLOGY

15/09/2004

10/941025US

20/09/2004

10/944269US

26/10/2004

10/972777US

PCT/US/2005/032312WO/2006/031683

A61K18182616/09/2005

– ATP תעלת על הפועלים רפואיים גורמיםNCCAבהם לשימוש ושיטות

THERAPEUTIC AGENTS TARGETING THE NCCA-ATP CHANNEL AND METHODS OF USE THEREOFUNIVERSITY OF MARYLAND

18/09/2004

60/610758US

11/07/2005

60/698272US

PCT/US/2005/033194WO/2006/034048

A61K18192228/09/2005

METHOD FOR TREATINGהדם בכלי בדלקת לטיפול שיטהVASCULITISGENENTECH, INC.

05/10/2004

60/616104US

PCT/US/2005/034647WO/2006/041680


G06Q18193608/04/2005

A SYSTEM FOR SALE OF ENTRANCEכניסה כרטיסי למכירת מערכתTICKETSSAZKA, A.S.

01/10/2004

PUV2004-15868CZ

PCT/CZ/2005/000033WO/2006/037281

G06Q18196619/09/2005

FRAUD RISK ADVISORהונאה לסיכון יועץDIGITAL ENVOY INC.

17/09/2004

10/943454US

23/08/2005

11/209885US

PCT/US/2005/033502WO/2006/034205

A61F18205114/03/2007

בעל קירור חומר הכוללים והתקן שיטה לא להסרה מעבר מצב טמפרטורת

עוריים תת מתאים חום של פולשניתבליפידים עשירים

METHOD AND APPARATUS FOR NON-INVASIVELY REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS INCLUDING A COOLANT HAVING A PHASE TRANSITION TEMPERATUREZELTIQ AESTHETICS, INC.

17/05/2006

11/435502US

PCT/US/2007/064016WO/2007/133839

G01N18206322/09/2005


של פרוגנוזה להערכת ותכשירים שיטותהשד סרטן

METHODS AND COMPOSITIONS FOR EVALUATING BREAST CANCER PROGNOSISTRIPATH IMAGING, INC.

22/09/2004

60/611965US

22/09/2004

60/612073US

PCT/US/2005/034152WO/2006/036788

A01N18208623/09/2005

COMPOSITIONS FOR USE AGAINSTיותר או אחד פתוגן כנגד לשימוש תרכובותONE OR MORE PATHOGENSBIONEXT

24/09/2004

04447209.0EP

PCT/EP/2005/010342WO/2006/032530

A61L18210121/09/2005

תאי של והתמיינות לריבוי ושיטות תכשיריםגזע

COMPOSITIONS AND METHODS FOR STEM CELL EXPANSION AND DIFFERENTIATION

& NVR LABS LTD. NEURALבע"מ עצבי שחזור אן.וי.אר מעבדותVASCULAR RECONSTRUCTION

21/09/2004

60/611566US

08/08/2005

60/706014US

PCT/IL/2005/001007WO/2006/033103


C07K18211613/10/2005

TM NANOBODIESאמילואיד–בטא נגד לטיפול אותם המכילים ופוליפפטידים

מחלת כגון ניווניות עצביות במחלותאלצהיימר

NANOBODIES TM AGAINST AMYLOID-BETA AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF DEGENERATIVE NEURAL DISEASES SUCH AS ALZHEIMER'S DISEASEABLYNX N.V.

13/10/2004

60/618148US

20/09/2005

60/718617US

PCT/EP/2005/011018WO/2006/040153

G06Q18216023/09/2005

שימוש ידי על מקוון פרסום ניהולרווח ו/או השקעה על חזרה כגון במטריצות

MANAGING ON-LINE ADVERTISING USING METRICS SUCH AS RETURN ON INVESTMENT AND/OR PROFITGOOGLE, INC.

29/09/2004

10/953861US

PCT/US/2005/034237WO/2006/039210

A61K18219812/09/2005

אוסטיוגניים אוליגונוקליאוטיידיםושימושיהם

OSTEOGENIC OLIGONUCLEOTIDES AND USES THEREOFIMMUNOTECH S.A.

27/09/2004

04077653.6EP

PCT/EP/2005/054521WO/2006/034956


A61K18220929/09/2005

שרשרת אורך בעלי שומניים כוהליםדם תאי היווצרות כמעוררי ממוצע

MEDIUM-CHAIN LENGTH FATTY ALCOHOLS AS STIMULATORS OF HEMATOPOIESISPROMETIC BIOSCIENCES INC

01/10/2004

60/614478US

PCT/CA/2005/001490WO/2006/086871

A23G18221528/09/2005

LOW FAT FROZEN CONFECTIONERYשומן דל קפוא קונפיטורה תוצרPRODUCTUNILEVER PLC

18/10/2004

04256393.2EP

PCT/EP/2005/010579WO/2006/042632

G06Q18226519/10/2005

SYSTEM AND METHOD FORעסקאות לבצוע ושיטה מערכתRESOLVING TRANSACTIONSAPOLLO ENTERPRISE SOLUTIONS, LLC

19/10/2004

60/620131US

PCT/US/2005/037949WO/2006/045060

A61K18228707/10/2005

בטיפול המשתמשת הריון למניעת שיטההורמוני

A METHOD OF CONTRACEPTION UTILIZING HORMONAL TREATMENTDURAMED PHARMACEUTICALS, INC


07/10/2004

60/616424US

26/05/2005

60/684568US

PCT/US/2005/035997WO/2006/042021

A61K18229728/09/2005

SATUREJAריחני" ) ב"חורף שימושMONTANAלצורך שלו במיצויים ( או

בשפיכה לטיפול תרופות הכנתמוקדמת

THE USE OF WINTER SAVORY (SATUREJA MONTANA) OR THE EXTRACTS THEREOF FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF THE PREMATURE EJACULATIONINDENA S.P.A.

01/10/2004MI2004A001871IT

PCT/EP/2005/010481WO/2006/037535

C12N18232328/09/2005

T2 מסוג מהונדס הומני ריבונוקליאזושימושיו

RECOMBINANT HUMAN T2 RNASE AND USES THEREOF

של המחקר לפיתוח חברה יישוםבירושלים העברית האוניברסיטה

YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM

29/09/2004

60/613702US

PCT/IL/2005/001041WO/2006/035439


A61K18235303/10/2005

בגליקוזאמינוגליקנים המשתמשות שיטותכליה במחלות לטיפול

METHODS USING GLYCOSAMINOGLYCANS FOR THE TREATMENT OF KIDNEY DISEASE

KERYX BIOPHARMACEUTICALS, INC.

01/10/2004

60/615472US

26/10/2004

60/622332US

PCT/US/2005/035790WO/2006/039709

A61K18246230/12/2005

אורח"( נגד )"שתלGVHD במחלת טיפול דיפרופיונאט בקלומתאזון עם ולוקמיהופרדניזון

TREATMENT OF GRAFT-VERSUS-HOST DISEASE AND LEUKEMIA WITH BECLOMETHASONE DIPROPIONATE AND PREDNISONEDOR BIOPHARMA, INC.

30/12/2004

60/640178US

PCT/US/2005/047666WO/2006/072093

A61K18246413/10/2005

לשימוש ושיטות פסק רצפי לדיכוי תרכובותבהן

COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USEPTC THERAPEUTICS, INC

13/10/2004

60/617633US

13/10/2004

60/617634US

13/10/2004

60/617653US

13/10/2004

60/617655US

13/10/2004

60/617670US


03/11/2004

60/624170US

PCT/US/2005/036761WO/2006/044502

A61K18257401/11/2005

41GPRבהפרעות לטיפול שלו ומווסטים לאינסולין הקשורות

GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERSARENA PHARMACEUTICALS, INC.

03/11/2004

60/624867US

PCT/US/2005/039551WO/2006/052566

A61K18258418/10/2005

קינז ומעכב בורטזומיב עם משולב טיפולאפידרמי גדילה גורם של קולטן של

COMBINED TREATMENT WITH BORTEZOMIB AND AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORPIPERDI, BILAL

18/10/2004

60/619844US

PCT/US/2005/037324WO/2006/110175

G06Q18279102/11/2005

איבחון ושפת חיזוי לאיבחון ושיטה מערכתמחיר תוספת חיזוי

SYSTEM AND METHOD FOR PREDICTIVE ANALYSIS AND PREDICTIVE ANALYSIS MARKUP LANGUAGEVIZIANT CORPORATION

02/11/2004

60/623868US


PCT/US/2005/039223WO/2006/050245

A61K18280531/10/2005

ההתנוונות להפחתת ותכשירים שיטות חוט צד מטרשת כתוצאה הנגרמת העצביתהשדרה

METHODS AND COMPOSITIONS FOR REDUCING NEURODEGENERATION IN AMYOTROPHIC LATERAL SCLEROSISYOO, SEO HONG

01/11/2004

60/624100US

16/11/2004

60/628421US

PCT/US/2005/039089WO/2006/050165

C08G18283210/04/2007

SILICONE MODIFIED POLYUREAסיליקון מוסגל פוליאוריאהREACTAMINE TECHNOLOGY, LLC

10/04/2006

11/400956US

PCT/US/2007/009017WO/2007/120759

A61K18283707/12/2005

במחלות לטיפול ותרכובות בדיקות שיטותברטינול הקשורות

METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES


SIRION THERAPEUTICS, INC.08/12/2004

60/634449US

10/03/2005

60/660924US

11/03/2005

60/660904US

18/04/2005

60/672405US

11/07/2005

60/698512US

PCT/US/2005/044416WO/2006/063128

C07K18288424/10/2005

CYCLIZATION OF A PEPTIDEפפטיד של ציקליזציהLONZA AG

01/11/2004

04025866.7EP

18/04/2005

05008380.7EP

PCT/EP/2005/011383WO/2006/048144

A61F18298927/04/2007

לקירור טיפול בהתקן לשימוש קור מגן עשירים עוריים תת תאים של משופר

בליפידים

CRYOPROTECTANT FOR USE WITH A TREATMENT DEVICE FOR IMPROVED COOLING OF SUBCUTANEOUS LIPID-RICH CELLSZELTIQ AESTHETICS, INC.

28/04/2006

60/795799US

27/04/2007

11/741271US


PCT/US/2007/067638WO/2007/127924

A61K18309316/11/2005

METHODS AND COMPOSITIONS FORבכאב לטיפול והרכבים שיטותTREATING PAINLIMERICK NEUROSCIENCES, INC.

16/11/2004

60/628646US

PCT/US/2005/041608WO/2006/055672

C07K18310911/11/2005

ANTIINFECTIVE LIPOPEPTIDESזיהום נוגדי ליפופפטידיםCUBIST PHARMACEUTICALS, INC.

12/11/2004

60/627056US

23/08/2005

60/710705US

PCT/US/2005/040919WO/2006/110185

A61K18311508/11/2005

בתרכובות המשתמשים והרכבים שיטות של וניהול לטיפול אימונומודולטוריות

טפיליות מחלות

METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT AND MANAGEMENT OF PARASITIC DISEASESCELGENE CORPORATION

12/11/2004

60/626975US

PCT/US/2005/040823WO/2006/053160

A61K18312914/11/2005


LIPASE INHIBITORSליפאז מעכביTRUSTEES OF TUFTS COLLEGE

12/11/2004

60/627476US

PCT/US/2005/041022WO/2006/053250

A61K18313428/11/2005

S1PDOSAGE REGIMEN OF AN S1P קולטן של לאגוניסט מינון תכניתRECEPTOR AGONISTNOVARTIS AG

29/11/2004

60/631483US

PCT/US/2005/043044WO/2006/058316

A61K18313828/11/2005

ומעכבי איפוטילונים הכוללים שילוביםהרפואיים קינאזות, ושימושיהם טירוזין

COMBINATIONS COMPRISING EPOTHILONES AND PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USES THEREOFNOVARTIS AG

30/11/2004

60/631837US

PCT/US/2005/042975WO/2006/060331

A61P18315210/11/2005

קפסידים: ארילHIV–1 הווצרות מעכבי מותמרות אוריאות תיאזול אמינומתיל

שלהן ואנלוגים

INHIBITORS OF HIV-1 CAPSID FORMATION: SUBSTITUTED ARYL AMINOMETHYL THIAZOLE UREAS AND ANALOGUES THEREOFUNIVERSITY OF MARYLAND, BALTIMORE COUNTY

11/11/2004

60/626902US

PCT/US/2005/041358WO/2006/053323


G06F18315501/12/2005

תלת–ממדית הדמיה עבור גראפי ממשקIN–VIVO

GRAPHICAL USER INTERFACE FOR 3-D IN-VIVO IMAGINGXENOGEN CORPORATION

06/12/2004

11/006294US

PCT/US/2005/043978WO/2006/062914

C07K18315814/11/2005

קישור יכולת בעליFC של וריאנטיםFCRN ל שינוי שעברה

FC VARIANTS WITH ALTERED BINDING TO FCRNXENCOR, INC

12/11/2004

60/627763US

11/01/2005

60/642886US

02/02/2005

60/649508US

15/03/2005

60/662468US

06/04/2005

60/669311US

16/05/2005

60/681607US

13/06/2005

60/690200US

05/07/2005

60/696609US

27/07/2005

60/703018US

12/10/2005

60/726453US

PCT/US/2005/041220WO/2006/053301

A61J18317818/11/2005


PHARMACEUTICAL PRODUCTרוקחות תוצרSMITHKLINE BEECHAM CORPORATION

19/11/2004

60/629838US

14/03/2005

60/661552US

PCT/US/2005/042216WO/2006/055928

A61K18319217/11/2005

BA METHOD OF MODULATING B תאי של תפקוד לוויסות שיטהCELL FUNCTIONINGANGIOGEN PHARMACEUTICALS PTY. LTD.

17/11/2004

60/628935US

PCT/AU/2005/001754WO/2006/053390

A61K18321217/11/2005

מותכות והטרוציקליות ציקליות תרכובות רוקחות ותכשירי לטובולין המתקשרות

אותן המכילים

FUSED CYCLIC AND HETEROCYCLIC COMPOUNDS WHICH BIND TO TUBULIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMETHRESHOLD PHARMACEUTICALS, INC.

22/11/2004

60/630422US

14/10/2005

60/726928US

PCT/US/2005/042095WO/2006/057946


A23G18325719/12/2005

FROZEN AERATED CONFECTIONSמאווררות קפואות מרקחותUNILEVER PLC

23/12/2004

04258092.8EP

PCT/EP/2005/014241WO/2006/066979

G06F18329917/11/2005

ביומטרי זיהוי ו/או לאימות ושיטות מערכותMETHODS AND SYSTEMS FOR USE IN BIOMETRIC AUTHENTICATION AND/OR IDENTIFICATIONTRIAD BIOMETRICS, LLC

19/11/2004

60/629295US

PCT/US/2005/041687WO/2006/055714

A61K18330722/11/2005

מתווכות והפרעות בסרטן הטיפול הגברת1–HIFאדנוזין לרצפטור אנטגוניסטים ע"י 3 A

ENHANCING TREATMENT OF CANCER AND HIF-1 MEDIATED DISORDERS WITH ADENOSINE A3 RECEPTOR ANTAGONISTSKING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC.

22/11/2004

60/630557US

PCT/US/2005/042551WO/2007/040565


A61K18331022/11/2005

HIF–1 מתווכות בהפרעות הטיפול הגברת3A אדנוזין רצפטור של אגוניסטים ע"י

ENHANCING TREATMENT OF HIF-1 MEDIATED DISORDERS WITH ADENOSINE A3 RECEPTOR AGONISTSKING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC.

22/11/2004

60/630555US

PCT/US/2005/042552WO/2006/055970

G06Q18331422/11/2005

לחשבון הקשור חיוב כרטיס טכנולוגיתנאנמות

TRUST-LINKED DEBIT CARD TECHNOLOGYALAIN L. DE LA MOTTE

22/11/2004

60/630234US

22/11/2004

60/630233US

PCT/US/2005/042566WO/2006/055972

C07D18332122/11/2005

המעכבות כרומנילאוראה תרכובות )1 תת–סוג רצפטור הוונילואיד רצפטור

VR1ושימושיהן )

CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOFABBOTT LABORATORIES

24/11/2004

60/630636US

PCT/US/2005/042545


WO/2006/065484

A61K18332918/11/2005

במערכת בפגיעה לטיפולJNK מעכביהמרכזית העצבים

JNK INHIBITORS FOR TREATMENT OF CNS INJURYCELGENE CORPORATION

23/11/2004

60/630598US

PCT/US/2005/042330WO/2006/058007

A61K18334902/12/2005

לטיפול3אומגה– שומן בחומצות שימוש טיפול עקב הנגרמת בדם כולסטרול ביתר נדבקו אשר חולים של רטרו–וירוסים נוגדHIVב–

USE OF OMEGA-3 FATTY ACID(S) FOR TREATING HYPERCHOLESTEROLEMIA CAUSED BY ANTI-RETROVIRAL TREATMENT OF HIV-INFECTED PATIENTSPIERRE FABRE MEDICAMENT

03/12/20040412862FR

PCT/EP/2005/056431WO/2006/058920

C07K18335323/12/2005

POLYPEPTIDES THAT BIND BR3 ANDבהם ושימוש3BR הקושרים פוליפפטידיםUSES THEREOFGENENTECH, INC.

31/12/2004

60/640323US

PCT/US/2005/047072April 13, 2008 –התשס"ח ח' בניסן 510

WO/2006/073941

C07K18340024/11/2005

של כמעכבים חדשים, שימושים פפטידים6/–2–CASPASEהביולוגיים ושימושים

NEW PEPTIDES USEFUL AS DUAL CASPASE-2/-6 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONSTHERAPTOSIS S.A.

24/11/2004

60/630249US

PCT/EP/2005/013976WO/2006/056487

H04J18341223/11/2005

של מסונכרן לביצוע והתקנים שיטותתקשורת חיבור לאורך פקודות

METHODS AND SYSTEMS FOR SYNCHRONOUS EXECUTION OF COMMANDS ACROSS A COMMUNICATION LINKQUALCOMM INCORPORATED

24/11/2004

60/630853US

PCT/US/2005/042415WO/2006/058053

A61K18342416/11/2005

AN IMPLANT FOR INTRAOCULARתוך–עינית תרופה מתן עבור שתלDRUG DELIVERYTHERAKINE CORPORATION

24/11/2004

60/630751US

PCT/US/2005/041330WO/2006/057859

G06F18342621/11/2005

MEDIA CONTENT PROTECTIONמדיה תוכן הגנתHADAS ARNONהדס ארנון

26/11/2004

60/630565US


PCT/IL/2005/001227WO/2006/056973

G06Q18351928/11/2005

תוכנה יישומי להגנת ומערכת שיטהמפירטיות

A METHOD AND SYSTEM FOR PROTECTING A SOFTWARE APPLICATION FROM PIRACY

ALADDIN KNOWLEDGE SYSTEMSבע"מ מידע מערכות אלדיןLTD.

29/11/2004

60/631150US

22/07/2005

11/186854US

PCT/IL/2005/001264WO/2006/056993

E04B18354030/11/2005

וציוד וקליעים לרסיסים הכלה מערכותלייצורן ושיטות

SHRAPNEL AND PROJECTILE CONTAINMENT SYSTEMS AND EQUIPMENT AND METHODS FOR PRODUCING SAMELIFE SHIELD ENGINEERED SYSTEMS, LLC,

01/12/2004

60/632074US

12/01/2005

60/642991US

PCT/US/2005/042983WO/2007/073363

C07K18358505/12/2005

EIF–5Aלאפופטוזיס ייחודיים להם המקודדים ופולינוקלאוטידים

APOPTOSIS-SPECIFIC EIF-5A AND POLYNUCLEOTIDES ENCODING SAMESENESCO TECHNOLOGIES, INC.

03/12/2004

60/632514US

31/03/2005

60/666626US


29/04/2005

60/675884US

26/08/2005

60/711397US

PCT/US/2005/044266WO/2006/060823

A61K18358702/12/2005

[0.2.3] בתרכובות לשימוש שיטותותולדותיהן הטרוציקליות

METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOFNEREUS PHARMACEUTICALS, INC.

03/12/2004

60/633379US

13/01/2005

60/643922US

04/03/2005

60/658884US

29/04/2005

60/676533US

PCT/US/2005/044091WO/2006/060809

A61K18361020/01/2006

פוליפפטידים תערובות לייצור תהליךהידרוגנוליזה על–ידי

PROCESS FOR PRODUCING POLYPEPTIDE MIXTURES USING HYDROGENOLYSIS

TEVA PHARMACEUTICALבע"מ פרמצבטיות תעשיות טבעINDUSTRIES LTD.

02/02/2005

60/649442US

PCT/US/2006/002351WO/2006/083608

C07K18371021/12/2005

CONJUGATION PRODUCTמצומד תוצרApril 13, 2008513 –התשס"ח ח' בניסן

MOLMED SPA23/12/2004

60/638158US

PCT/IB/2005/004058WO/2006/067633

G01N18372319/12/2005

קישור יכולת בעלות מולקולות מערבי, נילוס נגיף לנטרל היכולות

בהן ושימושים

BINDING MOLECULES CAPABLE OF NEUTRALIZING WEST NILE VIRUS AND USES THEREOFCRUCELL HOLLAND B.V.

20/12/2004PCT/EP2004/053609EP

12/05/2005PCT/EP2005/052160EP

08/06/2005PCT/EP2005/052648EP

23/06/2005PCT/EP2005/052946EP

15/08/2005PCT/EP2005/054002EP

PCT/EP/2005/056926WO/2006/067122

A61K18374403/12/2005

MEDICAMENT FOR HYGIENICהאוזן בתוך הגייני באופן למתן תרופהAPPLICATION INSIDE THE EARBAYER HEALTHCARE AG

09/12/2004

102004059220.9DE

17/11/2005

102005055385.0DE

PCT/EP/2005/012978


WO/2006/061156

A61K18376217/01/2006

DIRECT COMPRESSIONותהליך ישירה דחיסה של תכשיריםFORMULATION AND PROCESSNOVARTIS AG

18/01/2005

60/644645US

14/06/2005

60/690484US

PCT/US/2006/001473WO/2006/078593

A61L18378406/12/2005

זרימות תרכובות של למתן ושיטות חומריםמינימלית תאים, בחודרניות המכילות

MATERIALS AND METHODS FOR MINIMALLY-INVASIVE ADMINISTRATION OF A CELL-CONTAINING FLOWABLE COMPOSITIONPERVASIS THERAPEUTICS, INC.

08/12/2004

60/634155US

21/03/2005

60/663859US

18/05/2005

60/682054US

PCT/US/2005/043967WO/2006/062909

G06F18537416/02/2006


עבור בטוחה אוניברסאלית תצורה תוכנתמצרר כלי

SECURE UNIVERSAL CONFIGURATION SOFTWARE FOR CLUSTER TOOLSLAM RESEARCH CORPORATION

25/02/2005

60/656862US

31/03/2005

11/097839US

PCT/US/2006/005636WO/2006/093691

G06Q18641606/04/2006

תוך–יומי ערך לחישוב ומערכת שיטה ממונפות סחירות קרנות של אינדיקטיבי

מחירים וירידת לעליית נטייה בעלות

METHOD AND SYSTEM FOR CALCULATING AN INTRADAY INDICATIVE VALUE OF LEVERAGED BULLISH AND BEARISH EXCHANGE TRADED FUNDSPROFOUND ADVISORS, LLC

06/04/2005

60/668601US

26/09/2005

60/719985US

05/04/2006

11/397902US

PCT/US/2006/012717WO/2006/108062

G06F18647721/02/2001

הכוללת מסמכים ליצירת גלובלית מערכתמנהלי שרת מחשב

GLOBAL DOCUMENT CREATION SYSTEM INCLUDING ADMINISTRATIVE SERVER COMPUTERDICTAPHONE CORPORATION

29/02/2000

09/515902US

PCT/US/2001/005402WO/2001/065333


H04L18648801/06/2006

של סיגנל קולט של רגישות למדידת שיטהמידע חבילת

METHOD FOR MEASURING SENSITIVITY OF DATA PACKET SIGNAL RECEIVERLITEPOINT CORPORATION

01/06/2005

10/908946US

PCT/US/2006/021190WO/2006/130732

G06F18657022/03/2006

NATIVE SCRAMBLING SYSTEMצפנים המערבלת מערכתNDS LIMITED

02/05/2005168337IL

09/05/2005168496IL

20/09/2005170987IL

PCT/IL/2006/000367WO/2006/117775

G06K18675727/04/2006

IMAGE COMPARISON BY METRICמטרי קיבוע באמצעות דמויות השוואתEMBEDDINGSMICROSOFT CORPORATION

31/05/2005

11/141362US

PCT/US/2006/016609WO/2006/130292

A23G18702511/05/2006


ושיטה איזומלטולוז המכיל קשית קרמלליצורו

HARD CARAMEL CONTAINING ISOLMALTULOSE AND PROCESS FOR THE MANUFACTURE THEREOFSUDZUCKER AKTIENGESELLSCHAFT MANNHEIM/OCHSENFURT

11/05/2005

102005022601.9DE

PCT/EP/2006/004418WO/2006/119991

B66C18729003/11/2005

של ובקרה להנעה הידראולים מנועים המטפלים במנופים תנודות נוגדת מערכת

במיכלים

HYDRAULIC MOTORS FOR ACTUATING AND CONTROLLING AN ANTI-SWING SYSTEM IN CONTAINER-HANDLING CRANESMAERSK ESPANA S.A.

10/05/2005P200501200ES

PCT/ES/2005/000607WO/2006/136620

B01F18729211/05/2006

ראשוניות גז תערובות לייצור שיטהסטנדרטיות

SYSTEM FOR PRODUCING PRIMARY STANDARD GAS MIXTURESPRAXAIR TECHNOLOGY, INC.

12/05/2005

11/127144US

PCT/US/2006/018264WO/2006/124519

C12P18729310/05/2006

גליקוזילציה שעברו רקומביננטיים חלבוניםפרוקריוטים מתאיםN באתר

RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLSEIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH

11/05/2005

05010276.3EP


PCT/EP/2006/004397WO/2006/119987

H01F18729505/05/2006

ELECTRONIC COMPONENT ANDלהתקנתו ושיטה אלקטרוני רכיבMETHOD FOR FIXING THE SAMEWURTH ELEKTRONIK IBE GMBH

13/05/2005

102005022927.1DE

PCT/EP/2006/004206WO/2006/122660

B64C18729612/05/2006

מודל ידי על קולי על בום תופעת בחינתמוקטן

SUB-SCALE SONIC BOOM MODELINGGULFSTREAM AEROSPACE CORPORATION

12/05/2005

60/679980US

12/05/2005

60/680017US

PCT/US/2006/018485WO/2007/086917

H04L18729716/05/2006

למספר מוגבל לא לרישוי ומערכת שיטהמכשירים של קבוע

SYSTEM AND METHOD FOR UNLIMITED LICENSING TO A FIXED NUMBER OF DEVICESNAPSTER LLC

24/05/2005

11/137347US

PCT/US/2006/019103WO/2006/127359

E04H18729902/05/2006

ADAPTABLE NOZZLE ATTACHMENTבריכה למנקה צינור פי של מותאם חיבורFOR POOL CLEANER


WATER TECH LLC26/05/2005

11/139093US

PCT/US/2006/017790WO/2006/127259

C07D18730126/04/2006

–6 של נגזרות של לסינתזה שיטותאלקילאמינוקווינולין

METHODS OF SYNTHESIZING 6 - ALKYLAMINOQUINOLINE DERIVATIVESWYETH

25/05/2005

60/685040US

PCT/US/2006/015931WO/2006/127203

C07D18730211/05/2006

של לרצפטור כאגוניסטים הטרוציקליםבדיסליפידמיה לטיפול ניקוטינית חומצה

HETEROCYCLES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIASCHERING CORPORATION

17/05/2005

60/681848US

09/09/2005

60/715565US

28/10/2005

60/731039US

PCT/US/2006/018186WO/2006/124490

C07C18730327/04/2006

קווינולינים – – ציאנו3 להכנת שיטותאלו שיטות ע"י הנוצרים ביניים ותוצרי

METHODS OF PREPERING 3 - CYANO - QUINOLINES AND INTERMEDIATES MADE THEREBYWYETH

25/05/2005

60/684683US

PCT/US/2006/016019WO/2006/127205


C07D18730411/05/2006

IV פפטידאז דיפפטידיל של מעכביםושיטות פירולופירידין על המבוססים

PYRROLOPYRIDINE - BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODSBRISTOL-MYERS SQUIBB COMPANY

20/05/2005

60/682968US

09/05/2006

11/430657US

PCT/US/2006/018185WO/2006/127287

B65D18730715/05/2006

CLOSURE SYSTEM AND METHOD OFבקבוקון למילוי ושיטה סגירה מערכתFILLING A VIALGLAXOSMITHKLINE BIOLOGICALS S.A.

17/05/2005

0510057.3GB

PCT/EP/2006/004629WO/2006/122757

C07K18730805/06/2006

פוקוזיל רמות בעלי נוגדנים ליצור שיטהמותאמות

METHOD OF PRODUCING ANTIBODIES WITH MODIFIED FUCOSYLATION LEVELGENENTECH, INC.

03/06/2005

60/687625US


14/11/2005

60/736982US

PCT/US/2006/021854WO/2006/133148

A61K18730923/05/2006

בנידודי לטיפול ושיטות מוצקים תכשיריםהלילה באמצע שינה

SOLID COMPOSITIONS AND METHODS FOR TREATING MIDDLE-OF-THE NIGHT INSOMNIATRANSCEPT PHARMACEUTICALS, INC.

25/05/2005

60/684842US

01/12/2005

60/741673US

31/03/2006

60/788340US

31/03/2006

60/788249US

PCT/US/2006/020502WO/2006/128022

C07D18731028/06/2006

P38BICYCLIC DERIVATIVES AS P38 קינאז כמעכבות ביציקליות תולדותKINASE INHIBITORSPALAU PHARMA S.A.

29/06/2005

05380140.3EP

PCT/EP/2006/006255WO/2007/000339


C07D18731112/05/2006

–מותמרותN,N –אמינופירולידין3 תרכובות של מחדש ספיגה כמעכבי המשמשותמונואמינים

N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORSOTSUKA PHARMACEUTICAL CO, LTD

13/05/2005

2005-141230JP

PCT/JP/2006/309988WO/2006/121218

G09G18731212/05/2006

INPUT DEVICE INCLUDING Aגלילה גלגל הרכב הכולל קלט התקןSCROLL WHEEL ASSEMBLYMICROSOFT CORPORATION

28/06/2005

11/167286US

PCT/US/2006/018751WO/2007/001667

G06T18731322/05/2006

SYSTEM AND METHOD FORחוטים של פאסיבי לגילוי ושיטה מערכתPASSIVE WIRE DETECTIONTHE BOEING COMPANY

19/07/2005

11/184472US

PCT/US/2006/019542WO/2007/011450

B32B18731410/07/2006

העמידים ניילון מצופי חומרים ליצור שיטה מערכת של תאים תרמול עבור לשחיקהסולרית

METHOD FOR PRODUCING WEATHER-RESISTANT IAMINATES FOR ENCAPSULATING SOLAR CELL SYSTEMSISOVOLTA AG


21/07/2005A1230/2005AT

PCT/AT/2006/000295WO/2007/009140

E21D18731514/12/2006

FLUID RECOVERYבחזרה נוזל קבלתATLAS COPCO MAI GMBH

19/01/2006A87/2006AT

PCT/AT/2006/000516WO/2007/082319

C07K18731631/05/2006

2ANTI-INTERLEUKIN 2 ANTIBODIES אינטרלוקין נגד נוגדניםMICROMET AG

01/06/2005

05011845.4EP

PCT/EP/2006/005194WO/2006/128690

C07K18731717/05/2006

רוקחות ותכשירי פוליפפטידי תצמידאותו המכילים

A POLYPEPTIDE COMPLEX AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMEUNIVERSITY OF CONNECTICUT HEALTH CENTER

17/05/2005

60/681663US

17/05/2006

11/435497US

PCT/US/2006/019403WO/2007/001677

A61K18731801/06/2006


נגד מנטרל נוגדון המכילים רוקחות תכשירי לטיפול אנושי הפטוציט גדילת גורם

במוח ממאירים בגדולים

PHARMACEUTICAL COMPOSITIONS CONTAINING A NEUTRALIZYING ANTI-HUMAN HEPATOCYTE GROWTH FACTOR ANTIBODY FOR TREATING BRAIN TUMORSTHE JOHNS HOPKINS UNIVERSITY

02/06/2005

60/687118US

15/12/2005

60/751092US

PCT/US/2006/021293WO/2006/130773

C07F18731931/03/2006

–סליצילית5 או4 חומצה תולדותאותן המכילים רוקחות ותכשירי

DERIVATIVES OF 4 OR 5-AMINO-SALICYLIC ACID AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMEANTIBE THERAPEUTICS INC.

27/05/2005PCT/CA2005/000819CA

PCT/CA/2006/000484WO/2006/125295

C07K18732111/05/2006

מארח לתאי ספציפיות מולקולות לנטרל היכולות קישור יכולת בעלותבהן ושימושים נגיפים

HOST CELL SPECIFIC BINDING MOLECULES CAPABLE OF NEUTRALIZING VIRUSES AND USES THEREOFCRUCELL HOLLAND B.V.

12/05/2005PCT/EP2005/052160EP

08/06/2005PCT/EP2005/052648EP

23/06/2005PCT/EP2005/052946EP

15/08/2005PCT/EP2005/054002EP

PCT/EP/2006/062250WO/2006/120230


G01S18732212/05/2006

OBJECT DETECTION METHOD ANDעצמים לאיתור והתקן שיטהAPPARATUSTHE MACALEESE COMPANIES, INC. DBA SAFE ZONE SYSTEMS

12/05/2005

60/680627US

PCT/US/2006/018452WO/2007/086916

A61K18732312/05/2006

במחלות לטיפול אנטי–אנגיוגניים חומריםדלקתיות מעיים

TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) WITH ANTIANGIOGENIC COMPOUNDSATTENUON. LLC

12/05/2005

60/679977US

PCT/US/2006/018463WO/2006/124611

C03B18732419/04/2006

ויריעת זכוכית ליריעת כפוף ותחנת שיטהבהתאם מכופפת זכוכית

GLASS SHEET BENDING STATION AND METHOD AND RESULTING BENT GLASS SHEETGLASSTECH, INC.

13/05/2005

11/128450US

PCT/US/2006/014725WO/2006/124185

A01N18732515/05/2006

IMPROVED FISH PRODUCTIONמשופר דגים ייצור


ELI LILLY AND COMPANY26/05/2005

60/684886US

PCT/US/2006/018797WO/2006/127322

C07D18732622/05/2006

בנזאזפיניום של נגזרת של גבישית צורהמאלאט

CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVEGLAXO GROUP LIMITED

24/05/2005

0510599.4GB

PCT/EP/2006/004954WO/2006/125622

A01N18732710/05/2006

METHODS FOR TREATING DRUGלתרופות עמיד בסרטן לטיפול שיטותRESISTANT CANCERNOVARTIS AG

13/05/2005

60/680722US

PCT/US/2006/017922WO/2006/124413

C07D18732829/03/2006

DIARYLHYDANTOIN COMPOUNDSדיארילהידנתוין של תרכובותTHE REGENTS OF THE UNIVERSITY OF CALIFORNIA

13/05/2005

60/680835US

15/12/2005

60/750351US

06/01/2006

60/756552US

PCT/US/2006/011417WO/2006/124118


C07C18732912/06/2006

מתילבנזיל–אלכוהול של תהליך תוצרגרעינית הלוגנציה שעבר

PRODUCTION PROCESS OF NUCLEUS-HALOGENATED METHYLBENZYL ALCOHOLSHOWA DENKO K.K.

22/06/2005

2005-182323JP

PCT/JP/2006/312193WO/2006/137348

F25D18733024/05/2006

שבעל בניהול לשימוש הרכב לסימון שיטהפה

A METHOD OF MARKING COMPOSITION FOR ORAL ADMINISTRATIONEISAI R & D MANAGEMENT CO. LTD.

26/05/2005

2005-154745JP

PCT/JP/2006/310301WO/2006/126561

A61L18733117/05/2006

הניתנים קולגן מוצרי של סופי עיקורלהזרקה

TERMINAL STERILIZATION OF INJECTABLE COLLAGEN PRODUCTSALBIOREX, LLC

19/05/2005

60/682507US

PCT/US/2006/019064WO/2006/124988

G06K18733211/05/2006

ENDOSCOPIC MEASUREMENTאנדוסקופיות מדידה טכניקותTECHNIQUES

.G.I. VIEW, LTDבע"מ גי.איי.וויו13/05/2005

60/680599US

PCT/IL/2006/000563WO/2006/120690


F25D18733410/04/2006

טמפרטורה מבורקי פריטים להובלת מיכלCONTAINER FOR TRANSPORTING TEMPERATURE CONTROLLED ITEMSAMERICAN THERMAL WIZARDS INTERNATIONAL, INC.

17/05/2005

60/681769US

17/05/2005

60/681774US

17/05/2005

60/681770US

18/05/2005

60/682318US

17/11/2005

11/281548US

17/01/2006

11/333194US

30/04/2006

11/278506US

PCT/US/2006/013247WO/2006/124149

A61B18733512/05/2006

הדמייה קופסית ושיטות התקנים, מערכותחי בגוף הדמייה יישומי עבור

CAPSULE IMAGING DEVICES, SYSTEMS AND METHODS FOR IN VIVO IMAGING APPLICATIONS


THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

13/05/2005

60/680580US

02/12/2005

60/742199US

PCT/US/2006/018513WO/2006/124648

A61B18733618/05/2006

DYNAMIC SPINE STABILIZERדינמי שידרה עמוד מייצבYALE UNIVERSITY

19/05/2005

11/132538US

PCT/US/2006/019412WO/2006/125142

C01G18733731/05/2006

NIOBIUM SUBOXIDESסאבאוקסידים ניוביוםH. C. STARCK GMBH

03/06/2005

0511321.2GB

06/02/2006

0602330.3GB

PCT/EP/2006/005184WO/2006/128687

H01G18733801/06/2006

CAPACITORקבלH. C. STARCK GMBH

03/06/2005

0511321.2GB


06/02/2006

0602330.3GB

PCT/EP/2006/005220WO/2006/128698

C12N18734124/05/2006

SCALABLE FERMENTATIONבסקלה לאמידה שניתן תסיסה תהליךPROCESSCYTOS BIOTECHNOLOGY AG

26/05/2005

05011416.4EP

21/07/2005

05106729.6EP

PCT/EP/2006/062628WO/2006/125821

G08B18734219/05/2006

A REMOTE SENSING ANDמרוחקת ותקשורת חישה מערכתCOMMUNICATION SYSTEMHADRONEX, LLC.

20/05/2005

11/134691US

PCT/US/2006/019497WO/2006/127479

C07K18734314/06/2006

בגידול וטיפול לאבחון ושיטות תכשיריםCOMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORGENENTECH, INC.

20/06/2005

60/692092US

21/04/2006

60/793951US

PCT/US/2006/023099WO/2007/001851


C07D18734416/05/2006

ו–C– KIT פעילות מאפננות תרכובותFMS–Cשלהן ושימושים

COMPOUNDS MODULATING C-KIT AND C-FMS ACTIVITY AND USES THEREFORPLEXXIKON, INC.

17/05/2005

60/682063US

17/05/2005

60/682051US

17/05/2005

60/682042US

22/06/2005

60/692750US

22/06/2005

60/692960US

PCT/US/2006/018726WO/2007/013896

G01R18734508/06/2006

חיבור עם חשמלי מגע לבדיקת אמצעיתואם פנימי

ELECTRICAL CONTACT PROBE WITH COMPLIANT INTERNAL INTERCONNECTDELAWARE CAPITAL FORMATION, INC.

10/06/2005

60/689755US

PCT/US/2006/022311WO/2006/135680

C07J18734618/05/2006


ושימושים כתרסיס פלואורוקווינולוניםשלהם

AEROSOLIZED FLUOROQUINOLONES AND USES THEREOFMPEX PHARMACEUTICALS, INC.

18/05/2005

60/682530US

01/07/2005

60/696160US

13/02/2006

60/773300US

PCT/US/2006/019351WO/2006/125132

C07K18734724/05/2006

IGGINTERFERON-IGG FUSIONו– אנטרפרון של איחויSCHERING CORPORATION

26/05/2005

60/685018US

PCT/US/2006/020000WO/2006/127757

C12N18734814/05/2005

PIGGYBACלמניפולציה עבודה ככלי בחולייתנים ואנליזה גנטית

PIGGYBAC AS A TOOL FOR GENETIC MANIPULATION AND ANALYSIS IN VERTEBRATESFUDAN UNIVERSITY

PCT/CN/2005/000674WO/2006/122442

A61M18734907/04/2006

האף לחלל תרופה העברת מערכתנשימה באמצעות המופעלת

BREATH ACTUATED NASAL DRUG DELIVERY SYSTEMKOS LIFE SCIENCES, INC.

27/06/2005

11/160493US

PCT/US/2006/012949WO/2007/001585


A61C18735108/05/2006

קרינה הפולטת שיניים מברשת לניקוי תכשיר ומערכת אלקטרומגנטית

שיניים

ELECTROMAGNETIC RADIATION EMITTING TOOTHBRUSH AND DENTIFRICE SYSTEMBIOLASE TECHNOLOGY, INC.

18/05/2005

60/682752US

06/06/2005

60/688109US

23/11/2005

60/739314US

PCT/US/2006/019630WO/2006/125204

C12N18735217/05/2006

אנושיים עובריים גזע תאי קו של ייסודיונק בתאי שימוש ידי על

ESTABLISHMENT OF A HUMAN EMBRYONIC STEM CELL LINE USING MAMMALIAN CELLSRELIANCE LIFE SCIENCES PVT. LTD.

17/05/2005

595/MUM/2005IN

17/05/200611/436193US

PCT/IN/2006/000169WO/2007/020655

C07D18735317/05/2006

ושיטותMEK של הטרוסיקליקים מעכביםבהם שימוש

HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOFASTRAZENECA AB

18/05/2005

60/682335US

PCT/US/2006/019108WO/2007/044084


A61K18735405/06/2006

הרצפטור פפטיד של פורמולציותלאריתרופואטין, ושימושיהם

ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USESAFFYMAX, INC.

03/06/2005

60/687655US

PCT/US/2006/021845WO/2006/133144

B65H18735626/05/2006

IMPROVED REEL AND REELלסליל ובית משופר סלילHOUSINGGREAT STUFF, INC.

31/05/2005

60/686236US

21/07/2005

11/187187US

PCT/US/2006/020868WO/2006/130583

F16J18735710/10/2006

LOW WEAR PISTON SLEEVEנמוכה שחיקה בעלת בוכנה מעטפתRAYTHEON COMPANY

20/10/2005

11/255432US

PCT/US/2006/039447WO/2007/047220


C07C18735825/05/2006

–9 להכנת ושיטות טיגציקליןאמינומינוציקלין

TIGECYCLINE AND METHODS OF PREPARING 9-AMINOMINOCYCLINEWYETH

27/05/2005

60/685146US

PCT/US/2006/020536WO/2006/130500

C07C18735925/05/2006

טיגציקלין של מוצקות גבישיות צורותלהכנתן ושיטות

CRYSTALLINE SOLID FORMS OF TIGECYCLINE AND METHODS OF PREPARING SAMEWYETH

27/05/2005

60/684955US

PCT/US/2006/020871WO/2006/128150

C07C18736025/05/2006

TIGECYCLINE AND METHODS OFלהכנתו ושיטות טיגציקליןPREPARATIONWYETH

27/05/2005

60/685285US

PCT/US/2006/020229WO/2006/130418

C07C18736125/05/2006

METHODS OF PURIFYINGטיגציקלין לטיהור שיטותTIGECYCLINEWYETH

27/05/2005

60/685626US


WO/2006/130431

A01N18736230/05/2006

אנטי כגורמים –פנילטריאזול1 של תולדותפרזיטיים

DERIVATIVES OF A 1-PHENYLTRIAZOLE AS ANTIPARASITIC AGENTSBASF AKTIENGESELLSCHAFT

03/06/2005

60/687027US

PCT/EP/2006/062719WO/2006/128867

B32B18736313/06/2006

המכיל מרכיבים מרובה מעוצב גוףפוליאסטר שכבות

MULTIPLE COMPONENT MOULDED BODY COMPRISING POLYESTER LAYERSBASF AKTIENGESELLSCHAFT

14/06/2005

102005027549.4DE

PCT/EP/2006/063167WO/2006/134115

B65H18736423/05/2006

RECIPROCATING MECHANISM FORגלגול מכלול עבור השבה מנגנוןA REEL ASSEMBLYGREAT STUFF, INC.

27/05/2005

60/685637US

10/02/2006

60/772455US

PCT/US/2006/019726WO/2006/130377

A61K18758525/05/2006


TWEAK BINDING ANTIBODIESצובט באופן הנקשרים נוגדניםBiogen Idec MA Inc.

27/05/2005

60/685149US

PCT/US/2006/019706WO/2006/130374

A61N18774430/05/2006

אוסטאוחונדרל פיתוח לאיפנון שיטות בעל אלקטרומגנטי שדה בריפוי בשימוש

דופק

METHODS FOR MODULATING OSTEOCHONDRAL DEVELOPMENT USING PULSED ELECTROMAGNETIC FIELD THERAPYHEALTHONICS, INC.

03/06/2005

60/687430US

23/06/2005

60/693490US

07/04/2006

60/790128US

PCT/US/2006/020819WO/2006/132855

A63H18774530/03/2006

מחבר וסוג ומוט בלוק סוג בין מימשקבניה משחק במערכות

INTERFACINGS BETWEEN BLOCK TYPE AND ROD AND CONNECTOR TYPE CONSTRUCTION TOY SETSK'NEX LIMITED PARTNERSHIP GROUP

07/06/2005

11/146971US

PCT/US/2006/011550WO/2006/132693

C07D18774620/06/2006

בנזואימידאזול תולדות להכנת תהליך תרכובות להכנת ביניים כחומרי

בנזאמידאזול

PROCESS FOR THE PRODUCTION OF BENZOIMIDAZOLE DERIVATIVES AS INTERMEDIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLE COMPOUNDSNYCOMED GMBH


22/06/2005

05105566.3EP

15/02/2006

06101699.4EP

PCT/EP/2006/063350WO/2006/136552

A61K18774805/06/2006

PHARMACEUTICAL COMPOSITIONSמיסופרוסטול המכילים רוקחות תכשיריCONTAINING MISOPROSTALDURAMED PHARMACEUTICALS, INC.

03/06/2005

60/686973US

PCT/US/2006/021659WO/2006/133048

A23J18774926/05/2006

PROCESS FOR THE PREPARATION ANDפוספאטידים של ובידוד להכנה תהליךISOLATION OF PHOSPHATIDESFIDIA FARMACEUTICI S.P.A.

30/05/2005PD2005A000164IT

01/08/200560/703870US

PCT/EP/2006/005030WO/2006/128639

C07C18775023/06/2006


אלקילתיאופניל גוואנידינים הדמייתF18 אוC11 מסווגים

IMAGING 18F OR 11C-LABELLED ALKYLTHIOPHENYL GUANIDINESHAMMERSMITH IMANET LIMITED

23/06/2005

0512770.9GB

PCT/GB/2006/002315WO/2006/136846

H04L18775105/06/2006

PAGE-MODE MESSAGINGדף בתצורת מסרים משלוחNOKIA CORPORATION

06/06/2005

20055288FI

PCT/FI/2006/050234WO/2006/131597

A61K18775316/06/2006

WOUND HEALINGפצעים החלמת החשתGENENTECH, INC.

17/06/2005

60/691909US

21/04/2006

60/794008US

PCT/US/2006/023318WO/2006/138468

H02G18775420/06/2006

FLEXIBLE POWER RACEWAYגמיש הנעה מסלולCONNECTEURS ELECTRIQUES DEUTSCH

22/06/2005

05013505.2EP

22/06/2005

60/692904US

PCT/EP/2006/005914


WO/2006/136376

B22F18776119/05/2006

מתכתית אבקה של בחום לטיפול תהליךממנה העשויים ומוצרים

PROCESS FOR HEAT TREATING METAL POWDER AND PRODUCTS MADE FROM THE SAMECABOT CORPORATION

31/05/2005

11/141685US

PCT/US/2006/019353WO/2006/130355

F24J18776302/06/2006

SOLAR COLLECTOR HAVING ANאינטגראלי חום אחסון עם שמש קולטINTEGRATED HEAT STORAGEECONCERN B.V.

02/06/20051029168NL

PCT/NL/2006/000276WO/2006/130006

C07D18783006/06/2006

הצטברות מעכב טיאנופירידין של תכשירטסיות

FORMULATION OF A THIENOPYRIDINE PLATELET AGGREGATION INHIBITORELI LILLY AND COMPANY

10/06/2005

60/689183US

PCT/US/2006/021860WO/2006/135605

A61K18810115/06/2006

לטיפול –אלפאHIF 1 במאפנני שימושבסרטן

USE OF HIF 1-ALPHA MODULATORS FOR TREATMENT OF CANCERFIBROGEN, INC.


15/06/2005

60/691006US

PCT/US/2006/023399WO/2006/138511

C07C18810415/06/2006

COMPOUNDS USEFUL FORביפולריות במחלות לטיפול תרכובותTREATING BIPOLAR DISORDERS



16/06/2005

11/153894US

PCT/IL/2006/000697WO/2006/134600

H01F18823429/06/2006

MAGNETORHEOLOGICAL LIQUIDמגנטוריאולוגי נוזלBASF AKTIENGESELLSCHAFT

30/06/2005

102005030613.6DE

PCT/EP/2006/063702WO/2007/003580

C07D18823530/06/2006

–תיו–אנטראנילאמידיותN תרכובותהדברה כחומרי ושימושיהן

N-THIO-ANTHRANILAMID COMPOUNDS AND THEIR USE AS PESTICIDESBASF AKTIENGESELLSCHAFT

07/07/2005

60/697166US

PCT/EP/2006/063761WO/2007/006670

C07D18823828/06/2006


חרקים קוטלי להכנת משופר תהליך אלקיל די–מותמר( פניל )פרופניל

מותמרים הטרוציקלים

IMPROVED PROCESS FOR PREPARING INSECTICIDAL (DISUBSTITUTEDPROPENYL) PHENYLALKYL SUBSTITUTED HETEROCYCLESBAYER CROPSCIENCE AG

30/06/2005

60/695295US

PCT/US/2006/025143WO/2007/005454

C07D18823926/06/2006

IMIDAZOLE BASED LXRאימידזול על המבוססיםLXR מאפנניMODULATORSEXELIXIS, INC.

27/06/2005

60/694372US

10/11/2005

60/736120US

PCT/US/2006/024757WO/2007/002563

A01N18824019/06/2006

CRYSTALLINE MODIFICATIONS TOלפיראכלוסטרובין גבישיים שינוייםPYRACLOSTROBINBASF AKTIENGESELLSCHAFT

20/06/2005

102005028493.0DE

PCT/EP/2006/005869WO/2006/136357

C07D18824113/06/2006

שלהם סינטתיות ונגזרות קריפוווליניםכתרופות המשמשים

CRIPOWELLINS AND SYNTHETIC DERIVATIVES THEREOF USED AS MEDICAMENTSBAYER CROPSCIENCE AG

23/06/2005

102005029126.0DE


PCT/EP/2006/005650WO/2006/136309

G08G18824211/07/2005

והתקן תעבורתי מידע לקביעת שיטההשיטה לביצוע המאורגן

METHOD FOR DETERMINING TRAFFIC INFORMATION, AND A DEVICE ARRANGED TO PERFORM THE METHODTOM TOM INTERNATIONAL B.V

PCT/NL/2005/000496WO/2007/008055

G01C18824317/08/2005

מפה נתוני לגולל ושיטה ניווט מכשירהניווט מכשיר גבי על המוצגים

NAVIGATION DEVICE AND METHOD OF SCROLLING MAP DATA DISPLAYED ON A NAVIGATION DEVICETOM TOM INTERNATIONAL B.V

PCT/NL/2005/000595WO/2007/021169

C07D18824414/07/2006

UREA GLUCOKINASE ACTIVATORSגלוקוקינאז אוריאה משפעליNOVO NORDISK A/S

14/07/2005

05106449.1EP

PCT/EP/2006/064289WO/2007/006814

B01D18824530/06/2006

MICROBICIDAL AIR FILTERמיקרוביצידאלי אוויר מסנןBOLDUC LEROUX INC

30/06/2005

11/169636US

PCT/CA/2006/001092April 13, 2008 –התשס"ח ח' בניסן 544

WO/2007/003047

A46B18824603/08/2006

משופעים זיפים המכילה שיניים מברשתומחודדים

TOOTHBRUSH COMPRISING INCLINED AND POINTED BRISTLESGABA INTERNATIONAL AG

08/08/20051307/05CH

PCT/CH/2006/000405WO/2007/016802

B24B18824716/06/2006

של בתערובות לטיפול ומערכת תהליך בחזרה לקבלה שנשחקו שחיקה חומרי

חוזר לשימוש הניתנים רכיביהן של

PROCESS AND APPARATUS FOR TREATING EXHAUSTED ABRASIVE SLURRIES FOR THE RECOVERY OF THEIR REUSABLE COMPONENTSSIC PROCESSING AG

24/06/2005RM2005A000329IT

PCT/IT/2006/000461WO/2006/137098

C07D18824821/06/2006

כמעכבות [ פירידיןB– 3, 2] פירולו תולדותקינאז פרוטאין

PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORSPLEXXIKON, INC.

22/06/2005

60/692960US

28/10/2005

60/731528US

PCT/US/2006/024361WO/2007/002325


A61F18825130/06/2006

PROPHYLACTIC BACTERICIDALמחלות המונע חיידקים קוטל שתלIMPLANTWAYNE J. SEBASTIANELLI OF

30/06/2005

11/172138US

15/08/2005

60/708320US

PCT/US/2006/026000WO/2007/005842

C07K18825223/06/2006

אופיאויד של ההשפעה להגברת שיטהכאבים כמשכך

METHOD FOR THE POTENTIATION OF OPIOID ANALGESICS EFFECTS ON PAINLAY LINE GENOMICS S.P.A.

24/06/2005RM2005A000332IT

PCT/IT/2006/000488WO/2006/137106

A61K18825329/06/2006

של ניטרואוקסי תולדות של רוקחות הרכבNSAIDS

PHARMACUTICAL FORMULATION OF NITROOXYDERIVATIVES OF NSAIDSNICOX SA

26/07/2005

05106854.2EP

PCT/EP/2006/063672WO/2007/012539


C12Q18825728/06/2006

גן ( שלMISSENSE) סלף מוטציותABCG2בהן ושימושים שור של

BOVINE ABCG2 GENE MISSENSE MUTATIONS AND USES THEREOF

ופיתוח החקלאות - משרד ישראל מדינת החקלאי, מרכז המחקר הכפר, מינהל

וולקני

THE STATE OF ISRAEL- MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION VOLCANI CENTER

28/06/2005

60/694430US

01/07/2005

60/696294US

PCT/US/2006/025117WO/2007/002735

H04Q18826521/06/2006

נגישות בעלת ברשת יעיל עיתי מיקום דיווחלרדיו

EFFICIENT PERIODIC LOCATION REPORTING IN A RADIO ACCESS NETWORKQUALCOMM INCORPORATED

21/06/2005

60/693003US

25/08/2005

60/711801US

16/09/2005

60/718112US

06/02/2006

60/771180US


07/02/2006

60/771217US

08/02/2006

60/771706US

PCT/US/2006/024328WO/2007/002303

A61K18826813/07/2006

TRANSDERMAL SYSTEM FORלוארניקלין טרנסדרמלית מערכתVARENICLINEPFIZER PRODUCTS INC.

26/07/2005

60/702961US

PCT/IB/2006/002081WO/2007/012963

G05D18826922/06/2006

NAVIGATIONAL AID FOR DIVERלצוללן בניווט עזרהALBERT R. BASILICO

22/06/2005

11/158678US

PCT/US/2006/024234WO/2007/002246

G06F18827027/06/2006

רב במעבד כוח לשליטת ושיטה מערכתיישומים

SYSTEM AND METHOD OF CONTROLLING POWER IN A MULTI-THREADED PROCESSORQUALCOMM INCORPORATED

27/06/2005

11/167973US

PCT/US/2006/025299WO/2007/002801


G06F18827127/06/2006

יחידת מטמון של מרובות גישות מניעתבזיכרון עמוד לאותו מרכזית עיבוד

PREVENTING MULTIPLE TRANSLATION LOOKASIDE BUFFER ACCESSES FOR A SAME PAGE IN MEMORYQUALCOMM INCORPORATED

29/06/2005

11/174097US

PCT/US/2006/025301WO/2007/002803

C07D18827221/06/2006

BENZIMIDAZOLE תרכובות יצור תהליךSnAr בעזרת

SnAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDSASTRAZENECA AB

23/06/2005

60/693374US

PCT/US/2006/023986WO/2007/002092

C07D18827321/06/2006

BENZIMIDAZOLEPROCESS FOR PREPARING תרכובות יצור תהליךBENZIMIDAZOLE COMPOUNDSASTRAZENECA AB

23/06/2005

60/693270US

PCT/US/2006/024084WO/2007/002157

H01L18827627/06/2006

ליצורו ומתקן חשיפה ומתקן שיטתEXPOSURE METHOD AND EXPOSURE APPARATUS, AND DEVICE MANUFACTURING METHODNIKON CORPORATION


28/06/2005

2005-188837JP

PCT/JP/2006/312763WO/2007/000984

C07D18827722/06/2006

–4–כלורו–3–)4 של אמורפי מלח)ציקלופרופילאמינוקרבוניל(אמינופנוקסי(

–קוינולינקרבוקסאמיד6–מתוקסי–7–לייצורו ותהליך

AMORPHOUS SALT OF 4-(3-CHLORO-4-(CYCLOPROPYLAMINOCARBONYL) AMINOPHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE AND PROCESS FOR PRODUCING THE SAMEEISAI R&D MANAGEMENT CO. LTD.

23/06/2005

60/693044US

PCT/JP/2006/312487WO/2006/137474

A61K18827819/06/2006

ושיטות במים ממיסות מרדימות תערובותלייצורן

WATER SOLUBLE ANALGESIC FORMULATIONS AND METHODS FOR PRODUCTIONSOLUPRIN PHARMACEUTICALS, INC.

24/06/2005

60/693591US

PCT/US/2006/023737WO/2007/001957

C02F18827913/06/2006


תכונות של קבוצה למדידת התקןבפלאזמה חשמליות

APPARATUS FOR MEASURING A SET OF ELECTRICAL CHARACTERISTICS IN A PLASMALAM RESEARCH CORPORATION

29/06/2005

11/172014US

PCT/US/2006/023027WO/2007/005210

B63B18828019/12/2006

FLOATING PLATFORMצף משטח

ISRAEL AEROSPACE INDUSTRIESבע"מ לישראל האוירית התעשייהLTD.

19/01/2006173254IL

PCT/IL/2006/001457WO/2007/083292

C07K18828128/07/2006

CMACROCYCLIC INHIBITORS OF צהבת וירוס של מקרוציקליים מעכביםHEPATITIS C VIRUSTIBOTEC PHARMACEUTICALS LTD.

29/07/2005

05107066.2EP

03/02/2006

06101278.7EP

PCT/EP/2006/064812WO/2007/014918

C07K18828203/07/2006

IMMUNOGLOBULINESאימונוגלובוליניםGLAXO GROUP LIMITED

05/07/2005

0513766.6GB

14/12/2005

0525448.7GB

PCT/EP/2006/006535WO/2007/003421


C07D18828328/07/2006

CMACROCYLIC INHIBITORS OF צהבת וירוס של מקרוציקליים מעכביםHEPATITIS C VIRUSTIBOTEC PHARMACEUTICALS LTD.

29/07/2005

05107067.0EP

11/08/2005

05107413.6EP

PCT/EP/2006/064813WO/2007/014919

H04Q18828413/09/2006

נתונים וקליטת לשידור ומערכת שיטה בעלת אלחוטית תקשורת במערכתחכמות אנטנות

METHOD AND APPARATUS TO TRANSMIT AND RECEIVE DATA IN A WIRELESS COMMUNICATION SYSTEM HAVING SMART ANTENNASINTERDIGITAL TECHNOLOGY CORPORATION

16/09/2005

60/717673US

PCT/US/2006/035424WO/2007/035320

C07D18828520/06/2006

NOVEL THIOPHENE DERIVATIVESחדשות תיאופניות תולדותACTELION PHARMACEUTICALS LTD.

24/06/2005PCT/EP05/006840EP

PCT/IB/2006/051990WO/2006/137019

C12N18828823/06/2006


מזון אכילת לדיכוי פעילות עם פוליפפטידאותו המכילים רוקחות ותכשירי

POLYPEPTIDE HAVING AN ACTIVITY OF SUPPRESSING FOOD INTAKE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMETEIJIN PHARMA LIMITED

24/06/2005

05/184441JP

09/03/2006

06/064678JP

PCT/JP/2006/313041WO/2006/137597

H04L18828901/07/2005

INTERCEPTION OF MULTIMEDIAמולטימדיה שרותי ירוטSERVICESTELEFONAKTIEBOLAGET LM ERICSSON (PUBL)

PCT/SE/2005/001102WO/2007/004938

A61C18829022/06/2006

ומערכת אור להעברת ידני מכשירהיד במכשיר המשתמשת

A HAND PIECE FOR THE DELIVERY OF LIGHT AND SYSTEM EMPLOYING THE HAND PIECEONDINE INTERNATIONAL LTD.

29/06/2005

60/694952US

21/06/2006

11/425548US

PCT/US/2006/024272WO/2007/005313


G06K18829129/06/2006

IMAGE CORRECTION ACROSSקרינה מישטרי מכפל דרך בבואה תיקוןMULTIPLE SPECTRAL REGIMESFLIR SYSTEMS, INC.

01/07/2005

60/696299US

19/08/2005

11/207536US

PCT/US/2006/025504WO/2007/005567

G02B18829229/06/2006

IMAGE STABILIZATION SYSTEMבבואה יצוב מערכתFLIR SYSTEMS, INC.

01/07/2005

60/696306US

29/03/2006

11/393448US

PCT/US/2006/025789WO/2007/005721

C07D18829304/07/2006

NEW PYRIDINE ANALOGUESפירידין של חדשים אנלוגיםASTRAZENECA AB

13/07/2005

0501663-9SE

24/10/2005

0502354-4SE

PCT/SE/2006/000832WO/2007/008140

B65G18829413/07/2006


והתקן חומר חלקיקי להעברת שיטהחומר חלקיקי להעברת

A METHOD FOR TRANSPORTING A PARTICULATE MATERIAL AND A TRANSPORTATION DEVICE FOR A PARTICULATE MATERIALASTRAZENECA AB

15/07/2005

0501687-8SE

PCT/SE/2006/000877WO/2007/011283

H02K18829606/07/2005

ELECTRIC MOTORחשמלי מנועELCKON LIMITED

PCT/GB/2005/002673WO/2007/003868

H01L18829729/06/2006

ותהליך מצע לעיבוד חשיפה, תהליך מתקןמתקן ליצירת

EXPOSURE APPARATUS, SUBSTRATE PROCESSING METHOD AND DEVICE PRODUCING METHODNIKON CORPORATION

29/06/2005

2005-190254JP

17/04/2006

2006-113478JP

PCT/JP/2006/312973WO/2007/001045

G06F18829821/06/2006

הנוגע מידע ולנהל לתקשר ומערכת שיטההייצור במשטח עבודה להזמנות

A METHOD AND A SYSTEM TO COMMUNICATE AND MANAGE WORK-ORDER INFORMATION ON THE MANUFACTURING FLOOR

NAOMI NISHRIנשריי נעמי23/06/2005

60/693081US


04/10/2005

11/241940US

PCT/IL/2006/000724WO/2006/137065

A01N18829922/06/2006

) מצרי מזקום המופקים ספוניניםAEGYPTIACA BALANITESושימושיהם )

BALANITES AEGYPTIACA SAPONINS AND USES THEREOF

בנגב, הרשות בן-גוריון אוניברסיטתופיתוח למחקר

BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY

22/06/2005

60/692662US

13/03/2006

60/781332US

PCT/IL/2006/000733WO/2006/137069

C07K18830128/06/2006

של למניעה סי קינאז פרוטאין מעכבי2 מסוג וסוכרת אינסולין התנגדות

PROTEIN KINASE C INHIBITORS FOR PREVENTION OF INSULIN RESISTANCE AND TYPE 2 DIABETES

HADASIT MEDICAL RESEARCHבע"מ ופיתוח רפואי מחקר שרותי הדסיתSERVICES & DEVELOPMENT LTD.

29/06/2005

60/694691US

PCT/IL/2006/000755WO/2007/000770


B29C18830421/06/2006

וחלק מרוכב לחומר מחזק סיבי מבנהזה מבנה הכולל

REINFORCING FIBROUS STRUCTURE FOR A COMPOSITE MATERIAL AND A PART CONTAINING SAID STRUCTURESNECMA PROPULSION SOLIDE

24/06/20050506441FR

PCT/FR/2006/050617WO/2006/136755

A61F18830529/06/2006

CELL-FREE GRAFTתאים ללא הרכבהTRANSTISSUE TECHNOLOGIES GMBH

30/06/2005

102005030614.4DE

PCT/EP/2006/006281WO/2007/003324

C07D18830621/06/2006

פנילאלאנין, שיטה נגזרי של גבישיםבהם והשימוש לייצורם

CRYSTALS OF PHENYLALANINE DERIVES,, PRODUCTION METHOD THEREOF AND USE THEREOFAJINOMOTO CO., INC.

21/06/2005

2005-181219JP

PCT/JP/2006/312432WO/2006/137450

A61B18830721/06/2006


אפיזודות אחר ומעקב לחיזוי שיטותקליניות

TECHNIQUES FOR PREDICTION AND MONITORING OF CLINICAL EPISODES

EARLYSENSE LTDבע"מ ארליסנס21/06/2005

60/692105US

03/08/2005

11/197786US

PCT/IL/2006/000727WO/2006/137067

A23J18830822/06/2006

רע, טעם מופחתי סויה חלבון מוצרילהכנתם ושיטות

SOY PROTEIN PRODUCTS HAVING REDUCED OFF-FLAVOR AND PROCESSES FOR MAKING THE SAMESOLAE, LLC

23/06/2005

11/159547US

PCT/US/2006/024557WO/2007/002450

A61K18831023/06/2006

,1מתרומבוספונדין– שמוצאם פפטידיםלטיפול ושיטות

THROMBOSPONDIN-1 DERIVED PEPTIDES AND TREATMENT METHODSRAMTIN AGAH

24/06/2005

60/693574US

PCT/US/2006/024692WO/2007/002534

C07K18831223/08/2006

ILANTI-IL-23 ANTIBODIES –23 כנגד נוגדניםELI LILLY AND COMPANY

25/08/2005

60/711336US

10/02/2006

60/772355US

PCT/US/2006/032752WO/2007/024846


A61K18831313/07/2006

–O של אוראליות מינון צורות בעלות סוקצינט דסמתילוונלאפאקסיין

מבוקר ושחרור גבוהה ביולוגית זמינות

HIGHLY BIOAVAILABLE ORAL DELAYED RELEASE DOSAGE FORMS OF O-DESMETHYLVENLAFAXINE SUCCINATEWYETH

15/07/2005

60/699623US

PCT/US/2006/027106WO/2007/011619

C07D18831427/07/2006

– ציאנופירול של רצפטור של מודולטוריםושימושיהם פרוגסטרון סולפונאמיד

CYANOPYRROLE-SULFONAMIDE PROGESTERONE RECEPTOR MODULATORS AND USES THEREOFWYETH

29/07/2005

60/704009US

PCT/US/2006/029125WO/2007/016212

A01N18831528/06/2006

רבייה בחומרי לטיפול נוזליים תכשיריםצמחיים

LIQUID COMPOSITIONS FOR TREATING PLANT PROPAGATION MATERIALSSYNGENTA PARTICIPATIONS AG

29/06/2005

60/695143US

PCT/US/2006/025187WO/2007/005470

A61K18831604/07/2006

בהפרעות לטיפול לקינין אנטגוניסטיםהשתן בשלפוחית

KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTIONJERINI AG


05/07/2005

05014581.2EP

PCT/EP/2006/006504WO/2007/003411

G01N18831705/07/2006

להתחשב מבלי מטרה אנטיגן של זיהוימקביל טיפולי נוגדן של העדר או בנוכחות

DETECTION OF A TARGET ANTIGEN IRRESPECTIVE OF THE PRESENCE OR ABSENCE OF A CORRESPONDING THERAPEUTIC ANTIBODYF. HOFFMANN-LA ROCHE AG

06/07/2005

05014618.2EP

06/03/2006

06004447.6EP

PCT/EP/2006/006524WO/2007/003420

A61K18831828/06/2006

לטיפולMADCAM כנגד בנוגדנים שימושטרופית ובכרסת צליאק במחלת

USE OF ANTI-MADCAM ANTIBODIES FOR THE TREATMENT OF COELIAC DISEASE AND TROPICAL SPRUEPFIZER LIMITED

08/07/2005

60/697454US

PCT/IB/2006/001837WO/2007/007145

C12P18831928/06/2006

–1, 1, 1 של אסימטרית הפחתהטריפלואורואצטון

ASYMMETRIC REDUCTION OF 1,1,1-TRIFLUOROACETONEF. HOFFMANN-LA ROCHE AG

08/07/2005

05106261.0EP

PCT/EP/2006/063621WO/2007/006650


C07D18832028/07/2006

הפטיטיס וירוס של מקרוציקליים מעכביםC

MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUSTIBOTEC PHARMACEUTICALS LTD.

29/07/2005

05107057.1EP

25/04/2006

06113097.7EP

PCT/EP/2006/064822WO/2007/014927

A61B18832122/06/2006

של בניתוח לשימוש כירורגיים גישה כליאורתופדי או השדרה עמוד

SURGICAL ACCESS INSTRUMENTS FOR USE WITH SPINAL OR ORTHOPEDIC SURGERYVYCOR MEDICAL, INC.

22/06/2005

60/692959US

PCT/US/2006/024243WO/2007/002251

A61K18832222/06/2006

NANOPARTICULATE MEGESTROLמגסטרול של ננוחלקיקיות פורמולציותFORMULATIONSELAN PHARMA INTERNATIONAL LTD.

22/06/2005

60/693127US

PCT/US/2006/024349WO/2007/002315

C07D18832328/06/2006

השפעה בעלי מותמרים גליצינאמידיםXA גורם ומעכבת פקקת נוגדת

SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA -INHIBITING EFFECTBOEHRINGER INGELHEIM INTERNATIONAL GMBH


30/06/2005

05014270.2EP

PCT/EP/2006/063611WO/2007/003536

A61M18832412/05/2006

DOSAGE DELIVERY DEVICEמינון למשלוח מתקןSARDRETTE (GUERNSEY) LIMITED

24/06/2005

0512893.9GB

06/03/2006

0604420.0GB

PCT/GB/2006/001743WO/2006/136769

A62B18832517/07/2006

IMPROVED DISPENSING DEVICEמשופרים חלוקה ושיטת מכשירAND METHODVENTAIRA PHARMACEUTICALS , INC.

15/07/2005

60/699932US

13/07/2006

11/485787US

PCT/US/2006/027669WO/2007/011866

A61N18832623/06/2006

ELECTROMAGNETIC FORCE FORרקמה תיקון לחיזוק אלקטרומגנטי כחENHANCING TISSUE REPAIRREGENETECH, INC.

29/06/2005

11/169614US

PCT/US/2006/024814WO/2007/005373


C07C18832705/07/2006

INHIBITORS OF FIBROBLASTאלפא חלבון פיברובלסט מפעילי מעכביACTIVATION PROTEIN ALPHATRUSTEES OF TUFTS COLLEGE

05/07/2005

60/696772US

PCT/US/2006/026258WO/2007/005991

A61J18832827/06/2006

ARTIFICIAL NIPPLE WITHחיזוק עם מלאכותית פיטמהREINFORCEMENTMEDELA HOLDING AG

30/06/2005

11/173860US

PCT/US/2006/025010WO/2007/005427

C07C18832926/06/2006

ניאצין, הרכבים רצפטור של אגוניסטיםלטיפול ושיטות כאלה תרכובות המכילים

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENTMERCK & CO., INC.

28/06/2005

60/694711US

PCT/US/2006/024740WO/2007/002557


C07D18833029/06/2006

–2–אמינו–4 של תרכובות להכנת תהליכים–יל(איזואינדולין–3–דיאוקסופיפרידין–6,2)

–דיון1,3

PROCESSES FOR THE PREPARATION OF

4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDSCELGENE CORPORATION

30/06/2005

60/696224US

PCT/US/2006/026210WO/2007/005972

H05B18833230/06/2006

מבוקר כח ספק בעל מעמעםבמיקרו–פרוססור

DIMMER HAVING A MICROPROCESSOR-CONTROLLED POWER SUPPLYLUTRON ELECTRONICS CO. INC.

30/06/2005

60/695784US

PCT/US/2006/025662WO/2007/005651

H04N18833306/07/2006

METHOD FOR CONTROLLINGמוצפנים לנתונים גישה לבקרת שיטהACCESS TO ENCRYPTED DATANAGRAVISION S.A.

07/07/2005

05106186.9EP

PCT/EP/2006/063989WO/2007/006736


H04N18833406/07/2006

לנתונים גישה לבקרת והתקן שיטהמוצפנים

METHOD AND DEVICE FOR CONTROLLING ACCESS TO ENCRYPTED DATANAGRACARD S.A.

07/07/2005

05106185.1EP

PCT/EP/2006/063988WO/2007/006735

H02J18833528/06/2006

CONTACTLESS BATTERYסוללה לטעינת מגעים נטול לבושCHARGING APPARELCYNETIC DESIGNS LTD

28/06/2005

60/694248US

PCT/CA/2006/001078WO/2007/000055

A61K18833927/06/2006

המיני התפקוד להגברת ושיטות תכשיריםCOMPOSITIONS AND METHODS FOR ENHANCEMENT OF SEXUAL FUNCTION

SIVAN GORENגורן סיון27/06/2005

60/693798US

17/08/2005

60/708764US

PCT/IL/2006/000747WO/2007/000764


C08F18834014/06/2006

ברומינציה שעברו סטירניים פולימריםוהכנתם

BROMINATED STYRENIC POLYMERS AND THEIR PREPARATIONALBEMARLE CORPORATION

30/06/2005

60/696468US

06/04/2006

60/790431US

PCT/US/2006/023396WO/2007/005233

G06F18834123/06/2006

רנדומלי דינאמי לזיכרון גישה ללא מצבעי מאוחסנים שאינם לנתונים לגישה ושיטה

דינאמי לזיכרון גישה של נתונים במערךרנדומלי

NON-DRAM INDICATOR AND METHOD OF ACCESSING DATA NOT STORED IN DRAM ARRAY

QUALCOMM INCORPORATED23/06/2005

11/165950US

PCT/US/2006/024498WO/2007/002413

G01N18834210/07/2006

של נוירואינפלמטורי הרס לניטור שיטות מרכיב בעלות במחלות ולטיפול נוירוניםA 2 פוספוליפאז עם הקשור דלקתי

METHODS FOR MONITORING NEUROINFLAMMATORY DESTRUCTION OF NEURONS AND FOR TREATING DISEASES HAVING AN INFLAMMATORY COMPONENT RELATED TO PHOSPHOLIPASE A2PHILADELPHIA HEALTH AND EDUCATION CORPORATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE

08/07/2005

60/697598US

PCT/US/2006/026568WO/2007/008690


H04L18834329/06/2006

קונפליקטים לפתרון ושיטה מערכת במערכת מרובות זמניות בו בתקשורות

אלחוטית

SYSTEM AND METHOD FOR RESOLVING CONFLICTS IN MULTIPLE SIMULTANEOUS COMMUNICATIONS IN A WIRELESS SYSTEMQUALCOMM INCORPORATED

30/06/2005

11/173659US

PCT/US/2006/026208WO/2007/005971

G06F18834429/06/2006

לחריגה ושיטה לדיאגנוזה והתקנים שיטה חרידות ולסיווג לזיהוי שלמה רשת עבורתנועה חלוקת במאפייני שימוש תוך רשת

METHOD AND APPARATUS FOR WHOLE-NETWORK ANOMALY DIAGNOSIS AND METHOD TO DETECT AND CLASSIFY NETWORK ANOMALIES USING TRAFFIC FEATURE DISTRIBUTIONSTRUSTEES OF BOSTON UNIVERSITY

29/06/2005

60/694853US

29/06/2005

60/694840US

PCT/US/2006/025398WO/2007/002838

A61K18834525/07/2006

מולקולות באמצעותB תאי של הפחתהספציפי באופןCD 20 ו–CD 37 הקושרות

B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULESTRUBION PHARMACEUTICALS, INC.

25/07/2005

60/702499US

16/05/2006

60/800595US

PCT/US/2006/029038


WO/2007/014278

B01D18834622/06/2006

מתקני של מחדש למיקום ומתקן שיטהמדורג הזרמה במבנה הזרמה

METHOD AND APPARATUS FOR REPOSITIONING FLOW ELEMENTS IN A TAPERED FLOW STRUCTURE

בנגב, הרשות בן-גוריון אוניברסיטתופיתוח למחקר

BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY

23/06/2005

60/692963US

PCT/IL/2006/000728WO/2006/137068

G08B18834930/06/2006

אסורה תנועה לזיהוי ושיטה מעקב מערכתמראש הנקבע נתיב לאורך

SURVEILLANCE SYSTEM AND METHOD FOR DETECTING FORBIDDEN MOVEMENT ALONG A PREDETERMINED PATH

.PLANUM VISION LTDבע"מ ויז'ן פלנום30/06/2005169487IL

04/08/2005170124IL

PCT/IL/2006/000764WO/2007/004217

A61K18835020/07/2006

29 ו–IL 28 קטועים ציסטאינים מוטנטיםILבהם לשימוש אנטי–ויראליות ושיטות

IL-28 AND IL 29 TRUNCATED CYSTEINE MUTANTS AND ANTIVITAL METHODS OF USING SAMEZYMOGENETICS INC.


20/07/2005

60/700905US

PCT/US/2006/028215WO/2007/012033

A61K18835112/07/2006

PROMOTION OF EPITHELIALאפיתל התחדשות קידוםREGENERATIONRENOVO LTD

12/07/2005

0514262.5GB

PCT/GB/2006/002577WO/2007/007098

A61K18835212/07/2006

PHARMACEUTICAL COMPOSITIONSרוקחיים תכשיריםRENOVO LTD

12/07/2005

0514259.1GB

12/07/2005

0514260.9GB

PCT/GB/2006/002574WO/2007/007095

C07C18835314/07/2006

נמקA וגורם–1אינטגלןקין– מאפנני ושיטות אלו מאפננים של שאת, סינטזה

אלו במאפננים לשימוש

INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-A MODULATORS: SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORSNEREUS PHARMACEUTICALS, INC.

21/07/2005

60/701932US

07/11/2005

60/734590US

07/11/2005

60/734679US

12/12/2005

60/749542US


22/03/2006

60/785223US

PCT/US/2006/027385WO/2007/015757

A47G18835418/07/2006

HAND HELD OBJECT ANDלטיפול ותוויות ביד המוחזק פריטHANDLING LABELSSARDRETTE (GUERNSEY) LIMITED

18/07/2005

0514667.5GB

24/01/2006

0601362.7GB

PCT/GB/2006/002648WO/2007/010230

C07C18835617/07/2006

לקטית חומצה למצוי שיטהמיימיות מסוספנסיות

METHOD FOR EXTRACTING LACTIC ACID FROM AQUEOUS SUSPENSIONSBASF AKTIENGESELLSCHAFT

18/07/2005

102005033432.6DE

PCT/EP/2006/064324WO/2007/009970

A61K18835720/07/2006

ו–IL 28 ציסטאין קצוצי במוטנטים שימוש29 ILסדרים ובאי בסרטן לטיפול

אוטואימוניים

USE OF TRUNCATED CYSTEINE IL28 AND IL29 MUTANTS TO TREAT CANCERS AND AUTOIMMUNE DISORDERSZYMOGENETICS INC.


20/07/2005

60/700951US

08/02/2006

60/771260US

PCT/US/2006/028106WO/2007/013944

G06K18835823/06/2006

אוטומטי לחישוב ושיטות מערכת, מכשירקניות עבור הנחות של

SYSTEM, APPARATUS AND METHODS FOR AUTOMATICALLY CALCULATING DISCOUNTS FOR PURCHASESVISA U.S.A. INC.

24/06/2005

11/166473US

PCT/US/2006/024317WO/2007/002296

C09K18835926/06/2006

המותמרים אולפינים המכילים תכשיריםבפלואור

COMPOSITIONS CONTAINING FLUORINE SUBSTITUTED OLEFINSHONEYWELL INTERNATIONAL INC.

24/06/2005

60/693853US

PCT/US/2006/024886WO/2007/002625

G09G18836014/07/2006

לאבטחת העבודה לשולחן בפר הרכבהחמרה

SECURE HARDWARE DESKTOP BUFFER COMPOSITIONMICROSOFT CORPORATION

22/07/2005

11/187303US

PCT/US/2006/027235WO/2007/018957

H04L18836111/07/2006


קודים רצפי עבור אבטחה מפתח ניהוללדירוג הניתנים

SECURE KEY MANAGEMENT FOR SCALABLE CODESTREAMSMICROSOFT CORPORATION

11/07/2005

11/178943US

PCT/US/2006/027391WO/2007/009066

B01J18836323/06/2006

זעירים מרכיבים וציפוי ליצור שיטהMETHOD FOR MANUFACTURE AND COATING OF NANOSTRUCTURED COMPONENTSWASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION

24/06/2005

60/693683US

12/04/2006

60/744733US

PCT/US/2006/024435WO/2007/002369

F16J18836630/06/2006

RECIPROCATING PUMPחזרתית משאבהSEAPOWER PACIFIC PTY LTD.

30/06/2005

2005903457AU

PCT/AU/2006/000928WO/2007/002997

H01R18836730/06/2006

HIGH SPEED, HIGH DENSITYגדולה צפיפות ובעל חשמלי מחברELECTRICAL CONNECTORAMPHENOL CORPORATION

30/06/2005

60/695705US

18/07/2005

11/183564US

PCT/US/2006/025564


WO/2007/005599

H01R18836830/06/2006

גבוהה הגנה יכולת ובעל חשמלי מחברCONNECTOR WITH IMPROVED SHIELDING IN MATING CONTACT REGIONAMPHENOL CORPORATION

30/06/2005

60/695264US

29/06/2006

11/476758US

PCT/US/2006/025562WO/2007/005597

F02K18837021/06/2006

מסוג מניע חומר בסיס על הנעה מכשירמניע חומר להעביר ושיטה ג'ל

DRIVE DEVICE ON THE BASIS OF A GEL-TYPE PROPELLANT AND METHOD FOR CONVEYING PROPELLANTDEUTSCHES ZENTRUM FUR LUFT-UND RAUMFAHRT E.V.

30/06/2005

102005030437.0DE

PCT/EP/2006/005925WO/2007/003270

C07D18837119/07/2006

NOVEL PIPERIDINE DERIVATIVESפיפרידין של חדשות תולדותASTRAZENECA AB

21/07/2005

0501719-9SE

13/04/2006

0600838-7SE

PCT/SE/2006/000893WO/2007/011293


C07D18837217/07/2006

[פירימידין, חומריD –3 , 2] פירולו תולדותוסינתזה שלהן ביניים

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES; THEIR INTERMEDIATES AND SYNTHESISPFIZER PRODUCTS INC.

29/07/2005

60/704011US

PCT/IB/2006/002048WO/2007/012953

B32B18837329/06/2006

BALLISTIC-RESISTANT ARTICLEבליסטית עמיד פריטDSM IP ASSETS B.V.

30/06/2005

05076502.3EP

PCT/EP/2006/006301WO/2007/003334

C07K18837528/06/2006

?2 אינטרפרון של רקומביננטיים מוטנטים(2 ?IFN)

RECOMBINANT INTERFERON ?2 (IFN?2) MUTANTS


29/06/2005

60/694810US

PCT/IL/2006/000754WO/2007/000769

A61K18837629/06/2006

אנזימים המקודדים פולינוקליאוטידים לאיזופרנואיד, ושיטות מודיפיקציה העושיםבהם לשימוש

POLYNUCLEOTIDES ENCODING ISOPRENOID MODIFYING ENZYMES AND METHODS OF USE THEREOFTHE REGENTS OF THE UNIVERSITY OF CALIFORNIA

05/07/2005

60/697067US

PCT/US/2006/025572WO/2007/005604


C12N18837816/05/2006

גזע לתאי הגורמים שומן ברקמות שימושבפיסטולה לטיפול סטרומה

USE OF ADIPOSE TISSUE DERIVED STROMAL STEM CELLS IN TREATING FISTULAUNIVERSIDAD AUTONOMA DE MADRID

24/06/2005

11/167061US

PCT/EP/2006/004605WO/2006/136244

C07D18838013/06/2006

ISOQUINOLINE DERIVATIVESאיזוקווינולינים נגזרותSANOFI AVENTIS

28/06/2005

05013868.4EP

PCT/EP/2006/005648WO/2007/000240

C07D18838113/06/2006

1 קינאז כמעכבי פיראזולופירידינים נגזרותאדרנרגי ביתא קולטן של

PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF BETA-ADRENERGIC RECEPTOR KINASE 1SANOFI AVENTIS

27/06/2005

05013774.4EP

PCT/EP/2006/005649WO/2007/000241

C07D18838214/06/2006

המכילים הטרוארילים מותמרי אמידים בהם רוויה, והשימוש מקשרת קבוצה

רוקחיים כתכשירים

HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALSSANOFI AVENTIS


28/06/2005

05013870.0EP

PCT/EP/2006/005706WO/2007/000246

C07D18838314/06/2006

המכילים הטרוארילים מותמרי אמידים ציקלית, או רוויה בילתי מקשרת קבוצה

רוקחיים כתכשירים בהם והשימוש

HETEROARYL-SUBSTITUTED AMIDES COMPRISING AN UNSATURATED OR CYCLIC LINKER GROUP, AND THEIR USE AS PHARMACEUTICALSSANOFI AVENTIS

28/06/2005

05013869.2EP

PCT/EP/2006/005716WO/2007/000248

C08L18838528/06/2006

מוצרי עבור גבוהים ביצועים בעל רזיןהשחזה

HIGH PERFORMANCE RESIN FOR ABRASIVE PRODUCTSSAINT GOBAIN ABRASIVES, INC.

29/06/2005

60/695233US

PCT/US/2006/025133WO/2007/005452


A61K18838629/06/2006

SELF-STERILIZING PRODUCTSעצמי עיקור העוברים מוצריםL. MOLTENI & C. DEI FRATELLI ALITTI-SOCIETA DI ESERCIZIO S.P.A.

29/06/200560/695752US

04/04/2006FI2006A000089IT

PCT/EP/2006/063695WO/2007/000472

C07D18838817/07/2006

CBPYRAZOLE DERIVATIVES AS CB1 1 של כמודולטורים פיראזול נגזרותMODULATORSASTRAZENECA AB

19/07/2005

0514738.4GB

PCT/GB/2006/002631WO/2007/010217

C07D18838917/07/2006

–5– מתוקסי–N(–3 של אתנולאמין מלח–YL2–)2(–4[–4,3,1מתילפיריאזין–

–3[פניל(פירידין–YL–2אוקסאדיאזול–סולפונאמיד

ETHANOLAMINE SALT OF N-(3-METHOXY-5-METHYLPYRZIN-2YL)-2-(4-[1,3,4-OXADIAZOLE-2-YL]PHENYL)PYRIDINE-3-SULPHONAMIDEASTRAZENECA AB

19/07/2005

0514743.4GB

PCT/GB/2006/002654WO/2007/010235

C07D18839027/07/2006

לשימוש אימידאזוליל–פירימידין תרכובותמהירה תאים התרבות בהפרעות בטיפול

IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERSASTRAZENECA AB

30/07/2005

0515743.3GB


06/10/2005

0520281.7GB

22/12/2005

0526015.3GB

28/04/2006

0608371.1GB

PCT/GB/2006/002801WO/2007/015064

A61K18844224/07/2006

COMPOSITIONS FOR AFFECTINGמשקל איבוד להפעלת תכשיריםWEIGHT LOSSOREXIGEN THERAPEUTICS, INC.

27/07/2005

60/702877US

PCT/US/2006/028875WO/2007/016108

C12M18844322/06/2006

בזמן המשתנה אלקטרומגנטי כח שרוולבו לשימוש ושיטות תאים להרחבת

TIME VARYING ELECTROMAGNETIC FORCE SLEEVE FOR THE EXPANSION OF CELLS AND METHOD OF USING THE SAMEREGENETECH, INC.

29/06/2005

11/169386US

29/06/2005

11/169613US

PCT/US/2006/024241WO/2007/005306

A61J18844427/06/2006


בו ושימוש תרופות חבילת לאחסון מארזCASE FOR ACCOMMODATING A MEDICAMENT PACK, AND USE THEREOFBAYER SCHERING PHARMA AG

01/07/2005

102005032015.5DE

PCT/EP/2006/006533WO/2007/025593

H04L18844629/06/2006

SIGNAL MESSAGE COMPRESSORסיגנל להודעות מדחסNOKIA CORPORATION

30/06/2005

0513433.3GB

PCT/IB/2006/001850WO/2007/004042

A61K18844810/07/2006

של מוגברת רירית להעברה פורמולציותYY פפטיד

FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYYNASTECH PHARMACEUTICAL COMPANY INC.

11/07/2005

60/698052US

13/07/2005

60/699294US

PCT/US/2006/026707WO/2007/008778

A61K18844928/06/2006

של הספיגה מידת לשיפור תכשירים וטוקוטריאנולים פולימתוקסיפלבונים

הדם וכלי הלב של המחלה לטיפול

COMPOSITIONS TO IMPROVE THE BIOAVAILABILITY OF POLYMETHOXYFLAVONES AND TOCOTRIENOLS FOR THE TREATMENT OF CARDIOVASCULAR DISEASEKGK SYNERGIZE INC.

28/06/2005

60/694720US

PCT/US/2006/025588


WO/2007/002897

G01N18845030/06/2006

של פארמאקינטיקות לקביעת שיטותממוקדות תרופות

METHODS OF DETERMINING PHARMACOKINETICS OF TARGETED THERAPIESWYETH

01/07/2005

60/695419US

PCT/US/2006/025736WO/2007/005690

B32B18845129/06/2006

המכילות פולימריות ביניים שכבות פולי)ציקלוהקסאנדימתילן

טרפהלאט( טרפהלאט–קו–אתילןקופוליאסטר

POLYMER INTERLAYERS COMPRISING POLY (CYCLOHEXANEDIMETHYLENE TEREPHTHALATE-CO-ETHYLENE TEREPHTHALATE)COPOLYESTERSOLUTIA INC.

30/06/2005

11/170643US

30/06/2005

11/170445US

PCT/US/2006/025771WO/2007/005711

C07D18845230/06/2006

כמעכבי לשימוש –דיאמינו–פירימידינים4,2אורורה

2,4-DIAMINO-PYRIMIDINES USED AS AURORA INHIBITORSBOEHRINGER INGELHEIM INTERNATIONAL GMBH

01/07/2005

05106007.7EP


PCT/EP/2006/063736WO/2007/003596

F24C18845422/06/2006

עם אוויר ומנקה למטבח אדים קולטרטובה סינון מערכת

KITCHEN ASPIRATOR AND AIR CLEANER WITH WET FILTER SYSTEMYASAR BOZKURT ASICI

27/06/2005

2005/02480TR

PCT/TR/2006/000025WO/2007/001242

A61K18845620/07/2006

בקטריאלי בזיהום לטיפול ושיטות תכשירים ביוניקGRAM חיובי

COMPOSITIONS AND METHODS FOR TREATING GRAM POSITIVE BACTERIAL INFECTION IN A MAMMALIAN SUBJECTTHE SCRIPPS RESEARCH INSTITUTE

20/07/2005

60/701216US

19/07/2006

11/490457US

PCT/US/2006/028385WO/2007/120170

H01R18845930/06/2006


ELECTRICAL CONNECTOR FORחיבורים למכלול חשמלי מחברINTERCNNECTION ASSEMBLYAMPHENOL CORPORATION

30/06/2005

60/695308US

29/06/2006

11/476831US

PCT/US/2006/025563WO/2007/005598

G01N18846003/07/2006

ולטפול לאיבחון ותכשירים איבחון שיטותבשפעת

DIAGNOSTIC METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING INFLUENZAARBOR VITA CORPORATION

01/07/2005

60/696221US

13/10/2005

60/726377US

02/02/2006

60/765292US

14/04/2006

60/792274US

PCT/US/2006/026155WO/2007/018843

A61F18846916/05/2006

תרכובת של סטרילי לערבוב מחסנית אקריליים לשרפים דו–פאזית, במיוחד

מרכיבים שני בעלי

CARTRIDGE FOR STERILE MIXING OF A TWO-PHASE COMPOUND, PARTICULARLY FOR TWO-COMPONENT ACRYLIC RESINSTECRES S.P.A.

28/06/2005VI2005A000187IT

PCT/IB/2006/001275WO/2007/000631


H01L18847010/05/2006

של ערימה באמצעות מיסוך רב תהליךצריבה מסיכות

MULTIPLE MASK PROCESS WITH ETCH MASK STACKLAM RESEARCH CORPORATION

28/06/2005

11/170273US

PCT/US/2006/018144WO/2007/001647

C07D18847431/07/2006

INEW SALT I חדש מלחASTRAZENECA AB

02/08/2005

0501768-6SE

PCT/SE/2006/000920WO/2007/015666

C07D18847511/07/2006

–2,4[פירימידינ–D–2,3] פירידו תרכובותPTPIB כמעכבי דיאמין

PYRIDO [2,3-D]PYRIMIDINE-2,4-DIAMINE COMPOUNDS AS PTPIB INHIBITORSF. HOFFMANN-LA ROCHE AG

21/07/2005

60/701467US

PCT/EP/2006/064091WO/2007/009911

C07D18847611/07/2006

לרצפטור כאגוניסטים פירידאזינון תולדותטיירואיד להורמון

PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS


F. HOFFMANN-LA ROCHE AG21/07/2005

60/701215US

PCT/EP/2006/064093WO/2007/009913

C07D18847804/07/2006

–3אינדול– תולדות כאנטגוניסטים קרבוניל–ספירו–פיפרידין

A1V רצפטור של

INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTSF. HOFFMANN-LA ROCHE AG

14/07/2005

05106443.4EP

07/10/2005

05109364.9EP

PCT/EP/2006/063846WO/2007/006688

C07D18847912/07/2006

]אלפא/גאמא[PPAR של אגוניסטיםלהכנתם ותהליכים

PPAR [ALPHA/GAMMA]AGONISTS AND PROCESSES OF PREPARINGNOVARTIS AG

13/07/2005

60/698801US

PCT/US/2006/027441WO/2007/009080

C12N18848019/07/2006

7–ILושימושים גליקוזידציה, הכנה שעברGLYCOSYLATED IL-7, PREPARATION AND USESCYTHERIS

20/07/2005

05291556.8EP

PCT/IB/2006/002663WO/2007/010401


C07D18848131/07/2006

IINEW SALT II חדש מלחASTRAZENECA AB

02/08/2005

0501770-2SE

PCT/SE/2006/000921WO/2007/015667

B29C18848228/06/2006

בצורת חפצים לייצור ומפעל שיטה או מלוכדת אבן של בלוקים או יריעות

אבן דמוי חומר של

METHOD AND PLANT FOR MANUFACTURING ARTICLES IN THE FORM OF SHEETS OR BLOCKS OF CONGLOMERATE STONE OR STONE-LIKE MATERIALTONCELLI, LUCA

18/07/2005TV2005A000106IT

PCT/EP/2006/063632WO/2007/009860

C07D18848328/06/2006

–5–דיכלורו–2,4–])4 של קריסטליםמתוקסיפניל(אמינו[

–1–מתיל–4–)3–]7–מתוקסי–6––3פיפרזיניל(פרופוקסי[–

להכנתם ושיטות קווינוליינקרב–אוניטריל

CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE AND METHODS OF PREPARING THE SAMEWYETH

01/07/2005

60/696381US

PCT/US/2006/025160WO/2007/005462


C07D18848431/07/2006

IIINEW SALT III חדש מלחASTRAZENECA AB

02/08/2005

0501769-4SE

PCT/SE/2006/000922WO/2007/015668

C07D18848603/07/2006

24HT–5 ,6 HT–5BENZIMIDAZOLE DERIVATIVES ASכ– בנזימידאזול תולדות5-HT6,5-HT24F. HOFFMANN-LA ROCHE AG

13/07/2005

60/699435US

PCT/EP/2006/063788WO/2007/006677

A47G18848828/07/2006

DRINKING STRAWקשיתUNILEVER PLC

15/08/2005

05076887.8EP

PCT/EP/2006/007631WO/2007/019958

B01J18848908/01/2003

AIR-STABLE METAL OXIDEבאויר היציבים אוקסיד מתל ננו חלקיקיNANOPARTICLESNANOSCALE MATERIALS, INC.


07/06/2002

10/164901US

PCT/US/2003/000548WO/2003/103804

F16K18849010/08/2005

FLUID CONTROL DEVICEניגרים בקרת התקןFUJIKIN INCORPORATED

PCT/JP/2005/014653WO/2007/017937

B26D18849124/07/2006

חומר של יריעה של אורכי לחיתוך התקן פרופיל בעל פס ליצירת בתמידות הנעה

לאורכו המשתנה

DEVICE FOR LONGITUDINALLY CUTTING A WEB OF CONTINUOUSLY MOVING MATERIAL TO FORM A STRIP WITH VARIABLE LONGITUDINAL PROFILEMEGASPIREA PRODUCTION S.A.S.

25/07/20050507878FR

PCT/FR/2006/001798WO/2007/012739

B43M18849224/07/2006

ליישום ומכונה דואר מעטפות ליצירת שיטההשיטה

METHOD FOR MAKING MAILING COVERS AND MACHINE IMPLEMENTING SAID METHODMEGASPIREA PRODUCTION S.A.S.

25/07/20050507877FR

PCT/FR/2006/001799WO/2007/012740


C07D18849406/07/2006

–דיאנילינופירימידין,4,2 של חדשות תולדות רקחיים וכהרכבים כתרופות שימושן הכנתןIKK כמעכבי ובייחוד

NOVEL 2,4-DIANLINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORSSANOFI-AVENTIS

11/07/20050507370FR

25/11/20050511950FR

PCT/FR/2006/001619WO/2007/006926

A01N18849830/06/2006

מחלקיקי המורכב אנטיבקטריאלי גורם המכילים הידרוקסיד סולפאט אלומיניום

כסף

ANTIBACTERIAL AGENT COMPOSED OF SILVER-CONTAINING ALUMINUM SULFATE HYDROXIDE PARTICLES AND USE THEREOFKYOWA CHEMICAL INDUSTRY CO., LTD.

30/06/2005

2005-192471JP

01/07/2005

2005-194071JP

PCT/JP/2006/313527WO/2007/004713

C12N18850005/07/2006


תאי/מנגנוני המכילים ושיטות תכשירים תא לתוך ביולוגי חומר להחדרת צריבה

צמח

COMPOSITIONS AND METHODS COMPRISING STINGING CAPSULES/CELLS FOR DELIVERING A BIOLOGICALLY ACTIVE AGENT INTO A PLANT CELL

.CBD TECHNOLOGIES LTDבע"מ טכנולוגיות סי.בי.די07/07/2005

60/696799US

PCT/IL/2006/000779WO/2007/007316

C12N18850106/07/2006

H 19 של הביטוי לעיכוב גרעין חומצותבהם לשימוש ושיטות

NUCLEIC ACID AGENTS FOR DOWNREGULATING H19, AND METHOD OF USING SAME



07/07/2005

60/696795US

PCT/IL/2006/000785WO/2007/007317

A61K18850620/08/2002

רוקחי תכשיר להכנת באימונוגן שימושאלזהיימר במחלת לטיפול

USE OF AN IMMUNOGEN FOR PREPARATION OF PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASEPHARMEXA A/S

20/08/2001PA200101231DK

22/10/200160/337543US

16/04/2002PA200200558DK

16/04/200260/373027US

PCT/DK/2002/000547April 13, 2008589 –התשס"ח ח' בניסן

WO/2003/015812

G11B18850806/07/2006

מידע וקריאת להקלטת ומערכת שיטהמעוררים רבים פוטונים של בתווך

METHOD AND SYSTEM FOR DATA RECORDING AND READING IN MULTI-PHOTON EXCITABLE MEDIAMEMPILE INC.

07/07/2005

60/696810US

PCT/IL/2006/000788WO/2007/007319

A01N18851206/07/2006

לשימושים מאלאתיון להכנת תהליךרוקחיים

PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USETARO PHARMACEUTICALS U.S.A. INC.

06/07/2005

60/697010US

01/12/2005

60/741360US

24/03/2006

60/743741US

PCT/US/2006/026251WO/2007/005988

G01S18851401/11/2002

רשת בתוך ניידת עמדה מקלט מיקוםמיקום

LOCATING A ROVING POSITION RECEIVER WITHIN A LOCATION NETWORKQX CORPORATION PTY LTD.


02/11/2001PR8634AU

PCT/AU/2002/001495WO/2003/038469

G01S18851501/11/2002

FREQUENCY COHERENCE WITHIN Aמיקום רשת בתוך תדר קוהרנטיותLOCATION NETWORKQX CORPORATION PTY LTD.

02/11/2001PR8634AU

PCT/AU/2002/001495WO/2003/038469

G01S18851601/11/2002

של כרונולוגית לסינכרוניזציה ומכשיר שיטהרשת–מיקום

A METHOD AND DEVICE FOR CHRONOLOGICALLY SYNCHRONIZING ALOCATION NETWORKQX CORPORATION PTY LTD.

02/11/2001PR8634AU

PCT/AU/2002/001495WO/2003/038469

C12N18851830/06/2006

מיקום בשינוי שימוש תוך פאז'ים תצוגתמאוחים פוליפפטידים של תרגום כדי תוך

PHAGE DISPLAY USING COTRANSLATIONAL TRANSLOCATION OF FUSION POLYPEPTIDESUNIVERSITY OF ZURICH

08/07/2005

05106236.2EP

PCT/EP/2006/063729WO/2007/006665

A61M18851921/07/2000


UNIT DOSE CAPSULES AND DRYיבשה אבקה ומשאף מינון יחידת קופסיותPOWDER INHALERMANNKIND CORPORATION

23/07/1999

60/145464US

22/05/2000

60/206123US

PCT/US/2000/040454WO/2001/007107

C07D18852019/07/2006

–1H–)ארילאלקיל(–N תולדות קרבוקסאמיד, הכנתן2פירולופירידין–

בהן רפואיים ושימושים

N-(ARYLALKYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES PREPARATION AND USE THEREOFSANOFI-AVENTIS

22/07/20050507804FR

PCT/FR/2006/001767WO/2007/010138

C07K18852124/07/2006

COMPOSITIONS AND METHODS FORחלבון של לדהאגרגציה ושיטות הרכביםPROTEIN DEAGGREGATIONTRUBION PHARMACEUTICALS, INC.

25/07/2005

60/702545US

PCT/US/2006/028706WO/2007/014170


C12N18852217/08/1995

גרעין הגוף, חומצות משקל של מווסתים שלהם מתאימים, ושימושים וחלבוניםובאבחנה ברפואה

MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PROTEINS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOFTHE ROCKEFELLER UNIVERSITY

17/08/1994292345US

30/11/1994347563US

10/05/1995438431US

07/06/1995483211US

A61B18852501/07/2005

מטרה לשטח תת–שטח מבנה של היטלPROJECTION OF SUBSURFACE STRUCTURE ONTO AN OBJECT'S SURFACELUMINETX TECHNOLOGIES CORPORATION

PCT/US/2005/023522WO/2007/005018

H04L18852621/07/2006

ממשאבים תועלת להפקת ומערכות שיטות מנת על כלשהוא הספק תחת תחרותיים

בין רצוי פס רוחב מעבר על להקלסוגים ממספר או אחד מסוג התקנים

METHODS AND SYSTEMS FOR UTILIZATION OF RESOURCES OF CONTENTION UNDER ANY LOAD TO FACILITATE DESIRED BANDWIDTH ACROSS SINGLE OR MULTIPLE CLASSES OF DEVICESLUCENT TECHNOLOGIES INC.

29/07/2005

11/193522US


PCT/US/2006/028632WO/2007/016023

A01B18852726/06/2006

SOIL CONDITIONING DEVICEאדמה לריכוך התקןTERRACON TECHNOLOGIES LLC.

07/07/2005

11/176569US

PCT/US/2006/024803WO/2007/008393

A01N18852810/07/2006

עיניים בתנאים לטיפול ותכשירים שיטות סרום קושר רטינול, חלבון סרום באמצעות

רטינול סרום אפנון ( ו/אוRBP) רטינולRBP

METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATIONSIRION THERAPEUTICS, INC.

11/07/2005

60/698512US

PCT/US/2006/026770WO/2007/008821

G06F18853230/06/2006

במערכת הודעות תוכן העברת מערכתהחיוג צליל בזמן תקשורת

SYSTEM OF PROVIDING MESSAGE CONTENT IN A COMMUNICATION SYSTEM RING-BACK SPACEARAUZ, NICK

01/07/2005

60/696447US

06/08/2005

11/198341US

27/06/2006

11/475493US


WO/2007/005917

C07C18853422/11/2006

סינאקלסט של קריסטליניים פורמיםלהכנתם ותהליכים הידרוכלוריד

CRYSTAL FORMS OF CINACALCET HCI AND PROCESSES FOR THEIR PREPARATION

TEVA PHARMACEUTICALבע"מ פרמצבטיות תעשיות טבעINDUSTRIES LTD.

22/11/2005

60/739215US

05/12/2005

60/742626US

PCT/US/2006/045252WO/2007/062147

C07C18853519/10/2006

–2–]1 להכנת תהליך–4דימתילאמינו–)

מתוקסיפניל(אתיל[ הידרוכלוריד ציקלוהקסנול

גבוה בניקיון

PROCESS FOR THE PREPARATION OF HIGHLY PURE 1-[2-DIMETHYLAMINO-(4-METHOXYPHENYL)ETHYL]CYCLOHEXANOL HYDROCHLORIDE

.TEVA PHARMACEUTICAL INDUSTRIES LTDבע"מ פרמצבטיות תעשיות טבע19/10/200560/728632US03/04/200660/789086US08/05/200660/798877US

PCT/US/2006/041119WO/2007/047972

B65C18854228/08/2006


באמצעות לסימון ניתנת רב–שכבתית מדיהבנ"ל לשימוש והתקן אור, ושיטה

MULTI-LAYER, LIGHT MARKABLE MEDIA AND METHOD AND APPARATUS FOR USING SAMESINCLAIR SYSTEM INTERNATIONAL, LLC

29/08/2005

60/712640US

04/04/2006

60/789505US

PCT/US/2006/033586WO/2007/032900

H02M18854304/07/2006

METHOD AND DEVICE FOR SUPPLYמגנטי מצמד לאספקת ומתקן שיטהTO A MAGNETIC COUPLERUNIVETRSITE MONTPELLIER II

05/07/20050501736FR

PCT/FR/2006/001579WO/2007/006902

A61K18854410/07/2006

LIGANDS OF MELANOCORTINמלאנוקורטין קולטני של ליגנדיםRECEPTORSSOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S.

08/07/2005

60/697594US

PCT/US/2006/026554WO/2007/008684

A61K18854510/07/2006

MELANOCORTIN RECEPTORמלאנוקורטין קולטן של ליגנדיםLIGANDS


SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S.

08/07/2005

60/697779US

09/12/2005

60/748850US

PCT/US/2006/026586WO/2007/008704

D04B18854629/06/2006

CLEANROOM WIPERנקי לחדר מגבKIMBERLY-CLARK WORLDWIDE, INC.

11/07/2005

60/698116US

02/12/2005

11/292650US

PCT/US/2006/025453WO/2007/008444

D04B18854729/06/2006

CLEANROOM WIPERלניקוי מטליתKIMBERLY-CLARK WORLDWIDE, INC.

11/07/2005

60/698116US

02/12/2005

11/293449US

PCT/US/2006/025452WO/2007/008443

A47K18854829/06/2006

APPLIANCE FOR DELIVERING Aתכשיר להעברת כליCOMPOSITIONKIMBERLY-CLARK WORLDWIDE, INC.

26/07/2005

11/190597US

PCT/US/2006/025451


WO/2007/018822

C07D18855004/07/2006

כאגוניסטים הטרוציקליות תרכובותהתירואיד לרצפטור

HETEROCYCLIC COMPOUNDS AS AGONISTS FOR THE THYROID RECEPTORKARO BIO AB

04/07/2005

0513692.4GB

PCT/EP/2006/006522WO/2007/003419

C07J18855112/07/2006

התרכובת של משופרת גבישית צורה348441–A

IMPROVED CRYSTALLINE FORM OF THE COMPOUND A-348441KARO BIO AB

12/07/2005

0514302.9GB

PCT/EP/2006/006811WO/2007/006561

C12N18855406/07/2006

NOVEL PHAGE DISPLAYפאג'ים ליצוג חדשות טכנולוגיותTECHNOLOGIESRIBOVAX BIOTECHNOLOGIES S.A.

07/07/2005PCT/EP05/007325EP

PCT/IB/2006/001878WO/2007/007154

C07D18855528/07/2006

CYANOPYRIDINE PESTICIDESציאנופירידיניים חרקים קוטליBASF AKTIENGESELLSCHAFT

29/07/2005

60/703753US


PCT/EP/2006/064788WO/2007/014913

C07C18855619/07/2006

מפתח של יציבות מיימיות דיספרסיותצבעים

STABLE AQUEOUS DISPERSIONS OF COLOUR DEVELOPERCIBA SPECIALTY CHEMICALS HOLDING INC.

28/07/2005

05106950.8EP

PCT/EP/2006/064387WO/2007/014847

A61B18855705/07/2006

נוזלים לבספקת בקרה מערכתלאנדוסקוף

IMPROVED CONTROL SYSTEM FOR SUPPLYING FLUID MEDIUM TO ENDOSOCPE

.STRYKER GI LTDג'י. אי. בע"מ סטריקר28/07/2005

60/703200US

PCT/IL/2006/000776WO/2007/013055

C12N18855804/07/2006

של לייצור סרום ללא מדיוםרקומביננטים גונאדוטרופינים

SERUM-FREE CULTURE MEDIUM FOR THE PRODUCTION OF RECOMBINANT GONADOTROPINSARES TRADING S.A.

05/07/2005

05106060.6EP

06/07/2005

60/697077US

PCT/EP/2006/063862WO/2007/003640


A01N18856030/06/2006

המקודדים לאדנו הקשורים נגיף וקטורי רוקחות ותכשירי דיסמוטז חמצתית–על

אותם המכילים

ADENO-ASSOCIATED VIRUS VECTORS ENCODING SUPEROXIDE DISMUTASE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMEGENZYME CORPORATION

07/07/2005

60/697450US

PCT/US/2006/025980WO/2007/008486

A01N18856130/06/2006

הקשור נגיף המכילים רוקחות תכשיריחסינית המגווין טרנסגן המקודד לאדנו

PHARMACEUTICAL COMPOSITION CONTAINING AN ADENO-ASSOCIATED VIRUS ENCODING AN IMMUNOMODULATORY TRANSGENEGENZYME CORPORATION

07/07/2005

60/697459US

PCT/US/2006/025979WO/2007/008485

D01F18856205/07/2006

ותהליכים ארומטית מפוליאמיד סיביםלהכנתם

AROMATIC POLYAMIDE FILAMRNTS AND METHODS FOR THE PRODUCTION THEREOFKOLON INDUSTRIES, INC.

05/07/2005

10-2005-0060308KR

PCT/KR/2006/002625


WO/2007/004849

D01F18856305/07/2006


AROMATIC POLYAMIDE FILAMENTS AND METHODS FOR THE PRODUCTION THEREOFKOLON INDUSTRIES, INC.

06/07/2005

10-2005-0060501KR

PCT/KR/2006/002627WO/2007/004851

D01F18856405/07/2006


AROMATIC POLYAMIDE FILAMENTS AND METHODS FOR THE PRODUCTION THEREOFKOLON INDUSTRIES, INC.

06/07/2005

10-2005-0060502KR

PCT/KR/2006/002624WO/2007/004848

B02C18856605/07/2006

ו/או אלקטריים די גורמים לשיפור שיטהבערה מעכבי הרכבים של פיזור גורמי

METHOD TO IMPROVE DIELECTRIC AND/OR DISSIPATION FACTORS OF FLAME RETARDANT COMPOSITIONSALBEMARLE CORPORATION

05/07/2005

60/697705US

PCT/US/2006/026656April 13, 2008601 –התשס"ח ח' בניסן

WO/2007/006054

A61M18856703/07/2006

BALLOON CATHETERבלון צנתרANGIOSLIDE LTDבע"מ אנג'יוסלייד

05/07/2005

60/695868US

14/10/2005

60/726160US

PCT/IL/2006/000770WO/2007/004221

B26B18856820/06/2006

HAIR CLIPPER WITH MOTORISEDממונע חיתוך מוביל עם שיער קוצץCUTTING GUIDEFACO S.A.

07/07/2005

05447164.4EP

PCT/BE/2006/000069WO/2007/006106

F16L18857003/07/2005

COUPLING BETWEEN TWO TUBESצנורות שני בין חבורWIDEE B.V.

PCT/NL/2005/000471WO/2007/004860

F16L18857103/07/2005


חיתוך טבעת המכילים גופים שני בין חבור שפתי עם אלסטית בצורת המעוותת

הברגה היוצרים תתיכה

COUPLING BETWEEN TWO BODIES COMPRISING AN ELASTICALLY DEFORMABLE CUTTING RING WITH A SCREW THREAD FORMING CUTTING LIPSWIDEE B.V.

PCT/NL/2005/000472WO/2007/004861

F16L18857203/07/2005

כינון מחברי עם צנורות שני בין חבורנפרדים

COUPLING BETWEEN TWO TUBES WITH SEPARATE SET-UP CLAMPSWIDEE B.V.

PCT/NL/2005/000473WO/2007/004862

F16L18857303/07/2006

COUPLING BETWEEN TWO BODIESגופים שני בין חבורWIDEE B.V.

03/07/20051029412NL

PCT/NL/2006/050161WO/2007/004880

C02F18857505/07/2006

בביומסה לטיפול ושיטה מכשירקבועים מגנטים באמצעות

DEVICE AND METHOD FOR THE TREATMENT OF BIOMASSES WITH PERMANENT MAGNETSMEIER, TONIO

07/07/2005

102005031873.8DE

PCT/DE/2006/001160WO/2007/006269


C12N18857601/12/1999

טרנסממברנה של פוליפפטידיםלכך המקדדות גרעין וחומצות

SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAMEGENENTECH, INC.

16/12/199860/112851US

16/12/199860/113145US

22/12/199860/113511US

12/01/199960/115565US

12/01/199960/115558US

12/01/199960/115733US

09/02/199960/119341US

10/02/199960/119537US

12/02/199960/119965US

02/06/1999PCT/US99/12252US

PCT/US/1999/028634WO/2000/036102

C12N18857701/12/1999



16/12/199860/112851US

16/12/199860/113145US

22/12/199860/113511US

12/01/199960/115565US

12/01/199960/115558US


12/01/199960/115733US

09/02/199960/119341US

10/02/199960/119537US

12/02/199960/119965US

02/06/1999PCT/US99/12252US

PCT/US/1999/028634WO/2000/036102

C12N18857801/12/1999



16/12/199860/112851US

16/12/199860/113145US

22/12/199860/113511US

12/01/199960/115565US

12/01/199960/115558US

12/01/199960/115733US

09/02/199960/119341US

10/02/199960/119537US

12/02/199960/119965US

02/06/1999PCT/US99/12252US

PCT/US/1999/028634April 13, 2008605 –התשס"ח ח' בניסן

WO/2000/036102

C12N18857901/12/1999



16/12/199860/112851US

16/12/199860/113145US

22/12/199860/113511US

12/01/199960/115565US

12/01/199960/115558US

12/01/199960/115733US

09/02/199960/119341US

10/02/199960/119537US

12/02/199960/119965US

02/06/1999PCT/US99/12252US

PCT/US/1999/028634WO/2000/036102

C12N18858001/12/1999




16/12/199860/112851US

16/12/199860/113145US

22/12/199860/113511US

12/01/199960/115565US

12/01/199960/115558US

12/01/199960/115733US

09/02/199960/119341US

10/02/199960/119537US

12/02/199960/119965US

02/06/1999PCT/US99/12252US

PCT/US/1999/028634WO/2000/036102

C12N18858101/12/1999

טרנסממברנה של פולפפטידיםלכך המקדדות גרעין וחומצות


16/12/199860/112851US

16/12/199860/113145US

22/12/199860/113511US

12/01/199960/115565US

12/01/199960/115558US

12/01/199960/115733US

09/02/199960/119341US

10/02/199960/119537US


12/02/199960/119965US

02/06/1999PCT/US99/12252US

PCT/US/1999/028634WO/2000/036102

A61B18858206/07/2006

הידוק והתקני ניתוחיים מהדקיםSURGICAL FASTENERS AND DEVICES FOR SURGICAL FASTENING

.ENDOGUN MEDICAL SYSTEMS LTDבע"מ רפואיות מערכות אנדוגן06/07/2005

60/696516US

PCT/IL/2006/000783WO/2007/004228

B65D18858604/07/2006

לאריזה, שימור, בישול אריזה קופסתמזון וצריכת במיקרוגל באדים

PACKAGING BOX FOR PACKAGING, PRESERVING, MICROWAVE STEAM COOKING AND CONSUMPTION OF FOODSSEBBAN CLAUDE

05/07/20050507122FR

27/01/20060600747FR

PCT/FR/2006/050675WO/2007/003864

C07K18858830/06/2006


CTLA–4 כנגד נוגדן של משולב טיפול מוטיף המכיל סינטתי ואוליגונוקליאוטיד

CPGבסרטן לטיפול

ANTI-CTLA -4 ANTIBODY AND CPG-MOTIF-CONTAINING SYNTHETIC OLIGODEOXYNUCLEOTIDE COMBINATION THERAPY FOR CANCER TREATMENTPFIZER INC.

07/07/2005

60/697082US

PCT/US/2006/025711WO/2007/008463

G09F18858907/07/2006

לביגוד אביזרים להצמדת ומערכת שיטהSYSTEM AND METHOD FOR SECURING ACCESSORIES TO CLOTHINGJIBBITZ LLC

07/07/2005

60/697326US

02/08/2005

60/704645US

16/11/2005

60/737115US

PCT/US/2006/026508WO/2007/008655

C07K18859014/01/2000

PKSSCHIZOCHYTRIUM PKS GENES גנים–סכיזוקטריוםMARTEK BIOSCIENCES CORPORATION

14/01/1999

/09231899

US

PCT/US/2000/000956WO/2000/042195


A61K18859111/07/2006

ע"י אוטואימונית במחלה לטיפול שיטות מסוג נוגדנים של אנושית בגרסה שימוש

A16CD – אנטי

METHODS OF TREATING AUTOIMMUNE DISEASE USING HUMANIZED ANTI-CD16A ANTIBODIESMACROGENICS, INC.

11/07/2005

60/698623US

PCT/US/2006/027387WO/2007/009065

A61K18859211/07/2006

אוטואימוניות בהפרעות לטיפול שיטות מונוקלונלים בנוגדים שימוש באמצעות

את המדכאים מופחתת רעילות בעליהחיסונית הפעילות

METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS USING IMMUNOSUPPRESSIVE MONOCLONAL ANTIBODIES WITH REDUCED TOXICITYMACROGENICS, INC.

11/07/2005

60/698517US

PCT/US/2006/027386WO/2007/009064

F15B18859301/06/2006

אויר ומדחס אויר למדחס מתאםADAPTOR FOR AN AIR COMPRESSOR AND AN AIR COMPRESSOR


BGM INNOVATIONS LIMITED07/07/2005

2005903616AU

PCT/AU/2006/000748WO/2007/006074

A61K18859405/07/2006

ANTI-CCR7 RECEPTOR ANTIBODIES FORבסרטן לטיפול7CCR אנטי נוגדניםTHE TREATMENT OF CANCERUNIVERSIDAD AUTONOMA DE MADRID

06/07/2005PCT/EP2005/007371EP

PCT/EP/2006/006556WO/2007/003426

H04Q18859530/06/2006

התנגשות בקשת לפתרון ושיטה מתקניםגבוה תדרים בטווח אלחוטית ברשת

APPARATUS AND METHOD FOR RESOLVING REQUEST COLLISION IN A HIGH BANDWIDTH WIRELESS NETWORKQUALCOMM INCORPORATED

30/06/2005

11/173832US

PCT/US/2006/026083WO/2007/005897

C12N18859614/07/2006


ותכשירי אדיפוזית מרקמה המופקים תאיםאותם המכילים רוקחות

ADIPOSE TISSUE DERIVED CELLS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMECOGNATE THERAPEUTICS, INC.

15/07/2005

60/699553US

PCT/US/2006/027515WO/2007/011797

C07D18859712/07/2006

רוקחות ותכשירי בנזואימידאזול תולדותאותן המכילים

BENZOIMIDAZOLE DERIVATES AND PHARMACEUTICAL COMPOUNDS CONTAINING THE SAMETAIHO PHARMACEUTICAL CO., LTD.

13/07/2005

2005-204957JP

22/09/2005

2005-275919JP

PCT/JP/2006/313827WO/2007/007778

C07D18859827/07/2006

1 צורה להבנת ושיטות קברגולין של מימסבו המשתמשות קברגולין של

A SOLVATE OF CABERGOLINE AND METHODS OF PREPARING CABERGOLINE FORM 1 UTILIZING THE SAMERESOLUTION CHEMICALS LIMITED

27/07/2005

0515430.7GB

PCT/GB/2006/002784WO/2007/012846


C12Q18859918/08/2006

RNAMETHODS AND SUBSTANCES FOR מיקרו לבדידת וחומרים שיטותISOLATING MICRORNABIOVENTURES INC.

19/08/2005

60/709861US

PCT/US/2006/032264WO/2007/024653

C07D18860011/07/2006

METHOD FOR PREPARINGאסאומאפראזול להכנת תהליךESOMEPRAZOLEHANMI PHARM. CO., LTD.

28/07/2005

10-2005-0068761KR

PCT/KR/2006/002719WO/2007/013743

C07K18860308/07/2005

PREPARATION OF INSULINאינסולין תצמידי של הכנהCONJUGATESBIOCON LIMITED

PCT/IN/2005/000234WO/2007/007345

F16L18860407/07/2006

PIPE CONNECTIONלצינורות חיבורUPONOR INNOVATION AB

08/07/2005

05106243.8EP

PCT/FI/2006/050322WO/2007/006863


H04N18860529/06/2006

A METHOD AND A SYSTEM FORמודפסים מוצרים לעיבוד ומערכת שיטהPROCESSING PRINTED PRODUCTSePAC TECHNOLOGIES

06/07/2005

11/175676US

PCT/US/2006/025279WO/2007/008434

C07D18860613/07/2006

1,1 בנזותיאזפינים1,4 נגזרות משופרות, תכונות בעלי דיאוקסיד

המכילים ליצירתן, תכשירים שיטותבהם ושימוש אותם

NOVEL 1,4-BENZOTHIAZEPINE-1,1-DIOXIDE, DERIVATIVE HAVING IMPROVED PROPERTIES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUND, AND USE THEREOFSANOFI-AVENTIS DEUTSCHLAND GMBH

15/07/2005

102005033100.9DE

PCT/EP/2006/006849WO/2007/009656

C12N18860706/07/2006

HIGH TRYPTOPHAN SOYBEANבטריפטופן עשיר סויה מזוןMEALRENESSEN LLC

08/07/2005

60/697452US

PCT/US/2006/026269WO/2007/008546

C07D18860813/07/2006


–1,1 –בנזותיאזפינין1,4 נגזרות ליצירתו, ותרופות דיאוקסיד, תהליך

אותו המכילות

1,4-BENZOTHIAZEPINE 1,1-DIOXIDE DERIVATIVE, PROCESS FOR ITS PREPARATION, MEDICAMENTS COMPRISING THIS COMPOUND, AND USE THEREOF AS A HYPOLIPIDAEMICSANOFI-AVENTIS DEUTSCHLAND GMBH

15/07/2005

102005033099.1DE

PCT/EP/2006/006848WO/2007/009655

B41J18860911/07/2006

DROPLET DEPOSITION APPARATUSטיפונת להוצאת התקןXAAR TECHNOLOGY LIMITED

11/07/2005

0514202.1GB

PCT/GB/2006/002551WO/2007/007079

A61K18861014/06/2000

NOVEL ANTI-ALLERGIC AGENTSחדשניים אנטי–אלרגיים תכשירים

RAMOT AT TEL AVIV UNIVERSITYבע"מ אביב תל אוניברסיטת ליד רמותLTD.

17/06/1999130526IL

PCT/IL/2000/000346WO/2000/078346

C07K18861109/07/2006

ודומיהם, והשימוש1SP מסוג פוליפפטידיםבהם

SP1 POLYPEPTIDES, MODIFIED SP1 POLYPEPTIDES AND USES THEREOF

ס.פ. בע"מ פולכרוםYISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM

07/07/2005

60/696779US

PCT/IL/2006/000795


WO/2007/007325

H04L18861206/07/2006

ושירותים מיקום להגדרת ומכשירים שיטות לאזור אלחוטיות ברשתות מיקום מבוססי

מקומיות אלחוטיות רחב, לרשתותאיזוריות אישיות אלחוטיות ולרשתות

METHODS AND DEVICES FOR LOCATION DETERMINATION AND LOCATION-BASED SERVICES IN WIRELESS WIDE AREA NETWORKS, WIRELESS LOCAL AREA NETWORKS AND WIRELESS PERSONAL AREA NETWORKSQUALCOMM INCORPORATED

07/07/2005

60/697504US

29/08/2005

60/712320US

30/09/2005

11/240323US

PCT/US/2006/026309WO/2007/008574

H04L18861306/07/2006

לביצוע יחד לעבודה ומכשירים שיטות רחב לאיזור אלחוטיות רשתות של משימה

לרשתות או מקומיות אלחוטיות ולרשתותאזוריות אישיות אלחוטיות

METHODS AND DEVICES FOR INTERWORKING OF WIRELESS WIDE AREA NETWORKS AND WIRELESS LOCAL AREA NETWORKS OR WIRELESS PERSONAL AREA NETWORKSQUALCOMM INCORPORATED

07/07/2005

60/697504US

29/08/2005

60/712320US

30/09/2005

11/240045US

PCT/US/2006/026308WO/2007/008573

C07C18861413/07/2006


בעל דואלי מחדש קליטה– מעכב וסרוטונין נורפינפירין של גבוהה סלקטיביות

שלו ושימוש

HIGHLY SELECTIVE SEROTONIN AND NOREPINEPHRINE DUAL REUPTAKE INHIBITOR AND USE THEREOFWYETH

15/07/2005

60/699665US

PCT/US/2006/026991WO/2007/011594

C07D18861517/07/2006

TRANSCRIPTASE של מעכביםREVERSE HIV

HIV REVERSE TRANSCRIPTASE INHIBITORSMERCK & CO. INC.

22/07/2005

60/701797US

18/10/2005

60/727916US

10/04/2006

60/790705US

PCT/US/2006/027700WO/2007/015812

C07D18861604/07/2006

פרוליפרטור לפרוקסיסום אקטיבטורדלתא רצפטור המפעיל

ACTIVATOR OF PEROXISOME PROLIFERATOR ACTIVATED

RECEPTOR? NIPPON CHEMIPHAR CO., LTD.

06/07/2005

2005-197484JP

PCT/JP/2006/313636WO/2007/004733

C07C18861711/07/2006

GLUTAMATE AGGRECANASEאגרקנאז לגלוטמט מעכביםINHIBITORSWYETH


11/07/2005

60/697590US

PCT/US/2006/027066WO/2007/008994

C07K18861814/07/2006

3NS HCVפרוטאז מעכביHCV NS3 PROTEASE INHIBITORSMERCK & CO. INC.

20/07/2005

60/700764US

07/10/2005

60/724566US

PCT/US/2006/027573WO/2007/015787

C07J18861920/07/2006

,21–אן–4–אוקסו–פרגן–3 להכנת תהליך ללא חמצון באמצעות –קרבולקטונים17

–הידרוקסיפרופיל(–3–)17 של מתכת–דיהידרוקסיאנדרוסטאנים17,3

PROCESS FOR THE PRODUCTION OF 3-OXO-PREGN-4-ENE-21,17-CARBOLACTONES BY THE METAL-FREE OXIDATION OF 17-(3-HYDROXYPROPYL)-3,17 DIHYDROXYANDROSTANESBAYER SCHERING PHARMA AG

21/07/2005

05090214.7EP

21/07/2005

11/185984US

PCT/EP/2006/007287WO/2007/009821

B05C18862105/06/2006

ידית בעל דביק לסרט חיתוך סכיןאסימטרית

TAPING KNIFE WITH OFFSET HANDLEUNITED STATES GYPSUM COMPANY

22/07/2005

11/187569US

PCT/US/2006/021792WO/2007/018704


G08B18862329/07/2005

PORTABLE HANDHELD SECURITYביד שמוחזק נייד אבטחה התקןDEVICECATCHER, INC.

08/07/2005PCT/US2005/24506US

PCT/US/2005/026812WO/2007/008217

B26B18862401/06/2006

TAPING KNIFE HANDLE WITHמוחדר זיהוי עם סרטים חיתוך לסכין ידיתIDENTIFICATION INSERTUNITED STATES GYPSUM COMPANY

22/07/2005

11/187582US

10/01/2006

11/328530US

PCT/US/2006/021191WO/2007/018690

G08B18862508/07/2005

PORTABLE HANDHELD SECURITYביד המוחזק נייד אבטחה התקןDEVICECATCHER, INC.

PCT/US/2005/024506WO/2007/008204


A23L18862623/06/2006

FOOD ARTICLE COMPRSING Aכמוסת–מיקרו המכיל אוכל פריטMICROCAPSULEOCEAN NUTRITION CANADA LTD

07/07/2005

60/697092US

17/05/2006

11/435605US

07/06/2006

60/811503US

08/06/2006

60/811830US

PCT/US/2006/024735WO/2007/008384

G01N18862910/07/2006

של מודולטורים לחיפוש שיטות של (, מודוטוריםIL–32 )32 אינטרלאוקין

32–ILכאלה שיטות ידי על המזוהים בהם והשימוש

METHODS OF SCREENING FOR MODULATORS OF INTERLEUKIN-32 (IL-32), MODULATORS OF IL-32 IDENTIFIED BY SAID METHODS AND THEIR USE


11/07/2005169622IL

PCT/IL/2006/000798WO/2007/007327


H04L18863105/07/2006

הרשאות במערכת המצויד אחסון ציודאוטומטית

MASS STORAGE DEVICE WITH AUTOMATED CREDENTIALS LOADINGSANDISK CORPORATION

08/07/2005

60/697906US

27/12/2005

11/319259US

27/12/2005

11/319835US

PCT/US/2006/026241WO/2007/008540

C12P18863212/07/2006

HP–2 הגן את הנושאים טרנסגניים עכבריםדם כלי למחלות כמודלים והשימושים

TRANSGENIC MICE CARRYING HP-2 GENE AND USES AS MODELS FOR VASCULAR DISEASES



12/07/2005

60/698012US

PCT/US/2006/026842WO/2007/008870

H04R18863407/07/2006

ברורה לתפיסה המשמש להאזנה מכשיררועשת בסביבה קול אותות של

LISTENING DEVICE FOR CLEAR PERCEPTION OF SOUND SIGNALS IN A NOISY ENVIRONMENTAMPLIFON A.G.

08/07/200501138/05CH

PCT/IB/2006/052311WO/2007/007265


B24B18863510/07/2006

עבור לזרוע משופר קצה אפקטור סידור כימית לפלנריזציה רפידה ידי על התאמה

(CMP) מכנית

ENHANCED END EFFECTOR ARM ARRANGEMENT FOR CMP PAD CONDITIONINGTBW INDUSTRIES, INC.

09/07/2005

60/697893US

PCT/US/2006/026771WO/2007/008822

A61K18863907/07/2006

באמצעות שהוכנה פנטאניל תערובתחיוני שמן המכילה נוסחא

FENTANYL FORMULATION CONTAINING AN ESSENTIAL OILSOSEI R&D LTD

08/07/2005

0514043.9GB

PCT/GB/2006/002526WO/2007/007059

H04L18864006/07/2006


לביצוע יחד לעבודה ומכשירים שיטות רחב לאיזור אלחוטיות רשתות של משימה

לרשתות או מקומיות אלחוטיות ולרשתותאיזוריות אישיות אלחוטיות

METHODS AND DEVICES FOR INTERWORKING OF WIRELESS WIDE AREA NETWORKS AND WIRELESS LOCAL AREA NETWORKS OR WIRELESS PERSONAL AREA NETWORKSQUALCOMM INCORPORATED

07/07/2005

60/697504US

29/08/2005

60/712320US

30/09/2005

11/240725US

PCT/US/2006/026307WO/2007/008572

B64D18864125/07/2006

לשם במיוחד מותאמות התאמה מערכותכיסא תנוחות תיקון

FITTING SYSTEMS ADAPTED ESPECIALLY FOR FIXING SEAT POSITIONSWEBER AIRCRAFT LP

25/07/2005

60/702133US

PCT/US/2006/028753WO/2007/014184

C07K18864218/07/2006

HUMAN ANTI-B7RP1 NEUTRALIZINGאנוש ממקור1RP7Bאנטי– ניטרול נוגדניANTIBODIESMEDAREX, INC.

18/07/2005

60/700265US

PCT/US/2006/027862WO/2007/011941


C07D18864320/07/2006

–1 )הטרואריל(–Nתולדות––2–אינדול–1Hהטרוארילאלקיל–

ושימושיהן קרבוקסאמיד,הכנתן

N-(HETEROARYL)-1-HETEROARYLALKYL-1H-INDOLE-2-

CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOFSANOFI-AVENTIS

22/07/20050507803FR

PCT/FR/2006/001782WO/2007/010144

H04L18864409/07/2006

סיב ערוץ תנועת של שקופה תחבורהמידע חבילת החלפת ברשתות

TRANSPARENT TRANSPORT OF FIBRE CHANNEL TRAFFIC OVER PACKET-SWITCHED NETWORKS

.CORRIGENT SYSTEMS LTDבע"מ מערכות קוריגנט11/07/2005

60/698538US

29/06/2006

11/479595US

PCT/IL/2006/000794WO/2007/007324

H05H18865401/02/2002

מגנטי שדה בעזרת פלסמה הגבלתהפוכה שדה בתצורת ואלקטרוסטטי

MAGNETIC AND ELECTROSTATIC CONFINEMENT OF PLASMA IN A FIELD REVERSED CONFIGURATIONTHE REGENTS OF THE UNIVERSITY OF CALIFORNIA

01/02/2001

60/266074US

08/06/2001

60/297086US

31/01/2002

10/066424US

PCT/US/2002/002854WO/2002/062112


C12N18866710/03/2001

וציניה נגיף ע"י מודבק פונדקאי תא(MVA) ששונה אנקארה

HOST CELL INFECTED BY A MODIFIED VACCINIA VIRUS ANKARA (MVA)BAVARIAN NORDIC A/S

14/03/2000PA200000410DK

PCT/EP/2001/002703WO/2001/068820

A61B18867617/01/2002

חודרני גלאוקומה לניתוח ושיטה מכשירמזערית

MINIMALLY INVASIVE GLAUCOMA SURGICAL INSTRUMENT AND METHODTHE REGENTS OF THE UNIVERSITY OF CALIFORNIA

18/01/2001

60/263617US

PCT/US/2002/001665WO/2002/056805

A61K18868615/08/2000

VACCINEחדש חיסון תכשירSMITHKLINE BEECHAM BIOLOGICALS S.A.

17/08/1999

9919468.0GB

18/11/1999

9927336.9GB

PCT/EP/2000/007965


WO/2001/012797

C12N18871015/01/2002

NUCLEIC ACID AND PROTEINעל–ידה המקודד וחלבון גרעין חומצתENCODED THEREBYDSM FINE CHEMICALS AUSTRIA NFG GMBH & CO. KG

16/01/2001A60/2001AT

03/04/2001A523/2001AT

A61K18877403/10/2002

COMPOSITIONS FOR DELIVERY OFתרופות תערובות של לנתינה תכשיריםDRUG COMBINATIONSCELATOR PHARMACEUTICALS, INC.

03/10/2001

60/326671US

17/12/2001

60/341529US

15/02/2002

60/356759US

23/04/20022383529CA

07/08/2002

60/401984US

06/09/2002

60/408733US

PCT/CA/2002/001500WO/2003/028696

H01L18879001/06/2003

דיאלקטריות בעלי קרומים להכנת שיטות PROCESSES FOR PREPARING LOWנמוכה

DIELECTRIC FILMS

AIR PRODUCTS AND CHEMICALS, INC.


30/05/2002

60/384321US

20/05/2003

10/638942US

C12N18879121/08/1998

HYPOXIA-REGULATING GENESחמצן חוסר של מצב המסדירים גניםQUARK PHARMACEUTICALS, INC.

21/08/1997

60/056453US

PCT/US/1998/017296WO/1999/009049

G06F18882822/08/2006

MESSAGING SYSTEM AND METHODהודעות למשלוח ושיטה מערכתTRIPLAY COMMUNICATIONS LTDבע"מ תקשורת טריפליי

22/08/2005

60/709830US

13/12/2005

60/749625US

13/12/2005

60/749626US

PCT/IL/2006/000976WO/2007/023494

C02F18882907/07/2006

SYSTEM AND METHOD OF SLURRYעכורים במים לטיפול ושיטה מערכתTREATMENT


SIEMENS WATER TECHNOLOGIES CORP.

02/08/2005

11/195108US

PCT/US/2006/026336WO/2007/018854

A61B18883220/07/2006

עצם מבני לייצוב ושיטות מערכותSYSTEMS AND METHODS FOR STABILIZATION OF BONE STRUCTURESVERTIFLEX, INC.

22/07/2005

60/701660US

23/02/2006

11/362366US

PCT/US/2006/028586WO/2007/014119

A61K18883322/05/2000

עבור יציבים רוקחות הרכבי של תמיסותבלחץ קצובה מנה הנותנים משאפים

STABLE PHARMACEUTICAL SOLUTION FORMULATIONS FOR PRESSURISED METERED DOSE INHALERSCHIESI FARMACEUTICI S.P.A.

PCT/EP/2000/004635WO/2001/089480


C12N18883429/05/2002

NOVEL VACCINE COMPOSITIONחדש חיסון תכשירSAECHISCHES SERUNWERK DRESDEN BRANCH OF SMITHKLINE BEECHAM PHARMA GMBH & CO. KG

30/05/2001

0113083.0GB

21/02/2002

0204116.8GB

PCT/EP/2002/005883WO/2002/097072

F22B18883531/07/2006

PORTABLE VAPORIZING DISPENSERנייד אדים מחלקTEMPRA TECHNOLOGY, INC.

01/08/2005

60/704573US

PCT/US/2006/030572WO/2007/016705

G07F18883620/07/2006

ידי על שפות רב לבחירה והתקן שיטה ממשק בעלת מערכת עבור משתמשמשתמש

METHOD AND APPARATUS FOR MULTI-LANGUAGE USER SELECTION FOR SYSTEM USER INTERFACEGOLDMINE WORLD, INC.

20/07/2005

11/185030US

PCT/US/2006/028034WO/2007/013921

C22C18883713/07/2006

MAGNESIUM ALLOYמגנזיום סגסוגתGKSS-FORSCHUNGSZENTRUM GEESTHACHT GMBH

20/07/2005

102005033835.6DE


PCT/DE/2006/001212WO/2007/009435

C07D18883801/08/2006

ותכשירי מותכות הטרוצקליות תרבובותאותן המכילים רוקחות

FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMEPHARMA MAR, S.A.

01/08/2005

0515673.2GB

PCT/GB/2006/050229WO/2007/015112

A61K18883918/07/2006

ותכשירי מותמרות פרופאנאמיד תולדותאותן המכילים רוקחות

SUBSTITUTED PROPANAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMEDAIICHI SANKYO COMPANY, LIMITED

19/07/2005

2005-208036JP

PCT/JP/2006/314144WO/2007/010885

A61K18884019/07/2006

TWO-STAGE GAS REGULATINGגז לויסות שלבית דו מערכתASSEMBLY


FATS INC.19/07/2005

60/700595US

PCT/US/2006/028074WO/2007/012018

C12P18884121/07/2006

SORF מבני הכולל מרובה גנים ביטוי בפוליפרוטאינים, המשתמשות ושיטות

ופרוטאוליזה פרו–פרוטאינים

MULTIPLE GENE EXPRESSION INCLUDING SORF CONSTRUCTS AND METHODS WITH POLYPROTEINS, PRO-PROTEINS, AND PROTEOLYSISABBOTT LABORATORIES

21/07/2005

60/701855US

PCT/US/2006/028691WO/2007/014162

C07D18884422/01/2003

פלואור מותמרי ציקלואלקנואינדולים רצפטור של כאנטגוניסטים ושימושם

D2 פרוסטאגלנדין

FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTSMERCK FROSST CANADA LTD

24/01/2002

60/351384US

PCT/CA/2003/000084WO/2003/062200


A23L18884623/10/2006

DIETARY FIBER FORMULATIONאספקה ושיטת תזונתי סיב של פורמולציהAND METHOD OF ADMINISTRATIONNOVARTIS AG

24/10/2005

60/729767US

02/12/2005

60/742124US

PCT/US/2006/041568WO/2007/050656

A23L18884722/08/2006

NUTRITION FOR OBESE PATIENTSיתר בהשמנת חולים עבור תזונהNESTEC S.A.

26/08/2005

05018626.1EP

09/11/2005

05110556.7EP

PCT/EP/2006/065562WO/2007/042341

C07D18884824/07/2006

NOVEL HETEROCYCLIDENEאצטמיד הטרוציקלידין של חדשה נגזרתACETAMIDE DERIVATIVEMOCHIDA PHARMACEUTICAL CO., LTD.

22/07/2005

2005-213534JP

PCT/IB/2006/002016WO/2007/010383

C07D18885017/07/2006

KCATHEPSIN K INHIBITORS קתפסין מעכביF. HOFFMANN-LA ROCHE AG

27/07/2005

60/702937US

PCT/EP/2006/064306


WO/2007/014839

C07D18885127/07/2006

R–VEGFSALTS AND POLYMORPHS OF A מעכב של ופולימורפים מלחיםVEGF-R INHIBITORPFIZER INC.

08/08/2005

60/706332US

14/12/2005

60/750189US

PCT/IB/2006/002171WO/2007/017740

F16D18885231/07/2006

העשויים חלקים של חימצון נגד הגנהפחמן המכיל מורכב מחומר

ANTI-OXIDATION PROTECTION OF PIECES MADE FROM A COMPOSITE MATERIAL CONTAINING CARBONMESSIER-BUGATTI

01/08/20050508196FR

PCT/FR/2006/050765WO/2007/015026

C07D18885311/12/2001

יצירת של הטרוציקליים מעקבים על המבוססים ביטא–אמילואיד

סולפונאמיד

HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTIONWYETH

13/12/2000

60/255105US

PCT/US/2001/048375WO/2002/057252

C07D18885424/07/2006


רפואיים ושימושים בנזילפיפרזין תולדותשלהן

BENZYLPIPERAZINE DERIVATES AND THEIR MEDICAL USEGLAXO GROUP LIMITED

26/07/2005

0515381.2GB

09/06/2006

0611469.8GB

PCT/EP/2006/007390WO/2007/012479

C08J18885528/06/2006

PROCESS FOR THE RECYCLING OFמורחב פוליסטירן למיחזור תהליךEXPANDED POLYSTYRENEPOLIMERI EUROPA S.P.A.

22/07/2005MI2005A001409IT

PCT/EP/2006/006247WO/2007/009559

C07D18885631/07/2006

רצפטור כמווסתות חדשות פיפרידין נגזרות במחלות לטיפול השימושיות כימוקין של

נשימתיות

NOVEL PIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS USEFUL FOR THE TREATMENT OF RESPIRATORY DISEASESASTRAZENECA AB

01/08/2005

0501757-9SE

PCT/SE/2006/000918WO/2007/015664

C07D18885703/08/2006

NOVEL BENZOTHIAZOLONEחדשות בנזותיאזולון נגזרותDERIVATIVESASTRAZENECA AB

09/08/2005

0501793-4SE

30/08/2005

0501914-6SE


08/03/2006

0600515-1SE

PCT/SE/2006/000927WO/2007/018461

A61F18885814/07/2006

ציפוי עם המצופים רפואיים מכשיריםמהר המתמוסס ביולוגית מתאים

MEDICAL DEVICES COATED WITH A FAST DISSOLVING BIOCOMPATIBLE COATINGFMC BIOPOLYMER AS

21/07/2005

60/706396US

PCT/US/2006/027425WO/2007/015761

C07D18885907/03/2003

אפותילון של נגזרות המכילים שילוביםאלקילציה העושים וחומרים

COMBINATIONS COMPRISING EPOTHILONE DERIVATIVES AND ALKYLATING AGENTSUNIVERSITY OF NEWCASTLE UPON TYNE

08/03/2002

60/362738US

PCT/EP/2003/002364WO/2003/075899

C08L18886005/11/1997


ברי הטרופאזיים פולימרים של הרכבים עמילן המכילים ביולוגי פירוק

שאינו תרמופלסטי תרמופלסטי, פולימר שכבת המהווה ויסוד בעמילן מסיס

בהם ושימוש להכנתם ביניים, תהליךואי–אורגניים אורגניים במוצרים

BIODEGRADABLE HETEROPHASE POLYMERIC COMPOSITIONS COMPRISING A THERMOPLASTIC STARCH, A THERMOPLASTIC POLYMER INCOMPATIBLE WITH STARCH AND AN INTERFACIAL AGENT, PROCESS FOR THEIR PREPARATION AND THEIR USE IN ORGANIC AND INORGANIC PRODUCTSNOVAMONT S.P.A.

05/11/1996TO96A000890IT

09/12/1996TO96A000996IT

PCT/EP/1997/006103WO/1998/020073

C07D18886118/07/2006

–דיהידרופירידין–מאוחים,4,1 הטרוציקלים והרכבים להכנתם, שימושים שיטה


1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEMAventis Pharma S.A

20/07/2005

05291558.4EP

PCT/IB/2006/002734WO/2007/012972

A61F18886218/07/2006

EAR CLEANING DEVICEאוזניים לניקוי התקןRAFI KORENקורן רפי

18/07/2005

60/700543US

PCT/IL/2006/000827WO/2007/010529


H04Q18886322/06/2006

ומוצרים מחברים על אלקטרוני זיהוי תגים של בטכנולוגיה המשתמשים אחרים

) רדיו גלי באמצעות אלקטרוני תיוג שלRFIDקוראי/חוקרי גם כמו תוויות ( ו/או

רדיו גלי באמצעות אלקטרוני תיוג

DIGITAL CERTIFICATE ON CONNECTORS AND OTHER PRODUCTS USING RFID TAGS AND/OR LABELS AS WELL AS RFID READER/INTERROGATORSTRATOS INTERNATIONAL, INC.

18/07/2005

11/183525US

PCT/US/2006/024422WO/2007/011493

C07K18886423/06/2006

לשימוש צמיחה ממריצי פוליפפטידיםוסרטנים בדגים

GROWTH-STIMULATING POLYPEPTIDES FOR USE IN FISH AND CRUSTACEANSCENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA

21/07/2005

2005-0135CU

PCT/CU/2006/000006WO/2007/009403

A61K18886517/07/2006

REDUCTION IN MYOCARDIALהלב שריר אוטם גודל הקטנתINFARCTION SIZE




18/07/2005

11/183251US

PCT/US/2006/027476WO/2007/011773

H04N18886619/07/2006

טלפון ממכשיר חי טלויזיוני לשידור מערכתנייד

SYSTEM FOR LIVE TELEVISION BROADCASTING FROM A MOBILE TELEPHONECREATECNA XXI S.L.

20/07/2005P200501769ES

17/07/2006P200601898ES

PCT/ES/2006/000421WO/2007/010070

F41H18886818/07/2006

ARMORED VEHICLEמשוריין רכב כליMOWAG GMBH

18/08/2005

05405483.8EP

PCT/IB/2006/002276WO/2007/020531

G01N18886915/08/2006

TRAIL/L20APל/ אפופטוזיס רגישות 14T–GALNAC ביטוי של בחינה באמצעות

בתאים/רקמות

APOPTOSIS SENSITIVITY TO AP02L/TRAIL BY TESTING FOR GALNAC-T14 EXPRESSION IN CELLS/TISSUESGENENTECH, INC.

16/08/2005

60/708677US

24/05/2006

60/808076US


PCT/US/2006/031785WO/2007/022157

B65D18887002/06/2006

PULL TAB ACTIVATED SEALEDתווית במשיכת המופעלת חתומה אריזהPACKETKIMBERLY-CLARK WORLDWIDE, INC.

31/08/2005

11/217110US

PCT/US/2006/021356WO/2007/027255

A61F18887130/06/2006

PACKAGING FOR CONDOMSלקונדומים אריזהMAPA GMBH GUMMI-UND PLASTIKWERKE,

20/07/2005

102005033875.5DE

PCT/EP/2006/006364WO/2007/009570

A61H18887219/07/2006


של ביוכימיות תגובות להמרצת שיטה וברקמות, התקן באיברים לטיפול אורגניזם

ההתקן את הפולט ומכשיר השיטה לביצוע

METHOD FOR STIMULATING THE ORGANISM BIOCHEMICAL REACTIONS FOR TREATING ORGANS AND TISSUES, A BOARD FOR CARRYING OUT SAID METHOD AND A BOARD EMITTERNIKOLAY VENIAMINOVICH CHADAYEV OF

20/07/2005

2005123065RU

10/11/2005

2005134870RU

16/06/2006

2006121353RU

23/06/2006

2006122385RU

18/07/2006

2006125777RU

PCT/RU/2006/000385WO/2007/011266

A24F18887319/07/2006

SMOKE-FREE CIGARETTEעשן ללא סיגריהNICCULTO AG

21/07/2005

102005034169.1DE

PCT/EP/2006/007125WO/2007/009785

G01N18887415/08/2006

TRAIL/L02APל– אופופטוזיס רגישות GalNac 14Tביטוי– של בחינה באמצעות

בתאים/רקמות

APOPTOSIS SENSIVITY TO AP02L/TRAIL BY TESTING FOR GalNac -T14 EXPRESSION IN CELLS/TISSUESGENENTECH, INC.

16/08/2005

60/708677US

24/05/2006

60/808076US

PCT/US/2006/031894WO/2007/022214


C12N18887502/02/1999

הקשורותMAGE ממשפחת אנטיגן נגזרות המקודדים גרעין חומצות ורצפי לגידול

מותכים חלבונים להכנת המשמשים להםלחיסון ותכשירים

TUMOR-ASSOCIATED ANTIGEN DERIVATIVES FROM THE MAGE FAMILY, AND NUCLEIC ACID SEQUENCES ENCODING THEM, USED FOR THE PREPARATION OF FUSION PROTEINS AND OF COMPOSITIONS FOR VACCINATIONSMITHKLINE BEECHAM BIOLOGICALS S.A.

05/02/1998

9802543.0GB

06/02/1998

9802650.3GB

PCT/EP/1999/000660WO/1999/040188

A61N18887619/07/2006

ORGAN ASSIST SYSTEM ANDותהליך לאבר סיוע מערכתMETHOD

ZVI BEN SHALOMשלום בן צבי19/07/2005

60/700311US

PCT/IL/2006/000838WO/2007/010535

C07H18887724/07/2006

–6 של אנלוגיות לתרכובות שיפורים תלת–פוספט, שימושן תיוגואנוסיןלייצורן ותהליכים רפואיים בתחומים

IMPROVEMENTS TO ANALOGOUS COMPOUNDS OF 6-THIOGUANOSINE TRIPHOSPHATE, THEIR USE IN MEDICAL FIELDS AND PROCESSES FOR THEIR PREPARATIONGIULIANI INTERNATIONAL LIMITED


22/07/2005RM2005A000391IT

14/06/20062006/0448IE

PCT/IE/2006/000077WO/2007/010515

C07C18887824/07/2006

לקולטי– המיוחדות ומלחיהן תרכובותPPAR–ולקולטי EGFבתחום ושימושן

הרפואי

COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELDGIULIANI INTERNATIONAL LIMITED

22/07/2005RM2005A000389IT

PCT/IE/2006/000078WO/2007/010516

A47K18887915/06/2006

DRYING APPARATUSיבוש התקןDyson Technology Limited

30/07/2005

0515749.0GB

17/01/2006

0600879.1GB

PCT/GB/2006/002199WO/2007/015045

A47K18888013/06/2006

DRYERמייבשDyson Technology Limited

30/07/2005

0515752.4GB

PCT/GB/2006/002139


WO/2007/015043

A61H18888118/07/2006

ולמניעת לטיפול ברטט טיפל מכשורעמוקה ורידית תרומבוזה של התחלה

VIBRATIONAL THERAPY ASSEMBLY FOR TREATING AND PREVENTING THE ONSET OF DEEP VENOUS THROMBOSISJUVENT, INC.

18/07/2005

60/700092US

27/07/2005

60/702815US

27/07/2005

60/702735US

11/07/2006

60/830286US

18/07/2006

11/488227US

PCT/US/2006/027723WO/2007/011885

A61B18888220/06/2006

ABLATION CATHETERאיוד קתטרABLATION FRONTIERS, INC.

20/06/2005

60/692416US

PCT/US/2006/023808


WO/2007/001981

C09B18888621/07/2006

METHOD OF PREPARING PIGMENTפיגמנטים הרכבי להכנת שיטהCOMPOSITIONSCABOT CORPORATION

22/07/2005

60/702079US

PCT/US/2006/028319WO/2007/014007

F16K18888820/07/2006

קיבוצית שליטה עם נוזל זרימת שסתוםביסטאבילית אלקטרומגנטית

LIQUID FLOW VALVE WITH A BISTABLE ELECTROMAGNETIC CONTROL ASSEMBLYR.P.E. S.R.L.

21/07/2005MI2005A001404IT

PCT/EP/2006/064477WO/2007/010026

C07K18888907/07/2006

פפטידים ללא נוגדנים של הפרשהמבקטריות מסומנים

SECRETION OF ANTIBODIES WITHOUT SIGNAL PEPTIDES FROM BACTERIAKALOBIOS PHARMACEUTICALS , INC.

22/07/2005

60/701902US


14/11/2005

11/273906US

PCT/US/2006/026334WO/2007/018853

H01M18889019/07/2006

כח מתקן לבין התפלה מתקן בין שילוב אלקטרודיאליסטית הדרגתית מליחותחוזרת

COMBINATION OF A DESALINATION PLANT AND A SALINITY GRADIENT POWER REVERSE ELECTRODIALYSIS PLANT AND USE THEREOFVLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK

20/07/2005

05447175.0EP

PCT/BE/2006/000078WO/2007/009196

A61B18889121/07/2006

מפרק של השטח פני לגילוף ושיטה מכשירAPPARATUS AND METHOD FOR SCULPTING THE SURFACE OF A JOINTALEXANDRIA RESEARCH TECHNOLOGIES LLC

21/07/2005

60/701270US

20/07/2006

11/458942US

PCT/US/2006/028143WO/2007/013959


G06F18889231/07/2006

רפואית רשומה ליצירת ומערכת שיטהאישית אלקטרונית

METHOD AND SYSTEN FOR GENERATING INDIVIDUAL ELECTRONIC MEDICAL RECORDDR. MALIK M. HASAN

01/08/2005

60/704309US

PCT/US/2006/029694WO/2007/016468

C07C18889419/09/2005

מושפעות במחלות לטיפול תרכובותליפאז

COMPOUNDS FOR TREATMENT OF LIPASE-MEDIATED DISEASESRELIANCE LIFE SCIENCES PVT. LTD.

21/07/2005

864/MUM/2005IN

PCT/IN/2005/000318WO/2007/010546

C07D18889624/07/2006

שלהם, ותוצרי דיאזפינוקווינולינים, סינתזהשלהם הביניים

DIAZEPINOQUINOLINES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETOWYETH

26/07/2005

60/702509US

PCT/US/2006/028655WO/2007/016029

C07C18889720/07/2006

3(–2––1)דימתילאמינו(מתיל)ציקלוהקס–

שלו גבישיות וצורות מלאט איל(פנול

3(-2(-DIMETHYLAMINO)METHYL(CYCLOHEX

-1-YL)PHENOL MALEATE AND ITS CRYSTALLINE FORMSGRUNENTHAL GMBH

22/07/2007102005034974.9DE

PCT/EP/2006/007160WO/2007/009792


C07H18889820/07/2006

–Oפיראזול– של תולדות להכנת תהליכים תהליכים של חדשים ביניים ותוצרי גליקוציד

אלו

PROCESSES FOR PREPARING PYRAZOL-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSESBOEHRINGER INGELHEIM INTERNATIONAL GMBH

22/07/2005

05015935.9EP

PCT/EP/2006/064435WO/2007/010015

C07H18890020/07/2006

עם תיאוקולקיקוסיד של אנלוגיםדלקתית ואנטי מיאורלקסנטית פעילות

THIOCOLCHICOSIDE ANALOGUES WITH MYORELAXANT AND ANTI-INFLAMMATORY ACTIVITYINDENA S.P.A.

22/07/2005MI2005A001418IT

PCT/EP/2006/007108WO/2007/009772

G06F18890215/08/2006

קליק במרחק המשתמשות דרוג פונקציותברשת מסמך של מוטה

RANKING FUNCTIONS USING A BIASED CLICK DISTANCE OF A DOCUMENT ON A NETWORKMICROSOFT CORPORATION

15/08/2005

11/206286US


PCT/US/2006/031965WO/2007/022252

C07D18890321/08/2006

Nפיפראזין תולדות של –אוקסידים תרופות כמטרימי ופיפרידין

N-OXIDES AS PRODRUGS OF PIPERAZINE & PIPERIDINE DERIVATIVESSOLVAY PHARMACEUTICALS B.V.

22/08/2005

05107671.9EP

22/08/2005

60/709821US

PCT/EP/2006/065477WO/2007/023141

C07K18890422/09/2006

דמוי )פפטידGLP–1 פוליפפטידים מוגברת עמידות בעלי (מאוחים1גלוקגון–

לפפטידאז

GLP-1 (GLUCAGON-LIKE PEPTIDE-1) FUSION POLYPEPTIDES WITH INCREASED PEPTIDASE RESISTANCEBIOCOMPATIBLES UK LTD

22/09/2005

05020718.2EP

PCT/EP/2006/009226WO/2007/039140

B65D18890527/07/2006

CONTAINER CLOSURE ASSEMBLYלמיכל סגירה מכלולOBRIST CLOSURES SWITZERLAND GMBH

12/08/2005

05255021.7EP

PCT/EP/2006/064724WO/2007/020169

G05F18890610/08/2005


A VOLTAGE REGULATION DEVICEמתח לויסות מכשירENERGETIX VOLTAGE CONTROL LIMITED

PCT/GB/2005/003121WO/2007/017618

C12N18890713/07/2006

אוLUPINUS מסוג מצמחים חלבון תמצית רקומביננטית, רצף בצורה המיוצרת

ושימושה אותה המקודד נוקליאוטידי ובמלחמה צמח גידול חיות, כמקדם בהזנת

פתוגניות פטריות נגד

PROTEIN EXTRACTED FROM PLANTS OF THE GENUS LUPINUS OR PRODUCED IN RECOMBINANT FORM, NUCLEOTIDE SEQUENCE ENCODING IT AND ITS USE IN ANIMAL NUTRITION, AS A PLANT GROWTH PROMOTER AND IN THE FIGHT AGAINST PATHOGENIC FUNGIVIRGILIO BORGES LOUREIRO OF

21/07/2005103322PT

28/06/2006103511PT

PCT/IB/2006/052403WO/2007/010459

G01N18890812/07/2006

בעל פפטיד לזיהוי ותכשירים שיטות מטרה עם בין–מולקולרית אינטראקציה

עניין בעלת

METHODS AND COMPOSITIONS FOR IDENTIFYING A PEPTIDE HAVING AN INTERMOLECULAR INTERACTION WITH A TARGET OF INTERESTAEBI LTD.

21/07/2005

60/701092US

PCT/IL/2006/000815WO/2007/010525


A61K18891023/07/2006

לייצורו ושיטה משטחי רדיואקטיבי מקורA RADIOACTIVE SURFACE SOURCE AND A METHOD FOR PRODUCING THE SAME

RAMOT AT TEL-AVIV UNIVERSITYבע"מ אביב תל אוניברסיטת ליד רמותLTD.

26/07/2005

60/702288US

PCT/IL/2006/000850WO/2007/013060

G01N18891115/07/2006

עין–לובסטר במבנה רנטגן לדימות מערכתלהכנתה ושיטה

LOBSTER EYE X-RAY IMAGING SYSTEM AND METHOD OF FABRICATION THEREOFPHYSICAL OPTICS CORPORATION

27/07/2005

11/191095US

PCT/US/2006/027569WO/2007/015784

C07D18891326/07/2006

COMTNITROCATECHOL DERIVATIVES AS כמעכבי ניטרוקטכול תולדותCOMT INHIBITORSPORTELA & CA. S.A.

26/07/2005

0515327.5GB

20/04/2006

06008203.9EP

30/05/2006

06011073.1EP

PCT/PT/2006/000020WO/2007/013830

A61K18891508/08/2006


LIQUID FORMULATIONSנוזליים תכשיריםNOVARTIS AG

09/08/2005

60/706820US

PCT/US/2006/030836WO/2007/021666

C07D18891624/07/2006

–5,6–])4–בנזיל–1 לייצור תהליך–ילאידן[2–אינדאנונ(–1דימתוקסי–

מתילפיפרידין

PROCESS FOR PRODUCING 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANONE)-2-YLIDENE]METHYLPIPERIDINEEISAI R&D MANAGEMENT CO, LTD.

25/07/2005

2005-213820JP

PCT/JP/2006/314568WO/2007/013395

C07D18891718/07/2006

–הידרוקסי–פרופיונית2 חומצה תולדות –און2–הידרוקסי–בנזופוראנ–3 ותולדות

Bגאבא– לרצפטור אפיניות עם

2-HYDROXY-PROPIONIC ACID DERIVATIVES AND 3-HYDROXY-BENZOFURAN-2-ONE DERIVATIVES WITH AFFINITY FOR THE GABA-B-RECEPTORF. HOFFMANN-LA ROCHE AG

28/07/2005

05106979.7EP

PCT/EP/2006/064347WO/2007/014843

C07D18891807/08/2006

AMIDE DERIVATIVESאמיד תולדותASTRAZENECA AB

12/08/2005

0516570.9GB

PCT/GB/2006/003023WO/2007/020411


A61M18893027/07/2006

MEDICAMENT DISPENSERתרופות מחלקGLAXO GROUP LIMITED

28/07/2005

0515584.1GB

PCT/GB/2006/002831WO/2007/012871

H04B18893111/08/2006

המשתמש אלחוטי תקשורת מכשיר) אותות עיבוד בטכניקת

BEAMFORMINGלהתאמה ( הניתנת

A WIRELESS COMMUNICATION DEVICE USING ADAPTIVE BEAMFORMINGSIBEAM

12/08/2005

11/202995US

PCT/US/2006/031306WO/2007/021891

C07D18893203/08/2006

לשימוש ושיטות קינאז ספינגוזין מעכביבהם

SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USEAPOGEE BIOTECHNOLOGY CORPORATION

04/08/2005

60/705608US

PCT/US/2006/030327WO/2007/019251

C07C18893311/08/2006

אניליד תולדות של פלורינציה תהליך כגורמים פלורינאט בנזותיאזול ותולדותגופית תוך להדמיה

FLUORINATION PROCESS OF ANILIDE DERIVATIVES AND BENZOTHIAZOLE FLUORINATE DERIVATIVES AS IN VIVO IMAGING AGENTSGE HEALTHCARE LIMITED

12/08/2005

0516564.2GB


PCT/GB/2006/003009WO/2007/020400

A01N18893408/08/2006

EMULSIFIABLE CONCENTRATEתחליב ליצירת לשמש שיכול תרכיזBASF AKTIENGESELLSCHAFT

11/08/2005

60/707312US

PCT/EP/2006/065134WO/2007/017501

A01N18893508/08/2006

PESTICIDAL MIXTURESמזיקים קוטלות תערובותBASF AKTIENGESELLSCHAFT

11/08/2005

60/707312US

26/07/2006

60/833459US

PCT/EP/2006/065135WO/2007/017502

G01N18893621/07/2006

HEPARIN COMPOSTIONS ANDסלקטין ומעכבי הפארין תכשיריSELECTIN INHIBITIONTHE REGENTS OF THE UNIVERSITY OF CALIFORNIA

22/07/2005

60/701893US

PCT/US/2006/028404WO/2007/014049

C07K18893711/08/2006

HYBRID POLYPEPTIDES WITHנבחרות תכונות עם מוכלאים פוליפפטידיםSELECTABLE PROPERTIESAMYLIN PHARMACEUTICALS, INC.

11/08/2005

11/201664US


17/08/2005

11/206903US

12/12/2005

11/301744US

PCT/US/2006/031724WO/2007/022123

C12N18893827/07/2006

הינו הסמן כאשר תא/ליגנד סימון מערכת זו, מערכת המכיל תאי , חומרEPH מטיפוס

דם כלי ליצור בה ושימוש להכנתה שיטה

CELL/LIGAND MARKING SYSTEM, WHEREIN THE MARKER IS OF EPH TYPE, CELL MATERIAL COMPRISING SAID SYSTEM, METHOD FOR PREPARING SAME AND PROANGIOGENETIC USEUNIVERSITE PARIS 7-DENIS DIDEROT

27/07/20050508029FR

PCT/FR/2006/001837WO/2007/012764

C23F18893907/08/2006

ו–Cu לשכבות מיוצבות חריטה תמיסותCu/Ni

STABILIZED ETCHING SOLUTIONS FOR Cu AND Cu/Ni LAYERSBASF AKTIENGESELLSCHAFT

12/08/2005

102005038414.5DE

PCT/EP/2006/065104WO/2007/020206


A01N18894027/07/2005

PEST CONTROL COMPOSITIONמזיקים לבקרת תכשיריMITSUI CHEMICALS INC.

PCT/JP/2005/013728WO/2007/013150

C07D18894127/04/2006

רוקחות ותכשירי פיראזינוילגואנידין תולדותאותן המכילים

PYRAZINOL YGUANIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMEPARION SCIENCES INC.

03/08/2005

11/195758US

PCT/US/2006/015957WO/2007/018640

C07D18894221/07/2006

רוקחות ותכשירי בנזאימידאזול תולדותאותן המכילים

BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPSITIONS CONTAINING THE SAMEVERTEX PHARMACEUTICALS INCORPORATED


26/07/2005

60/702399US

PCT/US/2006/028149WO/2007/015923

C07C18894613/07/2006

קטליזה מבוססות טריטילציה תגובותמתכתית

TRITYLATION REACTIONS BASED ON METALLIC CATALYSISUNIVERSITA DEGLI STUDI DI ROMA "LA SAPIENZA"

21/07/2005RM2005A000386IT

PCT/EP/2006/064242WO/2007/009944

A61C18894726/07/2006

משתנה גובה עם חריצים קונטור עיצוב פצירות עבור משתנים מורמים חלקים ועם

אנדודונטיות

VARIABLE-LAND, MULTIPLE HEIGHT FLUTE CONTOUR DESIGN FOR ENDODONTIC FILESSTEPHEN L. BUCHANAN

28/07/2005

60/703766US

25/07/2006

11/493460US

PCT/US/2006/029262WO/2007/016278

A01N18894828/07/2006


של אמולסיה המכילים חקלאיים תכשירים שמנוניות כדוריות על המבוססת במים שמן

גבישיי נוזלי שטוח בכיסוי המכוסות

AGRICULTURAL COMPOSITIONS COMPRISING AN OIL-IN-WATER EMULSION BASED ON OILY GLOBULES COATED WITH A LAMELLAR LIQUID CRYSTAL COATINGDOW AGROSCIENCES LLC

28/07/2005

60/703525US

26/10/2005

60/730529US

PCT/US/2006/029743WO/2007/014386

C07D18894920/07/2006

ציקלוהקסילאמין איזוקווינולון נגזרות קינאזותRHO כמעכבי

CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORSSANOFI AVENTIS

26/07/2005

05016153.8EP

PCT/EP/2006/007140WO/2007/012422

C04B18895018/07/2006

ושיטות נדיר, זוהר אדמה אוקסי–סולפידלהפקתו

RARE EARTH OXYSULFIDE SCINTILLATOR AND METHODS FOR PRODUCING SAMESAINT-GOBAIN CERAMICS & PLASTICS, INC.

25/07/2005

60/702330US

PCT/US/2006/027850WO/2007/015862


G21G18895126/07/2006

מחולל עם לשימוש יישור מתאםבו לשימוש ושיטות רדיואיזוטופי

ALIGNMENT ADAPTER FOR USE WITH A RADIOISOTOPE GENERATOR AND METHODS OF USING THE SAMEMALLINCKRODT INC.

27/07/2005

60/703036US

PCT/US/2006/029057WO/2007/016172

A61N18895226/07/2006

מיצוי נוזל של כמויות לזיהוי ושיטה מערכתרדיואיזוטופי למחולל מסופקות

SYSTEM AND METHOD OF IDENTIFYING ELUANT AMOUNTS SUPPLIED TO A RADIOISOTOPE GENERATORMALLINCKRODT INC.

27/07/2005

60/702927US

PCT/US/2006/029055WO/2007/016170

G21F18895326/07/2006

RADIATION -SHIELDINGושיטות קרינה מפני להגנה מכלוליםASSEMBLIES AND METHODSMALLINCKRODT INC.

27/07/2005

60/703035US


PCT/US/2006/029059WO/2007/016174

C07D18895411/04/2003

תרופות לייצור בנזופירן נגזרות של שימוש KSP פעילות עצירת או התאמת לשם

לזאת המיוחסות קיניסין, ומחלות

USE OF DERIVATIVES OF BENZOPYRAN IN THE MANUFACTURE OF MEDICAMENTS FOR MODULATING OR INHIBITING KSP KINESIN ACTIVITY AND DISEASES RELATED THERETOSMITHKLINE BEECHAM CORPORATION

17/04/2002

60/373454US

13/09/2002

60/410682US

PCT/US/2003/011432WO/2003/088903

C07D18895411/04/2003

תרופות לייצור בנזופירן נגזרות של שימוש KSP פעילות עצירת או התאמת לשם

לזאת המיוחסות קיניסין, ומחלות

USE OF DERIVATIVES OF BENZOPYRAN IN THE MANUFACTURE OF MEDICAMENTS FOR MODULATING OR INHIBITING KSP KINESIN ACTIVITY AND DISEASES RELATED THERETOSMITHKLINE BEECHAM CORPORATION

17/04/2002

60/373454US

13/09/2002

60/410682US

PCT/US/2003/011432WO/2003/088903


A47K18895507/06/2006


30/07/2005

0515750.8GB

17/01/2006

0600872.6GB

PCT/GB/2006/002093WO/2007/015040

A47K18895626/06/2006


30/07/2005

0515749.0GB

17/01/2006

0600879.1GB

PCT/GB/2006/002347WO/2007/015046

H05B18895708/08/2005

BALLOON GUIDED ENDOSCOPYמונחית–בלון אנדוסקופייה.SMART MEDICAL SYSTEMS LTDבע"מ מערכות מדיקל סמארט

PCT/IL/2005/000849WO/2007/017854

C07C18895801/08/2006

FUEL ADDITIVESדלק תוספותINNOSPEC LIMITED

03/08/2005

0515998.3GB

PCT/GB/2006/002861WO/2007/015080


- תשכ"ז הפטנטים לחוק26 סעיף לפי הודעה1976

NOTICE UNDER SECTION 26 OF THE PATENTS LAW, 5727-1967

קובלו להלן מתפרסמים שפרטיהן הבקשות המעונין הפטנטים. כל לחוק17 סעיף לפי

מהבקשות בקשה פי על פטנט למתן להתנגד חדשים שלושה רשאי, תוך המתפרסמות

הפטנטים לרשם זה, להגיש יומן מתאריך לחוק30 סעיף לפי התנגדות הודעת

ואילך57 בתקנה הקבועה בדרך הפטנטים.1968 – הפטנטים, תשכ"ח לתקנות

The applications, particulars of which are set out below, have been accepted pursuant to Section 17 of the Patents Law. Any person wishing to oppose the grant of a patent on any of the applications published here, may, within three months from the date of this journal, give to the Commissioner of Patents notice under Section 30 of the Patents Law, in the manner prescribed in regulations 57 et seq of the Patents Regulations, 5728-1968

לפי מובאים ויישימים במידה הבקשות פרטיזה: סדר

Particulars of the applications, where applicable, are given in the following order:

Number of application [21] [11]הבקשה מספרTitle of invention [54]האמצאה שם

Application date [22]הבקשה תאריך מדינת – החוץ בקשות של ותאריך מספרהאגוד

[31] [32] [33] Number and date of foreign application – convention country.

.Int.Cl [51]*בינלאומי *סיווגApplication for patent of addition [61] מוסף לפטנט בקשהDivisional application [62]חלוקה בקשת

Applicant [71]המבקשInventor [72]הממציא

International Publication Number [87]הבינלאומית בקשה של מס' פרסום Address for service [74]מסמכים למסירת מען

Abridgement of invention (in the [57]הפירוט( ערוך בה )בשפה האמצאה תקצירlanguage in which the specification is drawn up)

מס' והמדגמים הפטנטים מיומן *הערה: החל לפי הסיווג פטנטים לבקשות ציון ניתן1/06

של הבינלאומי הסיווג של השמינית המהדורה(2006 )משנה פטנטים

*Note: As from Patents and Designs Journal No.1/06, patent applications are classified according to the Eighth Edition of the International Patent Classification (2006)


124907]21][11[

מפני צמחים גידולי על להגנה שיטהחרקים מסוג מזיקים

METHOD OF PROTECTING CROP PLANTS AGAINST INSECT PESTS

]54[

23.12.1996]22[GB]33[15.01.1996]32[96007869]31[

Int. Cl.8 A01H 005/00, 005/10, A01N 063/00, C07K 014/32, 014/325, C12N 015/32]51[SYNGENTA PARTICIPATIONS AG, SWITZERLAND

]71[

WO/1997/026339]87[לוצאטו, את לוצאטו

שבע , באר5352, ת.ד. תעשייה, עומר גן LUZZATTO & LUZZATTO,

INDUSTRIAL PARK, OMER,P.O.B. 5352,

BEER-SHEVA 84152

]74[

]57 [Method for protecting plants including the progeny thereof against damage caused by Sesamia species, comprising direct or indirect application of a toxin protein of a Bacillus species to the plant or the plant seed or to the growing area of the plant, wherein the toxin protein is a Vegetative Insecticidal Protein (VIP)-type protein, and wherein said direct or

indirect application comprises application of any of the following:

)i (a VIP-type protein,)ii (a microorganism of Bacillus species

expressing said VIP-type protein,)iii (a transgenic plant expressing said

VIP-type protein, or)iv (a composition comprising at least (i)

or (ii) together with an agronomically

__________


128332]21][11[

אינסולינוטרופיים פפטידים אנלוגים אותם המכילים גלוקגון, תכשירים דמויי

בהם ושימושים

GLUCAGON-LIKE INSULINOTROPIC PEPTIDE ANALOGS, COMPOSITIONS COMPRISING THEM AND USES THEREOF

]54[

22.08.1997]22[DK]33[30.08.1996]32[0931/96]31[DK08.11.19961259/96DK20.12.19961470/96

Int. Cl.8 A61K 038/26, 047/48, A61P 003/04, 003/10, C07K 014/435, 014/605]51[NOVO NORDISK A/S, DENMARK]71[WO/1998/008871]87[

ושותפיו, כהן ריינהולד , תל4060 , ת.ד. 21 העם אחד רחוב

אביב

REINHOLD COHN AND PARTNERS,

21 AHAD HA'AM ST ,.P.O.B. 4060 ,

TEL AVIV 61040

]74[

]57 [A derivative of GLP-1 (7-37) or an analogue of GLP-1 (7-37) which derivative is an agonist of the human GLP-1 receptor, characterized in that the derivative has only one lipophilic substituent which is

attached to an amino acid residue which is not the N-terminal or C-terminal amino acid residue.

מבקשה חלוקה בקשותפורסמו. שטרם זו

189136,The applications for division from this application have not yet been published

_________


129745]21][11[

ברי הטרופאזיים פולימרים הרכבים עמילן המכילים ביולוגי פירוק

תרמופלסטי תרמופלסטי, פולימר שכבת המווה ויסוד בעמילן מסיס שאינו

בהם ושימוש להכנתם ביניים, תהליךואי–אורגניים אורגניים במצורים

BIODEGRADABLE HETEROPHASE POLYMERIC COMPOSITIONS COMPRISING A THERMOPLASTIC STARCH, A THERMOPLASTIC POLYMER INCOMPATIBLE WITH STARCH AND AN INTERFACIAL AGENT, PROCESS FOR THEIR PREPARATION AND THEIR USE IN ORGANIC AND INORGANIC PRODUCTS

]54[

05.11.1997]22[IT]33[05.11.1996]32[TO96A000890]31[IT09.12.1996TO96A000996

Int. Cl.8 C08L 003/00]51[NOVAMONT S.P.A., ITALY]71[WO/1998/020073]87[

לוצאטו, את לוצאטו , באר5352, ת.ד. תעשייה, עומר גן

שבע

LUZZATTO & LUZZATTO, INDUSTRIAL PARK, OMER,

P.O.B. 5352,BEER-SHEVA 84152

]74[

]57 [Biodegradable heterophase polymeric compositions having improved resistance to ageing and to low humidity conditions, comprising:

)1 (a thermoplastic starch,)2 (a thermoplastic polymer incompatible

with starch,in which compositions, starch constitutes the dispersed phase and the thermoplastic polymer constitutes the continuous phase, and

)3 (an interfacial agent selected from the following (a) – (e) classes of compounds;

)4 (esters of polyols with mono-or polycarboxylic acids with values of the dissociation constant pK lower than 4.5 (the value relates to the pK of the first carboxyl group in the case of polycarboxylic acids), characterized by

hydrophilic/lipophilic balance index values (HLB) greater than 8;

)b (esters of pplyols with mono-or polycarboxylic acids with less than 12 carbon atoms and with pK values greater than 4.5 and having HLB indices between 5.5 and 8;

)c (esters of polyols with C12-C22 fatty acids having HLB indices lower than 5.5, the esters being used in quantities of from 10 to 40% by weight of the starch;

)d (non-ionic, water-soluble surfactants which, when added to the strarch/thermoplastic polymer compositions indicated above, migrate in water by no more than 30% wt of their concentration after the material containing them has been immersed in water for 100 hours at ambient temperature,


)e (reaction products of an aliphatic or aromatic diisocyanate with a polymer

containing terminal groups reactive with the diisocyanates.



___________

129919]21][11[

FORMULATION FORהעור דרך לחיסון פורמולציהTRANSCUTANEOUS IMMUNIZATION

]54[

14.11.1997]22[US]33[14.11.1996]32[08/749164]31[US17.07.199708/896085

Int. Cl.8 A61K 039/00, 039/39]51[THE GOVERNMENT OF THE UNITED STATES OF AMERICA, U.S.A.

]71[

WO/1998/020734]87[וגולר, וולף, ברגמן

, ירושלים1352, ת.ד. WOLFF, BREGMAN AND GOLLER,

P.O.B. 1352,JERUSALEM 91013

]74[

] 57 [Use of an antigen and an adjuvant, in the manufacture of a formulation for transcutaneous immunization of a subject wherein said formulation induces an immune response specific for the antigen

following application of the formulation to the subject's skin, and further wherein the formulation does not include a penetration enhancer.

__________


129994]21][11[

מותמרים – כלורוקוינוזולינים4באלקוקסי

ALKOXY-SUBSTITUTED 4-CHLOROQUINAZOLINES

]54[

21.03.1996]22[US]33[30.03.1995]32[413300]31[WO06.06.1995PCT/IB95/00436

Int. Cl.8 A61K 031/517, 031/5375, A61P 013/08, 017/06, 035/00, C07D 239/00, 239/86, 401/04, 401/14, 403/04, 403/12, 403/14, 413/04, 413/14, 491/04

]51[

DIVISION FROM 117598]62[PFIZER PRODUCTS, INC., U.S.A.

OSI PHARMACEUTICALS, INC., U.S.A.

]71[

לוצאטו, את לוצאטו , באר5352, ת.ד. תעשייה, עומר גן

שבע



]74[

]57 [4-Chloro-6,7-bis-(2-methoxy-ethoxy)-quinazoline.



__________


130330]21][11[

פנימיים בטפילים לטיפול תכשירים של תולדה המכילים וחיצוניים

או אברמקטין, דיהידרואברמקטין לקולטן ואגוניסט/אנטגוניסט מילבמיצין

בחרק הניקוטינארגי האצטילכולין

ENDO-/ECTOPARASITICIDAL COMPOSITIONS COMPRISING AN AVERMECTIN, DIHYDROAVERMECTIN OR MILBEMYCIN DERIVATIVE AND AN INSECT NICOTINERGIC ACETYLCHOLINE RECEPTOR AGONIST/ANTAGONIST

]54[

11.12.1997]22[DE]33[23.12.1996]32[19654079.

8]31[

Int. Cl.8 A01N 043/90, 047/44, C07H 017/08, C12P 019/62]51[BAYER AKTIENGESELLSCHAFT, GERMANY

]71[

WO/1998/027817]87[ושותפיו, כהן ריינהולד

, תל4060 , ת.ד. 21 העם אחד רחוב אביב



TEL AVIV 61040

]74[

]57 [An endo-/ectoparasiticidal composition comprising at least one

avermectin, 22, 23-dihydroavermectinמ B1

(ivermectins) or milbemycin with agonists

or antagonists of the nicotinergic acetylcholine receptors of insects selected from the compounds of the formula

in whichR represents hydrogen, or represents optionally substituted radicals from the group consisting of acyl, alkyl, aryl, aralkyl, heteroaryl and heteroarylalkyl;

A represents a monofunctional group from the group consisting of hydrogen, acyl,

alkyl and aryl or represents a bifunctional group linked to the radical Z;

E represents an electron-withdrawing radical;

X represents the radicals –CH= or =N-wherein in the radical –CH= the H-atom may be replaced by a link to the radical Z;


Z represents a munofunctional group selected from the group consisting of alkyl, - O-R, -S-R and –NR2 or represents a bifunctional group linked to the radical A or the radical X;

optionally in association with a diluent and/or excipient, provided that the at least one avermectin does not include abamectin.

___________

132113]21][11[

מעטפת חלבוני בעלי וירליים וקטוריים IgG הקישור אתר את המכילים כימריים

A חלבון של

VIRAL VECTORS HAVING CHIMERIC ENVELOPE PROTEINS CONTAINING THE IGG-BINDING DOMAIN OF PROTEIN A

]54[

30.03.1998]22[US]33[28.03.1997]32[08/829558]31[

Int. Cl.8 C07K 019/00, C12N 007/00, 015/63, 015/86]51[NEW YORK UNIVERSITY, U.S.A.]71[





TEL AVIV 61040

]74[

]57 [A Sindbis viral vector for transducing a target cell with high efficiency which comprises a gene encoding a chimeric envelope protein containing an IgG-binding domain of protein A sufficient to bind an Fc domain of an antibody with strong affinity wherein

the envelope protein is a Sindbis virus envelope protein; wherein the envelope protein is operatble to direct the assembly of the protein into a viral particle; and wherein said chimeric envelope protein alters natural viral tropism.

__________

132191]21][11[

METHOD FOR CALIBRATINGמצפן כיוון ואישור לאיפוס שיטהAND VERIFYING THE ATTITUDE OF A COMPASS

]54[

03.10.1999]22[Int. Cl.8 G01C 021/00]51[

]AZIMUTH TECHNOLOGIES, LTD.]71בע"מ טכנולוגיות אזימוטצדק, וכהן איתן, פרל, לצר

, הרצליה12688 , ת.ד. 7 שנקר רחוב EITAN, PEARL, LATZER AND COHEN ZEDEK,

]74[


P.O.B. 12688 ,HERZLIYA 46733

]57 [A method for verifying the attitude of a compass, the compass comprising an attitude determining device, a tilt sensor and an inertial sensor, the method comprising the steps of: determining the attitude of said compass with reference to the earth's axis from said attitude determining device; and determining the tilt of said compass from said sensor; determining the angular velocity of said compass from said inertial sensor; determining a predicted azimuth value from said angular velocity

and said compass attitude; and comparing the azimuth of said compass, obtained from said step of determining the attitude of compass with reference to the earth's axis, with the predicted azimuth value, and comparing the elevation of said compass, obtained from said step of determining the attitude of said compass with reference to the earth's axis with the elevation obtained from said step of determining the tilt, thereby verifying the attitude of said compass.

זו מבקשה חלוקה בקשותפורסמו. שטרם


_________

132699]21][11[

ACCESSORY FOR FASTENINGחוטים לאיבטוח אביזרWIRES

]54[

02.11.1999]22[Int. Cl.8 H01R 004/30]51[

]YAREL YAIROV]71יאירוב, ירושלים יראליאירוב, יראל

, ירושלים75/19 הנגבי רח' שבתאי YAREL YAIROV,

75/19 SHABTAY HANEGBI ST.,JERUSALEM

]74[

] מערכת לאבטוח חוטים זה לזה הכוללת:57[ ) המכיל4(א) אלמנט מאורך ראשון "זכר" (

באחד מקצותיו הברגה חיצונית ומגרעת להכלה של לפחות חוט אחד; והמכיל בקצהו השני

) ומשני צידיו לשוניות10מאפיין התאמה בולט (

) אבטחה, כך שביצירת המחבר זכר-נקבה,11(לשוניות אלו נמצאות משני צידי המחבר,

) המכיל5(ב) אלמנט מאורך שני "נקבה" ( באחד מקצותיו הברגה חיצונית ומגרעת להכלה

של לפחות חוט אחד; וכולל בקצהו השניApril 13, 2008669 –התשס"ח ח' בניסן

); כך שמאפיין14מאפיין התאמה חלול ( ההתאמה הבולט של הזכר, ומאפיין ההתאמה

החלול של הנקבה יוצרים בהתחברם מחברזכר-נקבה,

(ג) מכסה מתברג לאלמנט הראשון (זכר) לסגירה על ההברגה החיצונית ולאחיזה של

חוט, (ד) מכסה מתברג לאלמנט השני (נקבה)

לסגירה על ההברגה החיצונית ולאחיזה שלהחוט.

____________

134017]21][11[

CAMERA FOR VIEWING INSIDEמעיים בתוך לצילום מצלמהINTESTINES

]54[

13.01.2000]22[Int. Cl.8 A61B 001/04]51[CAPSULE VIEW INC., U.S.A.]71[

( בע"מ,1992) כלכלי וייעוץ פטנטים גולד, חיפה43רובינשטיין

GOLD PATENTS LTD,. 43 RUBINSTEIN ST,.

HAIFA 34987

]74[

מערכת לסריקה אופטית של מערכת] 57[העיכול של נבדק הכוללת:

) מוארך בצורת10מארז קטבים שני בעל ( מערכים שני הכולל לבליעה, הניתנת גלולה

) הממוקמים14אופטיים הגלולה, במארז ( גזרות לעבר והצופים הגלולה של בקטבים אמצעים הכוללים לגלולה, ביחס נגדיות

) שעליו ממוקד מידע18למיקוד, חיישן אופטי (מקור האופטי, המערך ע"י הנפצה אופטי

) השונות,16תאורה הגזרות לעבר המאיר ( ) ועיבוד המעבדת את המידע20יחידת בקרה (

הנקלט בחיישן האופטי למידע דיגיטלי, יחידתהדיגיטלי המידע את המשדרת תקשורת

למקלט חיצוני לצורך הצגתו או שמירתו.


___________

134114]21][11[

נשירה בעל כותנה צמח לייצור שיטהזו בשיטה המיוצר וצמח עצית

METHOD FOR PRODUCING A SELF-DEFOLIATING COTTON PLANT AND PLANT PRODUCED THEREBY

]54[

20.07.1998]22[AU]33[22.07.1997]32[PO8174]31[

Int. Cl.8 A01H 001/00, 005/00]51[VIRGIN COTTON COMPANY PTY LTD., AUSTRALIA

]71[





TEL AVIV 61040

]74[

]57 [A method for producing a self-defoliating cotton plant, comprising: (A) selfing a first cotton plant or crossing it with a second cotton plant, such that progeny seeds are produced, wherein said first cotton plant is of variety "Rainbow 39", represented by a deposit under AGAL

Accession No. NM 98/06259; (B) harvesting and growing said progeny seeds under conditions for plant growth, whereby progeny plants are produced; and (C) selecting among said progeny plants to obtain at least one progeny plant with a self-defoliating phenotype.


___________

134356]21][11[

מוצרים עבור צלוחית דו חיבור מערכתבהקפאה המיובשים

DUAL VIAL CONNECTING SYSTEM FOR LYOPHILIZED PRODUCTS

]54[

27.08.1997]22[Int. Cl.8 A61J 001/00]51[PENTAPHARM AG, SWITZERLAND

]71[

FRANCK MOISIO, FRANZ A. KLUG

]72[

WO/1999/009931]87[ושות' בע"מ, מ. בן-דוד ירמיהו

,45087, ת.ד. חוצבים המרפא, הר רחוב ירושלים

JEREMY M. BEN-DAVID & CO. LTD,.

HAR HOTZVIM HI-TECH PARK ,P.O.B. 45087 ,

JERUSALEM 91450

]74[

]57 [A dual vial connecting system for temporary connection of two containers, usually a glass or plastic vial (1) and plastic solvent bottle (3), the purpose being to reconstitute a dry product, such as a lyophilisate or powder contained in the glass or plastic vial with a corresponding solvent product contained in the plastic solvent bottle, the connecting system having a cylindrical closing and connecting plastic sleeve (4) with a lower portion (5) having inwardly directed securing means (24) for secure connection with the neck of the glass or plastic vial, an upper portion (6) having an internal thread (15) for screwing connection with the plastic solvent bottle and an integrated plastic membrane (7) being perforated by the orifice reducer (22) of the plastic solvent bottle when screwed into the upper inner threaded portion of the closing and connecting plastic sleeve, the perforable membrane separating the upper inner threaded portion from the lower portion of the closing and connecting plastic sleeve,

and an inner cylindrical plastic skirt (12) located in the inner lower portion of the closing and connecting plastic sleeve and extending downwardly from the lower surface of the perforable membrane (7), said skirt having an outer diameter coming in contact with the wall of the inner neck of the glass or plastic vial, characterized by an elastomer sealing ring (13) fixed at the uppermost position around the outer surface of the said skirt, an elastomer sealing plug (18) with a pre-cut section (21) and a cavity (19) in its centre, the said sealing plug being placed around a cylindrical collar (17) located in the upper inner portion of the closing and connecting plastic sleeve and extending upwardly from the upper surface of the perforable membrane and held in place by an annular rib (16), whereby the perforable membrane, the cylindrical skirt, the collar and the annular rib are integrally moulded parts of the said closing and connecting plastic sleeve.


__________

134937]21][11[

לטיפול ושיטות סינרגיסטיים הרכבים ולשיקום סרטניים או ממאירים בגידולים

הדם שורש תאי ייצור והאצת

SYNERGISTIC COMPOSITION AND METHODS FOR TREATING NEOPLASTIC OR CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING HEMATOPOIESIS

]54[

17.09.1998]22[US]33[18.09.1997]32[08/933359]31[

Int. Cl.8 A61K 039/12, 039/385, 039/395, 045/00, 045/06]51[BIOGEN IDEC INC., U.S.A.]71[





TEL AVIV 61040

]74[

]57 [Use of:)a (an admixture comprising a cancer or

tumor antigen expressed by cells of a cancer to be treated and a microfluidized

antigen formulation comprising :)i (a stabilizing detergent,

)ii (a micelle-forming agent, and)iii (a biodegradable and biocompatible oil,

said antigen formulation being formulated as a stable oil-in-water emulsion; said admixture being capable to induce a cytotoxic T-lymphocyte response in a patient which is specific for the cancer or tumor antigen contained in said admixture, and

)b (a therapeutically effective amount of at least one agent which is capable of neutralizing, blocking, antagonizing, or down regulating the activity or preventing activation of transforming growth factor β (TGFβ) specifically, which agent is selected from the group consisting of an anti-TGFβ antibody, a TGFβR-fusion protein, a TGFβ analog, a TGFβ binding protein, and a TGFβR blocking antibody; for the preparation of a combined medicament suitable for simultaneously, separate or sequential administration for treating cancer.


__________135415]21][11[

BAB אוABA טריבלוק של פולימריםביולוגי לפירוק הניתנים

BIODEGRADABLE ABA-OR BAB-TYPE TRI-BLOCK POLYMER

]54[

02.10.1998]22[US]33[03.10.1997]32[08/943167]31[US01.10.199809/164865

Int. Cl.8 A61K 009/00, 047/34, C08G 063/664, 063/91, 065/32, C08L 071/02]51[MACROMED, INC., U.S.A.]71[

RAMESH C. RATHI, GAYLEN M. ZENTNER, BYEONGMOON JEONG

]72[

WO/1999/018142]87[צדק, וכהן איתן, פרל, לצר


P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [A biodegradable ABA- or BAB-type triblock polymer, said ABA triblock of the formula:

PL(G)z-1 A-PEG-PL(G)z-1 Aand said BAB triblock of the formula:

PEG-PL(G)z-1 acid-PEGwherein z is an integer of 1 or 2, wherein the A-block is represented by GL(G)z-1 A such that when z is 2 the A-block is a poly(lactide-co-glycolide) or PLGA copolymer, and when z is 1 the A-block is a poly (lactide) or PLA polymer and

wherein the B-block is represented by PEG which is a hydrophilic polyethylene glycol polymer, said block copolymer having a weight average molecular weight of between about 2000 to 4990 and possessing reverse thermal gelation properties, and wherein said PL(G)z-1 A A-block comprises about 51 to 83% by weight of said polymer and the PEG B-block comprises about 17 to 49% by weight of said polymer.

_________


135524]21][11[

APROCESS FOR PRODUCING– טטראברומוביספנול לייצור תהליךTETRABROMOBISPHENOL – A

]54[

06.04.2000]22[US]33[08.04.1999]32[09/288195]31[

Int. Cl.8 C07C 037/62, 039/367]51[ALBEMARLE CORPORATION, U.S.A.

]71[

צדק, וכהן איתן, פרל, לצר, הרצליה12688 , ת.ד. 7 שנקר רחוב

EITAN, PEARL, LATZER AND COHEN ZEDEK,

P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [A process for the preparation of tetrabromobisphenol-A, which process

comprises :)a (brominating bisphenol-A in a liquid

phase reaction medium in which tetrabromobisphenol-A is relatively insoluble, using a stoichiometric deficiency of bromine to thereby form in the reaction mass a precipitate consisting

essentially of about 50 to about 95 wt% of tetrabromobisphenol-A and about 50 to about 5 wt% of underbrominated bisphenol-A;

)b (recovering precipitate from the reaction mass; and

)c (recovering tetrabromobisphenol-A from the precipitate.

____________

135704]21][11[

של סרטני גידול של לדיאגנוזה שיטה המופרש הפוליפפטיד זהוי ידי על תאים

WISP–1ידי על המושפע WNT–1

METHOD OF DIAGNOSING NEOPLASTIC CELL GROWTH BY DETECTION OF THE WNT-1 INDUCED SECRETED POLYPEPTIDE WISP-1

]54[

29.10.1998]22[US]33[29.10.1997]32[60/063704]31[US03.02.199860/073612US14.04.199860/081695

Int. Cl.8 C12Q 001/68, G01N 033/53]51[GENENTECH, INC., U.S.A.]71[




21 AHAD HA'AM ST ,.

]74[


P.O.B. 4060 ,TEL AVIV 61040

]57 [A method of diagnosing neoplastic cell growth or proliferation in a human comprising detecting the level of expression of a gene encoding a WISP-1 (Wnt-1-Induced) polypeptide having at least 85% amino acid sequence identity with human mature WISP-1 polypeptide having amino acid residues 23 to 367 of the amino acid sequence shown in Figures 3A and 3B (SEQ ID NO:3), or human full length WISP-1 polypeptide having amino

acid residues 1 to 367 of the amino acid sequence shown in Figures 3A and 3B (SEQ ID NO:4), (a) in a test sample of tissue cells obtained from the human, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher expression level in the test sample, relative to said control sample indicates the presence of a tumor in the human from which the test tissue cells were obtained.

__________

137442]21][11[

MAGE ממשפחת אנטיגן נגזרות גרעין חומצות ורצפי לגידול הקשורות

להכנת המשמשים להם המקודדיםלחיסון ותכשירים מותכים חלבונים

TUMOR-ASSOCIATED ANTIGEN DERIVATIVES FROM THE MAGE FAMILY AND NUCLEIC ACID SEQUENCES ENCODING THEM, USED FOR THE PREPARATION OF FUSION PROTEINS AND OF COMPOSITIONS FOR VACCINATION

]54[

02.02.1999]22[GB]33[05.02.1998]32[9802543.0]31[GB06.02.19989802650.3

Int. Cl.8 A61K 039/39, 048/00, C07K 001/00, 014/47, 019/00, C12N 001/21, 015/12, 015/62, 015/70

]51[

SMITHKLINE BEECHAM BIOLOGICALS S.A., BELGIUM

]71[





TEL AVIV 61040

]74[

]57 [A tumor-associated antigen derivative from the MAGE family wherein

the derivative comprises derivatised thiol residues.



188875,179010,The applications for division from this application have not yet been published

__________

137858]21][11[

משתנה, סיליארי ניורוטרופי פקטורבו לשימוש ושיטות להכנתו שיטה

MODIFIED CILIARY NEUROTROPHIC FACTOR, METHOD OF MAKING IT AND METHODS OF USE THEREOF

]54[

26.02.1999]22[US]33[27.02.1998]32[09/031693]31[

Int. Cl.8 A61K 038/18, 047/48, A61P 003/04, 003/10, 025/00, 025/14, 043/00, C07K 014/47, 014/475, C12N 001/21, 005/10, 015/12, 015/18

]51[

REGENERON PHARMACEUTICALS, INC., U.S.A.

]71[




BEER-SHEVA 84152

]74[

]57 [Modified human ciliary neurotrophic factor having the modification Cys 17-Ala,

Gln63-Arg, and a deletion of the terminal 15 amino acid residues.

___________

138565]21][11[

חקלאי ויישום ממויים פולימרי הרכבשלו

HYDRATED POLYMERIC COMPOSITION AND AGRICULTURAL APPLICATION THEREOF

]54[

19.09.2000]22[Int. Cl.8 C08L 089/00, C09K 015/34]51[

–גת בע"מ, קרית סולושין ביו אקסוטקבוצ'בסקי דן מירצ'הקולט מוניקה

EXOTECH BIO SOLUTION LTD.MIRCEA DAN BUCEVSCHIMONICA COLT

]71[

ושות', גבריאלי זליגסוןאביב , תל1426 , ת.ד. 31 רח' יבנה

SELIGSOHN GABRIELI & CO,. 31 YAVNE ST,.

P.O.B. 1426 ,

]74[


TEL AVIV 61013

]57 [A hydrated polymeric composition for application to soil comprising: a mixture of a modified collagen biopolymer, component A, and a synthetic ternary copolymer, component B, in the ratios of A:B = 10:90 to 75:20, wherein:

component A comprises a collagen biopolymer having an average molecular weight between 5000 and 80,000 and wherein 0 to 30% of the free carboxyl groups of the collagen material are esterified with a C1 to C6 alcohol, preferably ethanol, and 20 to 30% of the free amino groups are blocked with ionizable hydrophilic groups, preferably phthalic or succinic anhydride, and component B comprises a ternary copolymer having an average molecular weight between 20,000 and 200,000 Da, a glass temperature Tg = 5-110oC, formed by copolymerization of monomers C, D and

E, wherein: C-represents a vinyl or acrylic monomer of the formula :

CH2=CR1R2

wherein: R1=-H, or –CH3; R2 = -H, -C6H5, -CH2C6H5, -CH=CH2,

-COOR3 or CN, andR3 = -(CH2)k-H with k = 2-8;D-is a polar monomer having the formula:

CHR4=CHR5

wherein: R4= -H or-COOH; R5= -COOH, -CN,-O-CO-CH3, -OH, -NH2, -O-(CH2)2-OH, -O-NH2 or –NH-(CH2)2-NH2;

andE-is a reactive monomer selected from acryloyl chloride, acrolein, maleic anhydride, itaconic anhydride, glycidymethacrylate, vinyl oxazole and reactive acrylic ester, having the following formula:

CH2=CH(COOR6)wherein R6=phenyl, benzyl, pentachlorophenyl or p-nitrophenyl.

__________

139069]21][11[

של מדורגת להעברה והתקן שיטהיתרות מידע איחסון יחידות דרך נתונים

METHOD AND APPARATUS FOR CASCADING DATA THROUGH REDUNDANT DATA STORAGE UNITS

]54[

12.10.1999]22[US]33[17.02.1999]32[09/251812]31[

Int. Cl.8 G06F 011/14]51[EMC CORPORATION, U.S.A.]71[




]74[

]57 [A method for transferring data between a facility for altering data and facility for receiving data including the steps of establishing a first data store for

receiving the altered data, a second data store, and a first table for recording the identification of changes in the first data store produced by the facility for altering


data and a first (ESTABLISH or RE-ESTABLISH) of a plurality of operating modes during which the second data store receives data from the first data store

according to the identified changes in the first table, said method being characterized by:

)a (establishing a second table for recording the identification of changes in the first data store produced by the facility for altering data, and

)b (shifting operations to a second (CASCADE DIFFERENTIAL SPLIT) of a plurality of operating modes for copying data from the second data store to the receiving facility according to the changes

in the second table identified at the time the second operating mode is established, which changes correspond to changes in the first data store since a prior shift to the second operating mode.

__________

139515]21][11[

זרימה תכונות בעל רפואי שסתוםחיוביות

MEDICAL VALVE WITH POSITIVE FLOW CHARACTERISTICS

]54[

14.05.1999]22[US]33[14.05.1998]32[09/078941]31[

Int. Cl.8 A61M 039/26]51[ICU MEDICAL, INC., U.S.A.]71[

WO/1999/058186]87[



אביב



TEL AVIV 61040

]74[

]57 [A medical valve (20) for controlling the flow of fluid between a first medical implement and second medical implement, said valve comprising a housing (28) having a passage and a piston (42) comprising a rigid material and positioned within said passage, the valve adapted for connection to said second medical implement and having an opening adapted to receive said first medical implement, the piston having a first position in which said piston prevents fluid flow through said valve and a second position in which fluid

flow is permitted through said valve, said passage including a fluid space which automatically and reversibly increases in size when said first medical implement is connected to said valve and which contracts in size when said first medical implement is disconnected to generate a positive flow of fluid in the direction of said second medical implement, wherein said housing further comprises at least one screw thread on an outside surface of said housing, said valve further comprising at least one o-ring attached to said piston.

___________

141095]21][11[

בעלי פרופופול של מימיים פיזוריםהזקרה

INJECTABLE AQUEOUS DISPERSIONS OF PROPOFOL

]54[

18.08.1999]22[US]33[19.08.1998]32[60/097071]31[

Int. Cl.8 A61K 009/00, 009/107]51[RTP PHARMA INC., U.S.A.]71[

GARY W. PACE, AWADHESH K. MISHRA, MICHAEL G. VACHON

]72[

WO/2000/010531]87[April 13, 2008 –התשס"ח ח' בניסן 680

ושות' בע"מ, מ. בן-דוד ירמיהו ,45087, ת.ד. חוצבים המרפא, הר רחוב

ירושלים



JERUSALEM 91450

]74[

]57 [A stable, sterile, and injectable aqueous dispersion of a water-insoluble microdroplet matrix of mean diameter from about 50 nm to about 1000 nm consisting essentially of

)a (between about 1% to about 15% of propofol;

)b (between about 1% to about 8% of a propofol-soluble diluent;

)c (between about 0.5% to about 5% of a surface stabilizing amphiphilic agent;

)d (a pharmaceutically acceptable water-soluble polyhydroxy additive that acts as a tonicity modifier; and

)e (water;)f (provided the ratio of propofol to diluent

is about 1:4 to about 1:0.1 and the ratio of propofol to amphiphilic agent is about 1:0.8 to about 1:2.5, and the composition has a viscosity of from about 0.8 to about 15 centipoise, wherein the dispersion prevents microbial growth, defined as no more than 0.5 log increase from the initial inoculum, of each of Staphylococcus aureus (ATCC 6538), Escherichia coli (ATCC 8739 and ATCC 8454),

Pseudomonas aeruginosa (ATCC 9027), Candida albicans (ATTCC 10231), and Aspergillus niger (ATCC 16403) for at least 7 days as measured by a test wherein a washed suspension of each said organism is added to a separate aliquot of a dispersion at approximately 1000 colony forming units (cfu) per mL, at a temperature in the range 20-25oC, whereafter said aliquots are incubated at 20-25oC and are tested for viability of the microorganisms in the inoculated dispersion as determined by counting the colonies of said organism after 24, 48 hours and 7 days or other suitable length of time; and results in little or no irritation at the site of injection as evidenced by a test wherein said dispersion is administered as a single daily bolus injection of 12.5 mg/kg, given on the basis of body weight, for 2 to 3 successive days over a period of approximately 30 seconds, in the caudal vein of a rat such that no visual increase in the diameter of the rat tail is noted after 48 hours post injection.

_________

141371]21][11[

,DNA , רצףDNA רצף לגילוי שיטהבהם והשמושDNA מבנה להכנת שיטה

METHOD OF DETECTING A DNA SEQUENCE, A DNA SEQUENCE, A METHOD OF MAKING A DNA CONSTRUCT AND THE USE THEREOF

]54[

16.08.1999]22[NL]33[14.08.1998]32[1009862]31[NL27.11.19981010670

Int. Cl.8 C12N 015/09, 015/11, 015/12, 015/63, C12Q 001/68]51[CHROMAGENICS B.V., THE NETHERLANDS

]71[


ARIE PIETER OTTE]72[WO/2000/009749]87[



P.O.B. 12688 ,HERZLIYA 46733

]74[

]57 [Method of detecting, and optionally selecting, a DNA sequence, wherein the DNA sequence to be detected possesses a stable expression-enhancing quality, which method comprises the steps of:

)1 (cloning DNA fragments having a size of <5000 base pairs into a vector at a location between (i) a DNA sequence recognized by a repressor protein complex, which repressor protein complex is involved in the induction of gene-transcription repressing chromatin, and (ii) a reporter gene comprising a promoter, resulting in a variety of fragment-comprising vectors, wherein the distance

between the DNA sequence recognized by a repressor protein complex and the reporter gene is fewer than 5000 base pairs;

)2 (introducing the vectors into host cells, and wherein the repressor protein complex is expressed in the host cells, and in which host cells the promoter may be active but induction of gene-transcription repressing chromatin in the vectors results in the repression of the reporter gene; and

)3 (subjecting the host cells to a selection step in order to identify a host cell exhibiting reporter gene activity.

___________

141408]21][11[

בלב בפיברוסיס לטיפול תכשיריםהלופוגינון של נגזרות המכילים

COMPOSITIONS FOR TREATING CARDIAC FIBROSIS COMPRISING HALFUGINONE DERIVATIVES

]54[

13.08.1999]22[IL]33[13.08.1998]32[125790]31[US01.06.199960/137145

Int. Cl.8 A61K 031/505, 048/00, A61P 009/00, C07D 401/06]51[ החקלאות, מרכז ישראל, משרד מדינת

דגן וולקני, בית בע"מ, ופיתוח רפואי מחקר שרותי הדסית

ירושלים

STATE OF ISRAEL, MINISTRY OF AGRICULTURE , VOLCANI CENTERHADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.

]71[

WO/2000/009070]87[ושות', וב ד"ר

, רחובות2189 , ת.ד. 2 רח' פקריס WEBB & ASSOCIATES,

2 PEKERIS ST., P.O.B. 2189,REHOVOT 76121

]74[

]57 [Composition for treating cardiac fibrosis, comprising a pharmaceutically

effective amount of a compound in combination with a pharmaceutically


acceptable carrier, said compound being a member of a group of the formula:

wherein: n=1-2;R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;

R2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy; and

R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and pharmaceutically acceptable salts thereof.

___________

141620]21][11[

וידאו בהקלטת הכותרות הופעות סדרDVDאמת בזמן

ORDER OF TITLES IN A REAL-TIME DVD VIDEO RECORDING

]54[

21.06.2000]22[EP]33[25.06.1999]32[99202056.

0]31[

Int. Cl.8 G11B 027/034]51[KONINKLIJKE PHILIPS ELECTRONICS N.V., THE NETHERLANDS

]71[





TEL AVIV 61040

]74[

]57 [A method of recording an encoded bit stream, said encoded bit stream representing a plurality of video objects comprising a sequence of cells together constituting a part of an MPEG2 Program Stream, on a disc like record carrier, such as an optical disc, said method comprising: recording a collection of contiguously arranged video objects in a video object storage area of said disc, said collection being partitioned into adjacent recordings that represent playable titles; recording

management information in a management information area of said disc for storing information about recorded video objects; defining a playable title as a playback sequence of all completer cells or a subset of complete cells of a recording in the order of allocation within the video object storage area on the disc; and generating a title list of titles sorted in the order of arrangement within the video object storage area on the disc.


____________

142026]21][11[

IN VITRODEVICE AND METHOD FOR IN דם לזיהוי ושיטה מתקןVITRO DETECTION OF BLOOD

]54[

14.03.2001]22[US]33[14.03.2000]32[09/525016]31[

Int. Cl.8 G01N 021/77]51[ של המחקר לפיתוח חברה יישום

בירושלים, ירושלים העברית האוניברסיטהבע"מ, יקנעם אימג'ינג גיוון

YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMGIVEN IMAGING LTD.

]71[

GAVRIEL MERON, ITAMARוילנר מירון, איתמר גבריאלWILLNER

]72[

לצר, צדק כהן פרל , ת.ד.5 , רח' שנקר1 גב-ים מרכז

, הרצליה12704

PEARL COHEN ZEDEK LATZER, 5 SHENKAR STREET ,

P.O.B. 12704 HERZLIYA 46733

]74[

]57 [A device for in vitro detection of blood comprising a support (22) having immobilized thereon at least one polyelectrolyte reactant (24) configured to

come into unfiltered contact with a sample, and capable of reacting with blood, said reaction directly resulting in an optical change viewable by the naked human eye.


__________

142171]21][11[

ידי על מזיקים בזחלי לשליטה שיטהCry1F ברעלן שימוש

METHOD OF CONTROLLING CUTWORM PESTS USING A CRY1F TOXIN

]54[

23.08.2000]22[US]33[23.08.1999]32[60/150319]31[

Int. Cl.8 A01N 063/00, 063/02]51[MYCOGEN CORPORATION, U.S.A.]71[





TEL AVIV 61040

]74[

]57 [A method for controlling a cutworm pest wherein said method comprises contacting said pest with a Cry1F toxin.

__________

142461]21][11[


מחט ללא שער דרך הזרקה מערכתלניקוי הניתן נמוך ברפלוקס

SWABBABLE NEEDLELESS LOW REFLUX INJECTION PORT SYSTEM

]54[

01.10.1999]22[US]33[05.10.1998]32[09/166559]31[

Int. Cl.8 A61M 039/00]51[RYMED TECHNOLOGIES INC., U.S.A.

]71[

DANA W. RYAN]72[WO/2000/020070]87[

לנגר, אדוארדאביב , תל4 רח' ברקוביץ

EDWARD LANGER, C/O SHIBOLET, YISRAELI, ROBERTS, ZISMAN &

CO,. 4 BERKOWITZ ST,.

TEL AVIV 64238

]74[

]57 [An injection port assembly for coupling to and uncoupling from a first fluid pathway of a first connector and for receiving and passing a fluid into the first fluid pathway from a device provided with a second connector (102), said injection port assembly comprising:

)a (a body having a first end provided with a first mating structure adapted to mate with the first connecter, and a second end (196);

)b (a hollow spike (104) defining a shaft having a first end coupled to said body and a second end provided with a penetrating

tip, said first mating structure and said hollow spike being in fluid communication with each other;

)c (a resilient first barrier extending over said spike and having a tip portion about said tip of said spike;

)d (a resilient second barrier provided over and contacting said tip portion of said first barrier; and

)e (a hollow component having a first end and a second end, said first end being coupled to said body, said hollow component extending around at least portions of said spike, said first barrier and said second barrier, and said second end being provided with a second mating structure adapted to removably couple to the second connector, wherein when the second connector is coupled to said second mating structure, said second connector forces said second resilient barrier and said tip portion of said first resilient barrier over said spike such that said second connector and said first connector are in fluid communication with each other through said hollow spike and said first mating structure.


___________

143405]21][11[

QUINOLINE AND QUINOXALINEוקינוקסלין קינולין תרכובותCOMPOUNDS

]54[

23.11.1999]22[US]33[24.11.1998]32[09/198716]31[

Int. Cl.8 A61K 031/47, 031/498, A61P 035/00, C07D 215/16, 241/44, 405/12]51[AVENTIS PHARMACEUTICALS INC., U.S.A.

]71[




21 AHAD HA'AM ST ,.

]74[


P.O.B. 4060 ,TEL AVIV 61040

]57 [A stent device characterized by a polymeric coating into which is incorporated a restenosis inhibiting

effective amount of a compound of the formula

whereinR1a is one to three carbon alkoxy;R1b is one to three carbon alkoxy;

R2 is

R3 is hydrogen or meta-halo;Za is N or CH; andZb is N or CH; and

Zb is NH or O, oran N-oxide thereof, hydrate thereof, solvate thereof, or salt thereof.

__________

143528]21][11[

טוקסין המכילים תרופתיים גורמיםנחירות רעש להפחתת בוטולינום

THERAPEUTIC AGENTS CONTAINING BOTULINUM TOXIN FOR THE SUPPRESSION OF SNORING NOISES

]54[

10.12.1999]22[DE]33[10.12.1998]32[19856897.

5]31[

Int. Cl.8 A61K 009/08, 009/127, 009/19, 009/48, 035/66, 035/74, 038/16, 038/48, A61P 011/00, 011/02, 011/04, C07K 014/33, C12N 009/48

]51[

BIOTECON GESELLSCHAFT FUR BIOTECHNOLOGISCHE

]71[


ENTWICKLUNG UND CONSULTING MBH, GERMANYWO/2000/033863]87[

וגולר, וולף, ברגמן, ירושלים1352, ת.ד.

WOLFF, BREGMAN AND GOLLER, P.O.B. 1352,

JERUSALEM 91013

]74[

]57 [Use of high-purity Clostridium toxin BoNT/A for manufacturing a therapeutic

agent, to be administered intramuscularly, for suppressing snoring noises.

__________

143706]21][11[

תרחיף המכיל רוקחות תכשיר חלבון של ביוקומפטבילי

בפולי–אול/שמן

PHARMACEUTICAL COMPOSITION COMPRISING A BIOCOMPATIBLE SUSPENSION OF A PROTEIN IN A POLYOL/OIL

]54[

20.12.1999]22[US]33[23.12.1998]32[09/221181]31[US23.11.199909/448205

Int. Cl.8 A61K 009/00]51[AMGEN, INC., U.S.A.]71[

WO/2000/038652]87[ושות', ט. קולב סנפורד

,2273, ת.ד. , מרמורק4 הגיא שער רחובות

SANFORD T.COLB & CO,. P.O.B. 2273 ,

REHOVOT 76122

]74[

]57 [A pharmaceutical composition comprising an effective amount of a biologically active agent (BAA) incorporated into a biocompatible

polyol/oil suspension, wherein said suspension contains a thickener, and wherein said biologically active agent is a protein.

__________143768]21][11[

ניצולת להגברת תרופתיים תכשיריםבמוח גלוקוזה

PHARMACEUTICAL PREPARATIONS FOR INCREASING BRAIN GLUCOSE UTILIZATION

]54[

17.12.1999]22[US]33[17.12.1998]32[60/112669]31[US24.02.199960/122258

Int. Cl.8 A61K 031/42, 031/425, 031/44]51[MINDSET BIOPHARMACEUTICALS (USA), INC., U.S.A.

]71[






TEL AVIV 61040

]74[

]57 [Use of an agent that improves insulin sensitivity in the brain for the preparation of a pharmaceutical composition for improving mental performance in patients

having symptoms of reduced mental performance and are neither in a state of non-insulin dependent diabetes nor a state of general impaired glucose tolerance.

___________

143859]21][11[

5(– – אימידזולילבנזיל( – α 7 תולדות מחושלות, – קוינולין1,2 – – פניל

אותן, המכילים רוקחיים תכשירים מותמר קינולין של ביניים תרכובותוהכנתם

7(-Α-IMIDAZOLYL BENZYL-)5-PHENYL-1,2-ANNELATED QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THE CORRESPONDING SUBSTITUTED QUINOLINE INTERMEDIATES THEREOF AND THEIR PREPARATION

]54[

17.12.1999]22[EP]33[23.12.1998]32[98204444.

8]31[

Int. Cl.8 A61K 031/4709, A61P 035/00, C07D 403/06, 405/14, 471/04]51[JANSSEN PHARMACEUTICA N.V., BELGIUM

]71[



REINHOLD COHN AND PARTNERS, 21 AHAD HA'AM ST ,.

P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [A compound of the formula


or a pharmaceutically acceptable acid addition salt of a stereochemicallyisomeric form thereof, wherein =x1 x2- x3- is a trivalent radical of the formula

=N-CR6=CR7- =CR6-CR7=CR8-=N-N=CR6- =CR6-N=CR7-

=N-NH-C(=O)- =CR6-NH-C(=O)-=N-N=N- or =CR6-N=N-

=N-CR6=N-

wherein each R6, R7 and R8 are independently hydrogen, C1-4 alkyl, hydroxy, C1-4 alkyloxy, aryloxy, C1-4 alkyloxycarbonyl, hydroxy C1-4 alkyl, C1-4

<CH-CHR9-<CH=N-

<CH-NR9-or >C=CR9-

wherein R9 is hydrogen, halo, halocarbonyl, aminocarbonyl, hydroxy C1-4

alkyl, cyano, carboxyl, C1-4 alkyl, C1-4 alkyloxy, C1-4 alkyloxy C1-4 alkyl, C1-4 alkyl, aryl;

alkyloxy C1-4 alkyl, mono- or di(C1-4 alkyl) amino C1-4 alkyl, cyano, amino, mercapto, C1-4 alkylthio, arylthio or aryl; >Y1-Y2-is a trivalent radical of the formular and s are each independently 0,1,2,3,4, or 5;t is 0,1,2 or 3;

each R1 and R2 are independently hydroby, halo, cyano, C1-6 alkyl, trihalomethyl, trihalomethoxy, C2-6 alkenyl, C1-6 alkyloxy, hydroxy C1-6 alkyloxy, C1-6 alkylthio, C1-6 alkyloxy C1-6 alkyloxy, C1-6 alkyloxycarbonyl, amino C1-6 alkyloxy, mono- or di(C1-6 alkyl) amino, mono- or di(C1-6 alkyl) amino C1-6 alkyloxy, aryl, aryl C1-6 alkyl, aryloxy or aryl C1-6 isomeric form thereof, wherein=x1-x2-x3-is a trivalent radical of formulaalkyloxy, hydroxycarbonyl, C1-6 alkyloxycarbonyl, aminocarbonyl, amino C1-6 alkyl, mono- or di (C1-6 alkyl) aminocarbonyl, mono-or di (C1-6 alkyl) amino C1-6 alkyl; ortwo R1 or R2 substituents adjacent to one another on the phenyl ring may independently form together a bivalent radical of the formula

-O-CH2-O--O-CH2-CH2-O-

-O-CH=CH--O-CH2-CH2-

or –CH=CH-CH=CH--O-CH2-CH2-CH2-

R3 is hydrogen, halo, C1-6 alkyl, cyano, halo C1-6 alkyl, hydroxyl C1-6 alkyl, cyano, C1-6 alkyl, amino C1-6 alkyl, C1-6 alkyl, C1-6 alkyl, C1-6 alkyloxy C1-6 alkyl, C1-6 alkylthio C1-6 alkyl, aminocarbonyl C1-6 alkyl, hydroxycarbonyl, hydroxycarbonyl C1-6 alkyl, C1-6 alkyloxycarbonyl C1-6 alkyl, C1-6 alkylcarbonyl C1-6 alkyl, C1-6 alkyloxycarbonyl, aryl, aryl C1-6 alkyloxy

C1-6 alkyl, mono- or di (C1-6 alkyl) amino C1-6 alkyl; or a radical of the formula

-O-R10

-S-R10

-NR11R12

whereinR10 is hydrogen, C1-6 alkyl, C1-6 alkylcarbonyl, aryl, aryl C1-6 alkyl, C1-6 alkyloxcarbonyl C1-6 alkyl, or a radical of formula –Alk-OR13 or – Alk-NR14R15;

R11 is hydrogen, C1-6 alkyl, aryl or aryl C1-6 alkyl; R12 is hydrogen, C1-6 alkyl, aryl, hydroxy, amino, C1-6 alkyloxy, C1-6 alkylcarbonyl C1-6 alkyl, aryl, C1-6 alkyl, C1-

6 alkylcarbonylamino, mono-or di(C1-6 alkyl) amino, C1-6 alkylcarbonyl,


aminocarbonyl, arylcarbonyl, halo, C1-6 alkylcarbonyl, aryl C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, C1-6 alkyloxy C1-6 alkylcarbonyl, mono- di (C1-6 alkyl), aminocarbonyl wherein the alkyl moiety may optionally be substituted by one or more substitutents independently selected from aryl or C1-3 alkyloxycarbonyl, aminocarbonylcarbonyl, mono-or di (C1-6

alkyl) amino C1-6 alkylcarbonyl, or a radical of formula –Alk-OR13 or –Alk-NR14R15; wherein Alk is C1-6 alkanediyl; R13 is hydrogen, C1-6 alkyl, C1-6 alkylcarbonyl, hydroxy C1-6 alkyl, aryl or aryl C1-6 alkyl; R14 is hydrogen, C1-6 alkyl, aryl or aryl C1-6 alkyl; R15 is hydrogen, C1-6 alkyl, C1-6 alkylcarbonyl, aryl or aryl C1-6 alkyl; R4 is a radical of formula

wherein R16 is hydrogen, halo, aryl, C1-6 alkyl, hydroxy C1-6 alkyl, C1-6 alkyloxy C1-6

alkyl, C1-6 alkyloxy, C1-6 alkylthio, amino, mono- or di (C1-4 alkyl) amino, hydroxycarbonyl, C1-6 alkyloxycarbonyl, C1-6 alkylthio C1-6 alkyl, C1-6 alkyl S(O)C1-6 alkyl or C1-6 alkyl S(O)2 C1-6 alkyl; R17 is hydrogen, C1-6 alkyl, C1-6 alkyloxy C1-6

alkyloxy C1-6 alkyl, aryl C1-6 alkyl, trifluoromethyl or di (C1-4 alkyl) aminosulfonyl;R5 is C1-6 alkyl, C1-6 alkyloxy or halo;

aryl is phenyl, naphthalenyl or phenyl substituted with 1 or more substituents each independently selected from halo, C1-6

alkyl, C1-6 alkyloxy or trifluoromethyl.

___________

144683]21][11[

סבוציט, תאי סבוציטים, שורותשלהם ויישומים

SEBOCYTES, SEBOCYTE CELL LINES AND APPLICATIONS THEREOF

]54[

15.12.1999]22[DE]33[01.02.1999]32[19903920.

8]31[


Int. Cl.8 A61K 000/800000 035/36, A61P 017/00, A61Q 001/900000 C12N 005/06, 005/10

]51[

CHRISTOS ZOUBOULIS, GERMANY

]71[





TEL AVIV 61040

]74[

]57 [Sebocytes which are immortalized and of human origin, obtainable by transfection of sebocytes with a DNA comprising DNA sequences coding for the

large T protein of SV-40, characterized in that they possess features of normal, non-transfected and differentiating sebocytes.

__________

145450]21][11[

רצפטור של מודולטוריםגלוקוקורטיקואיד

GLUCOCORTICOID RECEPTOR MODULATORS

]54[

27.03.2000]22[US]33[30.04.1999]32[60/132130]31[

Int. Cl.8 C07C 035/42, 049/647, 069/76, 255/49, 271/44, C07D 213/24, 233/20, 239/26, 241/14, 249/08, 251/12, 263/30, 271/00, 277/22, 285/02

]51[

PFIZER PRODUCTS, INC., U.S.A.]71[WO/2000/066522]87[

לוצאטו, את לוצאטושבע , באר5352, ת.ד. תעשייה, עומר גן



]74[


an isomer thereof, or a pharmaceutically acceptable salt of said compound, or

isomer; wherein m is 1 or 2; D is CR7, or CR7R16; E is C, or CR6; F is CR4, or CR4R5;


R1 is aryl' wherein aryl' is substituted independently with 0,1 or 2 of the following:-Z-OH, -Z-NR12R13, -Z-NR12-het, -C(O)-(C1-C6) alkyl, -NR12-C(O)-(C2-C6) alkenyl, -NR12-C(O)-(C2-C6) alkynyl, -NR12-C(O)-Z-het, -CN, -Z-het, -O-(C1-C3) alkyl –C(O)O(C1-C6) alkyl, -NR12-Z-C(O)O(C1-C6) alkyl, -N(Z-C(O)O(C1-C6) alkyl)2, -NR12-Z-C(O)-NR12R13, -Z-NR12-SO2-R13, -NR12-SO2-het, -C(O)H, -Z-NR12-Z-O(C1-C6) alkyl, -Z-NR12-Z-NR12R13, -Z-NR12-(C3-C6) cycloalkyl, -Z-N(Z-O(C1-C6) alkyl)2, -SO2R12, -SOR12, -SR12, -SO2NR12R13, -O-C(O)-(C1-C4) alkyl, -O-SO2-(C1-C4) alkyl, -halo or –CF3; -SOR12, -SR12, -SO2NR12R13, -O-C(O)-(C1-C4) alkyl, -O-SO2-(C1-C4) alkyl, -halo, or –CF3; Z for each occurrence is independently (a) –(C0-

C6) alkyl, (b) –(C2-C6) alkenyl or (c) –(C2-C6) alkynyl; R2 is (a) –H, (b) –halo, (c) –OH, (d) –(C1-C6) alkyl substituted with 0 or 1 – OH, (e) –NR12R13, (f) –Z-C(O)(C1-C6) alkyl, (g) –Z-C(O)NR12R13, (h) –O-(C1-C6) alkyl, (i) –Z-O-C(O)-(C1-C6) alkyl, (j) –Z-O-(C1-C3) alkyl-C(O)-NR12R13, (k) –Z-O-(C1-C3) alkyl-C(O)-O(C1-C6) alkyl, (l) –O-(C2-C6) alkenyl, (m) –O-(C2-C6) alkynyl, (n) –O-Z-het, (o) –COOH, (p) –C(OH)R12R13 or (q) –Z-CN;

R3 is (a) –H,(b)-(C1-C10) alkyl wherein 1 or 2 carbon atoms, other than the connecting carbon atom, may optionally be replaced with 1 or 2 heteroatoms independently selected from S, O and N and wherein each carbon atom is substituted with 0, 1 or 2 Ry, (c) –(C2-C10) alkenyl substituted with 0, 1 or 2 Ry, (d) –(C2-C10) alkynyl wherein 1 carbon atom, other than the connecting carbon atom, may optionally be replaced with 1 oxygen atom and wherein each carbon atom is substituted with 0, 1 or 2 Ry, (e)-CH=C=CH2, (f) –CN, (g) –(C3-C6) cycloalkyl, (h) –Z-aryl (i) –Z-het (j) –C(O)O(C1-C6) alkyl, (k) –O(C1-C6) alkyl, (l)-Z-S-R12, (m) –Z-S(O)-R12, (n) –Z-S(O)2-R12, (o) –CF3 (p) –NR12O-(C1-C6) alkyl or (q) –CH2ORy;

provided that one of R2 and R3 is absent when there is a double bond between CR2R3, (the 7 position) and the F moiety (the 8 position) of the C-ring; Ry for each occurrence is independently (a) –OH, (b) –halo, (c) –Z-CF3, (d) –Z- CF(C1-C3 alkyl)2, (e) –CN, (f) –NR12R13, (g) –(C3-C6) cycloalkyl, (h) –(C3-C6) cycloalkenyl, (i) –(C0-C3) alkyl-aryl, (j)-het or (k) –N3;

or R2 and R3 are taken together to form (a) =CHR11, (b) =NOR11, (c) =O,(d) =N-NR12, (e) =N-NR12-C(O)-R12, (f) oxiranyl or (g) 1, 3-dioxolan-4-yl;

R4 and R5 for each occurrence are independently (a) –H(b) –CN,(c) –(C1-C6) alkyl substituted with 0 to 3 halo, (d) –(C2-C6) alkenyl substituted with 0 to 3 halo, (e) (C2-C6) alkynyl substituted with 0 to 3 halo, (f) –O-(C1-C6) alkyl substituted with 0 to 3 halo, (g) –O-(C2-C6) alkenyl substituted with 0 to 3 halo, (h) –O-(C2-C6) alkynyl substituted with 0 to 3 halo, (i) halo, (j) –OH(k) (C3-C6) cycloalkyl or (1) (C3-C6) cycloalkenyl; or R4 are taken together to form =O;

R6 is (a) –H, (b) –CN, (c) –(C1-C6) alkyl substituted with 0 to 3 halo, (d) –(C2-C6) alkenyl substituted with 0 to 3 halo, (e) –(C2-C6) alkynyl substituted with 0 to 3 halo or (f) –OH;

R7 and R16 for each occurrence are independently (a) –H, (b) –halo, (c) –CN, (d) –(C1-C6) alkyl substituted with 0 to 3 halo, (e) –(C2-C6) alkenyl substituted with 0 to 3 halo or (f) –(C2-C6) alkynyl substituted with 0 to 3 halo; or R7 and R16 are taken together to form =O;

R8, R9, R14 and R15 for each occurrence are independently (a) –H, (b)-halo, (c) (C1-C6) alkyl substituted with 0 to 3 halo, (d) –(C2-C6) alkenyl substituted with 0 to 3 halo ,

)e)– (C2-C6 (alkynyl substituted with 0 to 3 halo, (f) –CN, (g)-(C3-C6) cycloalkyl, (h) –(C3-C6) cycloalkenyl, (i) –OH, (j) –O-(C1-C6) alkyl, (k) –O-(C1-C6) alkenyl, (l) –O-(C1-C6) alkynyl, (m) –NR12R13, (n) –C(O)OR12 or (o) –C(O)NR12R13;


or R8 and R9 are taken together on the C-ring to form =O; provided that when m is 2, only one set of R8 and R9 are taken together to form =O;

or R14 and R15 are taken together to form =O; provided that when R14 and R15 are taken together to form =O, D is other than CR7 and E is other than C;

R10 is (a) –(C1-C10) alkyl substituted with 0 to 3 substituents independently selected from –halo, -OH and –N3, (b) –(C2-C10) alkenyl substituted with 0 to 3 substituents independently selected from –halo, -OH and –N3, (c) –(C2-C10) alkynyl substituted with 0 to 3 substituents independently selected from –halo, -OH and –N3, (d) –halo, (e) –Z-CN, (f) –OH, (g) –Z-het, (h) –Z-NR12R13, (i) –Z-C(O)-het, (j)-Z-C(O)- (C1-C6) alkyl, (k) –Z-C(O)-NR12R13, (l)-Z-C(O)-NR12-Z-CN, (m) –Z-C(O)-NR12-Z-het, (n) –Z-C(O)-NR12-Z-aryl, (o)-Z-C(O)-NR12-Z-NR12R13, (p) –Z-C(O)-NR12-Z-O(C1-C6) alkyl, (q) –(C0-C6) alkyl-C(O)OH, (r) –Z-C(O)O(C1-C6) alkyl, (s), -Z-O-(C0-C6) alkyl-het, (t)-Z-O-(C0-C6) alkyl-aryl, (u)-Z-O-(C1-C6) alkyl substituted with 0 to 2 Rx, (v) –Z-O-((C1-C6) alkyl-CH(O), (w)-Z-O-(C1-C6) alkyl-NR12-het, (x) –Z-O-Z-het-Z-het, (y) –Z-O-Z-het-Z-NR12R13, (z) –Z-O-Z-het-C(O)-het, (a1)-Z-O-Z-C(O)-het, (b1) –Z-O-Z-C(O)-het-het, (c1)-Z-O-Z-C(O)- (C1-C6) alkyl, (d1) –Z-O-Z-C(S)-NR12R13, (e1) –Z-O-Z-C(O)-NR12R13, (f1) –Z-O-Z-(C1-C3) alkyl-C(O)-NR12R13, (g1) –Z-O-Z-C(O)-O(C1-C6) alkyl, (h1) –Z-O-Z-C(O)-OH, (i1) –Z-O-Z-C(O)-NR12-O(C1-C6) alkyl, (j1), -Z-O-Z-C(O)-NR12-OH, (k1) –Z-O-Z-C(O)-NR12-Z-NR12R13, (ll) –Z-O-Z-C(O)-NR12-Z-het, (ml) –Z-O-Z-C(O)-NR12-SO2-(C1-C6) alkyl, (n1)-Z-O-Z-C (=NR12) (NR12R13), (o1) –Z-O-Z-C(=NOR12) (NR12R13, (p1) –Z-NR12-C(O)-Z-NR12R13, (q1) –Z-S-C(O)-NR12R13 (rl)-Z-O-SO2-(C1-C6) alkyl, (s1)-Z-O-SO2-aryl, (t1) –Z-O-SO2-NR12R13, (u1) –Z-O-SO2-CF3, (v1)- Z-NR12C(O)OR13 or (w1) –Z-NR12C(O)R13;

R11 is (a)-H, (b) –(C1-C5) alkyl, (c)-(C3-C6) cycloalkyl or (d) –(C0-C3) alkyl-aryl; R12 and R13 for each occurrence are each independently (a) –H, (b) –(C1-C6) alkyl wherein 1 or 2 carbon atoms, other than the connecting carbon atom, may optionally be replaced with 1 or 2 heteroatoms independently selected from S,O and N and wherein each carbon atom is substituted with 0 to 6 halo, (c)-(C2-C6) alkenyl substituted with 0 to 6 halo or (d) –(C1-C6) alkenyl wherein 1 carbon atom, other than the connecting carbon atom, may optionally be replaced with 1 oxygen atom and wherein each carbon atom is substituted with 0 to 6 halo;

or R12 and R13 are taken together with N to form het;

or R6 and R14 or R15 are taken together to form 1, 3-dioxolanyl; aryl is (a) phenyl substituted with 0 to 3 Rx, (b) naphthyl substituted with 0 to 3 Rx or (c) biphenyl substituted with 0 to 3 Rx; het is a 5-, 6- or 7-membered saturated or unsaturated ring containing from one (1) to three (3) heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocycle; and the nitrogen may be in the oxidized state giving the N-oxide form; and substituted with 0 to 3 Rx; Rx for each occurrence is independently (a) –halo, (b) –OH, (c) –(C1-C6) alkyl, (d) –(C2-C6) alkenyl, (e) –(C2-C6) alkynyl, (f)-O(C1-C6) alkyl, (g)-O(C2-C6) alkenyl, (h) –O(C2-C6) alkynyl, (i) –(C0-C6) alkyl-NR12R13, (j)-C(O)-NR12R13, (k) –Z-SO2R12, (l)-Z-SOR12, (m) –Z-SR12, (n) –NR12-SO2R13, (o)-NR12-C(O)-R13, (p)-NR12-OR13, (q) –SO2-NR12R13, (r) –CN,(s) –CF3,(t) –C(O) (C1-C6) alkyl, (u)=O, (v) –Z-SO2-phenyl or (w) –Z-SO2-het'; aryl' is phenyl, naphthyl or biphenyl; het' is a 5-, 6- or 7-membered saturated or unsaturated ring containing from one (1) to three (3) heteroatoms independently selected from


the group consisting of nitrogen, oxygen and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocycle; provided that: when R9 and R10 are substituents on the A-ring, they are other than mono- or di-methoxy; (2) when R2 and R3 are taken together to form =CHR11 or =O wherein

R11 is –O(C1-C6) alkyl, then –X-R1 is other than (C1-C4) alkyl; (3) when R2 and R3 taken together are C=O and R9 is hydrogen on the A-ring; or when R2 is hydroxy, R3 is hydrogen and R9 is hydrogen on the A-ring, then R10 is other than –O-(C1-C6) alkyl or –O-CH2-phenyl at the 2-position of the A-ring.



_________

145728]21][11[

(4 – X – 3)טריפלואורומתיל( פניל( – – – )פרפלואורואצילאמינו(3

פרופיונאמיד, להכנת ושימושם המכילותם תרכובותרפואים תכשירים

2 – HYDROXY – 2 – METHYL – N – (4 – X – 3 – (TRIFLUOROMETHYL) PHENYL) – 3 – (PERFLUOROACYLAMINO) PROPIONAMIDE DERIVATIVES, COMPOSITIONS THEREOF AND THE USE THEREOF IN THE

]54[


MANUFACTURE OF MEDICAMENTS

25.05.2000]22[US]33[11.02.2000]32[09/502376]31[

Int. Cl.7 A61K 031/165, C07C 237/22]51[143709]61[BIOPHYSICA, INC., U.S.A.]71[

WO/2001/058854]87[( בע"מ,1995) ג'י.אי.ארליך

בגין מנחם ,רחוב15 אילון, קומה מגדל גן , רמת11

G.E. EHRLICH (1995) LTD,. AYALON TOWER, 15TH FLOOR,

11 MENACHEM BEGIN ST,.RAMAT GAN 52521

]74[

]57 [A compound of the formula 2-hydroxy-2-methyl-N-(4-X-3-(trifluoromethyl) phenyl-3-(perfluoroacylamino) propionamide,

wherein X is nitro, cyano or halo of atomic number 9-35, and the perfluoroacylamido group has from 2 to 3 carbon atoms and 0 or 1 hydrogen atom.

__________

146547]21][11[

חדישים גנים גלוי קצב לשיפור שיטה חומצות של מולקולות באוכלוסיית

כן לפני מאופניינות לא גרעין

METHOD OF ENHANCING THE RATE OF NOVEL GENE DISCOVERY IN A POPULATION OF PREVIOUSLY UNCHARACTERIZED NUCLEIC ACID MOLECULES

]54[

19.05.2000]22[US]33[19.05.1999]32[09/314698]31[

Int. Cl.8 C12Q 001/68]51[AVENTIS PHARMACEUTICALS INC., U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A method for reducing redundancy in a sample of nucleic acid molecules, the method comprising:

)a (providing a heterogeneous sample of nucleic acid molecules ;

)b (immobilizing the sample of nucleic acid molecules on a first microarray;

)c (hybridizing to said sample one or more labeled probes corresponding to sequences

known to be or suspected of being present in said sample of nucleic acid molecules;

)d (identifying at least one immobilized molecule that hybridizes weakly or does not hybridize to the labeled probes,

)e (providing a probe which specifically recognizes the nucleic acid molecule of (d);

)f (optionally repeating steps (b)-(d) or (b)-(e) using a labeled probe which includes


the probe of step (e), thereby reducing redundancy in said sample of nucleic acid

.___________

147019]21][11[

בקשר שידור קצב להגדרת וציוד שיטהאל–חוטית תקשורת במערכת נגדי/הפוך

METHOD AND APPARATUS FOR DETERMINING A REVERSE LINK TRANSMISSION RATE IN A WIRELESS COMMUNICATION SYSTEM

]54[

30.06.2000]22[US]33[02.07.1999]32[09/346882]31[

Int. Cl.8 H04B 007/005, 007/26, H04J 013/00, H04L 001/00, H04Q 007/38]51[QUALCOMM INCORPORATED, U.S.A.

]71[




REHOVOT 76122

]74[

]57 [A communication system, comprising: a remote station configured to transmit reverse link data to a base station of a plurality of base stations, at a reverse link transmission rate in accordance with a combined reverse link busy signal generated in accordance with the reverse link busy bits transmitted by each of the

base stations of the plurality of base stations; and a plurality of base stations, each base station configured to transmit forward link data to the remote station, the forward link data including a reverse link busy bit, the reverse link busy bit indicating when a base station has reached its reverse link capacity limit.




________

147282]21][11[

אמינותיאזול, הכנתן של חדישות נגזרותאותן המכילים ריקחיים והרכבים

AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

]54[

11.07.2000]22[FR]33[15.07.1999]32[99/09144]31[

Int. Cl.8 A61K 031/426, A61P 025/00, C07D 277/48, 417/12, 417/14]51[SANOFI AVENTIS, FRANCE]71[WO/2001/005776]87[

ושות', ט. קולב סנפורד ,2273, ת.ד. , מרמורק4 הגיא שער

רחובות


REHOVOT 76122

]74[


in whichR1 and R2, which may be identical or different, each independently represent a halogen atom, a hydroxy (C1-C5) alkyl; a (C1-C5) alkyl; an aralkyl in which the aryl portion is (C6-C8) and the alkyl portion is (C1-C4); a (C1-C5) alkoxy; a trifluoromethyl group; a nitro group; a nitrile group; a group –SR in which R represents hydrogen, a (C1-C5) alkyl or an aralkyl in which the aryl portion is (C6-C8) and the alkyl portion is (C1-C4); a group –S-CO-R in which R represents a (C1-C5) alkyl or an aralkyl radical in which the aryl portion is (C6-C8) and the alkyl portion is (C1-C4); a

group –COORa in which Ra represents hydrogen or a (C1-C5) alkyl; a group –CONRaRb with Ra and Rb as defined above for Ra; a group –NRaRb with Ra and Rb as defined above for Ra; a group –CONRcRd or –NRcRd in which Rc and Rd constitute, with the nitrogen atom to which they are attached, a 5- to 7-membered heterocycle; or a group –NHCO-NRaRb with Ra and Rb as defined above for Ra;

R3 represents hydrogen or is as defined above for R1 and R2;

or alternatively R2 constitutes with R3, when the latter substitutes the phenyl in


position 5, a group –X-CH2-X- in which X independently represents a CH2 or an oxygen or sulphur atom; R4 represents hydrogen, a (C1-C5) alkyl; a hydroxymethyl group; a formyl group; a halogen atom; or a (C3-C5) cycloalkyl group; R5 represents an alkynyl of 3 to 6 carbon atoms; R6 represents a (C1-C6) alkyl; a (C1-C6) alkoxy (C1-C3) alkyl; a (C3-C5) cycloalkyl; a (C3-C6) cycloalkyl (C1-C6) alkyl; a (C1-C6) alkylthio (C1-C3) alkyl; a (C1-C6) alkylsulphoxy (C1-C3) alkyl; or a (C1-C6) alkylsulphodioxy (C1-C3) alkyl; R7 represents a phenyl which is unsubstituted,

mono- di-or trisubstituted in position 3, 4 or 5 with a halogen, with a (C1-C5) alkyl, with an –O-CH2 –O- group on two neighbouring carbon atoms of the phenyl, with a –CF3, -NO2 or –CN, with a group –COOR8 or –CONR8 R9 or with a group CH2 OR8 in which R8 and R9 represent a (C1-C3) alkyl, OR10 in which R10 represents a (C1-C5) alkyl; or alternatively R7 represents a pyridyl, thiophene, pyrazolyl, imidazolyl, (C3-C5) cycloalkyl or (C3-C6) cycloalkyl (C1-C6) alkyl group; or the acid or base addition salts thereof, the hydrates thereof and/or the solvates thereof.

___________

147379]21][11[

PROCESS FOR PREPARINGדיבנזותיאזפין נגזרות להכנת תהליךDIBENZOTHIAZEPINE DERIVATIVES

]54[

09.07.1999]22[Int. Cl.8 C07D 281/16]51[ASTRAZENECA UK LIMITED, UNITED KINGDOMUBE INDUSTRIES, LTD., JAPAN

]71[

WO/2001/004106]87[ושות', ש. הורוביץ

, תל41-45 רוטשילד ציון, שדרות בית אביב

S. HOROWITZ & CO,. ZION HOUSE,

41-45 ROTHSCHILD BLVD,.TEL AVIV 65784

]74[


]57 [A process for preparing a dibenzothiazepine compound of the formula

)5(

in which each of R1, R2, R3, R4, R5, R6, R7 and R8 independently represents a hydrogen atom, an alkyl group, an alkoxy group, an alkylcarbonyl group, an aryl group, an aryloxy group, or an

arylcarbonyl group, each group being optionally substituted, which comprises the steps of: reacting a nitrobenzene compound of the formula

)1(

in which X represents a halogen atom, with a thiosalicylic acid compound of the formula

)2(

wherein the step of reacting the compound of formula (1) with a compound of formula (2) is conducted in a solvent selected from the group consisting of water, amide

solvents, aliphatic alcohols, ketones, and nitriles, in the presence of a base, to obtain a 2-nitro-2'-carboxy-diphenylsulfide compound of the formula


)3(

reducing the obtained 2-nitro-2'-carboxy-diphenylsulfide compound, in the presence of a compound selected from the group consisting of Raney-nickel, a ferrous salt,

palladium/carbon, palladium/barium sulfate, a palladium compound and a platinum compound, to obtain a compound of the formula

and subjecting the obtained 2-amino-2'-carboxy-diphenylsulfide

compound to dehydration-condensation reaction.



__________

147401]21][11[

חולייתית אוסטאוסינתזה לוחותאוסטאוסינתזה ומערכת

VERTEBRAL OSTEOSYNTHESIS PLATE AND OSTEOSYNTHESIS SYSTEM

]54[

03.07.2000]22[FR]33[01.07.1999]32[99/08495]31[

Int. Cl.8 A61B 017/70]51[SPINEVISION, FRANCE]71[WO/2001/001874]87[


רחובות


REHOVOT 76122

]74[


]57 [Vertebral osteosynthesis plate for maintaining the correction of the relative orientation of the vertebrae by means of a correction instrument, said osteosynthesis plate being generally rectangular in shape and having at least four openings (1, 2, 4, 5) for fixing means to pass through each of the openings, characterized in that at least two of the openings (4, 5) open onto a lateral edge (6) of said osteosynthesis plate

so as to allow the plate to the installed and fixed without the prior removal of the instrument for correcting the relative orientation of the vertebrae, the edge of the plate being defined by an edge running in the same direction as the longitudinal direction of the plate, the longitudinal direction of the plate being approximately the same as the direction of the vertebral column.

_________

147403]21][11[

FIXING ELEMENT ANDחוליות לייצוב וסיוע קיבוע רכיבANCILLARY FOR STABILISING VERTEBRAE

]54[

30.06.2000]22[FR]33[01.07.1999]32[99/08498]31[

Int. Cl.8 A61B 017/70]51[SPINEVISION, FRANCE]71[WO/2001/001873]87[


רחובות


REHOVOT 76122

]74[


]57 [Implant of the type comprising a fastener that can be anchored to a vertebra and having a head in the shape of a fork in which the two branches define a substantially U-shaped reception space, intended for receiving a link element (1), and a closure part (3) that can be fixed to the head, said implant being characterized in that the closure part is generally U-shaped, whose branches cooperate with the branches of the fork-shaped part of the

head, and in that the head has, at the bottom of the "U", the general shape of a horse saddle allowing the link element to pivot about a transverse axis (24) of said implant, when said link element is housed in the reception space, and means for guiding the closure part on the outer side surfaces of the fork-shaped part, said guiding means being formed by an arched shoulder such as to allow the closure part to pivot about the transverse axis.

__________

147491]21][11[

בסיס לטבלת התאוששות מערכתנתונים

DATABASE TABLE RECOVERY SYSTEM

]54[

23.06.2000]22[US]33[07.07.1999]32[09/349198]31[

Int. Cl.8 G06F 012/00, 017/30]51[COMPUTER ASSOCIATES THINK, INC., U.S.A.

]71[




BEER-SHEVA 84152

]74[


]57 [A system for recovering a database table comprising: a database table recovery system, the database table recovery system operable to retrieve a backup copy of a tablespace and to apply updates to the backup copy from a log associated with a first database table generated from the tablespace in response to corruption of the first database table, and to restore the first database table associated with the

tablespace from the updated backup copy without affecting the tablespace; and a tablespace access system coupled to the database table recovery system, wherein the tablespace access system is operable to restrict access to the tablespace for other database tables associated therewith to read-only access until the first database table has been recovered.

__________

147734]21][11[

THERMISTOR AND METHOD OFלייצורו ושיטה תרמיסטורMANUFACTURE

]54[

20.01.2002]22[US]33[26.01.2001]32[770556]31[

Int. Cl.8 G01K 007/22, H01C 017/28]51[CORNERSTONE SENSORS, INC., U.S.A.

]71[

GREGG LAVENUTA]72[ושות' בע"מ, מ. בן-דוד ירמיהו




]74[


JERUSALEM 91450

]57 [A thermistor comprising:)a (a semiconductor body comprising two

opposed surfaces;)b (a first electrode layer (13a) deposited

on at least a portion of said opposed surfaces of the semiconductor body said first layer being formed of a first electrode material comprising a conductive metal taken from the group consisting of Au, Ag, Pt, Pd and combinations and alloys thereof and having a thickness of greater than about 5 micrometers;

)c (a second electrode layer (13b) deposited outward of said first layer, said second layer being formed of a second

electrode material comprising Ti, said second layer having a thickness of not more than about 5 micrometers;

)d (a third electrode layer (13c) deposited outward of said second layer, said third layer being formed of a third electrode material comprising Pt, said third layer having a thickness of not more than about 5 micrometers; and;

)e (optionally, a fourth electrode layer (13d) deposited outward of said third electrode layer, said fourth electrode layer comprising a conductive metal having a thickness of not more than about 5 micrometers.

___________

147953]21][11[

–N של רוקחיים ותכשירים נגזרות הידרוקסימתיל

טטראמתילציקלופרופיל–קרבוקסא אנטי פעילות מיד, בעלות ופעילות ונוירולוגית אפילפטית

להכנתם ושיטהCNSה– למערכת

DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS OF N-HYDROXYMETHYL

TETRAMETHYLCYCLOPROPYL -CARBOXAMIDE HAVING ANTI - EPILEPTIC, NEUROLOGICAL AND CNS ACTIVITY AND METHOD FOR THEIR PREPARATION

]54[

01.02.2002]22[Int. Cl.8 A61K 031/16, 031/325, A61P 025/00, C07C 233/60, 271/10]51[


של המחקר לפיתוח חברה יישום בירושלים, העברית האוניברסיטה

ירושלים


]71[

MEIR BIALER, BORIS YAGEN, NINAאיסוהרנן יגן, נינה ביאלר, בוריס מאירISOHERRANEAN

]72[

ושותפיו, כהן ריינהולד ,4060 , ת.ד. 21 העם אחד רחוב

אביב תל


P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [N-Hydroxyalkyl-tetramethylcyclopropane carboxamide derivatives of the formula

wherein n=1-6; and R is hydrogen, an alkyl group of 1-3 carbons, an arylalkyl

group, an aryl group, a carboxamide or N-methyl or N-dimethyl carboxamide.

__________

148057]21][11[

CGRP של באנטגוניסטים שימוש לטיפול רוקחות תכשיר להכנת

המעבר בתקופת חמים בהבזקים

USE OF CGRP ANTAGONISTS FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR TREATING MENOPAUSAL HOT FLASHES

]54[

05.08.2000]22[DE]33[10.08.1999]32[199373043]31[

Int. Cl.8 A61K 031/445, 031/495, 031/505, 031/54, 031/55, 045/06, A61P 015/12]51[BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, GERMANY

]71[





P.O.B. 4060 ,TEL AVIV 61040

]74[

]57 [Use of a CGRP antagonist for preparing a pharmaceutical composition for treating menopausal hot flushes, characterized in that the CGRP antagonist is selected from among:

)A (1-[N2[3, 5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinoazolin-3-yl)-1-piperidinyl] carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine ,

)B (1-[4-amino-3, 5-dibromo-N-[[4-(2, 3, 4, 5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine,

)C (1-[N2-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperazine,

)D (1-[N2-[4-amino-3, 5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-L-lysyl]-4-(4-pyridinyl)-piperidine,

)E (1-[N2-[3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-l-yl)-1-piperidinyl] carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine,

)F (1-[N2-[4-amino-3, 5-dibromo-N-[[4-(1, 3-dihydro-4-phenyl-2(2H)-oxoimidazol-l-yl)-1-piperidinyl] carbonyl]-D-phenylalnyl]-L-lysyl]-4-(4-pyridinyl)-piperazine,

)G (1-[3,5-dibromo-N-[[3,4-dihydro-2(1H)-oxothieno [3,4-d] pyrimidin-3-yl)-1-piperidinyl] carbonyl]-D-tyrosyl]-4-(1-piperidinyl) piperidine,

)H (1-[4-amino-3, 5-dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H0-oxo-1,2,4-triazol-2-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine,

)I (1-[4-amino-3,5-dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-

2-yl)-1-piperidinyl] carbonyl-D-phenylalanyl]-4-(1-piperidinyl)-piperidine,

)J (1-[4-amino-3, 5-dibromo-N-[[4-(2, 4-dihydro-5-phenyl-3(3H)-oxo-,1,2,4-triazol-2-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine,

)K (1-[4-amino-3, 5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxothieno [3,2-d] pyrimidin-3-yl)-1-piperidinyl] carbonyl] –D-phenylalanyl]-4-(1-piperidinyl)-piperidine,

)L (1-[4-amino-3, 5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl) phenyl]-2-(2H)- oxoimidazol-l-yl]-1-piperidin-yl] carbonyl]-D-phenylalanyl] -4-(1-ethyl-4-piperidinyl)-piperidine ,

)M (1-[4-amino-3,5-dibromo-N-[[4-[3, 4-dihydro-2(1H)-oxoquinoazolin-3-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-hexyl-4-piperidinyl)-piperidine,

)N (1-[4-amino-3,5-dibromo-N-[[4-[3, 4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-cyclopropylmethyl-4-piperidinyl)-piperidine,

)O (1-[4-amino-3,5-dibromo-N-[[4-[N-(aminocarbonyl)-N-phenylamino]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine,

)P) (R, S-(1-[4-[4-(3, 4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(4-hydroxy-3, 5-dimethylphenyl) methyl]-1,4-dioxobutyl]-4-(1-piperidinyl)-piperidine,

)Q (1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(5-methoxy-4-pyrimidinyl)-piperazine,

)S (1-[4-amino-3,5-dibromo-N-[[4-(1,1-dioxido-3(4H)-oxo-1,2,4-benzothiadiazin-


2-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine,

)T (1-[4-amino-3, 5-dibromo-N-[[4-[2(1H)-oxoquinolin-3-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine,

)U (1-[4-amino-3, 5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-[3-(dimethylamino) propyl]-piperazine,

)V (1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(4-methyl-1-piperazinyl)-piperidine ,

)W (1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-[(1-methyl-4-piperidinyl) carbonyl]-piperazine,

)X (1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-[(1-methyl-4-piperazinyl) carbonyl]-piperazine ,

)Y (1-[4-amino-3, 5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-[4-[4-(dimethylamino) butyl]phenyl]-piperazine ,

)Z (1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl-D-phenylalanyl]-4-[4-(dimethylamino)-1-piperidinyl]-piperidine,

)AA (1-[N2-[[4-(1, 3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl] carbonyl]-N'-methyl-D-tryptyl]-4-(4-methyl-1-piperazinyl)-piperidine,

)AB (1-[N2-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-l-yl)-l-piperidinyl] carbonyl]-N'-(1,1-dimethylethoxycarbonyl)-D-tryptyl]-4-(1-methyl-4-piperidinyl)-piperidine,

)AC) (R, S-(1-[4-[4-(3, 4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dibromo-4-methylphenyl) methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine,

)AD) (R, S-(1-[4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[(3,5-dibromo-4-methoxyphenyl) methyl]-1,4-dioxobutyl]-4-(1-methyl-4-piperidinyl)-piperidine,

)AE) (R, S- (1-[4-[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-2-[3,4-dibromophenyl) methyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-piperidine,

)AF (1-[N2-[N-[[-(1,3-dihydro-2(2H)-oxobenzimidazol-l-yl)-piperidinyl] carbonyl] 3, 5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine,

)AG (1-[4-amino-3,5-dibromo-N-[[4-(1, 3-dihydro-6-hydroxy-2(2H)-oxobenzimidazol-1-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine,

)AH (1-[N2-[4-amino-3,5-dibromo-N-[[4-(1,3-dihydro-2(2H)-oxobenzimidazol-l-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-N6, N6 –dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine,

)AI (1-[N2-4-amino-3,5-dibromo-N-[[4-(3, 4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-N6, N6-dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine,

)AJ) (R, S-(1-(2-(4-amino-3, 5-dibromobenzoyl)-4[4-(3, 4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]-4-oxobutyl]-4-(1-piperidinyl)-piperidine,

)AK (1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2,2-dioxido-2,1, 3-benzothiadiazin-3-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine ,

)AL (1-[4-amino-3,5-dibromo-N-[[4-[1,3-dihydro-2(2H)-oxoimidazo [4,5-c] quinolin-3-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-piperidinyl) carbonyl]-piperidine,

)AM (1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine,

)AN (1-[N2-[3,5-dibromo-N[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-


piperidinyl] carbonyl]-D-tyrosyl]-N6, N6-dimethyl-L-lysyl]-4-(4-pyridinyl)-piperazine,

)AO (1-[4-amino-N-[[4-[4-(3-bromophenyl)-1,3-dihydro-oxoimidazol-l-yl]-1-piperidinyl] carbonyl-3,5-dibromo-D-phenylalanyl]-4-(1-methyl-4-piperidinyl) piperidine,

)AP (1-[4-amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-l-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(4-methyl-1-piperazinyl)-piperidine,

)AQ (1-[4-amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl) phenyl]-2(2H)-oxoimidazol-l-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine,

)AR (1-[4-amino-3, 5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl) phenyl]-2(2H)-oxoimidazol-l-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo [3,2,1] oct-3-yl)-piperazine,

)AS (1-[3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-l-yl)-1-piperidinyl] carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine,

)AT (1-[4-amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-trifluoromethyl) phenyl]-2(2H)-oxoimidazol-l-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperazine,

)AU (1-[4-amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-phenyl-2(2H)-oximidazol-l-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl) piperidine,

)AV (1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3yl)-1-piperidinyl] carbonyl]-D-tyrosyl]-4-[1-(methylsulphonyl)-4-piperidinyl]-piperidine,

)AW (1-[4-amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-l-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine,

)AX (1-[3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl) phenyl]-2(2H)-oxoimidazol-1-yl]-1-piperidinyl] carbonyl-D-tyrosyl]-4-(hexahydro-1H-1-azepinyl)-piperidine,

)AY (1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperidine,

)AZ (1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo[3,2,1] oct-3-yl)-piperazine,

)BA (1-[4-amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-l-yl)-1-piperidinyl] carbonyl]-D-phenyl-alanyl]-4-(1-methyl-4-piperidinyl)-piperazine,

)BB (1-[3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-trifluoromethyl) phenyl]-2(2H)-oxoimidazol-l-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine,

)BC (1-[N6-acetyl-N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine,

)BD (1-[3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-l-yl)-1-piperidinyl] carbonyl]-D-tyrosyl]-4-(hexahydro-1H-1-azepinyl)-piperidine,

)BE (1-[4-amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-(3-thienyl)-2(2H)-oxoimidazol-1-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine,

)BF (1-[4-amino-3,5-dibromo-N-[[4-[1,3-dihydro-4[3-(trifluoromethyl) phenyl]-2(2H)-oxoimidazol-l-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine,

)BG (1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-tyrosyl]-4-[1-(hydroxycarbonylmethyl)-4-piperidinyl]-piperidine,

)BH (1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-


piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-methylsulphonyl-4-piperidinyl)-piperidine,

)BI (1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-tyrosyl]-4-(4-piperidinyl)-piperidine,

)BJ (1-[4-amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-ethyl-4-piperidinyl)-piperidine,

)BK (1-[4-amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-(3-hydroxyphenyl)-2(2H)-oxoimidazol-l-yl)-1-piperidinyl] carbonyl-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine,

)BL (1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(hexahydro-1H-1-azepinyl)-piperidine,

)BM (1-[4-amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-l-yl)-1-piperidinyl] carbonyl-D-phenylalanyl]-4-(1-piperidinyl)-piperidine,

)BN (1-[4-amino-3,5-dibromo-N-[[4-[4-(3-bromophenyl)-1,3-dihydro-2(2H)-oxoimidazol-l-yl]-1-piperidinyl] carbonyl-D-phenylalanyl]-4-(exo-8-methyl-8-methyl-8-azabicyclo[3,2,1]oct-3-yl)-piperazine,

)BO (1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-phenylalnyl]-4-(1-ethyl-4-piperidinyl)-piperidine,

)BP (1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-phenylalnyl]-4-(1-ethyl-4-piperidinyl)-piperazine,

)BQ (1-[4-amino-3, 5-dibromo-N-[[4-[1,3-dihydro-4-(3-methoxyphenyl)-2(2H)-oxoimidazol-l-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(exo-8-methyl-8-azabicyclo [3,2,1] oct-3-yl)-piperazine,

)BR (1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-piperidinyl] carbonyl]-D-tyrosyl]-4-[1-

(cyclopropylmethyl)-4-piperidinyl]-piperidine,

)BS (1-[4-amino-3,5-dibromo-N-[[4-(3-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine,

)BT (1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(piperidinyl)-piperidine,

)BU (1-[3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-2-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-4-(4-pyridinyl)-piperidine,

)BV (1-[3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl) phenyl]-2(2H)-oxoimidazol-l-yl]-1-piperidinyl] carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperdinyl)-piperazine,

)BW (1-[N2-[3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl) phenyl]-2(2H)-oxoimidazol-l-yl]-l-piperidinyl] carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine,

)BX (1-[3,5-dibromo-N-[[4-(1, 3-dihydro-4-(3-thienyl)-2(2H)-oxoimidazol-l-yl)-1-piperidinyl] carbonyl]-D-tyrosyl]-4-(1-piperidinyl)-piperidine,

)BY (1-[4-amino-N-[[4-[4-(3-chlorophenyl)-1,3-dihydro-2(2H)-oxoimidazol-l-yl]-l-piperidinyl] carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine,

)BZ (1-[4-amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl) phenyl]-2(2H)-oxoimidazol-l-yl]-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine,

)CA (1-[4-amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-[3-(trifluoromethyl) phenyl]-2(2H)-oxoimidazol-l-yl]-l-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine,

)CB (1-[4-amino-N-[[4-[4-(3-chlorophenyl)-1,3-dihydro-2(2H)-oxoimidazol-l-yl]-1-piperidinyl]carbonyl]-3,5-dibromo-D-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine,


)CC (1-[4-amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-l-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(4-pyridinyl)-piperazine,

)CD (1-[3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-l-yl)-l-piperidinyl] carbonyl]-

D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperidine,

)CE (1-[4-amino-3,5-dibromo-N—[[4-[1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-l-yl]-l-piperidinyl] carbonyl]-D-phenylalanyl]-4-[4-(1-oxoethyl) phenyl-piperazine,

)CF (1-[3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl] carbonyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)-piperazine,

)CG (1-[4-amino-3,5-dibromo-N-[[4-[1,3-dihydro-4-(3-nitrophenyl)-2(2H)-

oxoimidazol-l-yl]-l-piperidinyl] carbonyl]-D-phenylalanyl-4-(1-methyl-4-piperidinyl)-piperidine,

)CH (1-[4-amino-3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-pyrrolidinyl)-piperidine,

)CI (1-[4-amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-l-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(hexahydro-1H-1-azepinyl)-piperidine and

)CJ (1-[4-amino-3,5-dibromo-N-[[4-(1,3-dihydro-4-(3-thienyl)-2(2H)-oximidazol-1-yl)-1-piperidinyl] carbonyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperazine, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the physiologically acceptable salts thereof.

___________

148079]21][11[

ותכשיריםCTLA–4 אנושיים נוגדניםאותם המכילים

HUMAN CTLA-4 ANTIBODIES AND COMPOSITIONS CONTAINING THE SAME

]54[

24.08.2000]22[US]33[24.08.1999]32[60/150452]31[

Int. Cl.8 A61K 039/395, A61P 037/00, C07K 016/18, 016/28, C12N 015/13, 015/85]51[MEDAREX, INC., U.S.A.]71[

WO/2001/014424]87[




JERUSALEM 91013

]74[

]57 [A therapeutically effective human antibody or antigen-binding portion thereof that binds human CTLA4 with a binding affinity of about 108 M-1 or greater,

wherein the antibody or antigen binding portion thereof does not cross-react with non-lymphoid tissue.



___________

148180]21][11[

ואיזואינדולונים פירולוקרבזולים רוקחות ותכשירי איזומריים מאוחים


ISOMERIC FUSED PYRROLOCARBAZOLES AND ISOINDOLONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

]54[

18.08.2000]22[US]33[20.08.1999]32[60/150367]31[US17.08.200009/640825

Int. Cl.8 A61K 031/407, 031/437, A61P 013/08, 025/00, 027/02, 035/00, C07D 471/14, 487/00, 487/04, 491/147, 495/14, C12P 017/18

]51[

CEPHALON, INC., U.S.A.]71[WO/2001/014380]87[


רחובות


REHOVOT 76122

]74[


or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein:

ring D is selected from phenyl and cyclohexene with double bond a-b; ring B


and ring F, independently, and each together with the carbon atoms to which they are attached, are selected from:

)a (a 6-membered carbocyclic ring in which from 1 to 3 carbon atoms may be replaced by hetero atoms; and

)b (a 5-membered carbocyclic ring in which either

)1 (one carbon atom may be replaced with an oxygen, nitrogen, or sulfur atom;

)2 (two carbon atoms may be replaced with a sulfur and a nitrogen atom, an oxygen and a nitrogen atom, or two nitrogen atoms; or

)3 (three carbon atoms may be replaced with three nitrogen atoms, one oxygen and two nitrogen atoms, or one sulfur and two nitrogen atoms;G-X-W is selected from:

)a)-(A1A2(C-N(R1)-C(B1B2);-)b– (CH(R1A)-C(=O)-N(R1)-; and

)c– (N(R1)-C(=O)-CH(R1A);-R1 is selected from:

)a (H, substituted or unsubstituted alkyl of 1 to 6 carbons, substituted or unsubstituted C6-C12 aryl, substituted or unsubstituted C7-C15 arylalkyl, substituted or unsubstituted C6-C12 heteroaryl in which one or more ring carbon atoms is replaced by an O, N or S atom, or substituted or unsubstituted C7-C15 heteroarylalkyl in which one or more ring carbon atoms is replaced by an O, N or S atom;

)b– (C(=O)R7 where R7 is selected from substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C6-C12 aryl, substituted or unsubstituted C7-C8 carbocyclic group, and substituted or unsubstituted heterocyclyl groups;

)c– (OR8, where R8 is selected from H and alkyl having from 1 to 6 carbons;

)d– (C(=O)NHR8, -NR9R10, -(CH2)pOR8, -O(CH2)pOR8 and –O(CH2)pNR9R10, where p is from 1 to 4; and where either

)1 (R9 and R10 are each independently selected from H, unsubstituted alkyl of 1 to 5 carbons, and substituted alkyl; or

)2 (R9 and R10 together form a linking group of the formula –(CH2)2-X1-(CH2)2-, wherein X1 is selected from –O-, -S-, and –

CH2;-R1A is the same as R1;

R2, R3, R4 and R5 are each independently selected from:

a) H, C6-C12 aryl, C3-C8 carbocyclyl, heterocyclyl, -CN, CF3, -NO2, -OH, -OR7, Br, I, -O(CH2)pNR9R10, -OC(=O)R7, -OC(=O)NR9R10, -O(CH2)pOR8, F, Cl, -CH2OR8, -NR9R10, -NR8S(=O)R7, or NR8C(=S)R7;

b) –CH2OR11, where R11 is the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;

c) –NR8C(=O)NR9R10, -NR8C(=S)NR9R10, -CO2R12, -C(=O)R12, -C(=O)NR9R10, -C(=S)NR9R10, -CH=NOR12, -CH=NR7, -(CH2)pNR9R10, -(CH12)pNHR11, or –CH=NNR12R12A; where R12 is selected from H, alkyl of 1 to 6 carbons, -OH, alkoxy of 1 to 6 carbons, -OC(=O)R7, -OC(=O)NR9R10, -OC(=S)NR9R10, -O(CH2)pNR9R10, -O(CH2)pOR8, substituted or unsubstituted C7-C15 arylalkyl having from 6 to 10 carbons, substituted or unsubstituted heterocyclylalkyl in which one or more ring carbon atoms is replaced by an O, N or S atom, and a substituted or unsubstituted C3-C8 carbocyclic group;

R12A is the same as R12 ;d) –S(O)yR12, -(CH2)pS(O)yR7, -CH2S(O)yR11 where y is 0, 1 or 2;

e) alkyl of 1 to 8 carbons, alkenyl of 2 to 8 carbons, and alkynyl of 2 to 8 carbons, wherein:

)1 (each alkyl, alkenyl, or alkynyl group is unsubstituted; or

)2 (each alkyl, alkenyl or alkynyl group is substitutedwith 1 to 3 groups selected from aryl of 6 to 10 carbons, heterocyclyl, arylalkoxy, heterocycloalkoxy, hydroxylalkoxy, alkyloxy-alkoxy, hydroxyalkylthio, alkoxy-alkylthio, F, Cl, Br, I, -CN, -NO2, -OH, -OR7, -X2-(CH2)pC(=O)NR9R10, -X2(CH2)pC(=S)NR9R10, -


X2(CH2)pOC(=O)NR9R10, -X2(CH2)pCO2R7, -X2(CH2)pS(O)yR7, -X2(CH2)pNR8C(=O)NR9R10, -OC(=O)R7, -OC(=O)NHR12, O-tetrahydropyranyl,

-NR9R10, -NR8CO2R7, -NR8C(=O)NR9R10, -NR8C(=S)NR9R10, -NHC(=NH)NH2, -NR8C(=O)R7, -NR8C(=S)R7, -NR8S(=O)2R7, -S(O)yR7, -CO2R12, -C(=O)NR9R10, C(=S)NR9R10, -C(=O)R12, -CH2OR ,

-CH=NNR12R12A, -CH=NOR12, -CH=NR7, -CH=NNHCH(N=NH)NH2, -S(=O)2NR12R12A, -P(=O)(OR8)2, -OR11, and a monosaccharide of 5 to 7 carbons where each hydroxyl group of the monosaccharide is independently either unsubstituted or is replaced by H, alkyl of 1 to 4 carbons, alkylcarbonyloxy of 2 to 5 carbons, or alkoxy of 1 to 4 carbons;X2 is O, S, or NR8;

R6 is selected from H, -SO2R7, -C(=O)R7, -C(=O)NR9R10, alkyl of 1-8 carbons, alkenyl of 2-8 carbons, and alkynyl of 2-8 carbons; and either

)1 (each alkyl, alkenyl, or alkynyl group is unsubstituted; or

)2 (each alkyl, alkenyl, or alkynyl group independently is substituted, as defined for R2, R3, R4, and R5 in

)e (above;Y is selected from:

)a (an unsubstituted alkylene of 1-3 carbons;

)b (an alkylene of 1-3 carbons substituted with R13, where R13 is selected from R12, thioalkyl of 1-4 carbons, halogen, alkyl of 1-8 carbons, alkenyl of 2-8 carbons, and alkynyl of 2-8 carbons, where

)i (each alkyl of 1-8 carbons, alkenyl of 2-8 carbons, and alkynyl of 2-8 carbons is unsubstituted; or

)ii (each alkyl of 1-8 carbons, alkenyl of 2-8 carbons, and alkynyl of 2-8 carbons, independently, is substituted, as defined for R2, R3, R4, and R5 in e) above; and

)c (a functional group selected from –CH=CH-, -CH(OH)-CH(OH)-, -O-, -S-, -S(=O)-, -S(=O)2-, -C(R6)2-, -C=(R13)2-, -C(=O)-, -C(=NOR12)-, -C(OR12)R12, -C(=O)CH(R6), -CH(R6)C(=O)-, -C(=NOR12)CH(R6)-, -CHR8C(=NOR12)-, -C(=O)N(R8)-, -N(R8)C(=O)-, -CH2Z-, -ZCH2-, and –CH2ZCH2-, where Z is selected from –C(R12)-, -O-, -S-, -CO2R12, -

C(=NOR12)-, and –N(R12) ;-A1 and A2 are selected from H, H; H, OR12; H, -SR12;H, -N(R12)2; and a group where A1

and A2 together form a moiety selected from =O, =S, and =NR12; and,B1 and B2 are selected from H, H; H, -OR12; H, -SR12; H, -N(R12)2; and a group where B1 and B2 together form a moiety selected from =O, =S, and =NR12;

with the proviso that at least one of the pairs A1 and A2, or B1 and B2, form =O.

___________

148268]21][11[

והשימוש שינוי שעברו עמילן תמיסותבהן האישי

MODIFIED STARCH SOLUTIONS AND THEIR USE IN PERSONAL CARE

]54[

01.11.2000]22[US]33[03.12.1999]32[60/168939]31[

Int. Cl.8 A61K 000/806000 000/873000 000/89800]51[CALGON CORPORATION, U.S.A.]71[

WO/2001/039721]87[ושותפיו, כהן ריינהולד , תל4060 , ת.ד. 21 העם אחד רחוב

אביבREINHOLD COHN AND PARTNERS,

]74[



TEL AVIV 61040

]57 [An aqueous solution of a modified starch comprising:

)a (about 20% to about 98.599%, by weight water;

)b (about 1% to about 49.5%, by weight of a modified starch;

)c (about 0.2% to about 15%, by weight of urea;

)d (about 0.2% to about 10% by weight of an alpha hydroxy acid or the corresponding alpha hydroxy acid salt with

sodium, potassium, and/or substituted amine;

)e (zero up to about 5% by weight of an aliphatic carboxylic acid from C2 to C36 in chain length acid or the corresponding carboxylic acid salt with sodium, ammonium and/or potassium;

)f (about 0.001% to about 0.5% by weight of a preservative; and

)g (having a pH of from about 1 to 9 wherein the modified starch of (b) is of the

wherein R1 is selected from the group consisting of ethers (1,2,3 and 4), ester (5) and amphoteric substituents (6, 7, 8 and 9) generally described as:

)1– (CH2-(CHR2-)m-CH2-N+(CH3)3X wherein m is an integer from 0 to 34, each

R2 can independently be H or OH, and X is Cl or Br;-

)2– (CH2-(-CHR3-)m-CR3H2

wherein m is as defined above and each R3

can independently be H or OH;(3) –(-CH2-CHR4-O-)n-CH2-(-CHR5-)m-CH2-N+ (CH3)3 X-

wherein n is an integer from 1 to 100, m is as defined above, each R4 can independently be H, OH, CH3 or CH2OH, each R5 can independently be H or OH, and X- is Cl- or Br-;(4) -(-CH2-CHR6-O-)n –CH2-(CHR7-)m-CR7H2

wherein n and m are as defined above, each R6 can independently be H, OH, CH3 or CH2OH, each R7 can independently be H or OH, and X- is Cl- or Br-;(5) –CO-(CHR8)m-C R8H2

wherein m is as defined above and each R8

can independently be H, OH, CH3 or CH2OH;(6) –CH2- (-CHR9-)m-CH2-N+(R10)3

wherein m is as defined above, each R9 can independently be H, OH, CH3 or CH2OH, and each R10 can independently be:(A) ---(CR11H-)p –CH3

(B) ---CH2OH (C) ---(CR11H-)p-COOH(D) ---(CR11H-)p-COO-

(E) ---(CR11H-)p-SO3-

wherein p is an integer from zero to 10 and each R11 can independently be H, OH, CH3

or CH2OH;


(7) –CH2-(-CHR9-)m-CH2-CO-NH- CH2- CH2- CH2-N+(R10)3

wherein m, R9, and R10 are as defined above;(8) –CO-CH2-(-CHR9-)m-CH2-N+(R10)3

wherein m, R9, and R10 are as defined above;

(9) –CO –CH2- (-CHR9-)m-CH2-CO-NH- CH2- CH2- CH2-N+(R10)3 wherein m, R9, and R10 are as defined above;wherein the mol % of substituted sugar units (w) out of the total sugar units along the starch molecule is between about 2 mol % to about 80 mol % and the mol % of unsubstituted sugar units (x) is between about 20 mol % to about 98 mol %.

____________

148313]21][11[

– הטרוציקליות, תכשיריםN של נגזרות והישמושים אותן המכילים רוקחייםהאמורות בנגזרות

N - HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USES OF SAID DERIVATIVES

]54[

21.02.2002]22[US]33[26.08.1999]32[09/383813]31[

Int. Cl.8 C07D 403/00]51[BERLEX LABORATORIES, INC., U.S.A.PHARMACOPEIA, INC., U.S.A.

]71[





TEL AVIV 61040

]74[

[57] A compound of the formulae


wherein:n and m are independently an integer from 1 to 4;A is –C(O)OR1 or –C(O)N(R1)R2;each W is N or CH;each R1 is independently hydrogen, alkyl, aryl or aralkyl;each R2 is independently hydrogen, C1-C20 alkyl, -(CH2)n-N(R1)2, heterocyclylalkyl (optionally substituted by alkyl, halo, haloalkyl or alkoxy), aralkyl (optionally substituted by halo, alkyl, alkoxy, or –N(R1)2);

R4 can be cyano or heterocyclyl and, when m is an integer from 2 to 4, R4 can also be hydroxy, -N(R1)R2, -N(R1)-C(O)-R1, -N(R1)-C(O)OR1, -N(R1)-S(O)t-R1, or-N(R1)-C(O)-N(R1)2;R5 is hydrogen, halo, alkyl, aryl, aralkyl, or haloalkyl;t is zero, one or two;as a single stereoisomer or mixture thereto, or a pharmaceutically acceptable salt thereof.

___________


148326]21][11[

בברום, שיטות המותמרים אסטריםבעירה כמונעי ושימושם להכנתם

BROMINATED ESTERS, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FLAME RETARDANTS

]54[

21.02.2002]22[Int. Cl.8 C07C 067/02, 069/00, 069/63, C09K 021/00]51[

]BROMINE COMPOUNDS LTD.]71שבע בע"מ, באר ברום תרכובותלוצאטו, את לוצאטו



BEER-SHEVA 84152

]74[

[57] Polyhalogenated benzyl esters of the formula:

wherein X is halogen; n is an integer from 2 to 5; Y is a saturated aliphatic chain,

substituted or unsubstituted, having at least 4 carbon atoms or a radical

and wherein the substituents are selected from the group consisting of bromine, oxygen, and sulfur; wherein X is halogen; p is an integer from 0 to 5; and Z is

(CH2)m wherein m is zero or an integer greater than zero, with the proviso that Xp is not pentafluoro when m equals 2.

__________


148598]21][11[

לניתוב מולטיפונקציונלי קומפלקס מטרה גורם של ספציפית פאגוציטוזה

אותו המכיל ותכשיר

MULTIFUNCTIONAL COMPLEX FOR TARGETING SPECIFIC PHAGOCYTOSIS OF A TARGET AGENT AND A COMPOSITION COMPRISING IT

]54[

10.03.2002]22[Int. Cl.8 A61K 039/395, 039/40, 039/44, 047/00, C07K 016/12]51[

]YAMIT BIOTECHNOLOGIES LTD.]71שמונה בע"מ, קרית ביוטכנולוגיות ימית ,ELY MORAG, JACOB PITKOVSKIפנחסוב יעקב, יוסי מורג, פיטקובסקי אלי

YOSEF PINCHASOV]72[

ושות', בן-עמי, רחובות94ת.ד.

BEN-AMI & ASSOCIATES, P.O.B. 94, REHOVOT 76100

]74[

[57] A multi-functional targeting complex that induces a specific immuno-stimulatory reaction to at least one target agent, said complex comprising:(a) at least one target recognition component comprising a molecule which specifically binds to said agent or any functional fragment of said agent;

(b) an immunoactive component comprising an immuno-stimulatory agent; and(c) optionally, a connecting component that associates said at least one targeting component and said at least one active component, wherein the independent biological functions of said targeting component and said active component are retained.

____________

148627]21][11[

]ORTHODONTIC FACEBOW]54שניים ליישור פנים קשת

12.03.2002]22[Int. Cl.8 A61C 007/00, 007/06]51[

]ALINA LOZINSKI]71לוזינסקי, ירושלים אלינה YULI LOZINSKI, VLADIMIRצור דינקליס, בועז לוזינסקי, ולדימיר יולי

DINKELIS, BOAZ TSUR]72[


WOLFF, BREGMAN AND GOLLER,


]74[

[57] An orthodontic facebow of the type having an inner bow consisting of two inner arms (4, 4) each having an end

portion (16, 16) and an interconnected outer bow consisting of outer arms,


characterized in that the free ends of each inner arm are split into a plurality of arm portions and at least one arm portion is fitted with a ratchet type enlargement so as to allow it to be easily inserted into a tube

connected to a band affixed to a tooth, while preventing disengagement therefrom without at least one of said arm portions being squeezed towards the other or others.

_____________

148702]21][11[

התקנים והוצאת להכנסת מערכתמתנפחים

INSERTION AND RETRIEVAL SYSTEM FOR INFLATABLE DEVICES

]54[

14.03.2002]22[Int. Cl.8 A61F 002/00, A61M 029/00]51[INNOVENTIONS INC., U.S.A.]71[


אביב



TEL AVIV 61040

]74[

[57] A magazine unit comprising:a body (52) including a chamber configured for receiving an implantable device, said body including a passageway extending therethrough; a rod slidably received by said passageway in said body and of a length for sliding beyond said

body, said rod including a channel for fluid passage extending at least substantially therethrough, and a channel member in fluid communication with said channel, said channel member configured for receipt by said implantable device.


____________

148783]21][11[

METHODS FOR GENOMICגנומית לאנליזה שיטהANALYSIS

]54[

20.03.2002]22[US]33[30.03.2001]32[60/280530]31[US17.08.200160/313264US05.10.200160/327006US26.11.200160/332550

Int. Cl.8 C12Q 001/68]51[PERLEGEN SCIENCES, INC., U.S.A.]71[


אביב



TEL AVIV 61040

]74[

[57] A method for selecting SNP haplotype patterns, comprising: (a) isolating a set of substantially identical nucleic acid strands from a plurality of different origins for analysis; (b) determining more than one SNP location in each nucleic acid strand in said set; (c) identifying SNP locations that are linked in said nucleic acid, wherein said SNP locations that are linked form a SNP haplotype block, thereby identifying said SNP haplotype block; (d) identifying

isolate SNP haplotype blocks; (e) identifying SNP haplotype patterns that occur in the SNP haplotype block identified in step (c) and the isolate SNP haplotype blocks identified in step (d); and (f) selecting each identified SNP haplotype pattern that occurs in at least two of said substantially identical nucleic acid strands in said set.



____________


149083]21][11[

יחידות עבור מרחבית ממותג מנתבאלחוטיות נתונים

SPATIALLY SWITCHED ROUTER FOR WIRELESS DATA PACKETS

]54[

10.10.2000]22[US]33[13.10.1999]32[09/417416]31[US03.11.199909/433542

Int. Cl.8 H01Q 015/08, H04L 005/14, 012/28, 012/413, 012/46, 012/56]51[INTEL CORPORATION, U.S.A.]71[




]74[

[57] In a microwave network of the type having a plurality of spatially separated, mutually communicating network nodes with a number of the nodes having routing information regarding transmission and reception timing and a corresponding direction of transmission and reception for data packets, each node having a local transmitter port and a local receiver port, a spatially switched router apparatus comprising, an RF switch assembly associated with said mutually communicating network nodes, an RF optics focusing and collimating antenna capable of radiating RF energy from a curved, peripheral surface thereof, outwardly spanning an angular range covering the communicating nodes in line-of-sight relation without motion of the antenna, the antenna in RF communication with the RF switch assembly, and a plurality of RF optics feeding-ports disposed side-by-side about the curved peripheral surface of the antenna, the microwave feeding ports communicating RF energy from the RF switch assembly and the RF optics and collimating antenna

and using control signals that synchronously activate the RF switch assembly to route data packets modulating an RF signal from the local transmitter port towards the RF optics feeding-ports, through the antenna and outwardly toward one of the network nodes and from another of the network nodes into the antenna and toward the RF optics feeding-ports and then towards the local receiver port, the RF switch receiving routing information regarding transmission and reception of timing schedules and a corresponding direction of transmission and reception of data packets, the switch synchronously switching directions of transmission and reception of data packets between nodes upon the reception and transmission of data packets, wherein the control signals for switching are based on the routing information in the data packets, including updated schedule information for transmission and reception of timing and direction of transmission and reception of data packets between communicating nodes.


___________

149107]21][11[

של יציבות נוזל פורמולציות להכנתן מותמרים, תהליך בנזימידזולים

במחלות לטיפול תרופה בהכנת ושימושןומעיים קיבה

STABLE LIQUID FORMULATIONS OF SUBSTITUTED BENZIMIDAZOLES, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF GASTROINTESTINAL DISEASES

]54[

13.10.2000]22[SE]33[22.10.1999]32[9903831-7]31[

Int. Cl.8 A61K 045/06, C07D 235/28, 401/12, 471/02, 495/02]51[ASTRAZENECA AB, SWEDEN]71[MIKAEL BRULLS]72[WO/2001/028558]87[




]74[

[57] A water free or less that 6% by weight of water stable liquid formulation comprising polyethylene glycol and a sodium or potassium salt of a H+, K+-

ATPase inhibitor, and optionally pharmaceutically acceptable excipients that are soluble in the formulation.

__________


149154]21][11[

ותכשירי הכנה , שיטת אוליגוסכרידיםאותם המכילים רוקחות

OLIGOSACCHARIDES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

]54[

18.10.2000]22[FR]33[22.10.1999]32[99/13182]31[

Int. Cl.8 A61K 031/7024, A61P 009/10, 019/00, 019/02, 025/00, 025/14, 025/16, 025/18, C07H 003/00, 019/01, C08B 037/00, 037/10

]51[

AVENTIS PHARMA S.A., FRANCE]71[WO/2001/029055]87[




]74[

[57] A purified oligosaccharide of the formula:

in which n is 0 or is an integer from 1 to 25, R1, R3, R4 and R5, which may be identical or different, represent a hydrogen atom or an SO3M radical; R2 and R6, which

may be identical or different, represent a hydrogen atom or a radical selected from SO3M and COCH3 and M is sodium, calcium, magnesium or potassium.

____________


149491]21][11[

לריפוי גרעין חומצת המכיל קומפלקסגני

NUCLEIC ACID-CONTAINING COMPLEX FOR GENE THERAPY

]54[

09.11.2000]22[JP]33[09.11.1999]32[11/318187]31[JP13.09.20002000-278878

Int. Cl.8 A61K 047/48]51[HIDEZO MORI, JAPANYASUHIKO TABATA, JAPAN

]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[

[57] A nucleic acid-containing complex comprising a nucleic acid and a positively-charged water-insoluble biodegradable polymer having an introduced positively-charged group, wherein said nucleic acid can be released by degradation of the

biodegradable polymer, wherein said positively-charged water-insoluble biodegradable polymer is crosslinked before being complexed with the nucleic acid.

___________

149578]21][11[

המכילות רוקחיות פורמולציותלהכנתן ותהליך זולמיטריפטאן

PHARMACEUTICAL FORMULATIONS CONTAINING ZOLMITRIPTAN AND PROCESS FOR THEIR PREPARATION

]54[

28.11.2000]22[GB]33[03.12.1999]32[9928578.5]31[

Int. Cl.8 A61K 009/00, C07D 413/00, 413/06]51[ASTRAZENECA AB, SWEDEN]71[ALAN ROY DEARN, SARAH LOUISE WILLIAMSON, SIMON JOHN SUMMERS, TREVOR JOHN COOMBER

]72[




]74[


BEER-SHEVA 84152

[57] A pharmaceutical formulation for intranasal administration, which comprises

zolmitriptan and a pharmaceutically acceptable carrier wherein the pH of the formulation is below 6.0.

_________

149891]21][11[

פעילים ציאנוהידרינים לייצור שיטה–אוקסיניטרילאזR באמצעות אופטית

METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE CYANOHYDRINS USING R-OXYNITRILASE

]54[

25.11.2000]22[AT]33[15.12.1999]32[A2108/99]31[

Int. Cl.8 C12N 009/88, C12P 013/00, 041/00]51[DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO. KG, AUSTRIA

]71[





TEL AVIV 61040

]74[

[57] A method for the production of (R)-enantiomers of optically active cyanohydrins by reacting an aldehyde or a ketone with a cyanide group donor in the presence of an (R)-oxynitrilase, characterized in that a reaction mixture of(a) an aldehyde or ketone dissolved in an organic, water-immiscible or only slightly water-miscible diluent,

(b) an aqueous (R)-oxynitrilase solution and(c) a cyanide group donor is stirred in such a manner that an emulsion forms which is maintained up to the end of the enzymatic reaction, whereupon, after the enzymatic reaction is terminated, the corresponding (R)-cyanohydrin is isolated from the reaction mixture.

__________


150158]21][11[

קול/הודעות לאספקת ומכשיר שיטה מסוג קצה בציוד בשימוש אחידותCATV

METHOD AND APPARATUS FOR PROVIDING VOICE/UNIFIED MESSAGING SERVICES USING CATV TERMINALS

]54[

21.12.2000]22[US]33[28.12.1999]32[473294]31[

Int. Cl.8 H04M 003/53, 011/00, H04N 007/025, 007/173]51[]COMVERSE LTD.]71בע"מ קומברס

EREZ MICHAEL, SHLOMIקרינגל מיכאל, שלומי ארזKRINGEL

]72[





TEL AVIV 61040

]74[

[57] System for providing CATV subscribers an access to a UMS (Unified Messaging System) and/or VMS (Voice Mail System), wherein each subscriber is provided with a TV set connected to the CATV network directly or through a set-top box, comprising: a connection between subscribers of the CATV network and the UMS and/or VMS and an interface for permitting an exchange of information between said subscribers and said UMS

and/or VMS; and a client software for the UMS and/or VMS, which when the connection is through the set-top box, resides on, or is coupled to, said set-top box, wherein subscribers of the CATV network are able to exchange information with other subscribers of the CATV network via the UMS and/or VMS by transmitting information over only the CATV network.


__________

150324]21][11[

]PIPE COUPLING]54צינורות מחבר

19.06.2002]22[Int. Cl.8 F16L 023/08]51[

KRAUSZ METAL INDUSTRIESאביב בע"מ, תל מתכת תעשיות קראוסLTD.

]71[

ELIEZER KRAUSZ, AVIצ'יפרוט קראוס, אבי אליעזרCHIPROOT

]72[



P.O.B. 12688 ,HERZLIYA 46733

]74[

[57] A pipe coupling (10) comprising a tube-like member (12) with externally projecting flanges (14) at each extremity, said flanges being provided with an inner face (16) and an outer face (18), a pair of peripheral clamp members (20) being arranged to contact said projecting flanges on said inner face thereof and provided with a recess (22) delimited by an inward facing flange (24), said recess containing at least one resilient seal member (28), the

improvement being that at least one resilient ring member (30) in axial proximity to said seal member carries at least one metal gripping element (32) mounted on the inner diameter of said at least one resilient ring member, and tightening of said peripheral clamp member causes said metal gripping elements to bite into the outer surface of a pipe to be held in said coupling.


__________

150361]21][11[

של מניעה ו/או לטיפול ותכשיר שיטה עמידים מחיידקים זיהומים

לאנטיביוטיקה

METHOD AND COMPOSITION FOR TREATMENT AND/OR PREVENTION OF ANTIBIOTIC-RESISTANT MICROORGANISM INFECTIONS

]54[

19.12.2000]22[US]33[20.12.1999]32[60/172577]31[

Int. Cl.8 A61K 038/40, A61P 031/00, 031/04]51[SA MAJESTE LA REINE DU CHEF DU CANADA AGRICULTURE ET AGROALIMENTAIRE CANADA, CANADA

]71[





TEL AVIV 61040

]74[

[57] A composition comprising ampicillin, wherein said ampicillin is in a concentration of about 4 µg/ml, and a protein selected from the group consisting

of a lactoferrin, a lactoferricin or fragment thereof, in association with an acceptable carrier, for inhibiting β-lactamase in a microorganism.

__________April 13, 2008 –התשס"ח ח' בניסן 730

150411]21][11[

של כללי וניתוח לבדיקה ושיטה מערכתמידע

SYSTEM AND METHOD FOR GENERAL PURPOSE DATA PARSING AND ANALYSIS

]54[

25.06.2002]22[US]33[03.07.2001]32[898852]31[

Int. Cl.8 G06F 007/00, 017/27, 017/30]51[N B NETWORKS, U.S.A.]71[


אביב



TEL AVIV 61040

]74[

[57] A method for parsing data according to configurable criteria, the method comprising steps of: storing in a first data storage device a plurality of programmably configurable protocol descriptions that define a plurality of control character characteristics of the data; storing in a second data storage device a program for controlling a data parsing function to be executed by a processing unit, the program including instructions for causing the processing unit to selectively retrieve at

least one of the programmably configurable protocol descriptions from the first data storage device and to vary the execution of the data parsing function based upon the at least one retrieved protocol description file; delivering the program for controlling the data parsing function to the processing unit; delivering the data to the processing unit; and enabling the processing unit to execute the data parsing function.

__________

150599]21][11[

]FASTENING DEVICE FOR RAILS]54פס עבור הידוק אמצעי

11.01.2001]22[EP]33[14.01.2000]32[00100206.

2]31[

Int. Cl.8 E01B 009/48, 029/24]51[


VOSSLOH WERKE GMBH, GERMANY

]71[





TEL AVIV 61040

]74[

[57] Elastic tension clamp (10) composed of spring steel comprising: a central part (14) having two inner legs (12); and loops (16) adjoining the inner legs and running to the free ends (26) of the tension clamp; characterized in that in the unloaded state

of the tension clamp the open spacing between the central part and the loop in the region of the free end is less than the diameter of the spring steel in the region of the free end.

_________

150691]21][11[

לפחות של קריטי מימד למדידת התקןלמחצה מוליכה בפרוסה אחד מאפיין

MEASURING ARRANGEMENT FOR MEASURING A CRITICAL DIMENSION OF AT LEAST ONE FEATURE ON A SEMICONDUCTOR WAFER

]54[

11.07.2002]22[DE]33[17.07.2001]32[10134755.

3]31[

Int. Cl.8 H01L 021/66]51[INFINEON TECHNOLOGIES AG, GERMANY

]71[


אביב


P.O.B. 4060 ,TEL AVIV 61040

]74[

[57] A measuring configuration for measuring a semiconductor wafer (1)

having at least one feature (22) with a critical dimension (21), comprising: a


scanning electron microscope (2) for measuring the critical dimension of the at least one feature of the semiconductor wafer; at least one measuring device (3) for an angle-dependent measuring of one of a scattering and a diffraction of light at the least one feature of the semiconductor wafer; at least one loading and unloading station (5) for loading and unloading wafer transport containers (6) receiving the semiconductor wafer; a transport system (4) for transporting the semiconductor wafer, said transport system having transport paths including at least a respective transport path between said at least one loading and unloading station and

said scanning electron microscope, and between said at least one loading and unloading station and said at least one measuring device for an angle-dependent measuring of one of a scattering and a diffraction of light; and a control unit (7) operatively connected to said transport system, said control unit selecting and controlling one of said transport paths of said transport system in order to selectively make the semiconductor wafer available to said at least one measuring device for an angle-dependent measuring of one of a scattering and a diffraction of light and to said scanning electron microscope.

__________

150780]21][11[

לזיהוי תמונות לאספקת ומכשיר שיטהניידת טלפונית ברשת המתקשר

METHOD AND APPARATUS FOR PROVIDING IMAGES FOR CALLER IDENTIFICATION OVER A MOBILE NETWORK

]54[

16.07.2002]22[US]33[17.07.2001]32[09/907535]31[

Int. Cl.8 H04M 003/42]51[COMVERSE, INC., U.S.A.]71[

ARDA AKSU, MAKONNEN MELAKU, SESHADRI MOHAN

]72[

( בע"מ,1995) ג'י.אי.ארליך בגין מנחם ,רחוב15 אילון, קומה מגדל גן , רמת11


]74[



[57] A method comprising: providing interactive access to caller identification information associated with a caller, wherein the caller interactively enters and edits the caller identification information via the Internet; receiving a request for a call from the caller using a subscriber handset to a called party over a first wireless communication system; identifying the caller identification information associated with the caller; retrieving the caller identification information associated with the caller, wherein the caller identification information includes a PCLI header and an image; compressing the image in the caller

identification information; forwarding the PCLI header and the compressed image in the caller identification information to the called party over a second wireless communication system; comparing the PCLI header received over the second wireless communication system with a caller ID received over the first wireless communication system; displaying the image to the called party if the PCLI header matches the caller ID; and suspending the call over the first wireless communication system until a verification of receipt is received over the second wireless communication system.

__________

150820]21][11[

בין ממשך אותות לאספקת ומעגל שיטהמשולבים מעגלים

METHOD AND CIRCUIT FOR PROVIDING INTERFACE SIGNALS BETWEEN INTEGRATED CIRCUITS

]54[

17.10.2000]22[US]33[21.01.2000]32[09/489231]31[

Int. Cl.8 G06J 001/00, H03K 019/0175, H04L 027/00]51[QUALCOMM INCORPORATED, U.S.A.

]71[


,2273, ת.ד. , מרמורק4 הגיא שער SANFORD T.COLB & CO,.

P.O.B. 2273 ,]74[


REHOVOT 76122רחובות

[57] Circuitry to generate an interface signal between a first integrated circuit and a second integrated circuit comprising: a reference circuit configured to provide a reference signal; an interface circuit implemented on the first integrated circuit and operatively coupled to the reference circuit, the interface circuit configured to receive the reference signal and a data

input and to generate the interface signal in response thereto; and a circuit element implemented on the second integrated circuit and operatively coupled to the interface circuit, the circuit element configured to receive the interface signal and provide an output signal in response, wherein the interface signal is a differential current signal.



____________

150844]21][11[

היבריציזציה של הומוגנית בדיקה מדידות באמצעות משולשת או כפולה

משתנים תנאים תחת מרובות

HOMOGENEOUS ASSAY OF DUPLEX OR TRIPLEX HYBRIDIZATION BY MEANS OF MULTIPLE MEASUREMENTS UNDER VARIED CONDITIONS

]54[

23.01.2001]22[US]33[24.01.2000]32[490273]31[

Int. Cl.8 C12Q 001/68]51[INGENEUS INC., BARBADOS]71[WO/2001/053526]87[


אביב


21 AHAD HA'AM ST ,.

]74[


P.O.B. 4060 ,TEL AVIV 61040

[57] A method for assaying sequence-specific hybridization, said method comprising: providing a target comprising at least one nucleic acid sequence; providing a probe comprising a nucleic acid or nucleic acid analog sequence; adding said probe and said target to a hybridization medium to provide a test sample; applying a first stimulus to said test sample to provide a first stimulated test sample; detecting a first signal from said first stimulated test sample, wherein said first signal is correlated with a binding affinity between said probe and said target; calibrating said first signal against a first reference signal; determining from said first signal calibrating a first determination of an extent of matching between said probe and said target; applying a second stimulus to said first stimulated test sample to provide a second stimulated test sample; detecting a second signal from said second stimulated test sample, wherein said

second signal is correlated with said binding affinity between said probe and said target; calibrating said second signal against a second reference signal; determining from said second signal calibrating a second determination of said extent of matching between said probe and said target; comparing said first determination and said second determination to accomplish said assaying; and quantifying said binding affinity, wherein a fluorophore is provided in said test sample, and wherein: (a) said first stimulus is electrical voltage, said first signal is electrical conductance, said second stimulus is exciting radiation ad said second signal is fluorescent intensity; or (b) said first stimulus is exciting radiation, said first signal is fluorescent intensity, said second stimulus is electrical voltage and said second signal is electrical conductance.

___________

150983]21][11[

למשאבת קישור עם בריק למיצוי משגוחיד

VACUUM EXTRACTION MONITOR WITH ATTACHMENT FOR HAND PUMP

]54[

27.11.2001]22[US]33[30.11.2000]32[727124]31[

Int. Cl.8 A61B 017/44]51[VICTOR L. VINES, U.S.A.]71[





TEL AVIV 61040

]74[

[57] A method of using a recording device to record a pressure in a vacuum


extraction device, comprising: coupling a recording device to a vacuum extraction device; placing the vacuum extraction device on a fetus, the space between the fetus and the vacuum extraction device defining a pressure area in the vacuum extraction device, the vacuum extraction

device adapted to couple to a fetus via a suction device; inducing a vacuum pressure in the pressure area by hand-actuating the vacuum extraction device; detecting the vacuum pressure in the pressure area; and recording the vacuum pressure to produce a record.

_________

151009]21][11[

לאי מניעתי או תרופתי תכשיר תולדות המכיל ריאתית ספיקה

דיאמינוטריפלואורומתילפירידין

THERAPEUTIC OR PREVENTIVE AGENT FOR PULMONARY INSUFFICIENCY CONTAINING A DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVE

]54[

30.01.2001]22[JP]33[01.02.2000]32[2000-24349]31[

Int. Cl.8 A61K 031/44, A61P 011/00, C07D 213/72, 405/12, 409/12]51[ISHIHARA SANGYO KAISHA LTD., JAPAN]71[SHUICHI YOTSUYA, KYUYA MORINO, MASASHI INAMURA

]72[

WO/2001/056570]87[ - דין עורכי - מהולל איתן קבוצתפטנטים, עורכי

, ת.ד.10 אבן אבא שדרות , הרצליה2081

EITAN MEHULAL LAW GROUP, 10 ABBA EBEN BLVD,.

P.O. B. 2081,HERZLIYA 46120

]74[


[57] Use of a diaminotrifluoromethylpyridine derivative represented by the formula (I) or its salt for the manufacture of a medicament for the

treatment of Acute Respiratory Distress Syndrome (ARDS) or Chronic Obstructive Pulmonary Disease (COPD)

wherein X is a –CW1R1 group, a –COCOR2 group, a –CW1NHCOR2 group, a –C(=W1) W2R3 group or –SW1N(R4)R5 group; Y is an alkyl group, a –CW3R6 group, a –COCOR7 group, a –NHCOR7 group, a –C(=W3) W4R8 group, a –(NH)mSO2R9 group, a –(NH)mSO2OR10 group or a –(NH)MSO2N(R11)R12 group; each of R1, R6 and R9 which are independent of one another, is a chain hydrocarbon group which may be substituted, a monocyclic hydrocarbon group which may be substituted, a polycyclic hydrocarbon group which may be substituted, a monocyclic heterocycle group which may be substituted or a polycyclic heterocycle group which may be substituted; each of R2 and R7 which are independent of each other, is an alkyl group which may be substituted, an alkoxy group which may be substituted, a phenyl group which may be substituted or a phenoxy group which may be substituted; each of R3, R8 and R10 which are independent of one another, is an alkyl group which may be substituted,

an alkenyl group which may be substituted, an alkynyl group which may be substituted, a cycloalkyl group which may be substituted, a phenyl group which may be substituted or a benzyl group which may be substituted; each of R4, R5, R11 and R12 which are independent of one another, is an alkyl group which may be substituted; each of W1, W2, W3 and W4 which are independent of one another, is an oxygen atom or a sulfur atom; and m is 0 or 1, excluding a case where one of X and Y is a –COCF2X1 group (wherein X1 is a hydrogen atom, a halogen atom, an alkyl group or a haloalkyl group), and the other is –COCF2X2 group (wherein X2 is a hydrogen atom, a halogen atom, an alkyl group, a haloalkyl group or an alkylcarbonyl group), a –COOX3 group (wherein X3 is an alkyl group which may be substituted or a phenyl group which may be substituted) or a –COX4 group (wherein X4 is an alkyl group, a haloalkyl group, an alkenyl group, an alkynyl group, a phenyl group which may be substituted, a furanyl group or naphthyl group).

__________


151098]21][11[

DEVICE AND METHOD FORגבוה בלחץ רציף לטיפול ושיטה התקןCONTINUOUS HIGH-PRESSURE TREATMENT

]54[

16.02.2001]22[JP]33[17.02.2000]32[2000-

39327]31[

JP29.01.20012001-20505JP29.01.20012001-20526

Int. Cl.8 F15B 015/22]51[KANEKA CORPORATION, JAPANTHE JAPAN STEEL WORKS, LTD., JAPAN

]71[





TEL AVIV 61040

]74[

[57] A continuous high-pressure processing method comprising the steps of: supplying a feedstock continuously from a supply tank to processing container through a pressurizing pump; discharging the processed feedstock from said processing container through a

depressurizing pump disposed in piping; and setting a first delivery rate of said pressurizing pump to be larger than a second delivery rate of said depressurizing pump, whereby the interiors of said processing container and said piping are maintained in a high-pressure state.


___________151137]21][11[

מקור עם מזון צריכת להגבלת מתקןמבוקר אלחוטי אנרגיה

FOOD INTAKE RESTRICTION APPARATUS WITH CONTROLLED WIRELESS ENERGY SUPPLY

]54[

08.02.2001]22[US]33[11.02.2000]32[09/503149]31[US11.02.200009/502775

Int. Cl.8 A61F 002/02]51[OBTECH MEDICAL AG, SWITZERLAND

]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[

[57] A food intake restriction apparatus for an obese patient, comprising: an operable restriction device (56) adapted to be implanted in the patient to engage the stomach (59) or esophagus to form an upper pouch (60) of the stomach and a restricted stoma opening in the stomach or esophagus, an accumulator adapted to be implanted in the patient for supplying energy for the operation of said restriction device to vary the restriction of the stoma

opening, said accumulator being chargeable from outside the patient's body, a control device (62) operable from outside the patient's body for controlling said accumulator to supply energy, a source of energy (64) external to the patient's body and capable of releasing wireless energy, and an implantable energy transfer device adapted to transfer said wireless energy into an energy form suited for charging said accumulator, wherein said control


device is adapted to control said external source of energy to release said wireless energy.

_________

151172]21][11[

בהן והשימוש אמינו, הכנתן תולדותBAX כמווסתי

AMINE DERIVATIVES, THEIR PREPARATION AND USE AS BAX MODULATORS

]54[

13.02.2001]22[EP]33[15.02.2000]32[00810128.

9]31[

Int. Cl.8 A61K 031/16, 031/40, 031/425, 031/445, 031/47, A61P 009/00, 025/18, 031/12, 043/00, C07C 237/22, C07D 207/16, 207/48, 211/60, 211/96, C07F 007/08

]51[

LABORATOIRES SERONO SA, SWITZERLAND

]71[

SERGE HALAZY, DENIS CHURCH, MATTHIAS SCHWARZ, BRUNO ANTONSSON, AGNES BOMBRUN, JEAN-CLAUDE MARTINOU

]72[

WO/2001/060798]87[[57] Amine derivatives of the formula

and its geometrical isomers, in a optically active form as enantiomers, diastereomers, as well as in the form of racemate, as well

as pharmaceutically acceptable salts thereof, wherein


A1 and A2 are selected independently from each other from the group consisting of-C(O)-and –SO2-;Ra is C1-C10 alkyl, Rb is CH3, orRa and Rb taken together with the atoms to which they are attached form a five-membered saturated ring optically containing a sulfur atom or a six-membered saturated ring optionally fused with an aryl or heteroaryl group; R1 is either H or C1-C6 alkyl; R2 is –(Rd-X1)m-Re wherein m is an integer from 0 to 8; whereby Rd is selected from aryl, heteroaryl, C1-C18 alkyl, 3-8-membered cycloalkyl, C2-C18 alkenyl or 3-8-membered cycloalkenyl, C2-C18 alkynyl;X1 is a bond, O, NH, NRg, NRgNg, S, Si(Rg'Rg), SO, SO2, wherein Rg and Rg' are independently selected from the group consisting of substituted or unsubstituted C1-C6 alkyl, C2-C8 alkynyl, aryl or heteroaryl;Re is selected from aryl-C1-C18 alkyl, aryl- C2-C18 alkenyl, aryl-C2-C18 alkynyl, heteroaryl- C1-C18 alkyl, heteroaryl-C2-C18 alkenyl, heteroaryl-C2-C18 alkynyl, C1-C18 alkyl, C2-C18 alkenyl, C2-C18 alkynyl, whereby said C1-C18 alkyl, C2-C18 alkenyl and C2-C18 alkynyl have a terminal substituent of the formula –NRR' or –

N+RR'R'' wherein R, R', R'' are H, C1-C6-alkyl; orR1 and R2 together with the N atom to which they are attached form an unsubsituted or substituted 4-12 membered unsaturated or saturated ring containing one further heteroatom selected from O, N being optionally substituted by Re, or R1 and R2 together with the N atom to which they are attached form an unsubstituted or substituted 4-12 membered unsaturated or saturated ring being substituted by Re, or by a substituent of the formula –NRR' or –N+RR'R" wherein R, R', R" are H, C1-C6-alkyl;R0 is a{[({[(methyloxy) ethyl]oxy}ethyl)oxy]methyl} or Rf-Xx-Rf' wherein Rf and Rf' are independently from each other selected from the group consisting of aryl, heteroaryl, 3-8 membered cycloalkenyl, 3-8-membered cycloalkyl, C2-C18 alkyl, C2-C18 alkenyl, C2-C18 alkynyl, aryl- C2-C18 alkyl, aryl- C2-C18 alkenyl, aryl- C2-C18 alkynyl, heteroaryl, C1-C18 alkyl, heteroaryl- C2-C18

alkenyl, heteroaryl- C2-C18 alkynyl;X2 is a bond or O, S, Si(RgRg), SO, SO2, wherein Rg and Rg are selected as above defined.

_________

151477]21][11[

]MEDICAL DIAGNOSTIC SYSTEM]54רפואית אבחון מערכת

05.03.2001]22[US]33[09.03.2000]32[60/188115]31[US19.07.200060/219357

Int. Cl.8 G01N 027/26]51[CLINICAL ANALYSIS CORP., U.S.A.

]71[




BEER-SHEVA 84152

]74[


[57] A system for conducting a plurality of different medical diagnostic tests, the system comprising: a hand-held portable, self-contained electronic instrument (10) for engaging any one of a plurality of disposable test cells, each test cell (300) containing a fluid to be tested, the instrument for performing a diagnostic test selected from said plurality of tests upon the fluid within a selected test cell, the instrument including a reader (32) which reads indicia on the selected test cell prior to engagement of the test cell, the diagnostic test to be performed being selected by the instrument based upon identification information obtained from the indicia on the selected test cell; and a plurality of disposable, single use test cells, each test cell for receiving fluid to be diagnostically tested, each test cell

including identification information including indicia indicative of a particular diagnostic test to be performed upon the fluid contained therein, the indicia on each test cell being unique to each medical diagnostic test which may be performed and unique with respect to each test cell which may be used to perform the same medical diagnostic test so that no two test cells contain the same indicia, each test cell being sized and shaped for engagement by the instrument, the instrument, upon reading the unique indicia of a selected test cell comparing the identification information from the read indicia to identification information from indicia read from all previously selected test cells and proceeding with the selected diagnostic test only if the selected test cell has not been previously used.



178587,The applications for division from this application have


not yet been published_________

151821]21][11[

בטיחות עבור מחט להחזקת מוצב מבנהתת–עורית לזריקה מזרק

NEEDLE HOLDER POSITIONING STRUCTURE FOR SAFETY HYPODERMIC SYRINGE

]54[

19.09.2002]22[Int. Cl.8 A61M 005/32]51[CHANG-PI LO, TAIWAN R.O.C.]71[

ושותפיו, הס יצחק ד"ראביב , תל6451 , ת.ד. 279 הירקון רחוב

DR. YITZHAK HESS & PARTNERS, 279 HAYARKON ST,.

P.O.B. 6451 ,TEL AVIV 61063

]74[

[57] A needle holder positioning structure for a safety hypodermic syringe comprising: a barrel (1), said barrel comprising a fluid chamber, said fluid chamber having a front small inner diameter section, a rear big inner diameter section, a shoulder connected between said front small inner diameter section and said rear big inner diameter section, and an inside flange means disposed in said rear big inner diameter section adjacent to said shoulder; a needle holder (2) mounted in said barrel, said needle holder comprising a tubular center base and a sleeve coaxially formed integral with the periphery of said tubular center base, said tubular center base having a retaining portion near a rear side thereof, said sleeve having a front engagement section press-fitted into the inside of the front small inner diameter section of the fluid chamber of said barrel and a springy rear expansion section, said rear expansion section having a front side

edge corresponding to a back side of said shoulder of said barrel and a rear side edge stopped at a front side of the inside flange means of said barrel, said rear expansion section defining with the periphery of said tubular center base a backwardly extended annular coupling chamber; and a locating ring (3) mounted inside said barrel and coupled to said needle holder, said locating ring having an outside wall disposed in contact with an inside wall of the rear big inner diameter section of said fluid chamber of said barrel for enabling said locating ring to be moved axially in said barrel, an inside wall disposed in contact with the periphery of said tubular center base of said needle holder for enabling said locating ring to be moved axially relative to said needle holder, the outside wall of said locating ring having a front section forming a neck adapted for engaging into said rear expansion section of said sleeve of said needle holder, said neck having an


outer diameter not less than the inner diameter of said expansion section of said sleeve of said needle holder so as to expand said rear expansion section of said sleeve for enabling the rear side edge of the rear expansion section stopped at the front side of the inside flange means of said barrel, a first retaining portion integral

with a front part of the inside wall of said locating ring and adapted for engaging the retaining portion of said tubular center base of said needle holder, and a second retaining portion formed integral with a rear part of the inside wall of said locating ring.

___________

151905]21][11[

המשתמשתCDMA מערכתהעברה לפני בקדם–סיבוב

CDMA SYSTEM WHICH USES PRE-ROTATION BEFORE TRANSMISSION

]54[

28.03.2001]22[US]33[28.03.2000]32[60/192670]31[

Int. Cl.8 H04B 001/707, 007/216]51[INTERDIGITAL TECHNOLOGY CORPORATION, U.S.A.

]71[





TEL AVIV 61040

]74[


[57] A CDMA communication system for reducing transmission errors during communications between at least two communication units, each communication unit includes: a receiver for receiving a CDMA communication signal sent from another communication unit comprising; an analyzer for analyzing said received

signal for errors and for generating a correction signal; and a correction unit for correcting said received signal using the correction signal; a transmitter for correcting a signal prior to transmission to another communication unit using said correction signal.



_________

152104]21][11[

עבור זמני בו ביצוע לתיאום בסיס תחנתאל–חוטיות תקשורת מערכות

BASE STATION SYNCHRONIZATION FOR WIRELESS COMMUNICATION SYSTEMS

]54[

05.04.2001]22[US]33[07.04.2000]32[60/195543]31[US04.08.200060/223405

Int. Cl.8 H04B 001/707, 007/26, H04Q 007/36]51[INTERDIGITAL TECHNOLOGY CORPORATION, U.S.A.

]71[





]74[


TEL AVIV 61040

[57] A method for time synchronizing a plurality of base stations in a wireless communication system, the method comprising: determining an estimation of timing accuracy associated with each base station; for each base station having its estimation over a threshold; determining a neighboring one of the base stations having its determined estimation indicating a better timing accuracy than that over threshold base station; determining an

estimated time difference between that over threshold base station and the neighboring one base station; adjusting a timing of that over threshold base station in response to the estimated time difference; and updating the estimation of that over threshold base station wherein the updated estimation indicates a worse timing accuracy than the neighboring one base station.



________

152125]21][11[


PROCESS FOR THE MANUFACTUREאקטינאסידין תולדות להכנת תהליךOF ECTEINASCIDIN DERIVATIVES

]54[

15.05.2001]22[WO]33[15.05.2000]32[PCT/GB00/01852]31[

Int. Cl.8 C07D 515/22]51[PHARMA MAR, S.A., SPAIN]71[WO/2001/087895]87[



JERUSALEM 91013

]74[

[57] Process step in the manufacture of an ecteinascidin compound, wherein the step comprises deprotecting a compound of formula (A) by removing both protecting

groups is a single step, to give an α-aminelactone of formula (35), in accordance with the following scheme:

where ProtNH is an amino protecting group, and ProtOH is a hydroxy protecting group.

__________

152250]21][11[

IP הפניית עם לווין לניתוב פרוטוקולדינמית

SATELLITE ROUTING PROTOCOL WITH DYNAMIC IP ADDRESSING

]54[

04.04.2001]22[US]33[10.04.2000]32[60/196054]31[

Int. Cl.8 H04B 007/185, 007/204, H04L 012/56]51[VIASAT, INC., U.S.A.]71[




REHOVOT 76122

]74[


[57] A method for establishing routing of communications via a satellite for an IP-based Demand Assigned Multiple Access (DAMA) Wide Area Netwok (WAN), said DAMA WAN being characterized by a bandwidth constricted control channel under control of a centralized Network Control Station for communication of channel allocation and routing information to each node in said DAMA WAN, said method comprising: constructing a

network map of all directly and indirectly connected IP network prefixes reachable via said DAMA WAN; and allocating at said Network Control Station (NCS), DAMA WAN type communication channels via said satellite by a control channel message over said bandwidth constricted control channel directed to each involved subscriber terminal (ST) node connected to said WAN.

_________

152388]21][11[

של מותמרות בנגזרות שימוש תכשיר בייצור דיסטאמיצין אקרילאוליל

עם הקשורים בגידולים לטיפול רפואיגלוטאתיון של גבוה ריכוז

USE OF SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF TUMORS ASSOCIATED WITH HIGH LEVELS OF GLUTATHIONE

]54[

19.04.2001]22[GB]33[08.05.2000]32[0011059.3]31[

Int. Cl.8 A61K 031/40, C07D 403/00]51[PFIZER ITALIA S.R.L., ITALY]71[WO/2001/085144]87[


אביב



TEL AVIV 61040

]74[

[57] Use of an α-halogenoacryloyl distamycin derivative of the formula


wherein:R1 is a bromine or chlorine atom; andR2 is a group of the formula

whereinm is 0 or 1;n is 4;r is 0;X and Y are both a CH group;B is selected from the group consisting of

wherein R5, R6 and R7, the same or different, are hydrogen or C1-C4 alkyl; G is phenylene, a 5 or 6 membered saturated or

unsaturated heterocyclic ring with from 1 to 3 heteroatoms selected among N, O or S, or it is a group of the formula

wherein Q is a nitrogen atom or a CH group and W is an oxygen or sulfur atom or is a group NR3 wherein R3 is hydrogen or C1-C4 alkyl; or pharmaceutically

acceptable salt thereof; in the manufacture of a medicament for the treatment of tumors in a human being diagnosed with a tumor over-expressing GSH/GSTs system.

________


152509]21][11[

ברשת משולבים לשרותים ומערכת שיטהחכמה טלפונים

METHOD AND SYSTEM FOR INTEGRATED SERVICE FOR INTELLIGENT TELEPHONE NETWORKS

]54[

28.10.2002]22[Int. Cl.8 H04M 003/42, 007/00]51[

]INRA]71בע"מ אי.אן.אר.אי]AVIRAM DAHRI]72דהרי אבירם

עו"ד, זר יורם, 29לילינבלום

YORAM ZER, 29 LILIENBLUM ST,.

TEL-AVIV 65133

]74[

[57] A method for mediating between different (SSP) telephone switching message protocols and different control point system (SCP) message protocols, comprising the steps of: providing an SSP with a message having a first type of message protocols; providing an SCP with a second type of message protocols not directly communicable with the first type of message protocols; covering a message

from the SSP to a unified service request data format using an SSP conversion module; routing the converted message to an SCP conversion module; converting the converted message to the second type of message protocols using the SCP conversion module; and routing the converted message in the second type of message protocols format to the SCP.

__________

152571]21][11[

דרגת בעל פמירולאסט להכנת תהליךגבוהה ניקיון

PROCESS FOR THE PREPARATION OF HIGH PURITY PEMIROLAST

]54[

31.10.2002]22[Int. Cl.8 C07D 471/04]51[DINAMITE DIPHARMA S.P.A., ITALY

]71[



אביב



TEL AVIV 61040

]74[

[57] A process for the purification of Permirolast comprising:(a) salifying crude Pemirolast with a primary or secondary amine in the presence of solvents selected from water, C1-C3 alcohols or mixtures thereof;

(b) acidifying the solution obtained in (a) by addition of mineral or organic acids to pH ranging from 2 to 4;(c) isolating precipitated Pemirolast and optionally transforming it into the corresponding potassium salt.

_________

152768]21][11[

לקישור כבלים למערכת שידרוג ערכתהדדי

RETROFIT KIT FOR INTERCONNECT CABLING SYSTEM

]54[

11.11.2002]22[Int. Cl.8 H01R 011/00]51[

]RIT TECHNOLOGIES LTD.]71אביב בע"מ, תל טכנולוגיות ריטצדק, וכהן איתן, פרל, לצר


P.O.B. 12688 ,HERZLIYA 46733

]74[

[57] A system for automatically obtaining the connectivity status, or map, of a cabling system in data and/or voice networks, which includes patch panels each of which contains sockets, which sockets are data and/or voice ports to which one or more patch cords are connected, and for managing said cabling system by means of the obtained connectivity status, or map, said system comprising patch panels of the existing cabling system and retrofit kit, said retrofit kit comprising:(a) a plurality of upgraded patch cords for replacement of respective used patch cords, each of said upgraded patch cords including one or more internal scanning wires and one or more electrical scanning contacts in electrical contact with the

corresponding internal scanning wires, one or more scanning paths being formed in each of the upgraded patch cords by means of said internal scanning wires and one or more scanning contacts for allowing scanning signals to be forwarded by a scanning system (20);(b) a plurality of adapter panels (51) for facilitating cabling system management, each of said adapter panels being attached to a respective patch panel and including, for any given socket (38, 39) in the respective patch panel, a connectivity status indicator and one or more electrical contacts, each of said electrical contacts being intended to mate with a corresponding electrical scanning contact of an upgraded patch cord, said scanning signals being forwarded to said electrical


contacts from said scanning system or being forwarded to said scanning system from a respective scanning path, whereby a scanning signal received by one or more electrical contacts is processed to generate data that represents the current connectivity status, or map, of the cabling system; and(c) a plurality of adapted plugs for initializing the scanning system with a first connectivity status, or map, one of said adapter plugs being connected to each end of a used patch cord and to an adapter

panel, each of said adapter plugs comprising an adaptation socket, an adaptation plug, and one or more external electrical contacts connected to corresponding conductors associated with a used patch cord to which the adapter plug is attached; wherein determination of which patch cords are to be replaced by respective upgraded patch cords and, following completion of the replacement, management of said cabling system, are effected in conjunction with said first connectivity status, or map..

__________

152959]21][11[

באוליגודאוקסינוליאוטידים שימוש החיסונית המערכת את הממריצים

את הממריץ רוקחי תכשיר להכנתהחיסונית המערכת

USE OF IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES FOR THE PREPARATION OF IMMUNOSTIMULATORY PHARMACEUTICAL COMPOSITIONS

]54[

07.06.2001]22[AT]33[08.06.2000]32[A1000/2000]31[AT23.11.2000A1973/2000

Int. Cl.8 A61K 031/12, 039/39, A61P 037/04, C07H 021/00, 021/04, C12N 015/11]51[INTERCELL AG, AUSTRIA]71[WO/2001/093905]87[


אביב


P.O.B. 4060 ,

]74[


TEL AVIV 61040

[57] Use of an oligodeoxynucleic acid molecule (ODN) of the formula

any X is O or S, whereinany NMP is a 2' deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxygunanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxygunanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or monothiophosphate, NUC is a 2' deoxynucleoside, selected

from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, a and b are integers from 0 to 100 with the proviso that a + b is between 4 and 150, B and E are common groups for 5' or 3' ends of nucleic acid molecules, for preparing an immunostimulatory pharmaceutical composition.

_________

153292]21][11[

אלקטרוני להיצג ושיטה התקן, מערכתאמיתיים בצבעים

DEVICE, SYSTEM AND METHOD FOR ELECTRONIC TRUE COLOR DISPLAY

]54[

07.06.2001]22[US]33[07.06.2000]32[60/209771]31[US14.11.200009/710895

Int. Cl.8 G02B 027/18, G02F 001/13, 001/1335, G03B 021/00, G09F 009/00, H04N 009/31

]51[

GENOA COLOR TECHNOLOGIESבע"מ, הרצליה צבע טכנולוגיות גנואהLTD.

]71[

-ILAN BEN-DAVID, MOSHE BENבן-חורין בן-דוד, משה אילןCHORIN

]72[



P.O.B. 12688 ,

]74[


HERZLIYA 46733

[57] A method of producing a color image comprising: projecting polychromatic light from a light source onto a first side of a color wheel having at least four non-white and non-black color filters; rotating said color wheel such that the polychromatic light from said light source is sequentially filtered by transmission through said at least four color filters to sequentially produce at a

second said of said color wheel, opposite said first side, light of at least four colors, each of said at least four colors having a different chromaticity from the others of the at least four colors in accordance with a data signal; and spatially modulating said light of at least in accordance with a data signal four colors in accordance with a data signal to produce said color image.

__________

153350]21][11[

AUTOMATED HORSE TRAININGסוסים לאימון אוטומטית מערכתSYSTEM

]54[

01.09.2000]22[TR]33[22.06.2000]32[2000/0186

3]31[

TR02.08.20002000/2265Int. Cl.8 A01K 015/02]51[MEHMET KURT, TURKEY]71[WO/2001/097606]87[


אביב



TEL AVIV 61040

]74[


[57] An automated horse training system, including: at least one stable (3) with an associated corridor; a locking arrangement (15); at least one horse training device (1), lateral sides and a rear side of the at least one horse training device being covered by a flexible material and a front side of the at least one horse training device being closed by the locking arrangement; a tractor actuating the at least one horse training device, the tractor being arranged at one of the front side and the rear side of

the at least one horse training device; one of a plurality of rails and a line arranged on a side of the at least one horse training device for guiding the tractor; and one of an electrode and veterinarian measurement arrangement arranged on a body of a horse for monitoring a physical performance of the horse by one of remote electronic signal transmission and remote sensing; wherein mechanical movements of components of the horse training system are performed automatically.

___________

153367]21][11[

לשיטת בהתאם נתונים לשידור מערכתהתדרים דילוג

SYSTEM FOR DATA TRANSMISSION ACCORDING TO THE FREQUENCY HOPPING METHOD

]54[

01.06.2001]22[DE]33[14.06.2000]32[10029308.

5]31[

DE26.03.200110114834.8Int. Cl.8 H03M 013/00, 013/23, 013/29, H04B 001/713, H04L 001/00]51[ROHDE & SCHWARZ GMBH & CO. KG, GERMANY

]71[

WO/2001/097401]87[


- עורכי דין עורכי - מהולל איתן קבוצתפטנטים,

,2081 , ת.ד. 10 אבן אבא שדרות הרצליה

EITAN MEHULAL LAW GROUP, 10 ABBA EBEN BLVD,.

P.O. B. 2081,HERZLIYA 46120

]74[

[57] System for transmitting data by the frequency hopping method, in which the digital data are transmitted in abruptly changing transmission frequency segments (hops), wherein the data in the consecutive frequency segments are encoded according to a woven code that comprises the concatenation of an outer and an inner convolutional code, characterized in that encoding is performed according to the

woven code with outer warp, wherein the user information items are transmitted in one of the frequency segments, the test information items of the other code are transmitted in another of the frequency segments and the test information items of the inner code, together with the user information items and the test information items of the outer code, are transmitted in all the frequency segments.

_________

153386]21][11[

INTERNET USAGE CHARGEאינטרנט משתמשי חיוב מערכתBILLING SYSTEM

]54[

28.05.2001]22[JP]33[14.06.2000]32[2000-

179028]31[

Int. Cl.8 G06Q 003/000000 H04L 012/14, 012/46]51[HIROYUKI WAKAMATSU, JAPAN]71[WO/2001/097450]87[

בע"מ, פרידמן מרק ד"ר ז'בוטינסקי , רח54אביב, ק. משה מגדל

, רמת- גן7

DR. MARK FRIEDMAN LTD,. MOSHE AVIV TOWER, 54TH

FLOOR ,7 JABOTINSKY ST ,.

RAMAT GAN 52520

]74[


[57] An Internet usage charge billing apparatus for passing data passing through a second provider area when data sent from a first provider area which is a sender is sent to a destination of a third provider area which is different from said second provider area through said second provider area which is different from said first provider area, said system comprising passing data storing means for storing sender identifying information or destination identifying information given to said passing data, summarizing means

for summarizing information concerning said passing data for each said sender identifying information or said destination identifying information, and billed amount calculating means for determining a billed amount for each said sender identifying information or said destination identifying information in accordance with a passing information amount concerning said passing data summarized for each said sender identifying information or said destination identifying information.

__________

153412]21][11[

-METHOD FOR PRODUCING 4אנילין –ברומו4 תולדות להכנת שיטהBROMO ANILINE DERIVATIVES

]54[

29.06.2001]22[DE]33[30.06.2000]32[10030975.

5]31[

Int. Cl.8 C07C 211/52, 217/58, 255/58, C07D 261/02]51[BASF AKTIENGESELLSCHAFT, GERMANY

]71[





TEL AVIV 61040

]74[


[57] Process for preparing 4-bromoanilines of the formula

where:R1 is C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C3-C8-cycloalkyl, halogen; R2 is C1-C6-alkyl, C1-C6-alkoxy, C3-C8-cycloalkyl, C2-C6-alkenyl, cyano or a heterocyclic radical

selected from saturated, unsaturated or partially unsaturated heterocycle having 3-8 ring atoms and one, two or three oxygen, sulfur or nitrogen atoms;which comprises reacting a compound of the formula

with a brominating agent in the solvent pyridine or solvent mixture comprising at least 55% by weight of pyridine.

_________

153457]21][11[

INJECTABLE DISPERSIONS OFלהזרקה הניתנים פרופופול של פיזוריםPROPOFOL

]54[

14.06.2001]22[US]33[16.06.2000]32[60/211977]31[

Int. Cl.8 A61K 009/00, 009/10, C07C 039/00]51[SKYEPHARMA CANADA INC., CANADA

]71[

AWADHESH K. MISHRA, GARY PACE, MICHAEL G. VACHON, ROBERT A. SNOW

]72[





JERUSALEM 91450

]74[


[57] A sterile, injectable dispersion of micromatrices or microdroplets having a mean diameter from about 50 nm to about 1000 nm comprising: propofol in an amount of from about 1% to about 7.5% by weight/volume of the dispersion, a propofol-soluble diluent in an amount of from about 1% to about 8% by weight/volume of the dispersion, and a surface stabilizing amphiphilic agent in an amount of from about 0.67% to about 5%

by weight/volume of the dispersion, suspended in an aqueous medium containing a synergetic quantity of antimicrobial agent and a tonicity modifying amount of a pharmaceutically acceptable water-soluble hydroxyl-group-containing excipient, wherein the ratio of propofol to diluent is in the range of about 0.25 to about 7.5 and the ratio of propofol to amphiphilic agent is in the range from about 0.4 to about 1.5.

_________

153482]21][11[

SYSTEM FOR CONTROL OFדמות מגבר לבקרת מערכתIMAGE INTENSIFIER

]54[

16.12.2002]22[Int. Cl.8 H01J 040/14, H04N 005/238]51[

]ELBIT SYSTEMS LTD.]71בע"מ, חיפה מערכות אלביט OFER DAVID, YEHUDAבורנשטיין דוד, יהודה עופר

BORENSTEIN]72[



P.O.B. 12688 ,HERZLIYA 46733

]74[

[57] A system for handling light that is amenable for intensification by an image intensifier (20), and wherein the system includes – a light regulator (30) adapted to regulate light intensity, wherein said light regulator is either positioned externally to said image intensifier at a focal plane of the light to be intensified, or placed internally at a focal plane of said image intensifier before the photo sensitive area of said image intensifier; and a circuit comprising an image sensor (80), wherein

said image sensor is capable of detecting zones of intensely bright light areas in an acquired image and said circuit is coupled to an image processor (90) that relates the locations of said zones with the respective areas on said light regulator, in a manner enabling operation of said respective areas on said light regulator, so that image received from said image intensifier is influenced; and wherein said system is characterized by said light regulator being a transmissive MEMS component.


_________

153536]21][11[

]DRILLING TOOL]54קידוח מכשיר

16.06.2001]22[DE]33[27.06.2000]32[10030297.

1]31[

Int. Cl.8 B23B 051/02]51[KOMET GROUP HOLDING GMBH, GERMANY

]71[




]74[

[57] A drilling tool comprising a base body (14), which can be rotated about a drilling axis (36), comprising at least two plate seats (16) arranged on the front face in the base body, and comprising cutting plates (20), which can be interchangeably inserted into the plate seats, and are preferably identical, and which cutting plates each have a machining face (30) and clearance face (24) adjoining a principal cutting edge (28); a seat face (26) facing away from the clearance face, and a guiding land (34) adjoining radially on the outside through each edge the machining

face, the clearance face and optionally the seat face, and a hole (48) which extends through the clearance face and the seat face for a retaining screw which can be screwed into a threaded bore (50) open to the front face of the base body in the area of the plate seats, characterised in that the holes with their axis are aligned perpendicularly to the clearance face of the associated cutting plates, and that the axes of the threaded bores are aligned inclined with respect to the drilling axis and inclined to each other in the base body.


__________

153592]21][11[

PHARMACEUTICALקטוקונאזול המכיל רוקחות תכשירCOMPOSITION CONTAINING KETOCONAZOLE

]54[

14.08.2001]22[GB]33[18.08.2000]32[0020486.7]31[

Int. Cl.8 A61K 047/10, A61P 017/08, C07D 405/00, 405/12]51[DIOMED DEVELOPMENTS LTD., UNITED KINGDOM

]71[




]74[

[57] A pharmaceutical composition suitable for topical application comprising ketoconazole in a true solution which comprises:(i) 13 to 50 wt% water;(ii) 45 to 85 wt% of an alcohol having a boiling point of less than 100oC;

and(iii) 2 to 30 wt% of a non-volatile, water miscible, non-ionic surface active agent;the ketoconazole being present in an amount of 1.5 to 2.5 wt%, based on the total amount of components (i), (ii) and (iii).


_________

153594]21][11[

רוקחות ותכשירי כוהל אמינו תולדותאותן המכילים

AMINO ALCOHOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

]54[


10.07.2001]22[JP]33[13.07.2000]32[2000-

212246]31[

JP09.08.20002000-241744JP19.09.20002000-283218

Int. Cl.7 A61K 031/381, A61P 037/06, C07C 271/16, C07D 333/20, 333/22, 333/32, 409/06, 413/06, C12P 013/00

]51[

DAIICHI SANKYO COMPANY LIMITED, JAPAN

]71[




]74[

[57] A compound or a pharmacologically acceptable salt, ester or other derivative thereof, of the formula

wherein:R1 and R2 are the same or different and each represents a hydrogen atom or an amino protecting group;R3 represents a hydrogen atom or a hydroxy protecting group;R4 represents a lower alkyl group;n represents an integer from 1 to 6;X represents an ethylene group, a vinylene group, an ethynylene group, a group of formula-D-CH2-(wherein D represents a carbonyl group, a group of formula–CH(OH)-, an oxygen atom, a sulfur atom, or a nitrogen atom), an aryl group, or an aryl group substituted with 1 to 3 substituents selected from substituent group a;Y represent a single bond, a C1-C10 alkylene group, a C1-C10 alkylene group substituted with 1 to 3 substituents selected from substituent groups a and b, a C1-C10

alkylene group which has an oxygen atom or a sulfur atom in said carbon chain or at

the end of said carbon chain, or a C1-C10 alkylene group which is substituted with 1 to 3 substituents selected from substituent group a and b and has an oxygen atom or sulfur atom in said carbon chain or at the end of said carbon chain;R5 represents a hydrogen atom, a cycloalkyl group, an aryl group, a heterocyclic group, a cycloalkyl group substituted with 1 to 3 substituents selected from substituent groups a and b, an aryl group substituted with 1 to 3 substituents selected from substituent groups a and b, or a heterocyclic group substituted with 1 to 3 substituents selected from substituent groups a and b; R6 and R7 are the same or different and each represents a hydrogen atom or a group selected from substituent group a; with the proviso that when R5 is a hydrogen atom, Y is not a single bond or a straight chain C1-C10 alkylene group; substituent group a consists of a halogen


atom, a lower alkyl group, a halogenated lower alkyl group, a lower alkoxy group, a lower alkylthio group, a carboxyl group, a lower alkoxycarbonyl group, a hydroxyl group, a lower aliphatic acyl group, an amino group, a mono lower alkylamino group, a di lower alkylamino group, a lower aliphatic acylamino group, a cyano group, and a nitro group; substituent group

b consists of a cycloalkyl group, an aryl group, a heterocyclic group, a cycloalkyl group substituted with 1 to 3 substituents selected from substituent group a, an aryl group substituted with 1 to 30 substituents selected from substituent group a, and a heterocyclic group substituted with 1 to 3 substituents selected from substituent group a.



_________

153621]21][11[

METHOD AND DEVICE FORתחמושות תת לפיזור והתקן שיטהDISPERSING SUBMUNITIONS

]54[

20.06.2001]22[SE]33[03.07.2000]32[0002495-0]31[

Int. Cl.8 F42B 012/58]51[BAE SYSTEMS BOFORS AB, SWEDEN

]71[

TORSTEN RONN, JAN AXINGER]72[WO/2002/003013]87[


, הרצליה12704



]74[

[57] A method of firing submunitions, comprising: providing an airborne carrier (1) having a magazine (4) rotatably mounted with respect to a front section of a missile, the magazine housing a plurality of submunitions; activating a gas generator

(6), wherein gases from the gas generator cause the magazine to rotate; rotating the magazine relative to the front section of the airborne carrier to exert centrifugal forces on the submunitions; and allowing the submunitions to leave the magazine.


___________

153754]21][11[

]PYRIMIDINE DERIVATIVES]54פירימידין נגזרות

06.07.2001]22[GB]33[11.07.2000]32[0016877.3]31[

Int. Cl.8 A61K 031/505, A61P 035/00, C07D 239/48, 401/12, 403/04, 403/12]51[ASTRAZENECA AB, SWEDEN]71[WO/2002/004429]87[

ושות', ש. הורוביץ , תל41-45 רוטשילד ציון, שדרות בית

אביב



]74[

[57] A compound of the formula

wherein:April 13, 2008767 –התשס"ח ח' בניסן

R1 is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, C1-6 alkyl, C2-6 alkenyl or C2-6 alkenyl or C2-6 alkynyl;p is 0-4; wherein the values of R1 may be the same or different;R2 is sulphamoyl or a group B-E-;q is 0-2; wherein the values of R2 may be the same or different; and wherein p+q= 1-5; R3 is hydrogen, C1-6 alkyl, C1-6 alkyl, C2-6

alkenyl, C2-6 alkynyl or C3-8 cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more M;R4 is C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl or heterocyclyl; wherein R4 may be optionally substituted by one or more M; wherein if said heterocyclyl contains an –NH- moiety that nitrogen may be optionally substituted by a group selected from Z; or R3 and R4 together with the nitrogen to which they are attached form a heterocyclic ring optionally substituted on carbon by one or more M; wherein if said heterocyclic ring contains an –NH-moiety that nitrogen may be optionally substituted by a group selected from Q; B is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C3-8 cycloalkyl C1-6 alkyl, phenyl, a heterocyclic group, phenyl C1-6 alkyl or (heterocyclic group) C1-6 alkyl; wherein B may be optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an–NH-moiety that nitrogen may be optionally substituted by a group selected from G;E is –C(O)-, -N(Ra)C(O)-, -C(O)N(Ra)-, -S(O)r-, -SO2N(Ra)- or –N(Ra)SO2-; wherein Ra is hydrogen or C1-6 alkyl optionally substituted by one or more D and r is 1-2;D is independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 alkanoyl, C1-6 alkanoyloxy, N-(C1-6 alkyl) amino, N,N-(C1-6 alkyl)2 amino, C1-6 alkanoylamino, N-(C1-6 alkyl) carbamoyl,

N-N(C1-6 alkyl)2 carbamoyl, C1-6 alkylS(O)a

wherein a is 0 to 2, C1-6 alkoxycarbonyl, N-(C1-6 alkyl) sulphamoyl and N, N-(C1-6 alkyl)2 sulphamoyl; wherein D may be optionally substituted on carbon by one or more V;M is independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 alkanoyl, C1-6 alkanoyloxy, N-(C1-6 alkyl) amino, N,N-(C1-6 alkyl)2 amino, C1-6 alkanoylamino, N-(C1-6 alkyl) carbamoyl, N,N-(C1-6 alkyl)2 carbamoyl, C1-6 alkylS(O)a wherein a is 0 to 2, C1-6 alkoxycarbonyl, N-(C1-6 alkyl) sulphamoyl, N,N-(C1-6 alkyl)2 sulphamoyl, C3-8 cycloalkyl, phenyl or a heterocyclic group; wherein M may be optionally substituted on carbon by one or more P; and wherein if said heterocyclic group contains an –NH- moiety that nitrogen may be optionally substituted by a group selected from T; P, X and V are independently selected from halo, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; andG, Q, T and Z are independently selected from C1-4 alkyl, C1-4 alkanoyl, C1-4 alkylsulphonyl, C1-4 alkoycarbonyl, carbamoyl, N-(C1-4 alkyl) carbamoyl, N,N-(C1-4 alkyl) carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and


phenylsulphonyl wherein G, Q and T may be independently optionally substituted on carbon by one or more X; or a

pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.

_________

153755]21][11[

METHOD AND APPARATUS FORמחשב שירותי למתן ושיטה מכשירPROVIDING COMPUTER SERVICES

]54[

03.07.2001]22[US]33[05.07.2000]32[60/216347]31[

Int. Cl.8 G06F 002/120000 009/46, 009/50, 015/00]51[ERNST & YOUNG LLP, UNITED KINGDOM

]71[



P.O.B. 12688 ,HERZLIYA 46733

]74[

[57] Apparatus comprising a real computer (30) on which is set up plural virtual machines (VS), each virtual machine having an operating system running thereon; characterised by: the apparatus providing one or more computer

services for a plurality of customers (A, B, C); and by: there being at least one virtual machine for each of said customers that is set up at the request of each of said customers and that has a specification specified by and configurable by the respective customer.


_________

153825]21][11[

ותכשירי מותמרות אמינומתיל תרכובותאותן המכילים רוקחות

CYCLIC SUBSTITUTED AMINOMETHYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR PREPARATION

]54[


06.07.2001]22[DE]33[10.07.2000]32[10033459.

8]31[

Int. Cl.8 C07C 211/00]51[GRUNENTHAL GMBH, GERMANY]71[WO/2002/008218]87[


אביב


P.O.B. 4060 ,TEL AVIV 61040

]74[

[57] Analgesic cyclic substituted aminomethyl compounds of the formula

whereinR1 denotes H, F, Cl, OH, O-CH3, O-(C2-6-alkyl), O-(C3-7-cycloalkyl), CH3, C2-6-alkyl, CH2F, CHF2 or CF3, in each case in the 2-, 3-, 4-, 5- or 6-position of the phenyl ring,R2 denotes H, F, Cl, CH3, C2-6-alkyl, CH2F, CHF2 or CF3, in each case in the 2-, 3-, 4-, 5- or 6-position of the phenyl ring, R3 and R4

independently of one another denote H, F, Cl, OH, O-CH3, O-(C2-6-alkyl), O-(C3-7-cycloalkyl), CH3, C2-6-alkyl, CH2F, CF3, O-aryl, aryl or heterocyclyl, in each case in the α-, β-, γ- and/or δ-position of the

aromatic ring, R5 and R6 independently of one another denote CH3, C2-6-alkyl, C3-7-cycloalkyl, CH2-(C3-7-cycloalkyl), aryl, (C1-

6-alkyl) –aryl, heterocyclyl or (C1-6-alkyl)-heterocyclyl,X denotes CH2, O, S, SO or SO2,n is 0, 1, 2 or 3 if X denotes CH2 and is 1, 2 or 3 if X denotes O, S, SO or SO2, and the configuration of the exocyclic double bond in compounds of the general formula IB is E or Z, and their pharmaceutically acceptable salts.

_________

153838]21][11[

בעל אריפיפראזול של תרופתי חומר ותהליכים לחות לספיגת נמוכה יכולת

להכנתו

LOW HYGROSCOPICITY ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF

]54[


25.09.2002]22[JP]33[25.09.2001]32[2001-

290645]31[

JP14.11.20012001-348276CA27.03.20022379005

Int. Cl.8 A61K 031/496, A61P 025/18, C07D 213/00]51[OTSUKA PHARMACEUTICAL CO, LTD, JAPAN

]71[





TEL AVIV 61040

]74[

[57] Hydrate A of aripiprazole wherein said hydrate has a powder x-ray diffraction spectrum which is substantially the same as the following powder x-ray diffraction spectrum shown in Figure 3 as given in the specification; particular infrared absorption bands at 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963 and 784 cm-1 on the IR(KBr) spectrum;an endothermic curve which is substantially the same as the thermogravimetric/differential thermal analysis (heating rate 5oC/min) endothermic curve shown in Figure 1 as given in the speficiation; and a mean particle size of 50 µm or less.Anhydrous aripiprazole crystals B having low hygroscopicity wherein said low

hygroscopicity is a moisture content of 0.40% or less after placing said drug substance for 24 hours in a desiccator maintained at a temperature of 60oC and a humidity level of 100%, a powder X-ray diffraction spectrum which is substantially the same as the following powder X-ray diffraction spectrum shown in Figure 5, as shown in the specification and particular infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960 and 779 cm-1 on the IR (KBr) spectrum; and exhibiting an endothermic peak near about 141.5oC in thermogravimetric/differential thermal analysis (heating rate 5oC/min) and an endothermic peak near about 140.7oC in differential scanning calorimetry (heating rate 5 oC/min).



__________

154040]21][11[

–כלורומתיל5–כלורו–2 לטיהור תהליךתיאזול

METHOD FOR PURIFYING 2-CHLORO-5-CHLOROMETHYL THIAZOLE

]54[

30.07.2001]22[DE]33[10.08.2000]32[10038977.]31[


5Int. Cl.8 C07D 277/32]51[BAYER CROPSCIENCE AG, GERMANY

]71[




P.O.B. 4060 ,TEL AVIV 61040

]74[

[57] Process for purifying 2-chloro-5-chloromethyl-thiazole, characterized in that crude material of the compound is

distilled under reduced pressure in the presence of a polyether.

___________

154406]21][11[

חומר יריעת של מדוייק לכיפוף שיטהכך לשם מחורץ וחומר

METHOD FOR PRECISION BENDING OF A SHEET OF MATERIAL AND SLIT SHEET THEREFOR

]54[

16.08.2001]22[US]33[17.08.2000]32[09/640267]31[

Int. Cl.8 B21D 028/26]51[INDUSTRIAL ORIGAMI, INC., U.S.A.

]71[





TEL AVIV 61040

]74[

[57] A method for precision bending of a sheet of material along a bend line comprising the steps of: selecting a solid sheet of elastically and plastically deformable material; forming a plurality of longitudinally extending closed-ended slits through said sheet of material in axially spaced relation in a direction extending along and proximate said bend line to

define at least one bending web between adjacent ends of at least one pair of said slits; forming a stress reducing structure at each end of said pair of slits, said structure being formed on said bend line and connected to said slits; bending of said sheet of material substantially along said bend line and across said bending web between said openings; and during said


bending step, elastically and then plastically deforming said sheet at said web by interengagement of solid edges of

said sheet of material on opposite sides of said slits.



_________

154541]21][11[

הקושרים מהם מקטעים או נוגדנים של גידולם את הממריצים פוליפפטידים

עצב תאי

ANTIBODY OR FRAGMENTS THEREOF THAT BIND POLYPEPTIDES STIMULATING NEURONAL GROWTH

]54[

02.02.1998]22[US]33[03.02.1997]32[09/792019]31[US30.01.199809/016534

Int. Cl.8 C07K 014/475, 016/22, C12N 015/18]51[DIVISION FROM 131103]62[AMGEN, INC., U.S.A.]71[




REHOVOT 76122

]74[

[57] An isolated and purified antibody or fragment thereof which specifically binds to a polypeptide that has a biological activity of stimulating growth of motor or sympathetic neurons, said polypeptide selected from the group consisting of:(a) the polypeptide of SEQ ID NO:2;

(b) the polypeptide that is amino acid 1-198 of SEQ ID NO:2;(c) the polypeptide that is at least 70% identical to the polypeptide of (a) or (b); and(d) a fragment of any of (a)-(c) which has said biological activity.

__________


154542]21][11[

המקודדים גרעין חומצות גידולם את הממריצים לפוליפפטידים

עצב תאי של

NUCLEIC ACIDS ENCODING POLYPEPTIDES THAT STIMULATE NEURONAL GROWTH

]54[

02.02.1998]22[US]33[03.02.1997]32[09/792019]31[US30.01.199809/016534

Int. Cl.8 C12N 015/12, 015/18]51[DIVISION FROM 131103]62[AMGEN, INC., U.S.A.]71[




REHOVOT 76122

]74[

[57] An isolated nucleic acid molecule encoding a polypeptide which polypeptide has a biological activity of stimulating growth of motor or sympathetic neurons, selected from the group consisting of:(a) the nucleic acid molecule of SEQ ID NO:1;(b) the nucleic acid molecule of SEQ ID NO:3;(c) a nucleic acid molecule encoding a polypeptide consisting of amino acids 27

through 198 or 1 through 198 or 1 through 198 of SEQ ID NO:2;(d) a nucleic acid molecule that encodes a polypeptide that is at least 70 percent identical to a polypeptide of (c) above; and(e) a nucleic acid molecule that encodes a fragment of a polypeptide of (c) or (d) above, which polypeptide fragment has said biological activity.

_________

154631]21][11[

לא–ארוגה רשת של רציף לייצור סידורסיבים של

ARRANGEMENT FOR THE CONTINUOUS PRODUCTION OF A FILAMENT NONWOVEN FIBROUS WEB

]54[

26.02.2003]22[EP]33[28.02.2002]32[02004615.

7]31[

Int. Cl.8 D04H 003/14]51[REIFENHAUSER GMBH & CO. MASCHINENFABRIK, GERMANY

]71[



P.O.B. 12688 ,

]74[


HERZLIYA 46733

[57] An apparatus for producing a nonwoven fibrous web comprising a spinneret (1) for producing a descending curtain of thermoplastic synthetic resin filaments; a cooling chamber (2) below said spinneret and forming a passage (3) receiving said descending curtain of thermoplastic synthetic resin filaments; a stretching unit (4) below said passage and connected thereto to exclude entry of external air for aerodynamically stretching said filaments as said filaments pass downwardly from said passage through said stretching unit, said stretching unit having a draft channel (5) at a bottom thereof; an air supply chamber adjacent

said cooling chamber and communicating with said passage through openings in walls of cooling chamber for introducing process air into said passage, cooling said filaments and passing with said filaments into said stretching unit, said air supply chamber being subdivided into a first chamber section (8a) and a second chamber section (8b) in a direction of travel of said filaments provided with means for introducing air of different temperatures into said passage; and a collecting device (7) below said stretching unit for collecting aerodynamically stretched filaments in the form of a continuous web.

__________

154647]21][11[

תקשורת במערכות תעבורה ניהולאופטיות

TRAFFIC MANAGEMENT IN OPTICAL COMMUNICATION NETWORKS

]54[

27.02.2003]22[Int. Cl.8 H04B 010/18]51[


]ECI TELECOM LTD.]71תקוה בע"מ, פתח אי.סי.איי. טלקום ,URI MAHLAB, MICHAEL GUTINמלמד גוטין, בוריס מחלב, מיכאל אורי

BORIS MALMED]72[

בע"מ, אי. סי. איי. טלקוםתקוה , פתח30הסיבים רחוב

ECI TELECOM LTD,. 30 HASIVIM ST,.

PETACH TIKVA 49517

]74[

[57] A method of traffic management in an optical network, comprising detecting a condition of non-linearity in a network section corresponding to an optical path extending in said network by measuring chirp of an optical signal passing in the network section, comprising a value of the measured chirp with at least one chirp

threshold value preliminarily known for said network section when being in its linear condition, and in case the condition of non-linearity is detected in said network section, making a traffic management decision in said optical network for restricting or avoiding use of said network section in the network.

_________

154893]21][11[

המכילים צקליות אליפטיות תרכובות ותכשירי להכנתן חנקן, תהליכים

אותן המכילים רוקחות

ALIPHATIC NITROGEN-CONTAINING CYCLIC COMPOUNDS, METHODS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

]54[

05.10.2001]22[JP]33[06.10.2000]32[2000-]31[


308528JP12.10.20002000-312562JP30.03.20012001-099251

Int. Cl.8 A61K 031/395, A61P 003/10, 043/00, C07D 207/16, 277/06, 401/12, 401/14, 403/12, 403/14, 405/12, 405/14, 409/12, 409/14, 413/12, 413/14, 417/12, 417/14, 471/04, 491/048, 495/04

]51[

MITSUBISHI TANABE PHARMA CORPORATION, JAPAN

]71[




]74[

[57] An aliphatic nitrogen-containing 5-membered ring compound of the formula

whereinA represents –CH2–or –S--,R1 represents hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group or a lower alkoxy lower alkyl group, and R2 represents (1) a cyclic group which may be substituted, where the cyclic group portion

is (i) a monocyclic, bicyclic or tricyclic hydrocarbon group, or (ii) a monocyclic, bicyclic or tricyclic heterocyclic group, or (2) an amino group which may be substituted, or a pharmaceutically acceptable salt thereof.

_________

155001]21][11[

משתמש ממשק לניהול אירועים מנגנוןשרת לקוח

CLIENT SERVER USER INTERFACE EVENTS MECHANISM

]54[

19.03.2003]22[US]33[30.09.2002]32[60/415338]31[US14.02.200310/366941

Int. Cl.8 G06F 003/14, 009/44, 009/46, 009/54]51[MICROSOFT CORPORATION, U.S.A.

]71[


אביב


21 AHAD HA'AM ST ,.

]74[


P.O.B. 4060 ,TEL AVIV 61040

[57] An event mechanism within a client-server environment for keeping a client notified of changes in the user interface, the event mechanism comprising: a logical tree generation component for generating a logical tree representing a graphical user interface provided by an application, said logical tree generation component residing on the client and being configured to utilize an application programming interface (API) on the client to gather information from said application defining said graphical user interface and being further configured to filter said information to select one or more visual interface elements as interesting user interface information, wherein said logical tree representing said graphical user interface is constructed from said interesting user interface information; a registration mechanism for allowing the client to register to receive said interesting user interface information; a user interface

automation client for receiving registration information from the client and for conveying the interface information to the client upon receipt, wherein the user interface automation client uses the registration information to advise a user interface server;a user interface automation server for receiving registration information from the user interface information from a user interface engine, the user interface automation server including a filtering device for filtering out information that is uninteresting to the client and a notification device for notifying the user interface automation client of said interesting user interface information; and an assistive technology (AT) product configured to use said logical tree to generate a non-graphical representation of said graphical user interface and being further configured to convey said non-graphical representation to a user.


_________

155126]21][11[

METHOD FOR THERMAL PESTמזיקים על חומנית לבקרה שיטהCONTROL

]54[

27.03.2003]22[US]33[26.04.2002]32[132693]31[

Int. Cl.8 A01G 013/00]51[FLORENCIO LAZO BARRA, CHILE]71[


אביב



TEL AVIV 61040

]74[

[57] A method for thermal pest control in agriculture and fruit production which comprising projecting at least one stream of hot air which exits at a temperature between approximately 65oC and 250oC directly at a crop and at a minimum distance of about 0.20 m from the crop

from a vehicle which moves in a direction substantially parallel to rows of the crop so as to provide sufficient transference of heat to produce the thermal pest control without damaging the crop, wherein said at least one stream of hot air is projected at a speed between approximately 80 and 250 km per hour.

_________

155363]21][11[

מלחי או זולדרונית בחומצה שימוש בהכנת שלה הידרטים או רוקחותבכאב לטיפול תרופות

USE OF ZOLEDRONIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALTS OR HYDRATES THEREOF IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF PAIN

]54[

27.11.2001]22[GB]33[29.11.2000]32[0029111.2]31[

Int. Cl.8 A61K 031/66, A61P 019/00, 019/08, 019/10, 029/00, C07F 009/00, 009/38]51[NOVARTIS AG, SWITZERLAND]71[WO/2002/043738]87[




]74[


[57] Use of zoledronic acid or a pharmaceutically acceptable salt thereof, or any hydrate thereof, in the preparation

of a medicament for the treatment of pain wherein the medicament is to be administered once every six months.

__________

155460]21][11[

METHOD OF MANUFACTURINGמשולב למעגל מצע לייצור שיטהAN INTEGRATED CIRCUIT CARRIER

]54[

19.10.2001]22[US]33[20.10.2000]32[09/693484]31[

Int. Cl.8 H05K 003/02]51[SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[




BEER-SHEVA 84152

]74[

[57] A method of manufacturing an integrated circuit carrier, the method including the steps of: providing a substrate; demarcating at least one receiving zone for receiving an integrated circuit or chip on the substrate, the integrated circuit electrically associating with a plurality of electrical contacts within the at least one receiving zone, and a plurality of island-defining portions arranged about said at least one receiving

zone; forming an electrical terminal on island-defining portions, each electrical terminal being electrically connected to one or more of the plurality of electrical contacts within the at least one receiving zone; and creating one or more serpentine members between neighboring island-defining portions by removing material from the substrate, thereby reducing thermal strains involving the said island-defining portions.


__________

155564]21][11[

CELL UNION ASSEMBLY FORהילוכים למתג תא חיבור הרכבהELECTRIC SWITCHGEAR

]54[

24.10.2000]22[WO]33[24.10.2000]32[155564]31[

Int. Cl.8 H01R 013/64]51[ORMAZABAL Y CIA., S.A., SPAIN]71[WO/2002/035668]87[


רחובות


REHOVOT 76122

]74[

[57] An interconnection assembly for electrical switchgear cells, applicable to modular cells that incorporate parts of operation and protection equipment of electrical distribution and transformation stations, comprising an independent connector element housed in each pan, previously coupled to the cells, in correspondence with conductor terminals to be joined and permitting offsetting of misalignments between conductor terminals, the pans permitting an attachable cap when an electrical connection is not required, an electrical isolation of the terminal situated in a bottom of the cap itself being formed, providing a leakproof coupling both mechanically and electrically, of the independent connector element to the conductive terminal of the pan, the independent connector element comprising: an external mount (1) of elastic material provided internally and partially on the outside with a

semiconductor to assure good control of the electric field; a pair of metallic tubes (2) of a total length less than of the external elastic mount, arranged internally in the mount and approximately in correspondence with its outermost sectors, in order to leave a central zone of the external and elastic mount free; a metallic ring (3) and conductor housed directly in an interior of the elastic mount; and a bundle of conductive parts (5) mounted axially in respective passages provided radially in the metallic ring, the conductive ring being in correspondence with the central zone, intercalated between facing ends of the metallic tubes, and fitting tightly between the ring and the mount, the conductive parts being spaced sufficiently from the metallic tubes to permit a degree of swiveling of the bundle formed by those conductive parts in order to offset possible misalignments between the conductive terminals to be connected.


__________

155582]21][11[

SPACE-EFFICIENT TURBOשטח מבחינת יעיל טורבו מקודדDECODER

]54[

25.10.2001]22[US]33[27.10.2000]32[09/699252]31[

Int. Cl.8 H03M 013/00]51[QUALCOMM INCORPORATED, U.S.A.

]71[




REHOVOT 76122

]74[

[57] A turbo decoding circuit having a first and a second operational mode of operation, comprising:(a) a first functional loop for use in the first operational mode, the first loop including:

(1) a write interleaver (78) having an input and an output;(2) a dual port extrinsic memory (110) having an input and an output, the input


being coupled to the write interleaver output;(3) a read interleaver (106) having an input and an output, the input being coupled to the output of the dual port extrinsic memory;(4) a buffer circuit (74) having an input and an output, the input of the buffer being coupled to the output of the read interleaver; and(5) a log-MAP decoder (76) having an input and an output, the input being coupled to the output of the buffer and the output of the log-MAP decoder being coupled to the write interleaver; and

(b) a second functional loop for use in the second operational mode, the second loop including:(1) the dual port extrinsic memory;(2) the buffer circuit, the input of the buffer circuit being coupled to the output of the dual port extrinsic memory; and(3) the log-MAP decoder, the input of the log-MAP decoder being coupled to the output of the buffer circuit, and the output of the log-MAP decoder being coupled to the input to the dual port extrinsic memory.

__________

155645]21][11[

רוקחות פתאלאזינון, תכשירי נגזרותבסרטן לטיפול ושימושם אותם המכילים

PHTHALAZINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN ANTI-CANCER THERAPY

]54[

25.10.2001]22[GB]33[30.10.2000]32[0026505.8]31[US12.03.200160/275066

Int. Cl.8 A61K 031/502, A61P 035/00, C07D 237/32, 401/06, 401/10, 401/12, 403/12, 405/06, 405/12, 409/12, 409/14, 413/10, 413/12, 413/14, 417/10, 417/14

]51[

KUDOS PHARMACEUTICALS LIMITED, UNITED KINGDOMMAYBRIDGE PLC, UNITED KINGDOM

]71[

WO/2002/036576]87[



אביב



TEL AVIV 61040

]74[

[57] Use of a compound of the formula:

and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of PARP, wherein: A and B together represent an optionally

substituted, fused aromatic ring; Rc is –CH2-RL, where RL is an optionally substituted C5-20 aryl group; and RN

is hydrogen.

._________

155659]21][11[

METHOD AND APPARATUS FORחבויות דמויות להטבעת והתקן שיטהPROVIDING EMBOSSED HIDDEN IMAGES

]54[

29.04.2003]22[Int. Cl.8 B31F 001/07, B42D 015/00]51[

STARBOARD TECHNOLOGIESעיקבא בע"מ, אור טכנולוגיות סטארבורדLTD.

]71[

]RON GOLAN]72גולן רוןסורוקר-אגמון,

פיתוח , הרצליה14 שנקר נולטון, רחוב בית SOROKER-AGMON,

14 SHENKAR ST ,.HERZLIYA PITUAH 46725

]74[

[57] A method for providing a hidden image (88) within a substrate (84) the method comprising embossing recesses on

the substrate, the recesses forming an at least one hidden image, whereby the at


least one hidden image can be viewed with the use of at least one decoder.

________

155694]21][11[

מעגל של בשלבים לשלוט והתקן שיטהשלבי רב

METHOD AND APPARATUS FOR CONTROLLING STAGES OF A MULTI-STAGE CIRCUIT

]54[

31.10.2001]22[US]33[01.11.2000]32[09/703647]31[

Int. Cl.8 H03M 003/02]51[QUALCOMM INCORPORATED, U.S.A.

]71[




REHOVOT 76122

]74[

[57] A data conversion circuit comprising: a sigma-delta analog-to-digital converter (ΣΔ ADC) configured to receive an input signal and provide data samples, the ΣΔ ADC including a plurality of ΣΔ stages (1122) coupled in cascade; and a control circuit (1110) coupled to the ΣΔ ADC and configured to provide a control signal that selectively disables zero or more of the plurality of ΣΔ stages, the control circuit including one or more

detector stages (1112) configured to receive the input signal and provide a detected signal, a conditioning circuit (1114) coupled to the one or more detector stages, the conditioning circuit configured to receive the detected signal and provide conditioned samples, and a signal processor (1116) coupled to the conditioning circuit, the signal processor configured to receive the conditioned samples and provide the control signal.


________

155698]21][11[

של האבטחה לניצול ושיטה מערכת ערוץ לאבטחת מאובטח תקשורת ערוץ

לאמאובטח תקשורת

SYSTEM AND METHOD OF EXPLOITING THE SECURITY OF A SECURE COMMUNICATION CHANNEL TO SECURE A NON-SECURE COMMUNICATION CHANNEL

]54[

02.11.2001]22[US]33[03.11.2000]32[09/706117]31[

Int. Cl.8 H04L 009/00, 009/08, 009/32, 029/06]51[CITRIX SYSTEMS INC., U.S.A.]71[

WO/2002/044858]87[ושות', אליעזרי קורח בורוכוב

,58100, ת.ד. עתידים כלל מגדל תל-אביב

BOROCHOV, KORAKH, ELIEZRI & CO,.

15TH FLOOR, ATIDIM TOWER, KIRYAT ATIDIM,

P.O.B. 58100 ,TEL AVIV 61580

]74[

[57] A method for establishing a secure communication channel between a client and an application server comprising the steps of:(a) receiving, at a web server, a request from a client to have an application program executed on an application server and to have output from said application program executing on said application server transmitted to said client;

(b) generating, by a ticket service, a ticket having a identifier and a session key;(c) obtaining, by said web server, said ticket from said ticket service;(d) transmitting, by said web server, said ticket to said client over a secure communication channel;(e) transmitting, by said client, said identifier from said ticket to said application server;(f) obtaining, by said application server, a copy of said session key from said ticket service using said identifier;


(g) establishing an application communication channel between said client and said application server;(h) executing, by said application server, said application program identified in said request;(i) transmitting, by said application server, output of said application program over

said application communication channel via a remote display protocol; and(j) encrypting said output communicated to said client over said application communication channel using said session key.

_________

155943]21][11[

]MAGNETIC LOGIC ELEMENTS]54מגנטיים לוגים אלמנטים

19.11.2001]22[GB]33[17.11.2000]32[0028092.5]31[

Int. Cl.8 H03K 019/18]51[EASTGATE INVESTMENTS LIMITED, BERMUDA

]71[

RUSSEL PAUL COWBURN]72[WO/2002/041492]87[



, רמת- גן7



RAMAT GAN 52520

]74[

[57] A magnetic logic element for a logic device comprising at least one conduit capable of substaining and propagating a magnetic soliton, wherein the conduit is further adapted by the provision of nodes

and/or directional changes giving rise to discontinuities in soliton propagation energy as a result of which logical functions may be processed.

_________

155992]21][11[

פעילים חומרים של רוקחות תכשיריפה דרך למתן פרמקולוגית בצורה

PHARMACEUTICAL COMPOSITIONS FOR THE ORAL DELIVERY OF PHARMACOLOGICALLY ACTIVE AGENTS

]54[

05.12.2001]22[US]33[06.12.2000]32[60/251729]31[


Int. Cl.8 A61K 047/00, 047/16, A61P 019/08]51[NOVARTIS AG, SWITZERLAND]71[WO/2002/045754]87[




]74[

[57] A solid pharmaceutical composition suitable for the oral delivery of calcitonin comprising

(a) a therapeutically-effective amount of calcitonin;(b) a crospovidone or povidone; and(c) 5-CNAC.

__________

156053]21][11[

ריבוב ע"י דיגיטליים אותות של שידוראורטוגונלי תדרים חלוקת

TRANSMISSION OF DIGITAL SIGNALS BY ORTHOGONAL FREQUENCY DIVISION MULTIPLEXING

]54[

16.06.1998]22[US]33[19.06.1997]32[09/879297]31[

Int. Cl.8 H03M 013/15, 013/25, 013/27, 013/29, 013/45, H04J 011/00, H04L 027/26, H04N 007/24

]51[

DIVISION FROM 128579]62[QUALCOMM INCORPORATED, U.S.A.

]71[




REHOVOT 76122

]74[

[57] For a receiver receiving "n" substreams of an orthogonal frequency division multiplexed (OFDM) signal containing complex phase-adjusted symbols, each symbol representing "m" data bits, a device, comprising: for each substream, a soft decision quantizer for determining a binary value of each bit represented by each symbol in the substream, the soft decision quantizer further comprising: means for determining

a first set of possible values for each symbol, each value in the first set having a binary value of "0" in a predetermined bit; means for determining, for each symbol, a magnitude difference between the symbol and each possible value in the first set of possible values; and means for determining the smallest magnitude difference and generating a first signal representative thereof.


__________

156268]21][11[

יצירת של הטרוציקליים מעקבים על המבוססים ביטא–אמילואיד

סולפונאמיד

HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION

]54[

11.12.2001]22[US]33[13.12.2000]32[60/255105]31[

Int. Cl.7 A61K 031/341, 031/381, 031/4535, A61P 025/28, C07D 207/48, 307/64, 333, 333/34, 409/12

]51[

WYETH, U.S.A.ARQULE, INC., U.S.A.

]71[




BEER-SHEVA 84152

]74[

[57] A compound or pharmaceutically acceptable salt thereof of the formula

wherein:


R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, CF3, alkenyl, substituted alkenyl, alkynyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, phenyl, substituted phenyl, and (CH2)n(1, 3) dioxane, where n is 2 to 5; R3 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkylcycloalkyl, substituted alkylcycloalkyl, phenyl (substituted) alkyl, alkyl OH, substituted alkyl OH, alkyl OBn, substituted alkylOBn, alkylpyridyl, substituted alkylpyridyl, alkylfuranyl, substituted alkylfuranyl, CH(OH) phenyl, CH(OH) substituted phenyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, N-substituted-piperidinyl, piperidinyl, substituted piperidinyl, tetrahydrothiopyran, substituted tetrahydrothiopyran, 2-indane, substituted

2-indane, phenyl, substituted phenyl, alkyl NHR7, and substituted alkyl NHR7; with the proviso that R3 and R4 are not both hydrogen; R7 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, benzyl, substituted benzyl, alkylOH, substituted alkylOH, alkylSR8, or substituted alkylSR8; R8 is alkyl, substituted alkyl, benzyl, or substituted benzyl; or R3 and R4 may be joined to form a ring; R5 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, CH2cycloalkyl, substituted CH2cycloalkyl, benzyl, substituted benzyl, and CH2CH2QR9; Q is O, NH or S;R9 is lower alkyl, substituted lower alkyl, phenyl, or substituted phenyl; R6 is selected from the group consisting of hydrogen, halogen and CF3;T is selected from the group consisting of

W, Y and Z are independently selected from the group consisting of C, CR10 and N; R10 is selected from the group consisting of hydrogen and halogen, with the proviso that at least one of W, Y and Z must be C; X is selected from the group consisting of O, S, SO2, and NR11; R11 is selected from the group consisting

of hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, and substituted phenyl; provided that when the compound contains one or more chiral centers, at least one of the chiral centers must be of S-stereochemistry.



________


156298]21][11[

חיבור מבנה בעל משתנה הספק מדחסמתכוונן יד–ארכובה

VARIABLE CAPACITY COMPRESSOR HAVING ADJUSTABLE CRANKPIN THROW STRUCTURE

]54[

29.03.2002]22[US]33[30.03.2001]32[09/820983]31[

Int. Cl.8 F04B 049/12, F25B 001/00]51[BRISTOL COMPRESSORS, INC., U.S.A.

]71[




]74[

[57] A two stage reciprocating compressor comprising: a block with a single cylinder and associated single compression chamber and single piston; a crankshaft having an eccentric crankpin (14) the eccentric crankpin operatively connected to the piston; a reversible motor operable to rotate the crankshaft in a forward direction (270) and in a reverse direction; an eccentric cam rotatably mounted on the eccentric crankpin, the cam held stationary at a first position with respect to the crankpin when the crankshaft is rotating in the forward direction to drive the piston at a full stroke between a bottom position and a top dead centre position, the cam rotating with respect to the crankpin when the crankshaft is rotating in the reverse direction to drive the piston at a reduced stroke between an intermediate position and the top dead centre position; a connecting rod (27) operatively linking the

cam with the piston, and a first stop mechanism (250) for restricting relative rotation of the cam about the crankpin when the motor is running in the forward direction and a second stop mechanism (258) for restricting relative rotation of the cam with respect to the connecting rod when the motor is running in the reverse direction, wherein the first stop mechanism includes a mechanical member configured to selectively link the cam with the crankpin along an axis substantially parallel with an axis of the crankpin, the mechanical member comprising a pin (256) biased toward the crankshaft from the cam, configured to engage a catch in the crankshaft when the motor is running in the forward direction or a pin (264) biased toward the cam from the crankshaft, configured to engage a catch in the cam when the motor is running in the forward direction.


________

156302]21][11[

DEVICE FOR MEASURINGדם קרישת למדידת ושיטה התקןBLOOD COAGULATION AND METHOD THEREOF

]54[

19.12.2001]22[GB]33[19.12.2000]32[0030929.4]31[

Int. Cl.8 G01N 011/06]51[LIFESCAN SCOTLAND LIMITED, UNITED KINGDOM

]71[





TEL AVIV 61040

]74[

[57] A device for the measurement of clotting times of a fluid comprising an inlet port (106) for the collection of the fluid sample and at least one microchannel (102) with a lateral dimension of less than approximately 500 µm, the inlet port in fluid connection with the at least one microchannel, and at least two electrodes

(104) situated along the length of the microchannel, wherein the at least one microchannel is configured for the fluid sample to be transported therealong by capillary action and wherein the inlet port is an integrated penetration device for penetration into the skin of a user for collection of a capillary fluid sample.


________

156424]21][11[

לקביעת מבוססת–מיקום ושיטה מערכתנוכחי מזגאויר

LOCATION-BASED WEATHER NOWCAST SYSTEM AND METHOD

]54[

16.12.2001]22[US]33[15.12.2000]32[60/256149]31[

Int. Cl.8 G01W 001/02]51[]NOOLY TECHNOLOGIES LTD.]71בע"מ, הרצליה טכנולוגיות נולי

DANIEL ROSENFELD, YARONרייך רוזנפלד, ירון דניאלREICH

]72[

WO/2002/049310]87[בע"מ, ד. גרייזר ד"ר

, רעננה2496, ת.ד. DR. D. GRAESER LTD,.

P.O.B. 2496,RAANANA43650

]74[

[57] A method for providing a meteorological nowcast according to a location for a user, comprising: receiving a weather forecast request from an individual user, said request being associated with a location, determining an

area of up to about 5 kilometers in radius; and providing an updated meteorological nowcast requested by said user at intervals over a perid of less than about 60 minutes in said area.


__________

156513]21][11[

סיב קליפות ליצור ומכשיר שיטהאלקטרוספינינג ידי על פולימרי

METHOD AND APPARATUS FOR MANUFACTURING POLYMER FIBER SHELLS VIA ELECTROSPINNING

]54[

17.12.2001]22[US]33[19.12.2000]32[60/256323]31[US20.03.200160/276956US19.10.200109/982017

Int. Cl.8 B29C 041/02]51[]NICAST LTD.]71בע"מ, קיסריה נייקסט

]ELI BAR, ALEXANDER DUBSON]72דובסון בר, אלכסנדר אליWO/2002/049678]87[

( בע"מ,1995) ג'י.אי.ארליך בגין מנחם ,רחוב15 אילון, קומה מגדל

גן , רמת11



]74[

[57] An apparatus for manufacturing polymer fiber shell from liquefied polymer, the apparatus comprising:(a) a precipitation electrode (22) being for generating the polymer fiber shell thereupon;

(b) a dispenser (24), being at a first potential relative to said precipitation electrode so as to generate an electric field between said precipitation electrode and said dispenser, said dispenser being for:(i) charging the liquefied polymer thereby providing a charged liquefied polymer; and


(ii) dispensing said charged liquefied polymer in a direction of said precipitation electrode; and(c) a subsidiary electrode (26) being at a second potential relative to said

precipitation electrode, said subsidiary electrode being for reducing non-uniformities in said electric field between said precipitation electrode and said dispenser.

_________

156538]21][11[

מדפסת באמצעות גיליון לחיתוך שיטהעבורה ומדפסת מחשב

METHOD FOR CUTTING SHEET BY MEANS OF COMPUTER PRINTER AND COMPUTER PRINTER THEREFOR

]54[

19.06.2003]22[Int. Cl.8 B41J 011/68]51[

]IDAN MORADOV]71אביב מורדוב, תל עידןמורדוב, עידן

אביב , תל301 אפרים בני IDAN MORADOV,

301 BNEI EFRAIM ST.,TEL AVIV]74[

מדפסת ע"י גיליון לחיתוך שיטה [57] ו/או נוזלי דיו באמצעות הפועלת ביתית

הדיו נוזל ומילוי, החלפת ריקון צמיגי, ע"י למשל חיתוך בנוזל המדפסת במיכל מחשב בתוכנת ושימוש גופריתית חומצה וורד תמלילים מעבד כדוגמת

כביכול שהוא החיתוך איזור הגדרת לצורך גם צורך יש מסוים, לעיתים בצבע צביעה

הדיו ראש את מחדל כברירת בהגדרה

מיכל, באיזה כלומר החיתוך לשם הנדרש בעת מכך וכתוצאה תדפיס המדפסת צבע

באזור הגיליון חיתוך נגרם ההדפסה פעולת מעבד כדוגמת מחשב תוכנת ע"י מוגדר בו

הגיליון, אותו על להדפיס וורד תמלילים החותך החומר עם במגע יבוא הגיליון פעולת ע"י הצובע החומר עם במקום

האזור בכל לחיתוך יגרום ובכך המדפסת צבוע להיות אמור שהיה .

__________


156654]21][11[

]PIPE COUPLING]54צינורות מקשר

19.04.2002]22[AU]33[19.04.2001]32[PR4470]31[

Int. Cl.8 F16L 019/06, 035/00]51[PHILMAC PTY LTD., AUSTRALIA]71[WO/2002/086371]87[


אביב



TEL AVIV 61040

]74[

[57] A coupling (10) for connection of a polymeric pipe (2), said coupling including; a hollow body (20) having an external thread (28) extending at least in part therealong and having an inner surface (42); a nut (14) threadably engaging said body external threads (26), said nut having at one end an internal thread co-operable with said body external thread and including a hooked projection (36) adapted to extend over at least part of said body inner surface, said projection including a first inner surface (40) generally parallel to said body inner surface, a second outwardly converging surface (46) extending from the inner edge of said inner

surface; a deformable gripping member (16) having a first surface generally parallel to said body inner surface and having a second outwardly converging outer surface (48) extending from said first surface, said member including radially inward barbs; wherein upon tightening of said nut, said nut second surface abuts against and exerts a force on said gripping members second surface both in the longitudinal and radial directions to thereby cause the gripping member to be urged both radially and longitudinally into the body, said nut first surface sliding alongside said body first surface.


_________

156790]21][11[

גוף חלקי על להגנה למינציה חומרהלמינציה את המכיל ומתקן

LAMINATE MATERIAL FOR THE PROTECTION OF BODY PARTS AND DEVICE COMPRISING SUCH LAMINATE

]54[

22.02.2002]22[NL]33[22.02.2001]32[1017432]31[

Int. Cl.8 A41D 031/02, B23B 005/22]51[VERENIGDE BEDRIJVEN NIMCO B.V., THE NETHERLANDS

]71[

J.A.W. KROL, L.J.M. VAN DER MIJN]72[WO/2002/066187]87[


, הרצליה12704



]74[

[57] Laminate material, comprising an upper layer (I) and a lower layer (II) which is joined to the upper layer over substantially the entire surface thereof, the upper layer comprising a thin layer with a thickness of between 0.2 and 1.0 mm of leather material (1), and the lower layer comprising a layer of material which can

be stretched in two directions, characterized in that the lower layer comprises at least one support layer (3) which can be stretched in two directions and comprises at least two sorts of interwoven fibres, at least one type of fibres being produced from an elastic substance, as well as a layer (5) of a


compressible substance that has been joined to the support layer over substantially the entire surface thereof and can be compressed in three mutually

perpendicular directions, wherein the compressible substance comprises substantially open-cell, cured plastic foam.

________

156831]21][11[

חודרני גלאוקומה לניתוח מכשירמזעריות

MINIMALLY INVASIVE GLAUCOMA SURGICAL INSTRUMENT

]54[

17.01.2002]22[US]33[18.01.2001]32[60/263617]31[

Int. Cl.8 A61B 018/18, A61F 009/007]51[THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, U.S.A.

]71[




REHOVOT 76122

]74[

[57] A device for treating glaucoma, said device comprising: an elongate probe (700); a bipolar electrode (730) that is useable to form an opening in the trabecular meshwork such that fluid may drain through said opening into Schlemm's canal; and a protector configured to be advanced into Schlemm's canal, said

protector being configured and positioned in relation to the bipolar electrode such that the protector will substantially protect cells lining the scleral wall of Schlemm's cana from being substantially damaged by energy that emanates from the bipolar electrode.




_________

156995]21][11[

DESIGN FOR FRAMELESSמסגרת ללא מחסנית עם למנועים תכנוןCARTRIDGE MOTORS

]54[

04.02.2002]22[US]33[05.02.2001]32[60/266557]31[

Int. Cl.8 H02K 005/12]51[KOLLMORGEN CORPORATION, U.S.A.

]71[




REHOVOT 76122

]74[

[57] A cartridge motor comprising: a housing (10); a stator (18) affixed to the housing; a rotor (40) sharing a common central axis with stator; a shaft running through the rotor along the common central axis (20); a fastener for locking the rotor to the housing during shipment, and thereby maintaining an appropriate gap between the rotor and the stator; a flexible member connected to the shaft; a feedback device stator mounted on the cartridge

motor such that it is stationary relative to the rotor; a feedback device rotor connected to the flexible member, whereby the flexible member allows axial and radial adjustments between the shaft and the feedback device rotor while maintaining rotational alignment; and a feedback bearing providing rotational support between the feedback device rotor and the feedback device stator.


_________

157282]21][11[

התרבות לעיכוב פירימידין נגזרותהתאים

PYRIMIDINE DERIVATIVES FOR INHIBITION OF CELL-PROLIFERATION

]54[

12.02.2002]22[GB]33[17.02.2001]32[0103926.2]31[

Int. Cl.8 A61K 031/5025, A61P 035/00, C07D 487/04]51[ASTRAZENECA AB, SWEDEN]71[ANDREW PETER THOMAS]72[WO/2002/066481]87[

ושות', ש. הורוביץ , תל41-45 רוטשילד ציון, שדרות בית

אביב



]74[


wherein:ring A is a group of the formula


wherein one or more of X1, X2, X3 and X4 are nitrogen and the others are CR5 wherein the values of R5 may be the same or different; R1 is halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 alkanoyl, N-(C1-6 alkyl) amino, N,N-(C1-6 alkyl)2 amino, C1-6 alkanoylamino, N-(C1-6 alkyl) carbamoyl, N,N-(C1-6 alkyl)2 carbamoyl, C1-6 alkylS(O)a wherein a is 0 to 2, N-(C1-6 alkyl) sukphamoyl or N, N-(C1-6 alkyl)2 sukphamoyl; wherein R1 may be optionally substituted on carbon by one or more R6; R2 and R5 are independently of one other selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 alkanoyl, C1-6 alkanoyloxy, N-( C1-6 alkyl) amino, N,N-(C1-6 alkyl) amino, N,N-(C1-6 alkyl)2 amino, C1-6 alkanoylamino, N-(C1-6 alkyl) carbamoyl, N,N-(C1-6 alkyl)2 carbamoyl, C1-6 alkylS(O)a wherein a is 0 to 2, C1-6 alkoxycarbonyl, N-(C1-6 alkyl) sukphamoyl, N,N-(C1-6 alkyl)2 sulphamoyl, phenyl, heterocyclic group, phenylthio or (heterocyclic group) thio; wherein any R2

or R5 may be optionally substituted on carbon by one or more R7; and wherein if said heterocyclic group contains an –NH-moiety that nitrogen may be optionally substituted by a group selected from R8;n is 0 to 2, wherein the values of R1 may be the same or different;R3 is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C2-6 alkenyl or C2-6 alkynyl; p is 0-4; wherein the values of R3 may be the same or different;R4 is a group A-E-; whereinA is selected from C1-6 alkyl, phenyl, a heterocyclic group, C3-8 cycloalkyl, phenyl C1-6 alkyl, (heterocylic group) C1-6 alkyl or

C3-8 cycloalkyl C1-6 alkyl; wherein A may be optionally substituted on carbon by one or more R9; and wherein if said heterocyclic group contains an –NH-moiety that nitrogen may be optionally substituted by a group selected from R10;E is a direct bond or –O-, -C(O)-, -OC(O)-, -C(O)O-, -N(Ra)C(O)-,-C(O)N(Ra)-,-N(Ra)-, -S(O)a-, -SO2N(Ra)-or –N(Ra)SO2-; wherein Ra is hydrogen or C1-6 alkyl optionally substituted by one or more R11 and a is 0-2;R9 is independently selected from oxo, halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6 alkyl, C2-6 alkenyl, C2-6

alkynyl, C1-6 alkoxy, C1-6 alkanoyl, C1-6 alkanoyloxy, N-(C1-6 alkyl) amino,N-N-(C1-6 alkyl)2 amino, C1-6 alkanoylamino, N-(C1-6 alkyl) carbamoyl,N, N-(C1-6 alkyl)2 carbamoyl, C1-6 alkylS(O)a wherein a is 0 to 2, C1-6

alkoxycarbonyl, C1-6 alkoxycarbonylamino, benzyloxycarbonylamino, N-(C1-6 alkyl) sulphamoyl and N,N-(C1-6 alkyl)2 sulphamoyl; wherein R9 may be optionally substituted on carbon by one or more R12; q is 0-2; wherein the values of R4 may be the same or different; and wherein p+q≤5; R6, R7, R11 and R12 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-


diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; and R8 and R10 are independently selected from C1-4 alkyl, C1-4

alkanoyl, C1-4 alkylsulphonyl, C1-4 alkoxycarbonyl, carbamoyl, N-(C1-4 alkyl) carbamoyl, N-(C1-4 alkyl) carbamoyl, N,N-

(C1-4 alkyl) carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.

_________

157319]21][11[

CATHETER AND METHOD FORפורקיניה סיבי למיפוי ושיטה קטטרMAPPING PURKINJE FIBERS

]54[

10.08.2003]22[US]33[30.08.2002]32[10/231857]31[

Int. Cl.8 A61B 005/042, A61M 025/00]51[BIOSENSE WEBSTER, INC., U.S.A.]71[

ושות', כהן שלמה ד"ראביב , תל11490 , ת.ד. 124 גבירול אבן

DR. SHLOMO COHEN & CO,. 124 IBN GABIROL ST,.

P.O.B. 11490 ,TEL AVIV 62038

]74[

[57] A catheter comprising: an elongated catheter body (12) having a proximal end, a distal end and at least one lumen extending longitudinally therethrough; a mapping assembly (18) mounted at the distal end of the catheter body and comprising at least two spines (14), each spine having a proximal end attached at the

distal end of the catheter body and a free distal end, wherein each spine comprises at least one electrode (20); and an irrigation tube extending through the catheter body and having an open distal end that is in communication with the outside of the distal end of the catheter body.

________


157499]21][11[

IDLER ROLLER FORתובלה מסוע עבור סרק גלגלTRANSPORT CONVEYOR

]54[

05.03.2002]22[US]33[20.03.2001]32[812599]31[

Int. Cl.8 B65G 039/09, F16C 013/02]51[FMC TECHNOLOGIES INC., U.S.A.]71[





TEL AVIV 61040

]74[

[57] An idler roller (10) for a transport conveyor, comprising: a cylindrical roller shell (12) having opposite open ends; a pair of roller heads (14), each of which is fitted to a respective end of said roller shell; a pair of bearing assemblies, each of which is fitted in a respective roller head and each of which comprises a pair of roller bearings (26, 28); and a pair of stub shafts (24), each of which is fitted in a respective bearing assembly; wherein each

of said roller heads comprises an outer support surface (18) which is telescopically received within a respective open end of said roller shell, an inner bearing cavity (20) within which the respective one of said bearing assemblies is fitted, and a plurality of radially oriented reinforcing webs (22) which extend between said outer support surface and said inner bearing cavity.

_________


157522]21][11[

PARTIAL DENTIN CARIESבשיניים לחורים חלקי חופרEXCAVATOR

]54[

20.02.2002]22[US]33[23.02.2001]32[792711]31[

Int. Cl.8 A61C 001/00]51[TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, U.S.A.

]71[





TEL AVIV 61040

]74[

[57] A dental bur (210) for use in removing all or a portion of carious dentin and, optionally, a portion but not all of pre-carious dentin from teeth, said bur having a working surface including cutting elements (220) said cutting elements being

adapted to deflect, deform, or abrade upon encountering material having a preselected hardness in the range of about 1 KHN to abut 40 KHN, wherein said preselected hardness is less than the lower limit of hardness of normal dentin.

_________


157569]21][11[

יבשים חלקיקים תרסיס להכנת שיטהלשאיפה המתאימים

METHOD OF PRODUCING SPRAY DRIED PARTICLES SUITABLE FOR INHALATION

]54[

17.04.2002]22[US]33[18.04.2001]32[09/837620]31[

Int. Cl.8 A61K 009/00, 009/16]51[THE PENN STATE RESEARCH FOUNDATION, U.S.A.

ADVANCED INHALATION RESEARCH INC., U.S.A.

]71[




BEER-SHEVA 84152

]74[

[57] A method of producing spray dried particles suitable for inhalation comprising:(a) selecting a dew point between about 0o C and – 40oC of a nitrogen drying gas corresponding to a targeted median geometric diameter, targeted median aerodynamic diameter of less than about 5 microns and a targeted tap density of particles formed by contacting a sprayed liquid feed with the drying gas;

(b) generating a nitrogen drying gas having said selected dew point; and(c) contacting the sprayed liquid feed with the nitrogen drying gas having said selected dew point thereby producing particles having the targeted median aerodynamic diameter, targeted tap density and targeted median geometric diameter, wherein said particles are suitable for inhalation.

_________

157604]21][11[

DRIVE MECHANISM FOR ANהזרקה למכשיר הנעה מנגנוןINJECTION DEVICE

]54[

26.03.2002]22[GB]33[27.03.2001]32[0107604.1]31[

Int. Cl.8 A61M 005/00]51[DCA DESIGN INTERNATIONAL LIMITED, UNITED KINGDOM

]71[




REHOVOT 76122

]74[


[57] A drive mechanism for an injection device in which a piston is successively moved in relation to a first end of a medicament cartridge containing a medicament selectively to drive a bung closing a first end of the medicament cartridge into the medicament cartridge to expel medicament through a delivery member located at a second end of the

medicament cartridge, in which the drive mechanism further comprises a displaceable dosing spindle, a dial dose means, a transmission means (10), and cable means (12), the piston comprising a plurality of nested piston members, displacement of the transmission means causing the cable means to move at least one of the plurality of the nested piston members to drive the bung.

__________

157722]21][11[

מכות בפני העמיד קל–משקל שריון בליעה יכולת ובעל ונשנות חוזרות

אנרגיה של משופרת

LIGHTWEIGHT ARMOR WITH REPEAT HIT AND HIGH ENERGY ABSORPTION CAPABILITIES

]54[

15.03.2002]22[US]33[15.03.2001]32[09/809548]31[

Int. Cl.8 F41H 005/04]51[ATI PROPERTIES, INC., U.S.A.]71[





TEL AVIV 61040

]74[

[57] A ballistic armor capable of withstanding penetration by a projectile impacting the armor, the ballistic armor comprising: a first energy absorbing plate (20) consisting essentially of a metallic material said metallic material being at least one of a metallic material that undergoes a reversible phase change upon absorbing energy and a metallic material that exhibits an elastic strain deformation of at least 5%; and a second plate (30) of a metallic material that is contiguous with

and metallurgically bonded to the first energy absorbing plate, wherein said second plate comprises a material selected from the group consisting of an alpha titanium alloy is at least one of grades 1- 4 CPTi, an alpha beta titanium alloy that is Ti(6-4), and a beta titanium alloy that is at least one of Ti(10-2-3) or Ti(15-3-3-3): and the metallic material of said second plate is different from said metallic material of said first energy absorbing plate.


_________

157855]21][11[

סיגנל של יעיל לייצוג ושיטה מכשירלאנאליזה מחזורי וכמעט מחזורי

APPARATUS AND METHOD FOR EFFICIENT REPRESENTATION OF PERIODIC AND NEARLY PERIODIC SIGNALS FOR ANALYSIS

]54[

19.03.2002]22[US]33[19.03.2001]32[60/276481]31[

Int. Cl.8 A61B 005/0402, 005/0452, G06F 017/00, 017/14]51[ בע"מ, תל ביולוגיים אותות בי.אס.פי. עיבוד

אביבB.S.P. BIOLOGICAL SIGNAL PROCESSING LTD.

]71[

,ASSAF HASSON, AMIR BEKERדוד בן בקר, תמיר חסון, אמיר אסףTAMIR BEN DAVID

]72[

WO/2002/075584]87[( בע"מ,1995) ג'י.אי.ארליך




]74[

[57] Apparatus for graphically representing a substantially periodic signal having substantially periodic segments, the apparatus comprising: a graphic encoder for converting said periodic segments into encodings respectively of properties thereof for arrangement in a single first dimension, and an indexer, associated with

said graphic encoder, for successively indexing said encodings to show a succession of said segments over a second dimension, thereby to represent, within said two dimensions, dynamic changes of said properties of said periodic segments over said signal.


_________

157865]21][11[

יחידתי במגבר המשתמש אופטי מגברפעיל באופן

ACTIVE DOPED UNITARY OPTICAL AMPLIFIER

]54[

13.03.2002]22[US]33[13.03.2001]32[09/804813]31[

Int. Cl.8 G01S 007/40, H01S 003/063, 003/10]51[TEXTRON SYSTEMS CORPORATION, U.S.A.

]71[




REHOVOT 76122

]74[

[57] An optical amplifier for amplifying a plurality of input photons, each of the

plurality of input photons having a spatial orientation and phase, the optical amplifier


comprising: imaging optics optically coupled to the plurality of input photons, the imaging optics operative to provide an image of the input photons; a pump source for providing a pump signal; and a unitary optically transparent solid geometric glass chip, having at least a portion being homogeneously doped with rare earth ions to be optically active, the homogeneously doped portion of the unitary optically transparent solid geometric glass chip being coupled to the pump signal provided by the pump source, the homogeneously doped portion of the unitary optically transparent solid geometric glass chip being further optically coupled to the imaging optics and receiving therefrom the image of the plurality of input photons,

wherein at least one of the plurality of input photons generates a corresponding one or more generated photons within the homogeneously doped portion, wherein the one or more generated photons has substantially the same spatial orientation and phase as the corresponding at least one input photon, the homogeneously doped portion of the unitary optically transparent solid geometric glass chip being configured and arranged to provide output photons comprising input photons and generated photons, the output photons being greater in number than the plurality of input photons, the output photons having substantially the same spatial orientation and phase as a corresponding input photon..

________

157937]21][11[

Dהמקודד גרעין –הידאנטואינז, חומצת חומצת המכילים הבעה אותו, וקטורי

המבטאים פונדקאים ותאים זו גרעיןאותו

D-HYDANTOINASE, NUCLEIC ACID ENCODING THE SAME, EXPRESSION VECTORS INCLUDING SAID NUCLEIC ACID AND HOST CELLS EXPRESSING THE SAME

]54[

16.09.2003]22[US]33[03.04.2001]32[60/281150]31[

Int. Cl.8 C12N 005/10, 009/14, 009/86, 015/55, C12P 013/04]51[BRISTOL-MYERS SQUIBB COMPANY, U.S.A.

]71[




]74[

[57] An isolated nucleic acid molecule comprising a sequence that encodes a D-

hydantoinase polypeptide comprising the amino acid sequence of SEQ ID NO:2.

________


157985]21][11[

קו דרך משודר אות לניתוח והתקן שיטהתקשורת

METHOD AND DEVICE OF ANALYZING A SIGNAL TRANSMITTED VIA A COMMUNICATION LINK

]54[

18.09.2003]22[Int. Cl.8 H04B 010/08, H04J 014/02, H04L 001/20]51[

]ECI TELECOM LTD.]71תקוה בע"מ, פתח אי.סי.איי. טלקוםבע"מ, אי. סי. איי. טלקום

תקוה , פתח30הסיבים רחוב ECI TELECOM LTD,.

30 HASIVIM ST,.PETACH TIKVA 49517

]74[

[57] A method for estimating one or more characteristics of a main signal transmitted via a communication link, wherein said main signal is composed from one or more component signals possibly comprising respective data signals and transmitted via one or more respective communication channels, the method comprising: providing an analyzing circuit independent from said communication link, transmitting a probe data signal in the analyzing circuit, monitoring a bit error

rate BER parameter associated with the probe data signal; introducing into said analyzing circuit at least a portion of energy of the main signal, derived from a particular point of said communication link, as an interfering signal; judging about said one or more characteristics of the main signal at said particular point of the communication link, based at least on changes in the monitored BER parameter of the probe data signal.

________


158202]21][11[

ARIPIPRAZOLE ORALפומי למתן אריפיראזול תמיסתSOLUTION

]54[

24.04.2002]22[US]33[25.04.2001]32[60/286718]31[

Int. Cl.8 A61K 031/00, 031/496, C07D 401/12]51[BRISTOL-MYERS SQUIBB COMPANY, U.S.A.

]71[





TEL AVIV 61040

]74[

[57] A pharmaceutical solution suitable for oral administration comprising aripiprazole, a pharmaceutically suitable solvent system comprised of one or more agents selected from the group consisting of water, ethanol, glycerin, propylene

glycol and sorbitol, one or more taste-enhancing/masking agents and one or more other agents selected from the group consisting of lactic acid, tartaric acid and cirtric acid, wherein said solution has a pH from 2.5 to 4.0.

________

158244]21][11[

מואץ בגידול המאופיינים צמחים שימושיים גרעין חומצות ומבני ושיטות

ליצירתם

PLANTS CHARACTERIZED BY ENHANCED GROWTH AND METHODS AND NUCLEIC ACID CONSTRUCTS USEFUL FOR GENERATING SAME

]54[

26.03.2002]22[US]33[09.04.2001]32[09/828173]31[

Int. Cl.8 A01H 005/00, C07K 014/195, 014/705, C12N 015/31, 015/82]51[ של המחקר לפיתוח חברה יישום

בירושלים, ירושלים העברית האוניברסיטהYISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM

]71[

א. קפלן, ג'. ליימן-הורוביץ, ד. שץ, ר.מיטלר, ש. רחמילביץ

A. KAPLAN, J. LEIMAN-HURWITZ, D. SCHATZ, R. MITTLER, S. RACHMILEVITCH

]72[

WO/2002/081622]87[( בע"מ,1995) ג'י.אי.ארליך



]74[



[57] A method of enhancing growth and/or commercial yield of a plant grown under conditions selected from the group consisting of low humidity, low CO2 concentration and water stress, the method comprising expressing within the plant a

polypeptide including an amino acid sequence at least 65% identical to that set forth in SEQ ID NOs: 3, 5, 6 or 7, wherein said polypeptide is capable of enhancing photosynthesis in said plant under said growth conditions.

________

158414]21][11[

]EXPANSION RING ASSEMBLY]54מרחיבה טבעתית הרכבה

14.10.2003]22[US]33[25.10.2002]32[10/280917]31[

Int. Cl.8 F16L 017/00, 033/213]51[PRESS-SEAL GASKET CORPORATION, U.S.A.

]71[



P.O.B. 11490 ,TEL AVIV 62038

]74[

[57] A expansion ring assembly (20) for sealing a gasket (26) to an annular wall (22), said assembly comprising: a ring (36) defining a pair of end portions (28, 30); and a drive mechanism (38) disposed substantially within said ring, comprising: a pair of block members (58) each having a threaded bore (62) therethrough, said block members removably engaged with

respective end portions of said ring; and a bolt (60) including oppositely-threaded ends (70a, 70b) respectively threaded within said bores of said block members, wherein rotation of said bolt in a first direction causes said block members to be simultaneously driven apart from one another to thereby expand said ring.


_________

158432]21][11[

אנדופיתיות פטריות לקבלת שיטהלשימושן ושיטות חדשות

METHOD FOR OBTAINING NOVEL ENDOPHYTIC FUNGI AND METHODS OF USE

]54[

11.04.2002]22[US]33[16.04.2001]32[60/283902]31[US11.03.200260/363072

Int. Cl.8 A01N 003/02, 025/00, 063/04]51[GARY A. STROBEL, U.S.A.]71[

DENISE CAROL MANKER, JULIEN MERCIER

]72[





JERUSALEM 91450

]74[

[57] A method for obtaining novel Muscodor fungi comprising contacting an effective amount of the fungi to be screened with volatiles of Muscodor albus or Muscodor roseus under culturing

conditions, selecting fungi resistant to the volatiles of the Muscodor albus or Muscodor roseus, and identifying a novel Muscodor fungus.

________

158498]21][11[

ADJUSTABLE DEBURRINGגרדים להסרת מתכוונן כליTOOL

]54[

20.10.2003]22[Int. Cl.8 B23B 029/034]51[

]ISCAR LTD.]71בע"מ, תפן ישקר]GIL HECHT]72הכט גיל

בע"מ, ישקר, תפן11, ת.ד.

ISCAR LTD,. P.O.B. 11,

TEFEN 24959

]74[

[57] An adjustable deburring tool having a longitudinal axis of rotation and comprising a cutting head (12) adjustably coupled to a shank (14), the cutting head

having an insert pocket in which a cutting insert is retained; the cutting head having a front face (24) and a rear face (26) with a ridge (28) projecting from the rear face,


the ridge having a recessed portion (30); the shank having a groove (34) communicating with an open ended and open sided threaded adjusting bore (36), the ridge being slidably located in the

groove with an adjusting screw screw-threaded in the threaded adjusting bore and partially located in the recessed portion of the ridge.

__________

158848]21][11[

METHOD AND ASSEMBLY FORהשיער נפח להגדלת ומרכב שיטהINCREASING HAIR VOLUME

]54[

21.02.2002]22[IT]33[07.06.2001]32[RM2001A000317]31[

Int. Cl.8 A41G 003/00]51[INDORATA SERVICOS E GESTAO LDA., PORTUGAL

]71[




REHOVOT 76122

]74[

[57] A method for increasing hair volume or length, comprising the following steps: providing a plurality of extensions (C) comprising several hairs (3), which are connected by a fixing element (13), said

extensions being aligned and basically in parallel with their fixing elements located on a support tape (11) having an adhesive face; adhering the adhesive face of the support tape to head hair and positioning the extensions; connecting the extensions


with the head hair attaching the fixing elements to it.

_________

158931]21][11[

]VACCINE COMPOSITION]54חיסון תכשיר

29.05.2002]22[GB]33[30.05.2001]32[0113083.0]31[GB21.02.20020204116.8

Int. Cl.8 A61K 039/00, 039/145, A61P 031/16, C07K 014/11, C12N 007/04]51[SAECHISCHES SERUNWERK DRESDEN BRANCH OF SMITHKLINE BEECHAM PHARMA GMBH & CO. KG, GERMANY

]71[





TEL AVIV 61040

]74[

[57] An inactivated influenza virus preparation comprising a haemagglutinin antigen stabilized in the absence of thiomersal, or at low levels of thiomersal, wherein the haemagglutinin is detectable by

a SRD assay, and wherein the preparation comprising α-tocopherol succinate in a sufficient amount to stabilize the haemagglutinin antigen.




_________

158939]21][11[

ניידיםIP לצמתי ומערכת שיטההטרוגניות ברשתות

METHOD AND SYSTEM FOR MOBILE IP NODES IN HETEROGENEOUS NETWORKS

]54[

12.06.2002]22[EP]33[18.06.2001]32[01810594.

0]31[

Int. Cl.8 H04L 012/28, 012/46, 012/58, 029/06, H04Q 007/22, 007/38]51[SWISSCOM MOBILE AG, SWITZERLAND

]71[




REHOVOT 76122

]74[

[57] A method for mobile IP nodes (10) in heterogeneous networks (21-24), in which a home agent dynamically assigns a temporary IP care-of address to a static IP home address when the mobile node is moved in the heterogeneous networks, the dynamic care-of address indicating the topologically current network location of the mobile node and IP data packets having the IP home address of the mobile node as destination address being redirected to the care-of address of the mobile node, wherein an interface administration module (134) of the mobile node checks the mobile node for available physical network interfaces (14-17), draws up a lookup table with the available and configurable physical network interfaces,

and links itself to one of the available physical network interfaces, one or more IP applications (11) of the mobile node access the heterogeneous networks via a virtual IP network interface (133) generated in the mobile node, the generated permanent virtual IP network interface comprising a generated virtual L3 layer and a generated virtual L2 layer and being linked to the current network via the interface administration module (134), and during a change of the physical network interface (14-17) of the mobile node, the link of the permanent virtual IP network interface to the network is updated based on the lookup table by means of the interface administration module.


_________

158950]21][11[

שיכפול רבי באימונוגלובולינים שימושחיסון להכנת

USE OF POLYCLONAL IMMUNOGLOBULINS FOR PRODUCING A VACCINE

]54[

19.03.2002]22[AT]33[01.06.2001]32[A860/2001]31[

Int. Cl.8 A61K 039/395, A61P 031/04, 031/10, 031/12, 035/00, 037/04, 037/08]51[IGENEON KREBS-IMMUNTHERAPIE FORSCHUNGS-UND ENTWICKLUNGS AG, AUSTRIA

]71[





TEL AVIV 61040

]74[

[57] The use of a polyclonal immunoglobulin preparation for producing a vaccine formulation, containing antibodies of different specificities, for

immunising individuals of the same species from which the immunoglobulins have been derived.


_________

159366]21][11[

DEVICE AND METHOD FORבגוף אנטומי חלל לאיתור ושיטה התקןLOCATING AN ANATOMICAL CAVITY IN A BODY

]54[

20.06.2002]22[NL]33[20.06.2001]32[1018334]31[

Int. Cl.8 A61B 017/34]51[TIMOTHEUS JOAN MARIE LECHNER, THE NETHERLANDSJAN VAN NIEKERK, THE NETHERLANDSLEONARDUS JOHANNES MARIA TEUNISSEN, THE NETHERLANDSMAARTEN GERARDUS FRANCISCUS VAN WIJK, THE NETHERLANDSMARINUS ADRIAAN DROST, THE NETHERLANDSFRANKLIN ROBERT CHRISTIAAN VAN DORSTEN, THE NETHERLANDSCHRISTIANUS JACOBUS MARIA LANGENBERG, THE NETHERLANDSADRIANUS JACOBUS JOHANNES MAAS, THE NETHERLANDS

]71[

WO/2003/000146]87[ושות', גבריאלי זליגסון

אביב , תל1426 , ת.ד. 31 רח' יבנה SELIGSOHN GABRIELI & CO,.

31 YAVNE ST,.P.O.B. 1426 ,

TEL AVIV 61013

]74[

[57] Device for locating a region (15) which is situated in a body (10), comprising: a hollow needle (20); a fluid-filled reservoir (30) which is in communication with the needle; pump means for pressurizing the fluid; measuring means (40) for creating a pressure-measurement signal which is related to the pressure prevailing in the fluid; signal-conversion means (50) for converting the pressure-measurement

signal created by the measuring means into a form which is suitable for further processing, and reproduction means (60, 70) for emitting an acoustic signal which is related to the pressure-measurement signal which has been converted by the signal-conversion means, characterized in that the reproduction means is designed to emit the acoustic signal which is continuously representative of the pressure prevailing in the fluid.


_________

159592]21][11[

CLOSURE DEVICE WITH Aניקוב אלמנט עם סגירה התקןPIERCING ELEMENT

]54[

10.06.2002]22[CH]33[27.06.2001]32[1182/01]31[

Int. Cl.8 B65D 005/74]51[BERICAP HOLDING GMBH]71[WERNER FRITZ DUBACH]72[WO/2003/002419]87[


ירושלים



JERUSALEM 91450

]74[

[57] A closure device of plastic which may be attached via a piercable location of a closed receptacle (B) and which consists of a bung-like lower part (2) with a cylindrical pour-out spout which is connected or connectable to the receptacle, and of a screw cap (4) which may be screwed onto the lower part as well as of a cylindrical piercing element (3) which in the axial direction is open on both sides and which is displaceably mounted in the lower part, wherein in the screw cap there are present means (44) which during the screwing-off movement of the screw cap

for the first time move the piercing element helically downwards, characterised in that the piercing element is equipped with at least two cutting elements (33) which are arranged running after one another by an offset angle (α) of less than 180o and more than 100o so that after a rotation of the piercing element by the offset angle a continuous cutting line of 2α has arisen, and that now a displacing element (34, 35, 38) acts in the non-separated region, which pushes the partly cut-out lobe [tab] of the receptable out of the region of the pour-out spout.


_________

159647]21][11[

של פעילות מדכאות הינן אשר תרכובות NA+/CA²+ מיכנזים החלפת

בהפרעות בטיפול ושימושיות

COMPOUNDS WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS

]54[

10.07.2002]22[FI]33[10.07.2001]32[20011507]31[

Int. Cl.8 A61K 031/085, 031/353, 031/44, 031/4433, 031/4439, A61P 009/06, 009/10, C07C 217/14, 217/54, 217/90, C07D 213/64, 311/00, 311/28, 311/58, 311/60, 405/12, 405/14, 411/12

]51[

ORION CORPORATION, FINLAND]71[WO/2003/006452]87[



P.O.B. 6451 ,TEL AVIV 61063

]74[

[57] Use of a compound of the formula


whereinX is –O-, -CH2- or –C(O)-;Z is –CHR9- or valence bond;Y is –CH2-, C(O)-, CH(OR10)-, CH(NR11R12)-, -O-, -S- -S(O)- or –S(O2)- provided that in case Z is a valence bond,

Y is not C(O); the dashed line represents an optional double bond in which case Z is –CR9-and Y is –CH-, C(OR10)- or –C(NR11R12)-; R1 is –(CH2)nNR4R7 or one of the following groups:

n is 1-4,R2 and R3 are independently H, C1-7 alkyl, C1-7 alkoxy, -NO2, halogen, -CF3, -OH, -NHR8 or –COOH, R4 and R7 are

independently H, C1-7 alkyl or C1-7 hydroxyalkyl,R5 is H, C1-7 alkoxy, -CF3, NH2 or –CN, R6 is –NO2, -NR14R19, -CF3 or

R8 and R16 are independently H, alkylcarbonyl or alkenylcarbonyl;R9 is H or C1-7 alkyl;R10 is H, alkylsulfonyl, alkylcarbonyl or alkenylcarbonyl;R11 and R12 are independently H, C1-7 alkyl, alkylcarbonyl or alkenycarbonyl;R13 and R18 are independently H or –OR20,R14 and R19 are independently H, alkylcarbonyl, alkenylcarbonyl,

alkylsulfonyl, C(S)NHR17 or C(O)NHR17, R15 is H or NH2, R17 is H or C1-7 alkyl,R20 is H, alkylcarbonyl or alkenylcarbonyl, and pharmaceutically acceptable salts and esters thereof; in the manufacture of a medicament for inhibiting Na+/Ca2+

exchange mechanism in a cell or for the treatment of arrhythmias.

_________


159691]21][11[

ורוח ים גלי אנרגית להמרת ומתקן שיטהחשמלית לאנרגיה

METHOD AND APPARATUS FOR CONVERTING SEA WAVES AND WIND ENERGY INTO ELECTRICAL ENERGY

]54[

01.01.2004]22[Int. Cl.8 B63H 001/34, F03B 013/00, 013/12]51[

]HAIM MORGENSTEIN]71אריה מורגנשטיין, בית חייםלוצאטו, את לוצאטו



BEER-SHEVA 84152

]74[

[57] Energy converter, which comprises:(a) a buoy (105), substantially floating on the surface of the water and substantially maintained in a fixed horizontal position;(b) a water impervious outer sleeve (101) pivotally connected to said buoy such that most of said outer sleeve is submerged in the water, said outer sleeve comprising:(i) a cylindrical inner surface;(ii) a first wing (102) rigidly affixed to said outer sleeve, wherein in a rest position, said first wing floats essentially horizontally on the surface of the water, and is disposed at a wave side of said outer sleeve; and,(iii) a sleeve weight attached to the bottom of said inner surface, for assuring said first wing is returned to said rest position following rotation of said outer sleeve; and,(c) a generator, housed within said sleeve in a longitudinal manner, said generator

comprising magnetic field generation (MFG) means and a rotor, wherein:(i) said MFG means, or, alternatively, said rotor, is a stationary component that is maintained essentially in a fixed position with respect to said buoy;(ii) said rotor, or, alternatively, said MFG means, is a rotatable component that has an axis of rotation coinciding with the longitudinal axis of said stationary component, and wherein said rotatable component is angularly displaced by said sleeve, relative to said stationary component, in coordination with said first wing being angularly displaced by waves impacting upon said first wing, wherein said relative angular displacement generates electrical power; and(iii) on the shore side, a lower surface of said buoy is shaped to repel water flowing back from the shore.


_________

160109]21][11[

TOPICAL PHARMACEUTICALמקומי לטיפול תרופתי תכשירFORMULATION

]54[

23.07.2002]22[US]33[24.07.2001]32[60/307548]31[

Int. Cl.8 A61K 047/00, 047/02, 047/44, A61P 017/02]51[ADVANCED BIOTECHNOLOGIES, U.S.A.

]71[




REHOVOT 76122

]74[

[57] A wound dressing comprising a composition including a non-volatile

silicone fluid in admixture with fumed silica and an antibacterial active agent.

_________


160259]21][11[

PRINTING CARTRIDGE WITHקיבולי חיישן זיהוי עם הדפסה מחסניתCAPACITIVE SENSOR IDENTIFICATION

]54[

06.08.2002]22[US]33[06.08.2001]32[09/922112]31[

Int. Cl.8 B41J 002/175]51[SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[




BEER-SHEVA 84152

]74[

[57] A printing cartridge (1230) comprising: a housing (1231); and an actuating formation (1238) that is positioned on the housing and is capable of actuating a number of capacitive sensors in an array (1232) of such sensors, the

actuating formation being configured to represent data relating to at least one of: a serial number of the cartridge, a media and a media colorant, so that the capacitive sensors, when actuated, together generate a signal carrying such data.

__________


160467]21][11[

LARYNGEAL MASK AIRWAYאויר נתיבי לפתיחת גרוני התקןDEVICE

]54[

21.08.2002]22[US]33[23.08.2001]32[60/314438]31[US03.05.2002138806

Int. Cl.8 A61M 016/04]51[THE LARYNGEAL MASK COMPANY LIMITED, SEYCHELLES

]71[

ARCHIBALD IAN JEREMY BRAIN]72[WO/2003/018094]87[

דין, עורכי ושות' משרד אסיא נעמיהחייל, תל-אביב רמת32 רח' הברזל

NAOMI ASSIA & CO. LAW OFFICES,

32 HABARZEL ST.RAMAT HACHAYAL

TEL AVIV 69710

]74[

[57] A laryngeal mask airway device, comprising an inflatable cuff (3460) having a generally toroidal shape and defining a central opening when inflated; andan airway tube (3410) extending from a proximal end (3417) via a curved intermediate portion (3418) to a distal end (3419) and defining an internal passageway (3421), the airway tube being

connected at its distal end to the inflatable cuff with the internal passageway of the airway tube in communication with the central opening of the inflatable cuff, the curved intermediate portion of the airway tube being characterized by an elongated notch (3424) extending along the internal surface of the convex side (3410-0) thereof.


________

160479]21][11[

מומנט לרגישות פיצוי עם כפיפה מתמרפיתול

BENDING BEAM LOAD CELL WITH TORQUE SENSITIVITY COMPENSATION

]54[

19.02.2004]22[US]33[20.02.2003]32[368347]31[

Int. Cl.8 G01L 001/04]51[THE FLINTEC GROUP, LTD., HONG KONG

]71[

HARRY E. LOCKERY, ROBERT L. GRAY

]72[


ירושלים



JERUSALEM 91450

]74[

[57] A bending beam load cell (20) comprising: axially oriented strain gages (18, 18', 19, 19') sensing tension and compression strains connected in a main bridge circuit having two power input terminals and two signal output terminals providing an output signal proportional to

a load on the load cell; a shear sensing strain gage (22) sensing torque on said load cell; and means for connecting said torque sensing strain gage in series with one of said axially oriented strain gages to compensate for torque sensitivity in said output signal.


__________

160489]21][11[

פוליאמיד אריג פריטי לייצור תהליךשונים בצבעים מדגמים המניבים

PROCESS FOR MAKING POLYAMIDE TEXTILE ARTICLES BEARING DESIGNS IN DIFFERENT COLORS

]54[

19.02.2004]22[IL]33[20.02.2003]32[154571]31[

Int. Cl.8 D01D 005/08, D02G 003/02]51[]NILIT LTD.]71העמק בע"מ, מגדל נילית

ארושוב, גזית, מיכאל רותם, שמואל רן סטרלצס, טיירי, בוריס וייזר, ממודלי אלוןיירמולייב כץ, אלכסנדר אריאל, יוליה ידוב

RAN ROTEM, SAMUEL GAZIT, MICHAEL EROSHOV, ALON WEISER, MAMODALY THIERRY, BORIS STRELTSES, YEDVAB ARIEL, JULIA KATZ, ALEXANDER YERMOLAEV

]72[



P.O.B. 5352,

]74[


BEER-SHEVA 84152

[57] Process for manufacturing a fabric having distinctive and sharp differentially colored patterns or designs, which process comprises the steps of:(i) producing a first and a second polyamide, said polyamides having different concentrations of amine groups;(ii) producing a first and a second polyamide having different concentrations of carboxyl end-groups and sulfonate groups;(iii) producing a first yarn from said first polyamide and a second yarn from said second polyamide;

(iv) making a fabric having first surface areas defined by said first yarn and second surface areas defined by said second yarn; and(v) chemically dyeing said fabric in a dyeing bath comprising at least one anionic (acid) dyestuff and at least one cationic (basic) dyestuff, whereby said first yarn and therefore said first surface areas are dyed predominantly by said anionic dyestuff and said second yarn and therefore said second surface areas are dyed predominantly by said cationic dyestuff.

_________

160639]21][11[

לוויסות אמייל מטריצת חלבון תכשיריהחיסונית התגובה

ENAMEL MATRIX PROTEIN COMPOSITIONS FOR MODULATING IMMUNE RESPONSE

]54[

06.09.2002]22[DK]33[14.09.2001]32[PA200101340]31[US19.09.200160/323286

Int. Cl.8 A61K 035/32, 038/39, A61P 001/04, 003/10, 005/40, 007/08, 009/10, 011/06, 017/02, 017/06, 021/04, 029/00, 037/08

]51[

BIORA BIOEX AB, SWEDEN]71[WO/2003/024479]87[



אביב


P.O.B. 4060 ,TEL AVIV 61040

]74[

[57] Use of an active enamel substance and/or a preparation of an active enamel substance and/or a preparation of an active enamel substance for the manufacture of

pharmaceutical composition for the prevention and/or treatment of a systemic inflammation and/or systemic infection in a mammal.

__________

160688]21][11[

על המבוסס למחצה מוליך לייזר לייזר קרינת אופני סינון של האפקטמרווח–פס–פוטוני גביש ידי על גבוהים

SEMICONDUCTOR LASER BASED ON THE EFFECT OF PHOTONIC BAND GAP CRYSTAL-MEDIATED FILTRATION OF HIGHER MODES OF LASER RADIATION

]54[

29.08.2002]22[US]33[04.09.2001]32[09/946016]31[

Int. Cl.8 H01S 005/183]51[]PBC LASERS LTD.]71בע"מ, ד.נ. משגב פי. בי. סי. לייזרים

VITALY SHCHUKIN, NIKOLAI LEDENTSOV

]72[

WO/2003/021726]87[( בע"מ,1995) ג'י.אי.ארליך




]74[

[57] A semiconductor edge-emitting laser (100) comprising:(a) an n-doped region, at least a part of which comprises a photonic band gap crystal (120) including a layered structure comprising at least one layer, wherein each layer is doped by an n-typed impurity, wherein the layered structure has a periodically modulated refractive index, wherein the periodically modulated refractive index is modulated in a direction perpendicular to a direction of light propagation; (b) a defect (121) contiguous with said photonic band gap crystal (120), comprising a light generating layer that

emits light when exposed to an injection current when a forward bias is applied;(c) a p-doped layered structure, comprising at least one layer, wherein each layer is doped by a p-type impurity, and wherein said p-doped layered structure is located on a side of said defect opposite said n-doped region, wherein the p-doped layered structure has a variable refractive index that hinders an extension of a fundamental mode to at least one doped layer within the p-doped layered structure and to a p-contact (115) wherein the fundamental mode of laser radiation is localized by the defect, while all other modes are extended over the photonic band gap crystal;


wherein a total thickness of said photonic band gap crystal and said defect provides a low beam divergence.

__________

160902]21][11[

FLAT-PANEL PROJECTIONשטוח הקרנה צגDISPLAY

]54[

25.09.2001]22[Int. Cl.8 G03B 021/14]51[CAMBRIDGE FLAT PROJECTION DISPLAYS LIMITED, UNITED KINGDOM

]71[

ADRIAN ROBERT LEIGH TRAVIS]72[WO/2003/027754]87[

( בע"מ,1995) ג'י.אי.ארליך בגין מנחם ,רחוב15 אילון, קומה מגדל

גן , רמת11



]74[

[57] A flat-panel projection display comprising a waveguide system including a display slab waveguide (1) having a grating (2) acting to cause light propagating in the waveguide to emerge from one face of the waveguide, a lens element (3) for directing light into an edge of the waveguide system, and means (4) located in the focal plane of the lens

element for modulating the intensity of the light as a function of lateral position and of elevational direction of travel, relative to the waveguide, the grating being such as to eject light directed into the waveguide system from the slab towards a viewer at an angle depending on the said lateral position and elevational direction.

.


________

160934]21][11[

SHOE HAVING Aרב–שכבתית סוליה בעלת נעלMULTILAYERED INSOLE

]54[

18.03.2004]22[US]33[18.03.2003]32[390829]31[

Int. Cl.8 A43B 013/38]51[H.H. BROWN SHOE COMPANY, INC., U.S.A.

]71[


אביב



TEL AVIV 61040

]74[

[57] A shoe, comprising: a footbed (44); an insole (14) having a first layer (16) and a second layer (20); said first layer having a top surface (16), a bottom surface, and a hole extending from said top surface to said bottom surface; said second layer having a top surface, a bottom location, and a hole extending from said top surface

to said bottom location; a protrusion (46) extending from said footbed through said first layer to said bottom location of said second layer; and said protrusion is integrally connected to said footbed so that said protrusion and said footbed define a single unit.


________

160952]21][11[

FIBER OPTIC CIRCUIT BOARDאופטי סיב באמצעות אם לוח חיבורLINK

]54[

18.03.2004]22[Int. Cl.8 G02B 006/12, H04B 010/00]51[

בע"מ, מתקדמות לחימה מערכות רפאלחיפה

RAFAEL ADVANCED DEFENSE SYSTEMS LTD.

]71[

SHIMON WASSERMAN, RONENבטמן וסרמן, רונן שמעוןBETMAN

]72[


, רמת- גן7



RAMAT GAN 52520

]74[

[57] A device for fiber optic free-space optical communication between electronic components, the device comprising:(a) at least a first electronic component including:(i) at least a first fiber optic transceiver;(ii) at least a first optical fiber having a connection end that is connected to said first fiber optic transceiver and a first terminal free-end; and(iii) at least a first alignment mechanism configured to support said first optic fiber and align said first terminal free-end;and

(b) at least a second electronic component including:(i) at least a second fiber optic transceiver;(ii) at least a second optical fiber having a connection end that is connected to said second fiber optic transceiver and a second terminal free-end; and(iii) at least a second alignment mechanism configured to support said second optic fiber and align second said terminal free-end;wherein, when said first and said second electronic components are deployed, said first and said second terminal free-ends are aligned such that light emitting from one


of said first and said second terminal free-ends is received by the other of said first and said second terminal free-ends, and thereby transmitted to a corresponding one of said first and said second transceivers,

thereby establishing optical communication between said first and said second transceivers across the free-space separating said first and said second terminal free-ends.

_________

161150]21][11[

PASSIVE OPTO-ELECTRONICפסיבי אופטו-אלקטרוני ניטור התקןMONITORING DEVICE

]54[

01.10.2002]22[FR]33[02.10.2001]32[01/12667]31[

Int. Cl.8 G02B 017/08]51[THALES, FRANCE]71[WO/2003/029876]87[


רחובות


REHOVOT 76122

]74[

[57] An optronic passive surveillance device, comprising a front optic (1) of given useful instantaneous field, means (2) for scanning a scene with a given total field of observation, means (3) for forming the image of the scene and means (4) for

detecting said image, characterized in that the detection means comprise a two-dimensional matrix detector (41), the field of the detector along each of the dimensions being greater than or equal to said useful instantaneous field of the front


optic along said dimension, and allowing the acquisition, for each elementary area of the scene corresponding to the useful instantaneous field of the front optic, of N subimages formed on said detector (N≥1), with a given integration time for each

subimage, and in that the device includes counterscanning means (6) to make it possible to compensate for the movements of the image that are due to the scanning of the scene during the acquisition of the N subimages.

_________

161638]21][11[

גל של מהירות מודל לקביעת שיטההטרוגני תת–קרקעי מבנה סיסמיב

METHOD FOR DETERMINING A SEISMIC WAVE VELOCITY MODEL IN A HETEROGENEOUS UNDERGROUND FORMATION

]54[

26.04.2004]22[FR]33[29.04.2003]32[03/05292]31[

Int. Cl.8 G01V 001/28]51[INSTITUT FRANCAIS DU PETROLE, FRANCE

]71[

KARINE BROTO]72[לוצאטו, את לוצאטו



BEER-SHEVA 84152

]74[

[57] A method for determining a velocity model of seismic waves picked up by seismic receivers coupled with an underground formation, in response to the

emission of subsoil seismic waves by a seismic source, after reflection by geologic interfaces of the formation, from multi-offset records of the waves, for each


seismic event located for the multi-offset records and for each layer delimited by the interfaces comprising:(a) from the prestack seismic records, constructing an iso-offset collection from which kinematic information or travel times associated with the event are extracted;(b) selecting a velocity distribution around a reference velocity in the layer, that is sampled with a predetermined interval;(c) for each velocity sample, applying an inversion technique at a fixed velocity so as to determine, from the travel times extracted from the iso-offset collection, a geometry of the interface for the velocity sample in order to obtain a series of interface/velocity pairs for the event;(d) calaculating the kinematic information associated with each obtained interface/velocity pair, for source-receiver pairs corresponding to multi-offset

collections existing in the multi-offset seimic records;(e) for each interface/velocity pair and for each multi-offset collection selected, evaluating coherence between calculated multi-offset travel times and the seismic records, and selecting for each multi-offset collection a travel time curve showing maximum coherence with the seismic records;(f) applying a prestack kinematic inversion method using the multi-offset travel times obtained for all the multi-offset collections selected, in order to determine a geometry and a velocity of the layer being considered; and(g) iterating n times steps (a) to (f) by considering for each iteration a velocity model obtained during a previous iteration as a reference velocity model to define the reference velocity, and wherein n is an integer.

________

161713]21][11[

METHOD FORרב–מוקדיות עדשות לייצור שיטהMANUFACTURING MULTIFOCAL LENSES

]54[

17.10.2002]22[US]33[02.11.2001]32[003991]31[

Int. Cl.8 G02C 007/06]51[ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE), FRANCE

]71[





TEL AVIV 61040

]74[

[57] A method for manufacturing a progressive addition spectacle lens, comprising depositing on at least a portion

of a surface of a lens substrate at least one layer of surface forming amount of an inorganic high refractive index material,


wherein the material is deposited under conditions suitable so that the material

forms on the lens substrate surface a progressive surface.

__________

161732]21][11[

לתאורה טריז דמוי חלול אור מוליךאחורית

HOLLOW WEDGE SHAPE LIGHT GUIDE FOR BACK ILLUMINATION

]54[

30.10.2002]22[US]33[02.11.2001]32[60/336350]31[US30.10.2002284838

Int. Cl.8 G02B 006/10]51[HONEYWELL INTERNATIONAL INC., U.S.A.

]71[





TEL AVIV 61040

]74[

[57] A hollow wedge shaped light guide comprising:(a) a rectangular input aperture having parallel opposing top and bottom edges and parallel opposing side edges (30); (b) a transparent top planar sheet (10) orthogonally affixed to the top edge of said rectangular aperture;(c) a bottom planar sheet (20) affixed to the bottom edge of said rectangular aperture, wherein said bottom planar sheet slopes toward said top planar sheet, forming a gap between the top planar sheet and the bottom planar sheet that decreases along the length of said light guide;

(d) wherein said top planar sheet further comprises a top surface having total internal reflecting features thereon, said total reflecting features comprisinga plurality of right triangle cross-sections (11) that run for substantially the length of said top planar sheet perpendicular to said top edge of said rectangular aperture; and(e) wherein said bottom planar sheet includes reflective light extraction features (21) on one surface,said light extraction features including surfaces that are angularly displaced from being parallel to rectangular aperture by a predefined clocking angle.


________

162199]21][11[

בעלות פרטים של אופטיות מדידותמחזוריות תבניות

OPTICAL MEASUREMENTS OF ARTICLES WITH PERIODIC PATTERNS

]54[

27.05.2004]22[Int. Cl.8 G01N 021/88]51[

NOVA MEASURINGבע"מ, רחובות מדידה מכשירי נובהINSTRUMENTS LTD.

]71[


אביב



TEL AVIV 61040

]74[

[57] A method for use in measuring/inspecting an article having a substantially periodic pattern, the method comprising applying optical measurements to a measurement site on the article by illuminating the measurement site with a plurality of wavelengths at substantially normal incidence of the illuminating light,

detecting light returned from the illuminated site, and generating measured data indicative thereof, wherein the measurements are applied to the measurement site through a polarizer rotatable between its different orientations selected from a number of pre-calibrated orientations.


________

162291]21][11[

CLAMP WITH CLAMP FORCEלחיצה לכח חיישן בעלת מלחצתSENSOR

]54[

01.06.2004]22[Int. Cl.8 B25B 001/20]51[

]TEFENTOOLS LTD.]71תפן התעשיה בע"מ, איזור תפנטולס]DAVID KLEIN, ZION BEN-GIGI]72בן-גיגי קליין, ציון דוד

בע"מ, פטנט דקל, רחובות27 ,חדר18 ונחלה מנוחה

DEKEL PATENT LTD,. 18 MENUHA VENAHALA ST.

REHOVOT 76209

]74[

[57] A clamp comprising: at least one clamping element and a hand-operated actuator operative to move the at least one clamping element in a clamping direction; and a clamping force sensor in operative connection with said at least one clamping element, wherein said clamping element

comprises a clamping jaw, and wherein said clamping force sensor is disposed on a clamping face of said clamping jaw, and wherein said clamping force sensor is in operative connection with a clamping force indicator.


________

162767]21][11[

COLLISION AVOIDANCEהתנגשות למניעת ומערכת שיטהSYSTEM AND A METHOD THEREOF

]54[

29.06.2004]22[Int. Cl.8 G08G 001/0969, 001/16]51[

ISRAEL AEROSPACEבע"מ, לוד לישראל האוירית התעשייהINDUSTRIES LTD.

]71[


אביב



TEL AVIV 61040

]74[

[57] A collision avoidance system mounted onboard a rotary-winged host vehicle participating in a data link communication network, comprising: an Inertial Navigation System (INS) providing inertial motion information; a Global Positioning System (GPS) receiver providing position information and time synchronization; a data link radio for receiving data indicative of state information of at least one participant vehicle; a central processing unit configured for receiving said inertial

motion information from said INS, said position information and time synchronization from said GPS and said data indicative of state information of said at least one participant from the data link radio, and for producing a collision avoidance data regarding said host and said at least one participant; at least one display unit for presenting said collision avoidance data, wherein said central processing unit is further configured, in the case that state information in respect of said participant is not received, for


providing approximated data indicative of state information of said participant based on previously received data indicative of state information of said participant; and for a duration that does not exceed a predetermined value, using said

approximated data for generating collision avoidance data regarding said host and said participant, thereby enabling overcoming discrepancies in said state information of said participant due to rotor interruption.

לתקנות35 לתקנה בהתאם נבחן זה פירוט1968 – הפטנטים, תשכ"ח

This specification was examined in accordance with regulation 35 of the Patent Regulations, 5728 - 1968



________

162787]21][11[

בעלי סיגנלים עם ישירה המרהמקומי מתנד של משתנה אמפליטודה

DIRECT CONVERSION WITH VARIABLE AMPLITUDE LO SIGNALS

]54[

14.11.2003]22[US]33[15.11.2002]32[10/295639]31[

Int. Cl.8 H04B 001/30]51[QUALCOMM INCORPORATED, U.S.A.

]71[




REHOVOT 76122

]74[

[57] An integrated circuit (120) comprising: a local oscillator (LO)

generator (144) operative to receive a voltage controlled oscillator (VCO) signal


(142) and generate an LO signal having a variable amplitude and a frequency that is related to the frequency of the VCO signal; and a variable gain amplifier (132) operative to receive a first control signal

and adjust the amplitude of the LO signal based on the first control signal, wherein the variable amplitude LO signal is used for frequency upconversion of an input signal to obtain an output signal.



_________

163318]21][11[

חניונים לניטור אלחוטית ומערכת שיטהעירוניים

MUNICIPAL WIRELESS PARKING MONITORING SYSTEM AND METHOD

]54[

02.08.2004]22[Int. Cl.7 G06Q 003/000000 G07B 015/02]51[

שבע ראובן, באר ברמןשבע דהאן, באר אברהם

דנינו, אופקים יצחק

BERMAN REUBENAVRAHAM DAHANITZHAQ DANINO

]71[

ראובן, ברמןשבע , באר16זלמן רח' ארן

BERMAN REUBEN, 16 ZALMAN ARAN ST.

BEER-SHEVA 84789

]74[

[57] A parking monitoring system (100) comprising: a control center (400) having a computer (400), transceiver (410), and database (420) which associates each authorized user name with a specified car license plate number and a specified

cellular phone number (240), one or more wireless mobile terminals (310), each of which in data communication with said control center and being associated with different municipal inspector (300); and one or more requesting cellular phones by


which a request signal for initiating a parking operation for corresponding parked car is transmittable to said control center, wherein said control center is provided with means for preventing each

mobile terminal from issuing a ticket when parked car is engaged in a parking operation and for enabling each mobile terminal to issue a ticket when a parked car is not engaged in a parking operation.





________


163618]21][11[

בזיקוק אלקילציה של ריאקטיבי תהליךהזרז של רגנרציה בתוכו הכולל

REACTIVE DISTILLATION ALKYLATION PROCESS INCLUDING IN SITU CATALYST REGENERATION

]54[

16.01.2003]22[US]33[05.03.2002]32[090859]31[

Int. Cl.8 B01D 003/00, B01J 029/90, 038/56, C07B 061/00]51[SASOL NORTH AMERICA INC., U.S.A.

]71[





TEL AVIV 61040

]74[

[57] A process for the regeneration of a solid acid alkylation catalyst in a reactive distillation alkylation process taking place in a pressurized distillation column including an intermediate reactive catalyst zone having supported therein a solid acid alkylation catalyst, a first rectification zone at the top of the distillation column and a second rectification zone including a reboiler below said reactive catalyst zone wherein at least a portion of an olefin-containing feedstock is brought into contact with at least a portion of an aromatic hydrocarbon feedstock in counter-current flow within the reactive catalyst zone, wherein the internal pressure in the reactive catalyst zone is maintained above one atmosphere and the temperature maintained at reflux of said aromatic hydrocarbon feedstock comprising:(A) periodically ceasing the introduction into the distillation column of the olefin-

containing feedstock while continuing the flow of aromatic hydrocarbon feedstock and introducing into the column an effective amount of a paraffin feedstock at a point such that the paraffin feedstock intermixes in counter-current flow with the refluxing unreacted aromatic hydrocarbon feedstock as it flows through the catalyst to remove by-products from the catalyst;(B) adjusting the reflux rate of said aromatic hydrocarbon to achieve a desired temperature in the catalyst reaction zone above about 175oC at a column operating pressure within the range of from about 125 to about 370 psig;(C) separating said by-products from said paraffin and aromatic hydrocarbon in said second rectification zone; and(D) removing said by-products from said rectification zone.


________

163728]21][11[

BATCHWISE QUILTING OFמודפסים חומרים של רפודPRINTED MATERIALS

]54[

26.02.2003]22[US]33[01.03.2002]32[60/361127]31[

Int. Cl.8 D05B 011/00, 021/00]51[L&P PROPERTY MANAGEMENT COMPANY, U.S.A.

]71[





TEL AVIV 61040

]74[

[57] A method of quilting a material having printing thereon comprising: feeding, into a quilting station of a quilting machine, a layer of a material having coded information thereon that relates to a product to be quilted on the material, the layer of material having one or more of the following properties: the material has printed thereon a series of panels printed on the material and wound onto a roll in an order that is opposite the order in which the panels are to be quilted, the coded information contains information of the amount of shrinkage expected to occur

during quilting and the layer of material has printed thereon one or more panels having a longitudinal dimension increased by said amount, and the coded information contains information of the amount of crop to be made between adjacent ones of a plurality of panels to be quilted from the layer of material; reading the coded information from the material with a sensor at the quilting machine; quilting the material at the quilting station in accordance with the information read from the material with the sensor.


_________

164022]21][11[

של פוספטיות תולדות רוקחות ותכשירי פלואורואקסאינדול

אותן המכילים

PHOSPHATE DERIVATIVES OF FLUOROOXINDOLE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

]54[

20.03.2003]22[US]33[20.03.2002]32[60/366010]31[

Int. Cl.8 A61K 031/675, A61P 009/00, 013/00, 015/00, 025/00, 025/08, 039/02, C07F 009/00, 009/572

]51[

BRISTOL-MYERS SQUIBB COMPANY, U.S.A.

]71[




]74[



wherein the wavy bond represents the racemate, the (R)-enantiomer or the (S)-enantiomer;A is a direct bond or (C=O);B is a direct bond, oxygen, or nitrogen;m is 0 or 1;n is 1, 2 or 3;R1 and R2 each are independently hydrogen, C1-6 alkyl, benzyl, 4-methoxybenzyl, (lower) alkanoyloxy (lower) alkyl, (lower) alkoxycarbonyloxy (lower) alkyl, (lower) alkoxycarbonyl (lower) alkyl, (5-methyl-2-oxo-1,3-dioxol-

4-yl) methyl or dihydroxypropyl; and when R1 is hydrogen, R2 may also be –P(O)OR5OR6 or heteroaryl; R3 and R4 each are independently hydrogen or C1-4 alkyl; and R5 and R6 each are independently hydrogen, C1-6 alkyl, benzyl, 4-methoxybenzyl, (lower) alkanoyloxy (lower) alkyl, (lower) alkoxycarbonyloxy (lower) alkyl, (lower) alkoxycarbonyl (lower) alkyl, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl or dihydroxypropyl; or a nontoxic pharmaceutically acceptable salt or solvate thereof.

__________

164076]21][11[

מתוגברי פלסטיק חלקי לציפוי שיטהזו בשיטה שיוצרו וחלקים סיבים

METHOD FOR COATING FIBER-REINFORCED PLASTIC STRUCTURAL PARTS AND STRUCTURAL PART SO PRODUCED

]54[

20.03.2003]22[DE]33[21.03.2002]32[10212415.

9]31[

DE05.03.200310309811.9Int. Cl.8 B29C 037/00]51[MENZOLIT-FIBRON GMBH, GERMANY

]71[





TEL AVIV 61040

]74[

[57] Method for refining surfaces of structural parts made from fiber-reinforced plastics materials that may be deformed by means of extrusion or thermal molding,

characterized in that, firstly, a two-layer or three-layer co-extruded film with a dyed layer for the refining of the construction element is placed on a mold, which


displays the topography of the surface of the structural part, in that the film already displays the final desired properties with regard to the structure and color of the surface, in that the film is deformed in accordance with the topography of the surface of the structural part, in that the preformed film is inserted into a corresponding mold, in that an already impregnated fiber mat or a polymer melt is placed in the mold facing the side of the

film that is not the surface, in that the forming is done and/or the mat is impregnated with resin and hardener under vacuum and filled into the mold, and in that, after cooling and/or hardening of the fiber-reinforced plastics material, the finished structural part consisting of the film and the fiber-reinforced plastics material bonded to it, is removed from the mold.

________

164160]21][11[

יצוקים גופים של הזרקה ליציקות מתקןמפלסטיק עשויים

DEVICE FOR THE INJECTION MOULDING OF MOULDED BODIES MADE FROM PLASTIC

]54[

17.04.2002]22[Int. Cl.8 B29C 045/12]51[MONIKA WERNER, GERMANY]71[WO/2003/086729]87[



P.O.B. 12688 ,HERZLIYA 46733

]74[

[57] A device for the injection molding of parts made of plastic, comprising an injection molding machine (1) and a tool (2) dedicated thereto, where said tool contains at least two cavities (11, 12) that correspond to the dimensions of the molded parts to be produced, where the tool comprises at least three parts which are moveable in relation to each other, a front part (4), a central part (5) and a rear part (6), and which in the operating position are firmly pressed against each other by the pressure force of a pressure generator (8) along separation planes (9, 10) that pass through the cavities and are parallel to each other and at right angles to the moving direction of the parts, and where the tool contains at least one channel for supplying molten plastic, which on the one hand ends in the cavities

and on the other hand on the surface of the tool which in the operating position is connected to the injection molding machine, characterized in that for the use of a conventional, customary injection molding machine a centrally located channel (13) is provided in that front part of the tool which extends from the inlet area to a first separation plane, and continues to the second separation plane within the central part of the tool, the channel having a conical shape within the front part of the tool as well as in the central part and partial channels (15, 16) extending from the channel to the cavities, and that a lock, which can be adjusted in two positions, is located on the parts of the tool, where after lifting of the pressure


force, from the pressure generator in a first position only the central part and the front

part of the tool that contains the inlet area of the channel are locked together, and in a second position only the central part and the rear part of the tool are locked together.

________

164206]21][11[

SOLID DISPERSIONמוצקה פיזור תערובתCOMPOSITION

]54[

15.04.2003]22[US]33[16.04.2002]32[60/372416]31[

Int. Cl.8 A61K 009/00, 009/14, 031/50]51[KOWA COMPANY, LTD., JAPAN]71[WO/2003/086405]87[



P.O.B. 6451 ,TEL AVIV 61063

]74[

[57] A solid dispersion composition containing 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio) phenyl]-2H-pyridazin-3-

one, hydroxypropylmethyl cellulose, and polyoxyethylene polyoxypropylene glycol.

.__________


164234]21][11[

PROCESS FOR THE REMOVALחנקן תחמוצות של להסרה תהליךOF NITROGEN OXIDES

]54[

21.03.2003]22[DE]33[09.04.2002]32[10215605.

0]31[

Int. Cl.8 B01D 053/86]51[UHDE GMBH, GERMANY]71[WO/2003/084646]87[



P.O.B. 12688 ,HERZLIYA 46733

]74[

[57] A process for reducing the content of NOx and N2O in gases, in particular in process gases and offgases, which comprises the measures:(a) addition of at least one nitrogen-containing reducing agent to the NOx- and N2O-containing gas in at least the amount required for complete reduction of the NOx,

(b) addition of a hydrocarbon, of carbon monoxide, of hydrogen or of a mixture of one or more of these gases to the NOx- and N2O-containing gas for the reduction of the N2O and(c) introduction of the gas mixture into at least one reaction zone at temperatures of up to 450oC which contains one or more iron-laden zeolites.

__________

164274]21][11[

בשכבת פלטינה ציפוי ליצירת תהליךמזרז

PROCESS FOR FORMING A PLATINUM COATING CATALYST LAYER

]54[

14.10.2003]22[JP]33[16.10.2002]32[2002-

301423]31[

Int. Cl.8 B01J 021/04, 023/42]51[TADAHIRO OHMI, JAPANFUJIKIN INCORPORATED, JAPAN

]71[




]74[

[57] A process of forming a platinum coating catalyst layer in a moisture-

generating reactor where a moisture-generating reactor having a platinum


coating catalyst layer on the inner wall surface in the reaction space is formed and hydrogen and oxygen supplied into the reaction space are both brought into contact with the platinum coating catalyst layer and radicalized thereby so that the radicalized hydrogen and oxygen are reacted to generate moisture without high temperature combustion wherein the moisture-generating reactor is made of an

alloy containing aluminum, a principally aluminum oxide (Al2O3)-composed barrier film is formed by applying an aluminum selective oxidation treatment on the inner wall surface of the moisture generating reactor, and thereafter a platinum layer is stacked on and affixed to the barrier film such that a platinum coating catalyst layer is formed.

_________

164412]21][11[

ושיטה אבקה בצורת לעיסה גומילהכנתו

CHEWING GUM IN POWDER FORM AND METHOD OF PREPARATION

]54[

04.04.2003]22[EP]33[05.04.2002]32[02425209.

0]31[

Int. Cl.8 A23G 000/40600]51[GUM BASE CO. S.P.A., ITALY]71[WO/2003/084338]87[




]74[

[57] Method of producing chewing gum in powder form, constituted by the following steps:(a) mixing of a soft basic gum with at least one sweetener and, optionally, at least one other typical chewing gum ingredient, at a temperature of between about 35 and 75oC,

(b) cooling of the mixture thus obtained to a temperature of between about 0 and -40oC,(c) grinding and subsequent screening of the mixture thus obtained to give a powder

having a particle size less than about 10 mesh,(d) mixing of the powder thus obtained with at least one anti-agglutination agent,(e) optional mixing of the powder thus obtained with one or more of sweeteners, flavourings, colourings, food acids, or other additives, (f) optional compression of the mixture thus obtained.

__________


164633]21][11[

]TRACING DEVICE]54העתקה מתקן

15.10.2004]22[Int. Cl.8 B41F 031/10, G09B 011/06]51[

בע"מ, פתח עומק עם משחקים שורשיםתקוה

SHORASHIM GAMES WITH DEPTH LTD.

]71[

בע"מ, פטנט דקל, רחובות27 ,חדר18 ונחלה מנוחה

DEKEL PATENT LTD,. 18 MENUHA VENAHALA ST.

REHOVOT 76209

]74[

[57] A tracing device (10) comprising:a mounting surface (12) for placing thereon a design (14); a translucent substrate (16) generally parallel to said mounting surface for tracing the design thereon; and a resting element (18) extending from said mounted surface

against which an edge of said design is abuttable, wherein said resting element connects said mounting surface to said translucent substrate, said translucent substrate being spaced from said mounting surface to define a pocket in which the design is placeable.

_________


164868]21][11[

]DOOR JAMB ASSEMBLY]54דלת משקוף מכלול

27.10.2004]22[Int. Cl.8 E06B 001/04, 001/08, 001/18, 001/52, 001/56, 001/60]51[

RAV BARIACH SECURITYבע"מ, יבנה בטחון מוצרי בריח רבPRODUCTS LTD.

]71[

]EYAL ARTSIELY]72ארציאלי איילבע"מ, פטנט דקל

, רחובות27 ,חדר18 ונחלה מנוחה DEKEL PATENT LTD,.

18 MENUHA VENAHALA ST.REHOVOT 76209

]74[

[57] A door jamb assembly comprising: a door jamb (10), installable either as a strike jamb (12) or hinge jamb, comprising an outer face (14) configured to face an outside (15) of a doorway (16), an inner face (18) configured to face an inside (17) of the doorway, and a door-edge face (20) extending between the outer and inner faces of the door jamb and configured to face either a strike edge (22) or hinge edge of a door (24), and a recess (30) formed in

the door-edge face, said recess being distanced from both the outer and inner faces, and configured to receive therein a door retainer assembly (32) for a door to move thereagainst, and wherein a groove (26) is formed in the outer face generally parallel to and spaced from the door-edge face, and another groove (28) is formed in the inner face generally parallel to and spaced from the door-edge face


__________

165211]21][11[

פעילות התחלת לגרימת מוצריםבהם ולשימוש לייצורם ותהליכים

TRIGGERED START PRODUCTS AND PROCESSES FOR THE PRODUCTION AND USE THEREOF

]54[

08.05.2003]22[US]33[15.05.2002]32[146314]31[

Int. Cl.8 A01N 025/26, B01J 002/00, C05F 011/08]51[OMS INVESTMENTS, INC., U.S.A.]71[

ושות', גבריאלי זליגסוןאביב , תל1426 , ת.ד. 31 רח' יבנה

SELIGSOHN GABRIELI & CO,. 31 YAVNE ST,.

P.O.B. 1426 ,TEL AVIV 61013

]74[

[57] A coated triggered start product comprising: a particulate core material comprising at least one water soluble active constituent, and at least one coating layer applied on the particulate core material; the coating layer causing the product to exhibit "lock-off" type release

characteristics whereby release of the active constituent of the core material from the coated product is essentially completely suppressed until release is initiated by application of a trigger material to the coating layer after the product is exposed to moisture.


__________

166446]21][11[

נוגדת פעילות בעלי פלטינה תצמידי מרה חומצות המכילים גידוליםכימי שינוי שעברו

PLATINUM COMPLEXES CONTAINING CHEMICALY MODIFIED BILE ACIDS HAVING ANTITUMOR ACTIVITY

]54[

08.05.2003]22[IT]33[10.05.2002]32[MI2002A000992]31[

Int. Cl.8 A61K 031/58, A61P 035/00, C07F 015/00, C07J 051/00]51[ICE S.R.L., ITALY]71[WO/2003/095462]87[


אביב


P.O.B. 4060 ,TEL AVIV 61040

]74[

[57] Platinum (II) complex of the formula

in which n is 0 or 1 and A is C or the CH-CH group.

_________

166661]21][11[

CRYO-SURGICAL APPARATUSבו לשימוש ושיטה קריו–ניתוחי מתקןAND METHOD OF USE

]54[

07.07.2003]22[US]33[06.08.2002]32[10/213568]31[

Int. Cl.8 A61B 018/02, 018/14, 018/18]51[ERBE ELEKTROMEDIZIN GMBH, GERMANY

]71[



]74[


P.O.B. 12688 ,HERZLIYA 46733

[57] Cryosurgical apparatus comprising an elongate cryoprobe (10) having a proximal end (12b) a distal end (12a), a cooling portion (16) adapted to be positioned in tissue (70) to be treated and operative to cool tissue to form an ice ball (72) in such tissue upon activation, and an electrically conductive first portion (12), an energy conducting element (14) coupled to said cryoprobe and having an

electrically conductive second portion (46) in a region spaced from said first portion, electrical insulation (38) interposed between said first portion and said second portion, and a source (66) of electromagnetic energy operatively connected to one of said first portion and second portion operable to produce heating of tissue in the region of said iceball to control the configuration of the iceball.

_________

166774]21][11[

]PROCESS FOR THE ]54מאווררים קפואים תוצרים ליצור תהליך


MANUFACTURE OF FROZEN AERATED PRODUCTS

01.08.2003]22[EP]33[20.08.2002]32[02255801.

9]31[

Int. Cl.8 A23G 009/20, 009/28]51[UNILEVER PLC, UNITED KINGDOM

]71[




P.O.B. 4060 ,TEL AVIV 61040

]74[

[57] Process for the manufacture of frozen aerated products comprising; providing two separate forming elements, providing at least one open cavity on a surface of each forming element, providing filling devices for filling said cavities with a frozen aerated material, filling two cavities, one on each forming element, with a frozen aerated material, wherein

(a) at least one of the cavities is filled with a frozen aerated product having an overrun of between 30% and 130%, (b) this product is then allowed to expand outside its cavity,(c) the two cavities are then moved opposite one another and the frozen aerated product in each cavity is pressed against the frozen aerated product in the other cavity.

________

167080]21][11[

שכבת עם בררני קרינה קולט ציפויליצורו ושיטה נדבקת אוקסיד

RADIATION-SELECTIVE ABSORBER COATING WITH AN ADHERENT OXIDE LAYER AND METHOD OF MAKING SAME

]54[

24.02.2005]22[DE]33[27.02.2004]32[1020040106

89.4]31[

Int. Cl.8 B32B 003/00, F24J 002/48]51[SCHOTT AG, GERMANY]71[


אביב


P.O.B. 4060 ,TEL AVIV 61040

]74[

[57] Absorber having a radiation-selective absorber coating (3), having a metal substrate, a diffusion barrier layer

(11), a metallic reflection layer (12), a cermet layer (13) and an antireflection coating (14), characterized in that the


diffusion barrier layer is an oxide layer which consists of oxidized components of the metal substrate.

_________

167646]21][11[

פנימית בעירה למנוע קירור מערכתפעימות ערבה

COOLING SYSTEM FOR A FOUR-STROKE INTERNAL COMBUSTION ENGINE

]54[

24.03.2005]22[Int. Cl.8 F01P 001/00, 001/02, 005/00, 005/02, 005/06]51[

]SERGEI LATYSHEV]71לטישב, ירושלים סרגיילטישב, סרגיי

, ירושלים2/6 יסמין מבוא SERGEI LATYSHEV,

JASMIN ALLEY 2/6, JERUSALEM 93750

]74[

[57] A cooling system for a four-stroke internal combustion engine comprising:(a) a compressor (1) rigidly connected to the engine body (12) and designed for the supply of air under high pressure to the working cylinder (8) of the engine; (b) an air inlet manifold (7A) connecting said compressor with said working cylinder and designed for an entry of fresh air into working cylinder of the engine;

(c) inlet (9A) and exhaust (9B) valves are situated on the walls of the combusting chamber of said working cylinder and are set into motion through cams of a gas distribution system designed both for gas distribution, compressor supercharging in engine operation and for cooling of inside walls of said working cylinder and engine exhaust manifold by blowing air under high pressure from said compressor.


________

167788]21][11[

בתוך ושימוש נייד ופילטר מים מתיזהמים מתיז

WATER DISPENSER AND FILTER CARTRIDGE FOR USE THEREIN

]54[

31.03.2005]22[US]33[02.04.2004]32[60/559351]31[

Int. Cl.8 B67D 001/16]51[ ( בע"מ, אור1991) תעשיות תנה חברתיהודה

TANA INDUSTRIES (1991) LTD.]71[


רחובות


REHOVOT 76122

]74[

[57] A water dispenser (100) comprising: a water inlet adapted to receive water from a water supply; a water filter operative to filter water received from said water supply via said water inlet; a water outlet (120) operative to provide filtered water received from said water filter; a water spill collector (116) and a pivotably mounted drainage-equipped water container support (108) having a first operative orientation underlying said water outlet and defining a downwardly inclined

water spill drainage pathway communicating with said water spill collector and a second, non-operative, orientation not underlying said water outlet, said pivotably mounted drainage-equipped water container support comprising a perforated grid element (150) which is seated in a recess (152) formed in a tray element (154), having a drain aperture (155), said tray element being attached to a pivotable tray element support (156) which is pivotably supported


onto a chassis by means of a pair of pivot axle assemblies.


181068,181067,181066,181065,

The applications for division from this application have not yet been published

_________

167966]21][11[

מודולרי מדפסת ראש עבור כוח ספק צבעים4 בעל

POWER SUPPLY FOR A FOUR COLOR MODULAR PRINTHEAD

]54[

07.12.2000]22[AU]33[09.12.1999]32[PQ4559]31[

Int. Cl.8 B41J 002/145]51[DIVISION FROM 149966]62[SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[




BEER-SHEVA 84152

]74[

[57] An inkjet printhead assembly (10) comprising:an elongate support member (14) for mounting in an inkjet printer, the support member having an ink reservoir (16) with an ink outlet; a printhead module (12) with ink ejection nozzles and an ink inlet in fluid communication with the nozzles; the printhead module and the support having

mutually interengeable snap locking formations for mounting the printhead module to the support member such that the ink outlet establishes fluid communication with the fluid inlet; and a resilient seal element for creating a fluid seal between the ink inlet and the ink outlet when the module is mounted to the support member and simultaneously


maintaining the snap locking formation in firm engagement.

_________

168331]21][11[

THERMAL ACTUATOR WITHחום אגני עם חומני מפעילHEAT SINKS

]54[

20.04.2000]22[AU]33[22.04.1999]32[PP9931]31[

Int. Cl.8 B41J 002/05, 002/35, B81B 003/00]51[DIVISION FROM 145972]62[SILVERBROOK RESEARCH PTY. LTD., AUSTRALIA

]71[





TEL AVIV 61040

]74[

[57] A thermal actuator (7) for a micro electro-mechanical device (1), the actuator comprising a first conductive material arm (11) which is attached at one end to a substrate and which, at its other end, is connected to or integrated with a movable element, the first arm being arranged, in use, to be heated by passage of electrical

current and the first arm being formed along its length with a profile that functions to concentrate heating in the arm to a region adjacent the attachment to the substrate, the actuator further comprising one or more heat sinks in a central portion of the arm.


________

168485]21][11[

]PISTON COMPRESSOR]54בוכנה מדחס

09.12.2003]22[DE]33[12.12.2002]32[10257951.

2]31[

Int. Cl.8 F04B 027/04, 039/10, F25B 009/14]51[LEYBOLD VACUUM GMBH, GERMANY

]71[

WO/2004/053331]87[ושות', גבריאלי זליגסון

אביב , תל1426 , ת.ד. 31 רח' יבנה SELIGSOHN GABRIELI & CO,.

31 YAVNE ST,.P.O.B. 1426 ,

TEL AVIV 61013

]74[

[57] Piston compressor comprising: a piston (12) which oscillates in a cylinder (14) and, in filling position, compresses gas in a cylinder pressure space (20), gas bearing nozzles (28) arranged in the piston area for gas-supporting the piston, a compressed-gas accumulator (34) connected with the gas bearing nozzles, a compressed-gas supply line (18) between the cylinder pressure space and the

compressed-gas accumulator, and an inlet valve (42) in the compressed-gas supply line, the inlet valve being open in the filling position of the piston, characterized in that the inlet valve is defined by a cylinder wall opening (22) and a piston wall opening (38) which, in the filling position of the piston, are located opposite each other and define an open valve, and, in a non-filling position, are closed by the


piston wall (40) and the cylinder wall (24), respectively, and define a closed valve.

_________

176033]21][11[

CDMACDMA RADIO NETWORK רדיו לרשת בקרCONTROLLER

]54[

19.05.2000]22[US]33[20.05.1999]32[60/135073]31[

Int. Cl.8 H04J 013/00, H04L 012/56, H04Q 007/00]51[DIVISION FROM 146571]62[INTERDIGITAL TECHNOLOGY CORPORATION, U.S.A.

]71[





TEL AVIV 61040

]74[

[57] A code division multiple access (CDMA) radio network controller (RNC) comprising: a medium access controller-controlling/shared (MAC-c/sh) entity having a flow control entity, the flow control entity controls a flow of data by a plurality of sources through a forward

access common channel (FACH), each source has a specified amount of data that it is permitted to buffer for transfer over the FACH, the flow control entity controls the flow of the data for each source in response to the specified amount and an


associated priority of the data for the source.



________

177357]21][11[

יעילים ביניים חומרי להכנת שיטהD ויטמין של אנלוגים של לסינטזה

METHOD FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF VITAMIN D ANALOGUES

]54[

23.03.2005]22[US]33[02.04.2004]32[60/558546]31[

Int. Cl.8 C07C 401/00, C07F 009/40]51[LEO PHARMA A/S, DENMARK]71[WO/2005/095336]87[


אביב



TEL AVIV 61040

]74[

[57] A method of preparing a compound of the formulae


wherein R1 and R2 are the same or different and represent hydrogen or a hydroxy

protecting group, and wherein R5 represents hydrogen or a hydroxy


protecting group; the method comprising reacting a compound of the formulae

wherein R1, R2 and R5 are as definedabove; with a phosphonate of the formula


wherein R3 and R4 are the same or different and represent alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, aralkyl, aralkenyl aralkynyl, aryl, each being optionally substituted with one or more substituents selected from the group consisting of alkyl, aralkyl, cycloalkyl,

cycloalkenyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, aryl, oxo, alkoxycarbonyl, alkylcarbonyloxy, halogen, alkoxy, carboxy, sulfo or hydroxy, in the presence of a base.



_________

177522]21][11[

ידי על אנרגיה לייצור ושיטה מערכתהידרותרמיים אמצעים

SYSTEM AND METHOD FOR POWER GENERATION BY HYDROTHERMAL MEANS

]54[

16.08.2006]22[US]33[03.11.2005]32[60/732670]31[

Int. Cl.8 F01D 001/00, 001/02, F24J 001/00]51[]YAD KONENA LTD.]71בע"מ, ירושלים כוננה יד

]SHMUEL TZIVYON]72ציביון שמואלבע"מ, כוננה יד

,6868- , ת.ד. שמואל ציביון - לידי ירושלים

YAD KONENA LTD,. P.O.BOX 6868

JERUSALEM 91068

]74[

[57] A system for generating power, said system comprising: a working liquid; a low-boiling point fluid flowing through the system with said working liquid; at least two flow-through tanks, including a first tank (1) and a second tank (2), through which said working liquid and said low

boiling point fluid flow; a first conduit (19) and a second conduit (13) for connecting and bringing said first and second flow-through tanks into fluid communication with each other; an energy collector (11) in thermal communication with said working liquid and said low boiling point fluid; and


at least one power generating means (7) each of which being in fluid communication with a single one of said first and second conduits, wherein at least a portion of said low boiling point fluid in said first tank absorbs energy from said energy collector and is thereby brought to its gas phase forming bubbles causing said working liquid and said low boiling point

fluid to flow from one of said first and second flow-through tanks to the other and then back again, said flow passing through said first and second conduits, and said working liquid while passing through at least one of said first and second conduits transfers energy to said at least one power generating means thereby providing power.



_________

177841]21][11[

לפוטנציאלים דו–פולרי מיפויקרדיולוגיים

BIPOLAR MAPPING OF INTRACARDIAC POTENTIALS

]54[

04.07.2001]22[US]33[07.07.2000]32[09/612490]31[

Int. Cl.8 A61B 005/04, 005/042]51[DIVISION FROM 144153]62[BIOSENSE, INC., U.S.A.]71[



P.O.B. 11490 ,TEL AVIV 62038

]74[

[57] A method for measuring near-field electrical activity at a location in a heart comprising: introducing into the heart a

catheter comprising: an elongated tubular body having a distal region and a circumferential recess along the length of


the distal region, a first electrode mounted on the distal region in close proximity to the circumferential recess, and a second electrode mounted within the circumferential recess, the second electrode being configured such the second electrode is not is direct contact with heart tissue but is in contact with blood when the distal region is positioned against heart tissue at a side of the distal region;

positioning the distal region at the location in the heart so that the first electrode is in direct contact with heart tissue; obtaining a first signal with the first electrode; obtaining a second signal with the second electrode; comparing the first signal and the second signal to obtain the near-field electrical activity at the location in the heart.

_________

178910]21][11[

(RF) רדיו תדרי המשדר מוטס פתיון על מכ"ם מונחי טילים להטעיית ושיטה

ניצולו ידי

AIRBORNE RF DECOY AND METHOD FOR DECEIVING RADAR-BASED MISSILES USING IT

]54[

26.10.2006]22[Int. Cl.8 F41H 011/02]51[

וטכנולוגיות מערכות אר.אס.טי. רעותבע"מ, רעננה מתקדמות

RST REUT SYSTEMS & ADVANCED TECHNOLOGIES LTD.

]71[

ושות', עמי , בן בן-עמי פאולינה, רחובות94ת.ד.

PAULINA BEN-AMI, BEN-AMI & ASSOCIATES,

P.O.B. 94 ,REHOVOT 76100

]74[

[57] A stand-alone airbone RF decoy (20) adapted for protecting an airbone platform (10) against multiple enemy radar-based threats (40) said airborne RF decoy comprising: (i) means for receiving a plurality of radar signals from one or more directions;

(ii) means for storing said plurality of radar signals;(iii) means for analyzing said plurality of radar signals to identify threat parameters;(iv) means for altering said plurality of radar signals in order to deceive said multiple enemy radar-based threats;


(v) means for transmitting the altered radar signals; and

(vi) an independent power supply source.



________

180455]21][11[

קולב עבר להסרה הניתן גודל מצייןלבוש לדברי

REMOVABLE SIZE INDICATOR FOR A GARMENT HANGER

]54[

05.04.2002]22[US]33[05.04.2001]32[09/827072]31[

Int. Cl.8 A47G 025/14]51[DIVISION FROM 158169]62[SPOTLESS PLASTICS PTY. LTD., AUSTRALIA

]71[




]74[

[57] A triangular cross-section size indicator (111a) to be removably secured to a web (106a) of a garment hanger, the size indicator comprising two sides (126, 128) depending from an apex (125) defining a V-shaped channel (113), each of the sides terminating in a foremost edge (130, 132), the apex defining a trough

substantially configured to receive an outermost portion of the web therebetween for preventing a lateral movement of the size indicator when the size indicator is secured on the web, each of the sides having an inwardly facing ridge (134a, 134b) disposed at each of the foremost edges and projecting inwards towards the


V-shaped channel for engaging a fixed ridge and a pivoting ridge on the web.

_________

183096]21][11[

של מדורגת להעברה והתקן שיטהיתרות מידע איחסון יחידות דרך נתונים

METHOD AND APPARATUS FOR CASCADING DATA THROUGH REDUNDANT DATA STORAGE UNITS

]54[

12.10.1999]22[US]33[17.02.1999]32[09/251812]31[

Int. Cl.8 G06F 011/14]51[DIVISION FROM 139069]62[EMC CORPORATION, U.S.A.]71[




]74[

[57] In a data processing network having a production site, first and second remote sites, a first communications link between the production and first remote sites and a communication link between the first and second remote sites wherein the production site includes a magnetic disk storage

device and a host adapted to update the data in the magnetic disk storage device, wherein the first remote site includes a first data store that mirrors the data in the magnetic disk storage device, a second data store that operates in a first mode to mirror the data on the first data store, first


and second tables for recording the occurrence of any change in the data in first data store and a copy programme and wherein the second remote site includes another data store, the data processing network being characterized by a method for providing a backup of the data at the production site in each of the first and second remote sites by:(a) establishing in the first remote site a third table for recording the need for any transfer of data from the second data store

to the data store in the second remote site;(b) initially establishing a state whereby the data in the data store in the second remote site corresponds to the data in the first data store at a point in time;(c) re-establishing the first operating mode for the second data store by combining information in the first and third tables to identify the changes made to the first data store while the second data store was operating in the second operating mode, and(d) differentially splitting, after synchronism is achieved between the first and second data stores, the second data store from the first data store by:(i) copying the information in the second table to the third table,(ii) clearing the second table, and(iii) enabling the copy programme to transfer the changed data in the second data store to the data store in the second remote site whereby the data store in the second remote site is brought into synchronism with the data that existed in the first data store at the time of said differential splitting.


__________


PATENTSפטנטים

שניתנו פטנטיםPATENTS GRANTED

156242156240155935155862155782132226130890129139157212157157157146156972156928156623156554156245158365158284157814157761157700157542157277157219160189159186159166159075158872158845158621158470134366133282133039118579161280161254160910160738145950145922145757145307136076135343135036135020148200147983147871147522147293146681146233146126148635148532148360148327148309148216148212148209149159149138149082149081149021148925148875148680149957149824149625149419149319149260149227149188142629141899141486126971126138125464125177150011164761164578164113144994144777143574143153143149137691113465172040168911166920166727166160164977141145139687138347138221138034137841137809137766150690150570150568150480150446150359150182150154151602151545151522151402151330151135150823150737152073152027151816151752151725151715151703151637152820152687152570152494152409152349152340152247153587153535153509153490153299153234153161153110154835154655154616154453154298154252153842153739

155425155359155298155271155229155207154862


שחודשו פטנטיםPATENTS RENEWED

93679936609364693606935949354593432928329373893733937329372093718936949369393680938469383693771937709376493755937549373993887938839388293881938769386493851938479399193964939639393793926939099390893896108867108851108836108832108707108652108610105826108934108921108916108911108910108894108892108879108980108979108971108966108957108955108948108937109015109009109002108998108995108993108991108983109072109071109059109056109054109053109040109027109122109116109114109108109097109086109085109077109176109172109163109160109154109153109151109146117492117491115770109294109223109190109189109177123549123531123512123369123290123059123028122802123682123681123670123669123648123647123587123586123765123734123716123715123712123708123685123683123831123813123807123800123794123770123769123766123894123882123877123876123869123858123852123845127220126794126567126213124118123907123906123895129852129657129575128960128727128580127255127230131407131397131247131181131041130927130595130362131547131513131498131473131468131456131454131418131655131651131640131631131604131597131586131548131750131742131697131684131679131678131670131665131831131818131812131811131772131769131758131752131898131873131871131870131865131858131855131840131956131953131950131944131918131917131911131902132123132114132077132041132040132031132003131980132380132358132238132235132157132145132127132126136905136634136225134728133959133511132480132440140975139786138765138347138098137841137774136934143280142820142448142389142290141670141659141017145320144477144205143889143865143864143863143675147832147673147632147310147215146818146454146185148539148533148530148528148502148492148475148054148704148703148662148637148602148569148557148554148808148804148794148768148740148727148721148705149438149319149110149059148838148834148819148811150768150715149904149879149678149617149543149490152166152102152093151922151260151060150801150800


152538152463152430152398152365152344152337152167152968152952152942152911152821152782152617152599153404153250153223153156153154153153152997152969154489154487154066153847153792153738153711153440154973154859154858154716154703154610154546154535156454155854155834155586155288155193155149155003156951156885156846156763156726156674156645156497157497157403157368157346157252157139157074157051157852157798157791157778157717157711157582157574158133158123158081158034157906157899157888157862158291158270158210158206158138158137158135158134159253158659158652158607158429158326158313158296161510161492161289161175160947160671160384160077164197163871163727163619163104162687162160161561170763167682167154166720166081165400165345164441

178092178091171711171479


חידוש אגרת תשלום אי בגלל פקעו שתוקפם פטנטיםPATENTS NOT IN FORCE DUE TO NON-PAYMENT OF RENEWAL

FEES

9125091238912309119491138911269110191079106462106459106458106453105594912899128891287106511106509106502106497106493106491106483106477106607106598106592106588106584106578106540106520106691106680106677106676106673106672106644106626121390121359119751119750119699119698119118116216121534121527121523121471121463121448121446121410128191128181128120128080127923127799127797127772129176129175129059128505128504128435128370128230144575144553143816143544143543141505139186130261148434147746146700145240145105145104144832144809154362154354154154153974151682149143148888148435

157986156318155630


שנה לעשרים שחודשו פטנטיםPATENTS RENEWED FOR 20 YEARS

148824


תוקפם שפג פטנטיםPATENTS EXPIRED

7145570311


NOTICEהודעה לחוק60 סעיף לפי

1967הפטנטים, תשכ"ז-Under section 60 of the Patent Law, 5727-1967

תוקפו להחזר בקשה הוגשה מטה, המפורט הפטנט של

אי מחמת פקע שתוקפו החידוש אגרות תשלום

הקבועות:

Application has been filed for the restoration of the patent recorded below, which has lapsed through non-payment of the prescribed renewal fees:

125296No. of Patentמס' הפטנט 10/2003Acceptance published inמס': ביומן פורסם קיבול

journal no::Proprietorsהפטנט: בעל שם

גוגנהיים יעקבYAKOV GUGENHIM

:Title of inventionהאמצאה: שםאקוסטית הדמיה

ACOUSTIC IMAGING להתנגד רשאי אדם כל

תוך האמורה לבקשה יומן מתאריך חודשים שלושה שנקבע זה, כפי פטנטים ובתקנה לחוק61 בסעיף

הפטנטים, לתקנות921968תשכ"ח-

Any person may oppose the said application within three months from the date of this Patents Journal, as prescribed by section 61 of the law and by regulation 92 of the Patent Regulations, 5728-1968






הקבועות:




קראוס מנחםMENAHEM KRAUS

:Title of inventionהאמצאה: שםטפטוף לתא ממברנה תומך

MEMBRANE SUPPORT FOR DRIP CHAMBER להתנגד רשאי אדם כל









הקבועות:




סנסולו אריהARIE SANSOLO

:Title of inventionהאמצאה: שםנפץ מדמה התקן

EXPLOSION SIMULATION DEVICE להתנגד רשאי אדם כל









הקבועות:




VISSON IP, LLC:Title of inventionהאמצאה: שם

לייצורו ושיטה אלקטרולומינסי מתקןELECTROLUMINESCENT DEVICE AND METHOD OF MANUFACTURING SAME

להתנגד רשאי אדם כל תוך האמורה לבקשה יומן מתאריך חודשים שלושה שנקבע זה, כפי פטנטים ובתקנה לחוק61 בסעיף








הקבועות:




PLAIN SIGHT SYSTEMS, INC.:Title of inventionהאמצאה: שם

מיקרו–מראה במערך המשתמש הדמייה ומכשיר קרינה, ספקטרומטר מסנןRADIATION FILTER, SPECTROMETER AND IMAGER USING A MICRO-MIRROR

ARRAY להתנגד רשאי אדם כל









הקבועות:




JOSEPH A. MCGILL:Title of inventionהאמצאה: שם

איוורור מערכות עבור מתכווננת עמעמתADJUSTABLE DAMPER FOR AIRFLOW SYSTEMS

להתנגד רשאי אדם כל תוך האמורה לבקשה יומן מתאריך חודשים שלושה שנקבע זה, כפי פטנטים ובתקנה לחוק61 בסעיף



NOTICEהודעהApril 13, 2008 –התשס"ח ח' בניסן 886

הפטנטים, לחוק66 סעיף לפי1967תשכ"ז-

Under section 66 of the Patents Law, 5727-1967

רשות ניתנה כי בזאת מודעמס' הפטנט בקשת לבעלת

119002This is to notify that permission has been granted to the owner of Patent Application No.

6/2000Acceptance published in journalביומן פורסם הקיבול דבר בקשת של הפירוט את לתקן

האמורה הפטנטTo amend the specification of the said Patent Application.

למתן להתנגד רשאי אדם כל חודשים שלושה תוך הרשות

זה, כפי פטנטים יומן מתאריך ובתקנה לחוק67 בסעיף שנקבע

הפטנטים, התשכ"ח- לתקנות991968.

Any person may oppose such grant of permission within three months from the date of this Patents Journal, as prescribed by section 67 of the Law and by regulation 99 of the Patent Regulations, 5728-1968.


NOTICEהודעה הפטנטים, לחוק66 סעיף לפי

1967תשכ"ז-Under section 66 of the Patents Law, 5727-1967































בפנקס רשומים בפרטים שינוייםApril 13, 2008 –התשס"ח ח' בניסן 890

CHANGES IN PARTICULARS ENTERED IN REGISTER

הבעלים שם שינויCHANGE OF NAME OF PROPRIETORS

:153394No. of Patent, 152461, 132098, 115535, 106724מס' פטנט::Previous nameהקודם: השם

NOVEON, INC:New nameהחדש: השם

LUBRIZOL ADVANCED MATERIALS, INC.

בכתובת שינוייםCHANGES IN ADDRESS


:34119No. of design, 34118מס' המדגם::New addressהחדשה: הכתובת

14 Siriusdreef Hoofddorp, The Netherlands 2132 WT

מס' המדגם:

החדשה: הכתובת

38984 ,38985 ,38986,38987 ,40574 ,40575,40576 ,40577 ,40578,41218 ,41219 ,41220,41221 ,41222 ,41223,41224 ,41225 ,41226,41227 ,41228 ,41229,41230 ,41231 ,41232

No. of design:

New addressArastirma Teknoloji Gelistirme Merkezi

34950 Tuzla, Istanbul, Turkey

Dr. Meir NoamCommissioner of Patents,Designs and Trade Marks

נועם מאיר ד"רהפטנטים, המדגמים רשם

מסחר וסימני

טעויות תיקוניCORRIGENDA


Journal 11/2007 יומןP. 4496 Patent application No. 166282 166282מס' פטנט בקשת4496ע' Correct name of applicant to-LUZZATTO & LUZZATTOP.O.B. 5352BEER-SHEVA 84152Correct international publication no. to-

למסירת המען תקןלוצאטו את לוצאטו

5352ת.ד. 84152 שבע בארל הבינלאומי הפרסום מספר את תקן -

WO/2000/71358

Journal 11/2007 יומןP. 4495 Patent No. 165539 165539מס' פטנט4495ע' Correct name of applicant to-LUZZATTO & LUZZATTOP.O.B. 5352BEER-SHEVA 84152Correct international publication no. to-

למסירת המען תקןלוצאטו את לוצאטו

5352ת.ד. 84152 שבע בארל הבינלאומי הפרסום מספר את תקן -

WO/2000/71356

ביומן המופיעים למדינת קודיםCOUNTRY CODES APPEARING IN THIS JOURNAL

Code Country or OrganizationAR Argentina


AT AustriaAU AustraliaBA HerzegovinaBE BelgiumBR BrazilCA CanadaCH SwitzerlandCN ChinaCU CubaCZ Czech RepublicDE GermanyDK DenmarkEC EcuadorEP European Patent OfficeES SpainFI FinlandFR FranceGB United KingdomGE GeorgiaGR GreeceGT GuatemalaHR CroatiaHU HungaryIE IrelandIL IsraelIN IndiaIT ItalyJP JapanKR Republic of KoreaLK Sri LankaLU LuxembourgLV LatviaMX Mexico

MY MalaysiaNL The NetherlandsNO NorwayNZ New ZealandPL PolandPT PortugalRU Russian Federation


SE SwedenSG SingaporeSI SloveniaSK SlovakiaTH ThailandTR TurkeyTW TaiwanUA UkraineUS United States of AmericaUY UruguayUZ UzbekistanWO World Intellectual Property Organization (W.I.P.O.)ZA South Africa

DESIGNS מדגמיםשנרשמו מדגמים

DESIGNS REGISTERED

41000April 13, 2008895 –התשס"ח ח' בניסן

Class 25(01) סוג12. 7.2005

KOL CHEN LTD. AND HAIM AZOULAY

אזולאי וחיים בע"מ חן כל

Profile פרופיל

41780, 41781Class 3(01) סוג

22. 12.2005AMNON BEN MOSHE משה בן אמנוןTalit and tefillin bag ותפילין לטלית תיק

41945Class 21(01) סוג

2.2.2006JESSICA COHEN כהן ג'סיקהPillow for modular children's furniture לילדים מודולרי לריהוט כרית

42121Class 9(03) סוג

9.3.2006DAR PLAST LTD. בע"מ פלסט דרContainer מיכל

42125Class 25(01) סוג

9. 3.2006KLIL INDUSTRIES LTD. בע"מ תעשיות קלילProfile פרופיל


11. 5.2006ITZHAK KLEIMAN AND EDI KLEIMAN

קליימן ואדי קליימן יצחק

Decorative tea דקורטיבי תה

42469Class 14(02) סוג

17. 5.2006ON TRACK INNOVATIONS LTD. בע"מ אינובישנס טרק און


Smart card reader חכם כרטיס קורא


18. 5.2006SHAHAL TELEMEDICINE LTD. בע"מ טלרפואה שחלResuscitation bag החייאה תיק


6. 6.2006NEVIOT-NATURE OF GALILEE LTD.

בע"מ הגליל נביעות-טבע

Bottle בקבוק


15. 6.2006SHALEM PRODUCTS PACKAGING (1998) LTD.

( בע"מ1998) אריזות שלם מוצרי

Package אריזה


5. 7.2006ISRAEL AZRIEL עזריאל ישראלRoof for sukkah toy צעצוע לסוכת סכך

43030Class 11(01) סוג

4. 11.2004

H. STERN COMERCIO E INDUSTRIA S.A.Earring עגיל


13. 9.2006YUVAL ALDUBI AND SHACHAR LIFSHITZ LTD.

בע"מ ליפשיץ ושחר אלדובי יובל

Newspaper rack לעיתונים מעמד

43190Class 26(05) סוג


15. 10.2006GIDEON YASKIROVITZ AND YOSEF COHEN

כהן ויוסף יסקרביץ גדון

Lighting fixture תאורה גוף

43259, 43260Class 6(06) סוג

1. 11.2006DUBY OFIR-INDUSTRIAL DESIGN LTD.

בע"מ תעשייתי עיצוב – אופיר דובי

Control stand לבקרה עבודה עמדת

43266, 43268, 43269Class 25(01) סוג

1. 11.2006PROFILE GLASS LTD. בע"מ גלס פרופילProfile פרופיל

43420Class 24(04) סוג

3. 12.2006CIPLA LIMITED

Inhaler container למשאף מיכלConvention date (India)

הברית( )ארצות אמנה תאריך 23.6.2006 )הודו( האמנה תאריך

43549Class 26(01) סוג

26. 12.2006JONATHAN BAR-OR INDUSTRIAL DESIGN LTD.

תעשייתי עיצוב בר-אור יונתן בע"מ

Hanukah candles array and package ואריזה חנוכה נרות של יומית מערכת

43668Class 13(03) סוג

25. 1.20073M INNOVATIVE PROPERTIES COMPANY

Electrical connector חשמלי מחברConvention date (U.S.A.)

הברית( )ארצות אמנה תאריך 24.7.2006 הברית( )ארצות האמנה תאריך



20. 3.2007METZERPLAS INDUSTRIES LTD. בע"מ תעשיות מצרפלסBase plate בסיס פס


1. 4.2007ISRAEL BEER BREWERIES LTD. בע"מ ישראל בירה מבשלותBottle בקבוק


1. 4.2007GILI GOLAN LITMAN ליטמן גולן גיליPlaymat פעילות מזרון


8. 5.2007MUL-T-LOCK TECHNOLOGIES LTD.

בע"מ טכנולוגיות מולטילוק

Key head מפתח ראש

44205Class 25(03) סוג

21. 5.2007WOLFMAN INDUSTRIES LTD. בע"מ תעשיות וולפמןSystem of prefabricated graves טרומיים קברים מערכת

44218Class 24(04) סוג

24. 5.2007CIPLA LIMITED

Capsule chamber for inhaler device שאיפה למכשיר קפסולה תאConvention date (India)

הברית( )ארצות אמנה תאריך 27.11.2006 )הודו( האמנה תאריך

44223Class 28(03) סוג

24. 5.2007RAHAMIM GIL AND SAR SHALOM

שלום ושר גיל רחמים


Illuminated tweezers מוארת פינצטה

44228Class 24(04) סוג

27. 5.2007NICHOLAS WILLIAM GILES FINN

Absorbent genital shield סופגני גניטאלי מגןConvention date (South Africa)

הברית( )ארצות אמנה תאריך 28.11.2006 אפריקה( )צפון האמנה תאריך


28. 5.2007BINYAMIN YIRMIYAHU AND MORDECHAI YIRMIYAHU

ירמיהו ומרדכי ירמיהו בנימין

Piston pump בוכנה משאבת


28. 5.2007BINYAMIN YIRMIYAHU AND MORDECHAI YIRMIYAHU

ירמיהו ומרדכי ירמיהו בנימין

Base for piston pump בוכנה למשאבת בסיס

44264Class 2 (04) סוג

31. 5.2007CROCS, INC.

Footwear נעלConvention date (U.S.A.)

הברית( )ארצות אמנה תאריך 4.12.2006 הברית( )ארצות האמנה תאריך

(U.S.A.) 23.5.2007 ( הברית ארצות )


18. 6.2007AMRAZ LTD. בע"מ אמרזLid for container לאריזה מכסה


20. 6.2007SHACHAR LIFSHITZ LTD. AND YUVAL ALDUBI

אלדובי ויובל בע"מ ליפשיץ שחר

Shelf support מדף תומך



3. 7.2007CARMIT MEDINA PLATKIN פלטקין מדינה כרמיתPlastic bag ניילון שקית




Bottle בקבוק




Bottle בקבוק

44549Class 25 (01) סוג

23. 7.2007SAVIO S.P.A.

Profile פרופילConvention date (OHIM)

הברית( )ארצות אמנה תאריך 29.1.2007 )אוהיים( האמנה תאריך

44550Class 19(02) סוג

24. 7.2007DANIEL ZACH זך דניאלBook holder ספר מחזיק

44559Class 14 (03) סוג

25. 7.2007POLYMER VISION LTD.

Communication Device תקשורת התקןConvention date (OHIM)


44560, 44561, 44562,44563, 44564, 44565,

44566, 44567Class 25(02) סוג


26. 7.2007

RAV-BARIACH SECURITY PRODUCTS LTD.

בע"מ בטחון מוצרי בריח רב

Door דלת


29. 7.2007HAIM HOENIG הניג חייםBottle packing לבקבוק אריזה

44582, 44583, 44584,44585, 44586, 44587,

44588Class 11(02) סוג

1. 8.2007ISAAC KEN-TOR קן-תור יצחקHamsa חמסה

44600Class 10(01) סוג

5. 8.2007SHACHAR LIFSHITZ LTD. AND YUVAL ALDUBI

אלדובי ויובל בע"מ ליפשיץ שחר

Clock שעון

44637Class 23(01) סוג

14. 8.2007GARY FAVEL פייבל גריContainer for collection of rain water גשם מי לאגירת מיכל


15. 8.2007MORDEHAY CABASSO קבסו מרדכיLever for shutter לתריס מנוף


15. 8.2007ALICIA GUBLER BERDUGO ברדוגו גובלר אליסיהFrame for hanging earrings עגילים לתליית מסגרת


44644, 44646, 44647,44648

Class 21 (01) סוג15. 8.2007

SMART BABY TOYS AND SMART TRIKEChild vehicle toy לילדים רכב צעצוע


20. 8.2007AFIF TANUS טנוס עפיףJar צנצנת


10. 9.2007ISCAR LTD. בע"מ ישקרKey for drill cutting head למקדח חיתוך לראש מפתח


17. 9.2007CECLILIA KASHER VOLCOFF VITAS

ויטס וולקוב כשר ססיליה

Serving dish הגשה כלי

44791Class 21(01) סוג

16. 9.2007SMART BABY TOYS AND SMART TRIKE

Tricycle אופן תלת

44825Class 11(02) סוג

19. 9.2007ERAN GREBLER גרבלר ערןMezuzah dreidel סביבון מזוזת

44873Class 11(01) סוג

10. 10.2007H. STERN COMERCIO E INDUSTRIA S.A.

Jewel תכשיט


44897Class 14 (03) סוג

16. 10.2007SOMFY SAS

Remote control רחוק שלטConvention date (OHIM)


44925, 44926Class 11(02) סוג

24. 10.2007ADI FAINER פיינר עדיMezuzah מזוזה

44927, 44928Class 26(01) סוג

24. 10.2007ADI FAINER פיינר עדיCandlestick פמוט

44929Class 11(02) סוג

24. 10.2007ADI FAINER פיינר עדיStatuette פסלון

44930Class 11(02) סוג

24. 10.2007ADI FAINER פיינר עדיBowl קערה

44931Class 11(02) סוג

24. 10.2007ADI FAINER פיינר עדיPassover plate פסח צלחות

44933


Class 9(07) סוג25. 10.2007

RAN SAGY שגיא רןDispensing plug מושיט פקק

44986, 44987Class 7 (04) סוג

6. 11.2007KONINKLIJKE PHILIPS ELECTRONICS N.V.

Blender מזון מערבלConvention date (OHIM)


45028Class 8 (03) סוג

12. 11.2007

ROSENFELD PROMOTION LTD. בע"מ פרומושיין רוזנפלגFret saw מסורית

45031, 45032Class 7 (04) סוג

13. 11.2007KONINKLIJKE PHILIPS ELECTRONICS N.V.

Blender מזון מערבלConvention date (OHIM)



18. 5.2006SHAHAL TELEMEDICINE LTD. בע"מ טלרפואה שחלDoctor's bag רופא תיק

שחודשו מדגמיםDESIGNS RENEWED


296042960329536295282939229369293652906137614375523752937490374803149229724297233770337702376783767737676376753765037620

394133810137866378083774437740

שבוטלו מדגמיםDESIGNS VOID


204222042020419204182041720416204152041420491204902048920488204862047920468204672057720576205192051820500204992049820497205912058820586205852058420580205792057828306283052830028288282702059420593205922836028350283332831428310283092830828307283722837128369283682836428363283622836128398283972839628395283942839328392283912845628450284042840328402284012840028399368203681930004300033000230001300002999936856368553685036848368443683436832368283689836897368963689436881368803687936878

36912

Dr. Meir NoamCommissioner of Patents,Designs and Trade Marks

נועם מאיר ד"רהפטנטים, המדגמים רשם

מסחר וסימני


שקובלו לבקשות מפתחותINDICES OF APPLICATIONS ACCEPTED

NAME INDEXשמי מפתח

163318 דהאן אברהם132191 בע"מ טכנולוגיות אזימוט

152509 בע"מ אי.אן.אר.אי ,154647 בע"מ אי.סי.איי. טלקום

157985153482 בע"מ מערכות אלביט148627 לוזינסקי אלינה148627 בע"מ רפואי מיכשור אלקור

138565 בע"מ סולושין ביו אקסוטק וטכנולוגיות מערכות אר.אס.טי. רעות

178910 בע"מ מתקדמות

בע"מ ביולוגיים אותות בי.אס.פי. עיבוד157855

163318 ראובן ברמן

142026 בע"מ אימג'ינג גיוון153292 בע"מ צבע טכנולוגיות גנואה

בע"מ ופיתוח רפואי מחקר שרותי הדסית141408 בע"מ לישראל האוירית התעשייה162767

( בע"מ1991) תעשיות תנה חברת167788

159691 מורגנשטיין חיים

177522 בע"מ כוננה יד148627 לוזינסקי יולי

של המחקר לפיתוח חברה יישום בירושלים העברית האוניברסיטה

142026 של המחקר לפיתוח חברה יישום

בירושלים העברית האוניברסיטה147953

של המחקר לפיתוח חברה יישום בירושלים העברית האוניברסיטה

158244

148598 בע"מ ביוטכנולוגיות ימית163318 דנינו יצחק132699 יאירוב יראל158498 בע"מ ישקר158498 בע"מ ישקר

החקלאות, מרכז ישראל, משרד מדינת141408 וולקני

138565 קולט מוניקה138565 בוצ'בסקי דן מירצ'ה

162199 בע"מ מדידה מכשירי נובה156424 בע"מ טכנולוגיות נולי

156513 בע"מ נייקסט160489 בע"מ נילית

155659 בע"מ טכנולוגיות סטארבורד167646 לטישב סרגיי

156538 מורדוב עידן

160688 בע"מ פי. בי. סי. לייזרים

150158 בע"מ קומברס150324 בע"מ מתכת תעשיות קראוס

164868 בע"מ בטחון מוצרי בריח רב152768 בע"מ טכנולוגיות ריט

בע"מ מתקדמות לחימה מערכות רפאל160952

בע"מ עומק עם משחקים שורשים164633

162291 בע"מ תפנטולס148326 בע"מ ברום תרכובות

April 13, 2008 –התשס"ח ח' בניסן i

ADRIANUS JACOBUS JOHANNES MAAS 159366ADVANCED BIOTECHNOLOGIES 160109ADVANCED INHALATION RESEARCH INC. 157569ALBEMARLE CORPORATION 135524ALCOR MEDICAL INSTRUMENTS LTD. 148627ALINA LOZINSKI 148627AMGEN, INC. 143706AMGEN, INC. 154541, 154542APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. 151172ARQULE, INC. 156268ASTRAZENECA AB 149107, 149578ASTRAZENECA AB 153754, 157282ASTRAZENECA UK LIMITED 147379ATI PROPERTIES, INC. 157722AVENTIS PHARMA S.A. 149154AVENTIS PHARMACEUTICALS INC. 143405AVENTIS PHARMACEUTICALS INC. 146547AVRAHAM DAHAN 163318AZIMUTH TECHNOLOGIES, LTD. 132191

B.S.P. BIOLOGICAL SIGNAL PROCESSING LTD. 157855BAE SYSTEMS BOFORS AB 153621BASF AKTIENGESELLSCHAFT 153412BAYER AKTIENGESELLSCHAFT 130330BAYER CROPSCIENCE AG 154040BERICAP HOLDING GMBH 159592BERLEX LABORATORIES, INC. 148313BERMAN REUBEN 163318BIOGEN IDEC INC. 134937BIOPHYSICA, INC. 145728BIORA BIOEX AB 160639BIOSENSE WEBSTER, INC. 157319BIOSENSE, INC. 177841BIOTECON GESELLSCHAFT FUR BIOTECHNOLOGISCHE

ENTWICKLUNG UND CONSULTING MBH 143528BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG 148057BRISTOL COMPRESSORS, INC. 156298BRISTOL-MYERS SQUIBB COMPANY 157937BRISTOL-MYERS SQUIBB COMPANY 158202BRISTOL-MYERS SQUIBB COMPANY 164022BROMINE COMPOUNDS LTD. 148326

CALGON CORPORATION 148268CAMBRIDGE FLAT PROJECTION DISPLAYS LIMITED 160902CAPSULE VIEW INC. 134017CEPHALON, INC. 148180CHANG-PI LO 151821CHRISTIANUS JACOBUS MARIA LANGENBERG 159366CHRISTOS ZOUBOULIS 144683CHROMAGENICS B.V. 141371CITRIX SYSTEMS INC. 155698CLINICAL ANALYSIS CORP. 151477COMPUTER ASSOCIATES THINK, INC. 147491COMVERSE LTD. 150158COMVERSE, INC. 150780CORNERSTONE SENSORS, INC. 147734

DAIICHI SANKYO COMPANY LIMITED 153594DCA DESIGN INTERNATIONAL LIMITED 157604DINAMITE DIPHARMA S.P.A. 152571DIOMED DEVELOPMENTS LTD. 153592DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO. KG 149891

EASTGATE INVESTMENTS LIMITED 155943ECI TELECOM LTD. 154647, 157985ELBIT SYSTEMS LTD. 153482

March 20, 2008 –ב' התשס"ח באדר י"ג ii

EMC CORPORATION 139069, 183096ERBE ELEKTROMEDIZIN GMBH 166661ERNST & YOUNG LLP 153755ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) 161713EXOTECH BIO SOLUTION LTD. 138565

FLORENCIO LAZO BARRA 155126FMC TECHNOLOGIES INC. 157499FRANKLIN ROBERT CHRISTIAAN VAN DORSTEN 159366FUJIKIN INCORPORATED 164274

GARY A. STROBEL 158432GENENTECH, INC. 135704GENOA COLOR TECHNOLOGIES LTD. 153292GENOA COLOR TECHNOLOGIES LTD. 153292GIVEN IMAGING LTD. 142026GRUNENTHAL GMBH 153825GUM BASE CO. S.P.A. 164412

H.H. BROWN SHOE COMPANY, INC. 160934HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. 141408HAIM MORGENSTEIN 159691HIDEZO MORI 149491HIROYUKI WAKAMATSU 153386HONEYWELL INTERNATIONAL INC. 161732

ICE S.R.L. 166446ICU MEDICAL, INC. 139515IDAN MORADOV 156538IGENEON KREBS-IMMUNTHERAPIE FORSCHUNGS-UND ENTWICKLUNGS AG 158950INDIAN OCEAN MEDICAL INC. 160467INDORATA SERVICOS E GESTAO LDA. 158848INDUSTRIAL ORIGAMI, INC. 154406

INDUSTRIAL ORIGAMI, INC. 154406INDUSTRIAL ORIGAMI, LLC. 154406INFINEON TECHNOLOGIES AG 150691INGENEUS CORPORATION 150844INGENEUS INC. 150844INNOVENTIONS INC. 148702INRA 152509INSTITUT FRANCAIS DU PETROLE 161638INTEL CORPORATION 149083INTERCELL AG 152959INTERDIGITAL TECHNOLOGY CORPORATION 151905, 152104, 176033ISCAR LTD. 158498ISCAR LTD. 158498ISHIHARA SANGYO KAISHA LTD. 151009ISRAEL AEROSPACE INDUSTRIES LTD. 162767ITZHAQ DANINO 163318

JAN VAN NIEKERK 159366JANSSEN PHARMACEUTICA N.V. 143859JOHNSON & JOHNSON VISION CARE, INC. 161713

KANEKA CORPORATION 151098KOLLMORGEN CORPORATION 156995KOMET GROUP HOLDING GMBH 153536KONINKLIJKE PHILIPS ELECTRONICS N.V. 141620KOWA COMPANY, LTD. 164206KRAUSZ METAL INDUSTRIES LTD. 150324KUDOS PHARMACEUTICALS LIMITED 155645

L&P PROPERTY MANAGEMENT COMPANY 163728LABORATOIRES SERONO SA 151172LEHMANN GMBH & CO. KG 164160LEO PHARMA A/S 177357LEONARDUS JOHANNES MARIA

April 13, 2008 –התשס"ח ח' בניסן iii

TEUNISSEN 159366LEYBOLD VACUUM GMBH 168485LIFESCAN SCOTLAND LIMITED 156302

MAARTEN GERARDUS FRANCISCUS VAN WIJK 159366MACROMED, INC. 135415MARINUS ADRIAAN DROST 159366MAYBRIDGE PLC 155645MEDAREX, INC. 148079MEHMET KURT 153350MENZOLIT-FIBRON GMBH 164076MICROSOFT CORPORATION 155001MINDSET BIOPHARMACEUTICALS (USA), INC. 143768MIRCEA DAN BUCEVSCHI 138565MITSUBISHI TANABE PHARMA CORPORATION 154893MONICA COLT 138565Monika Werner 164160MYCOGEN CORPORATION 142171

N B NETWORKS 150411NEW YORK UNIVERSITY 132113NICAST LTD. 156513NILIT LTD. 160489NOOLY TECHNOLOGIES LTD. 156424NOVA MEASURING INSTRUMENTS LTD. 162199NOVAMONT S.P.A. 129745NOVARTIS AG 155363, 155992NOVO NORDISK A/S 128332

OBTECH MEDICAL AG 151137OMS INVESTMENTS, INC. 165211ORION CORPORATION 159647ORMAZABAL Y CIA., S.A. 155564OSI PHARMACEUTICALS, INC. 129994OTSUKA PHARMACEUTICAL CO, LTD 153838

PBC LASERS LTD. 160688PENTAPHARM AG 134356PERLEGEN SCIENCES, INC. 148783PFIZER INC. 129994

March 20, 2008 –ב' התשס"ח באדר י"ג iv

PFIZER ITALIA S.R.L. 152388PFIZER PRODUCTS, INC. 129994, 145450PHARMA MAR, S.A. 152125PHARMACOPEIA, INC. 148313PHILMAC PTY LTD. 156654PRESS-SEAL GASKET CORPORATION 158414

QUALCOMM INCORPORATED 147019QUALCOMM INCORPORATED 150820, 155582, 155694, 156053, 162787

RADIANT NETWORKS PLC 149083RAFAEL ADVANCED DEFENSE SYSTEMS LTD. 160952RAV BARIACH SECURITY PRODUCTS LTD. 164868REGENERON PHARMACEUTICALS, INC. 137858REIFENHAUSER GMBH & CO. MASCHINENFABRIK 154631RIT TECHNOLOGIES LTD. 152768ROHDE & SCHWARZ GMBH & CO. KG 153367RST REUT SYSTEMS & ADVANCED TECHNOLOGIES LTD. 178910RTP PHARMA INC. 141095RYMED TECHNOLOGIES INC. 142461

SA MAJESTE LA REINE DU CHEF DU CANADA AGRICULTURE ET AGROALIMENTAIRE CANADA 150361SAECHISCHES SERUNWERK DRESDEN BRANCH OF SMITHKLINE BEECHAM PHARMA GMBH & CO. KG 158931SANOFI AVENTIS 147282SASOL NORTH AMERICA INC. 163618SCHOTT AG 167080SERGEI LATYSHEV 167646

shorashim games with depth ltd. 164633

SILVERBROOK RESEARCH PTY.

April 13, 2008 –התשס"ח ח' בניסן v

LTD. 168331SILVERBROOK RESEARCH PTY. LTD. 155460, 160259, 167966SKYEPHARMA CANADA INC. 153457SMITHKLINE BEECHAM BIOLOGICALS S.A. 137442SPINEVISION 147401, 147403SPOTLESS PLASTICS PTY. LTD. 180455STARBOARD TECHNOLOGIES LTD. 155659STATE OF ISRAEL, MINISTRY OF AGRICULTURE , VOLCANI CENTER 141408SWISSCOM MOBILE AG 158939SYNGENTA PARTICIPATIONS AG 124907

TADAHIRO OHMI 164274TANA INDUSTRIES (1991) LTD. 167788TEFENTOOLS LTD. 162291TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 157522TERXO AG 159592TEXTRON SYSTEMS CORPORATION 157865THALES 161150THE FLINTEC GROUP, LTD. 160479THE GOVERNMENT OF THE UNITED STATES OF AMERICA 129919THE JAPAN STEEL WORKS, LTD. 151098THE LARYNGEAL MASK COMPANY LIMITED 160467THE PENN STATE RESEARCH FOUNDATION 157569THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 156831TIMOTHEUS JOAN MARIE LECHNER 159366

UBE INDUSTRIES, LTD. 147379UHDE GMBH 164234UNILEVER PLC 166774

VERENIGDE BEDRIJVEN NIMCO

B.V. 156790VIASAT, INC. 152250VICTOR L. VINES 150983VIRGIN COTTON COMPANY PTY LTD. 134114VOSSLOH WERKE GMBH 150599

WYETH 156268

YAD KONENA LTD. 177522YAMIT BIOTECHNOLOGIES LTD. 148598YAREL YAIROV 132699YASUHIKO TABATA 149491YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM 147953YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM 142026YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM 158244YULI LOZINSKI 148627

March 20, 2008 –ב' התשס"ח באדר י"ג vi

ענייני מפתחSUBJECT MATTER INDEX

A01G – 155126

A01H – 134114, 158244

A01K – 153350

A01N – 142171, 158432

A23G – 164412, 166774

A41G – 158848 A43B – 160934

A47G – 180455

A61B – 134017, 147401, 147403, 150983 ,156831 ,157319, 157855 ,159366 ,166661,

177841

A61C – 148627, 157522

A61F– 148702, 151137

A61J– 134356

A61K – 129919, 134937, 141095, 141408 ,143706 ,143768, 148057 ,148268 ,148598, 149107 ,149491 ,149578, 150361 ,152959 ,153457, 153592 ,155363 ,155992, 157569 ,158202 ,158950, 160109 ,160639 ,164206

A61M– 139515, 142461, 151821, 157604 ,160467

B01D – 163618, 164234

B01J – 164274, 165211

B21D – 154406

B23B – 153536, 156790, 158498

B25B– 162291

B29C – 156513, 164076, 164160

B31F – 155659

B32B – 167080

B41J – 156538, 160259, 167966, 168331

B63H – 159691

B65D – 159592 B65G – 157499

B67D – 167788

C07C– 135524, 145728, 147953, 148326 ,153412 ,153825

C07D – 129994, 143405, 143859,

145450 ,147282 ,147379, 148313 ,151009 ,151172, 152125 ,152388 ,152571, 153594 ,153754 ,153838, 154040 ,154893 ,155645,

156268 ,157282 ,159647

C07F –164022, 166446, 177357

C07H – 149154 C07K – 128332, 143528, 154541 C08G – 135415

C08L – 129745, 138565

C12N – 124907, 132113, 137442, 137858 ,141371 ,144683, 148079 ,154542 ,157937,

158931

C12P –130330, 148180, 149891

C12Q – 135704, 146547, 148783, 150844

D02G – 160489

D04H – 154631

D05B –163728

E01B – 150599

E06B –164868

F01D – 177522

F01P – 167646

F15B – 151098

F16L – 156654, 158414

F25B – 156298, 168485

F41H – 157722, 178910

F42B –153621

G01C – 132191

G01K – 147734

G01L – 160479

G01N – 142026, 151477, 156302, 162199

G01V – 161638

G01W – 156424

G02B – 161150, 161732

G02C – 161713

G02F – 153292

G03B – 160902

G06F – 139069, 147491, 150411, 153755 ,155001 ,183096

G06Q – 153386, 163318

G08G – 162767

G09B – 164633

G11B – 141620

H01J – 153482

H01L – 150691

H01R – 132699, 152768, 155564

H01S – 157865

H02K – 156995

H03K – 150820, 155943

H03M – 155582, 155694

H04B – 151905, 152250, 153367, 154647 ,157985 ,160952,

162787

H04J – 156053

H04L – 147019, 149083, 155698, 158939 ,176033

H04M – 150158, 150780, 152509

H04Q –152104

H05K – 155460

April 13, 2008viii –התשס"ח ח' בניסן

המשפטים, ירושלים הפטנטים, משרד רשות ע"י נערךהממשלתי, ירושלים במדפיס והודפס הופק

EDITED BY THE PATENT OFFICE, MINISTRY OF JUSTICE, JERUSALEMPRINTED AND PUBLISHED BY THE GOVERNMENT PRINTER

Documents

ידיעות כלליות - נבו - המאגר המשפטי - 13-04-2008... · Web viewG06F 188828 22/08/2006 מערכת ושיטה למשלוח הודעות MESSAGING SYSTEM AND